ensg-20230930

0001125376-23-000184.txt : 20231025 0001125376-23-000184.hdr.sgml : 20231025 20231025160351 ACCESSION NUMBER: 0001125376-23-000184 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 105 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231025 DATE AS OF CHANGE: 20231025 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENSIGN GROUP, INC CENTRAL INDEX KEY: 0001125376 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SKILLED NURSING CARE FACILITIES [8051] IRS NUMBER: 330861263 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33757 FILM NUMBER: 231345721 BUSINESS ADDRESS: STREET 1: 29222 RANCHO VIEJO RD. STREET 2: SUITE 127 CITY: SAN JUAN CAPISTRANO STATE: CA ZIP: 92675 BUSINESS PHONE: (949) 487-9500 MAIL ADDRESS: STREET 1: 29222 RANCHO VIEJO RD. STREET 2: SUITE 127 CITY: SAN JUAN CAPISTRANO STATE: CA ZIP: 92675 FORMER COMPANY: FORMER CONFORMED NAME: ENSIGN GROUP INC DATE OF NAME CHANGE: 20000930 10-Q 1 ensg-20230930.htm 10-Q ensg-20230930

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________

FORM 10-Q



☑			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended September 30, 2023.


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
			For the transition period from to .

Commission file number: 001-33757

_____________________________

THE ENSIGN GROUP, INC.

(Exact Name of Registrant as Specified in Its Charter)


Delaware			33-0861263
(State or Other Jurisdiction of			(I.R.S. Employer
Incorporation or Organization)			Identification No.)

29222 Rancho Viejo Road, Suite 127

San Juan Capistrano, CA 92675

(Address of Principal Executive Offices and Zip Code)

(949) 487-9500

(Registrant’s Telephone Number, Including Area Code)

_____________________________

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	ENSG	NASDAQ Global Select Market

Indicate by check mark:

whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

☐

whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes

☐

whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Yes

☐

whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

☐

Yes

As of October 20, 2023, 56,452,238 shares of the registrant’s common stock, $0.001 par value, were outstanding.

Table of Contents

THE ENSIGN GROUP, INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE THREE MONTHS AND NINE MONTHS ENDED SEPTEMBER 30, 2023

TABLE OF CONTENTS


PART I. Financial Information			Pg.
Item 1. Financial Statements (unaudited):

Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022			1

Condensed Consolidated Statements of Income for the three and nine months ended September 30 , 2023 and 2022			2

Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2023 and 2022			3

Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022			5

Notes to Condensed Consolidated Financial Statements			7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			33

Item 3. Quantitative and Qualitative Disclosures About Market Risk			72

Item 4. Controls and Procedures			73

P ART II. Other Information
Item 1. Legal Proceedings			73

Item 1A. Risk Factors			76







Item 5. Other Information			106

Item 6. Exhibits			108

Signatures

Table of Contents

PART I.

Item 1. FINANCIAL STATEMENTS

THE ENSIGN GROUP, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par values)


	September 30, 2023		December 31, 2022




ASSETS
Current assets:
Cash and cash equivalents	$	467,870	$	316,270
Accounts receivable—less allowance for doubtful accounts of $9,422 and $7,802 at September 30, 2023 and December 31, 2022, respectively	472,123		408,432

Investments—current	16,433		15,441

Prepaid expenses and other current assets	37,921		40,982


Total current assets	994,347		781,125
Property and equipment, net	1,067,902		992,010
Right-of-use assets	1,773,751		1,450,995
Insurance subsidiary deposits and investments	86,818		67,652

Deferred tax assets	39,968		39,643
Restricted and other assets	35,979		37,291
Intangible assets, net	6,347		6,437
Goodwill	76,869		76,869


TOTAL ASSETS	$	4,081,981	$	3,452,022
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	77,091	$	77,087

Accrued wages and related liabilities	311,509		289,810
Lease liabilities—current	80,956		65,796
Accrued self-insurance liabilities—current	50,197		48,187


Other accrued liabilities	148,128		97,309
Current maturities of long-term debt	3,916		3,883

Total current liabilities	671,797		582,072
Long-term debt—less current maturities	146,453		149,269
Long-term lease liabilities—less current portion	1,657,955		1,355,113
Accrued self-insurance liabilities—less current portion	97,502		83,495
Other long-term liabilities	42,832		33,273


TOTAL LIABILITIES	$	2,616,539	$	2,203,222

Commitments and contingencies (Notes 15, 17 and 19)

EQUITY
Ensign Group, Inc. stockholders' equity:
Common stock: $0.001 par value; 150,000, 59,803 and 56,413 shares authorized, shares issued and shares outstanding at September 30, 2023, respectively, and 100,000, 59,029 and 55,661 shares authorized, shares issued and shares outstanding at December 31, 2022, respectively	60		59
Additional paid-in capital	451,883		415,560
Retained earnings	1,124,358		946,339
Common stock in treasury, at cost, 3,390 and 3,368 shares at September 30, 2023 and December 31, 2022, respectively	(116,555)		(114,626)
Total Ensign Group, Inc. stockholders' equity	1,459,746		1,247,332
Non-controlling interest	5,696		1,468
Total equity	$	1,465,442	$	1,248,800
TOTAL LIABILITIES AND EQUITY	$	4,081,981	$	3,452,022

See accompanying notes to condensed consolidated financial statements.

Table of Contents

THE ENSIGN GROUP, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022

	(In thousands, except per share data)
REVENUE
Service revenue	$	935,324	$	765,883	$	2,733,343	$	2,203,386
Rental revenue	5,467		4,122		15,634		12,550
TOTAL REVENUE	$	940,791	$	770,005	$	2,748,977	$	2,215,936


Expense:
Cost of services	741,069		601,623		2,160,080		1,720,905



Rent—cost of services	50,357		38,907		146,754		111,897
General and administrative expense	51,127		39,247		156,448		116,030
Depreciation and amortization	18,446		15,941		53,154		45,475
TOTAL EXPENSES	860,999		695,718		2,516,436		1,994,307
Income from operations	79,792		74,287		232,541		221,629
Other income (expense):
Interest expense	(2,024)		(2,108)		(6,083)		(6,864)
Other income (expense)	4,277		276		15,022		(3,127)
Other income (expense), net	2,253		(1,832)		8,939		(9,991)
Income before provision for income taxes	82,045		72,455		241,480		211,638
Provision for income taxes	18,077		16,213		53,453		47,505


NET INCOME	63,968		56,242		188,027		164,133
Less:


Net income (loss) attributable to noncontrolling interests	105		63		319		(77)
Net income attributable to The Ensign Group, Inc.	$	63,863	$	56,179	$	187,708	$	164,210





NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC.



Basic	$	1.14	$	1.02	$	3.38	$	3.00



Diluted	$	1.11	$	0.99	$	3.28	$	2.89
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic	55,829		54,882		55,582		54,819
Diluted	57,337		56,761		57,245		56,829

See accompanying notes to condensed consolidated financial statements.

Table of Contents

THE ENSIGN GROUP, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY


	Common Stock			Additional Paid-In Capital		Retained Earnings		Treasury Stock			Non-Controlling Interest
(In thousands)	Shares	Amount						Shares	Amount				Total
BALANCE - JANUARY 1, 2023	55,661	$	59	$	415,560	$	946,339	3,368	$	(114,626)	$	1,468	$	1,248,800
Issuance of common stock to employees and directors resulting from the exercise of stock options	145	1		2,653		—		—	—		—		2,654
Issuance of restricted stock, net of forfeitures	102	—		5,068		—		—	—		—		5,068
Shares of common stock used to satisfy tax withholding obligations	(1)	—		—		—		1	(20)		—		(20)
Dividends declared ($0.0575 per share)	—	—		—		(3,215)		—	—		—		(3,215)
Employee stock award compensation	—	—		6,573		—		—	—		—		6,573

Acquisition of noncontrolling interest shares	—	—		(77)		—		—	—		—		(77)
Net income attributable to noncontrolling interest	—	—		—		—		—	—		117		117
Noncontrolling interests attributable to subsidiary equity plan	—	—		6		—		—	—		(4)		2
Net income attributable to the Ensign Group, Inc.	—	—		—		59,852		—	—		—		59,852
BALANCE - MARCH 31, 2023	55,907	$	60	$	429,783	$	1,002,976	3,369	$	(114,646)	$	1,581	$	1,319,754
Issuance of common stock to employees and directors resulting from the exercise of stock options	253	—		5,905		—		—	—		—		5,905
Issuance of restricted stock, net of forfeitures	54	—		—		—		—	—		—		—
Shares of common stock used to satisfy tax withholding obligations	(21)	—		—		—		21	(1,909)		—		(1,909)
Dividends declared ($0.0575 per share)	—	—		—		(3,231)		—	—		—		(3,231)
Employee stock award compensation	—	—		8,881		—		—	—		—		8,881

Acquisition of noncontrolling interest shares	—	—		(100)		—		—	—		—		(100)
Net income attributable to noncontrolling interest	—	—		—		—		—	—		97		97
Noncontrolling interests attributable to subsidiary equity plan	—	—		(3,937)		—		—	—		3,940		3
Net income attributable to the Ensign Group, Inc.	—	—		—		63,993		—	—		—		63,993
BALANCE - JUNE 30, 2023	56,193	$	60	$	440,532	$	1,063,738	3,390	$	(116,555)	$	5,618	$	1,393,393
Issuance of common stock to employees and directors resulting from the exercise of stock options	180	—		4,148		—		—	—		—		4,148
Issuance of restricted stock, net of forfeitures	40	—		—		—		—	—		—		—

Dividends declared ($0.0575 per share)	—	—		—		(3,243)		—	—		—		(3,243)
Employee stock award compensation	—	—		7,230		—		—	—		—		7,230

Acquisition of noncontrolling interest shares	—	—		(57)		—		—	—		—		(57)
Net income attributable to noncontrolling interest	—	—		—		—		—	—		105		105
Noncontrolling interests attributable to subsidiary equity plan	—	—		30		—		—	—		(27)		3
Net income attributable to the Ensign Group, Inc.	—	—		—		63,863		—	—		—		63,863
BALANCE - SEPTEMBER 30, 2023	56,413	$	60	$	451,883	$	1,124,358	3,390	$	(116,555)	$	5,696	$	1,465,442

Table of Contents


	Common Stock			Additional Paid-In Capital		Retained Earnings		Treasury Stock			Non-Controlling Interest
(In thousands)	Shares	Amount						Shares	Amount				Total
BALANCE - JANUARY 1, 2022	55,190	$	58	$	369,760	$	733,992	2,944	$	(83,042)	$	946	$	1,021,714
Issuance of common stock to employees and directors resulting from the exercise of stock options	147	—		2,768		—		—	—		—		2,768
Issuance of restricted stock, net of forfeitures	104	—		5,241		—		—	—		—		5,241
Shares of common stock used to satisfy tax withholding obligations	—	—		—		—		—	(15)		—		(15)
Dividends declared ($0.0550 per share)	—	—		—		(3,042)		—	—		—		(3,042)
Employee stock award compensation	—	—		5,167		—		—	—		—		5,167
Repurchase of common stock (Note 20)	(133)	—		—		—		133	(9,882)		—		(9,882)
Acquisition of noncontrolling interest shares	—	—		245		—		—	—		(271)		(26)
Net loss attributable to noncontrolling interest	—	—		—		—		—	—		(252)		(252)

Net income attributable to the Ensign Group, Inc.	—	—		—		50,340		—	—		—		50,340
BALANCE - MARCH 31, 2022	55,308	$	58	$	383,181	$	781,290	3,077	$	(92,939)	$	423	$	1,072,013
Issuance of common stock to employees and directors resulting from the exercise of stock options	223	—		3,303		—		—	—		—		3,303
Issuance of restricted stock, net of forfeitures	38	—		—		—		—	—		—		—
Shares of common stock used to satisfy tax withholding obligations	(20)	—		—		—		20	(1,687)		—		(1,687)
Dividends declared ($0.0550 per share)	—	—		—		(3,040)		—	—		—		(3,040)
Employee stock award compensation	—	—		5,616		—		—	—		—		5,616
Repurchase of common stock (Note 20)	(271)	—		—		—		271	(20,000)		—		(20,000)
Issuance of noncontrolling interests through subsidiary equity plan	—	—		6,693		—		—	—		—		6,693
Net income attributable to noncontrolling interest	—	—		—		—		—	—		112		112
Noncontrolling interests attributable to subsidiary equity plan	—	—		—		—		—	—		(8)		(8)
Net income attributable to the Ensign Group, Inc.	—	—		—		57,691		—	—		—		57,691
BALANCE - JUNE 30, 2022	55,278	$	58	$	398,793	$	835,941	3,368	$	(114,626)	$	527	$	1,120,693
Issuance of common stock to employees and directors resulting from the exercise of stock options	151	—		2,635		—		—	—		—		2,635
Issuance of restricted stock, net of forfeitures	36	—		—		—		—	—		—		—
Shares of common stock used to satisfy tax withholding obligations	—	—		—		—		—	—		—		—
Dividends declared ($0.0550 per share)	—	—		—		(3,051)		—	—		—		(3,051)
Employee stock award compensation	—	—		5,898		—		—	—		—		5,898
Acquisition of noncontrolling interest shares	—	—		(1,774)		—		—	—		1,105		(669)
Repurchase of common stock (Note 19)	—					—							—
Net income attributable to noncontrolling interest	—	—		—		—		—	—		63		63
Noncontrolling interests attributable to subsidiary equity plan	—	—		3		—		—	—		(3)		—
Net income attributable to the Ensign Group, Inc.	—	—		—		56,179		—	—		—		56,179
BALANCE - SEPTEMBER 30, 2022	55,465	$	58	$	405,555	$	889,069	3,368	$	(114,626)	$	1,692	$	1,181,748

See accompanying notes to condensed consolidated financial statements.

Table of Contents

THE ENSIGN GROUP, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS


	Nine Months Ended September 30,
(In thousands)	2023		2022
Cash flows from operating activities:
Net income	$	188,027	$	164,133

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	53,154		45,475

Amortization of deferred financing fees	802		770

Non-cash leasing arrangement	692		351

Write-off of deferred financing fees	—		566
Deferred income taxes	(325)		(585)
Provision for doubtful accounts	3,081		2,301
Stock-based compensation	22,691		16,681
Cash received from insurance proceeds	1,396		—
Gain on sale of assets	—		(3,467)
(Gain)/loss on insurance claims, legal adjustments and asset disposals	(1,813)		5,499

Change in operating assets and liabilities
Accounts receivable	(66,630)		(27,552)
Prepaid income taxes	4,643		(9,846)
Prepaid expenses and other assets	1,459		(8,479)

Cash surrender value of life insurance policy premiums	(11,723)		(5,378)
Deferred compensation liability	11,663		5,371
Operating lease obligations	(6,345)		215
Accounts payable	704		4,878
Accrued wages and related liabilities	24,700		14,307
Income taxes payable	40,781		—
Other accrued liabilities	11,387		5,163
Accrued self-insurance liabilities	13,090		11,968
Other long-term liabilities	(37)		(34)
NET CASH PROVIDED BY OPERATING ACTIVITIES	$	291,397	$	222,337


Cash flows from investing activities:
Purchase of property and equipment	(77,360)		(59,735)
Cash payments for business acquisitions (Note 7)	—		(16,400)
Cash payments for asset acquisitions (Note 7)	(53,684)		(65,699)
Escrow deposits	(325)		(8,287)

Cash from insurance proceeds	1,129		1,143
Cash proceeds from the sale of assets	48		8,626


Purchases of investments	(20,538)		(15,497)
Maturities of investments	12,103		11,905
Other restricted assets	873		173
NET CASH USED IN INVESTING ACTIVITIES	$	(137,754)	$	(143,771)



Cash flows from financing activities:
Proceeds from debt (Note 15)	—		211
Payments on debt (Note 15)	(2,917)		(2,908)


Issuance of common stock upon exercise of options	12,707		8,706
Repurchase of shares of common stock to satisfy tax withholding obligations	(1,929)		(1,702)

Repurchase of shares of common stock (Note 20)	—		(29,882)
Dividends paid	(9,647)		(9,118)


Proceeds from sale of subsidiary shares (Note 6)	—		6,693
Non-controlling interest distribution	(4)		(11)
Purchase of non-controlling interest	(234)		(695)
Payments of deferred financing costs	(19)		(3,197)



NET CASH USED IN FINANCING ACTIVITIES	$	(2,043)	$	(31,903)


Net increase in cash and cash equivalents	151,600		46,663
Cash and cash equivalents beginning of period	316,270		262,201
Cash and cash equivalents end of period	$	467,870	$	308,864

Table of Contents


	Nine Months Ended September 30,
(In thousands)	2023		2022
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION

Cash paid during the period for:
Interest	$	5,287	$	5,800
Income taxes	$	8,480	$	57,880
Lease liabilities	$	146,162	$	110,942
Non-cash financing and investing activity
Accrued capital expenditures	$	4,100	$	4,200



Right-of-use assets obtained in exchange for new and modified operating lease obligations	$	373,832	$	254,742

See accompanying notes to condensed consolidated financial statements.

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars, shares and options in thousands, except per share data)

1. DESCRIPTION OF BUSINESS

The Company — The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company's independent operating subsidiaries provide health care services across the post-acute care continuum and engage in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties and other ancillary businesses. As of September 30, 2023, the Company's independent operating subsidiaries operated 295 facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The Company's independent operating subsidiaries have a collective capacity of approximately 30,500 operational skilled nursing beds and 3,000 senior living units. As of September 30, 2023, the Company's independent operating subsidiaries operated 213 facilities under long-term lease arrangements, and had options to purchase 11 of those 213 facilities. The Company's real estate portfolio includes 112 owned real estate properties, which includes 82 facilities operated and managed by the Company's independent operating subsidiaries, 30 operations leased to and operated by third party operators, and the Service Center location. Of those 30 operations, one senior living facility is located on the same real estate property as a skilled nursing facility that the Company owns and operates.

Certain of the Company’s wholly owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly owned captive insurance subsidiary that provides some claims-made coverage to the Company’s operating subsidiaries for general and professional liabilities, as well as coverage for certain workers’ compensation insurance liabilities.

In 2022, the Company formed a captive real estate investment trust (REIT), which owns and manages its real estate business, called Standard Bearer Healthcare REIT, Inc. (Standard Bearer). The REIT structure provides the Company with an efficient vehicle for future acquisitions of properties that could be operated by Ensign affiliates or other third parties. Refer to Note 6, Standard Bearer for additional information on Standard Bearer.

Each of the Company's affiliated operations are operated by separate, wholly owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Quarterly Report is not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.

Other Information — The accompanying condensed consolidated financial statements as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 (collectively, the Interim Financial Statements) are unaudited. Certain information and note disclosures normally included in the annual consolidated financial statements have been condensed or omitted, as permitted under applicable rules and regulations. Readers of the Interim Financial Statements should refer to the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2022 which are included in the Company’s Annual Report on Form 10-K, File No. 001-33757 (the Annual Report) filed with the Securities and Exchange Commission (SEC). Management believes that the Interim Financial Statements reflect all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position and results of operations in all material respects. The results of operations presented in the Interim Financial Statements are not necessarily representative of operations for the entire year.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation — The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interests in its condensed consolidated statements of income.

The Interim Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Estimates and Assumptions — The preparation of the Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities and income taxes. Actual results could differ from those estimates.

Fair Value of Financial Instruments —The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, deferred compensation investment funds, equity investments, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations.

Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions. See Note 5, Fair Value Measurements for additional information.

Service Revenue Recognition — The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606). The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to patients at the amount that reflects the consideration that the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services provided pursuant to skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services that are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.

Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration that is included in the transaction price may be constrained, and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.

Rental Revenue Recognition — The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue for operating leases is recognized on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, Leases (ASC 842). The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met.

Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under the new lease standards. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s condensed consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.

Accounts Receivable — Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Property and Equipment — Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.

Leases and Leasehold Improvements — The Company leases skilled nursing facilities, senior living facilities and commercial office space. The Company determines if an arrangement is a lease and performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of September 30, 2023, the Company has one financing lease that is not material to the condensed consolidated balance sheets. Rights and obligations of these leases are included as right-of-use assets, current and long-term lease liabilities on the Company's condensed consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate.

The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.

The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional ten to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The Company subleases skilled nursing facilities to third-party operators and considers the subleases to be separate contracts because the Company is not relieved of its primary obligation under its operating lease. The rental income from third-parties related to these subleases is presented on a gross basis from the rent expense associated with the Company's lease obligations and is not material to the condensed consolidated statements of income.

Impairment of Long-Lived Assets — The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and determined there was no impairment during the three and nine months ended September 30, 2023 and 2022.

Intangible Assets and Goodwill — Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.

The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year. Management has evaluated its intangible assets and determined there was no impairment during the three and nine months ended September 30, 2023 and 2022.

Self-Insurance — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,250 for California affiliated operations and a separate, one-time, deductible of $1,250 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.

The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider.

The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $90,811 and $79,781 as of September 30, 2023 and December 31, 2022, respectively.

The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $28,733 and $27,301 as of September 30, 2023 and December 31, 2022, respectively.

In addition, the Company has recorded an asset and corresponding liability of $13,439 and $10,512 as of September 30, 2023 and December 31, 2022, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12, Restricted and Other Assets.

The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal year 2023. As of September 30, 2023 and December 31, 2022, the Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $14,716 and $14,088, respectively.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.

Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.

In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.

Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer believes it has been organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions.

Noncontrolling Interest — The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.

Stock-Based Compensation — The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.

3. REVENUE AND ACCOUNTS RECEIVABLE

Disaggregation of Revenue

The Company disaggregates revenue from contracts with its patients by payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Revenue by Payor

The Company’s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rates, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed.

Revenue from the Medicare and Medicaid programs accounted for 72.1% and 72.8% for the three and nine months ended September 30, 2023, respectively, and 73.7% and 73.5% for the three and nine months ended September 30, 2022. Settlements with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on the final settlement. The Company recorded adjustments to revenue which were not material to the Company's revenue for the three and nine months ended September 30, 2023 and 2022.

Service revenue for the three and nine months ended September 30, 2023 and 2022 is summarized in the following tables:



	Three Months Ended September 30,
	2023				2022
	Revenue		% of Revenue		Revenue		% of Revenue
Medicaid(1)	$	374,838	40.1	%	$	302,615	39.5	%
Medicare	237,531		25.4		211,104		27.6
Medicaid — skilled	62,452		6.6		50,643		6.6
Total Medicaid and Medicare	674,821		72.1		564,362		73.7
Managed care	170,747		18.3		132,663		17.3
Private and other(2)	89,756		9.6		68,858		9.0
SERVICE REVENUE	$	935,324	100.0	%	$	765,883	100.0	%

(1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.



	Nine Months Ended September 30,
	2023				2022
	Revenue		% of Revenue		Revenue		% of Revenue
Medicaid(1)	$	1,074,883	39.3	%	$	863,091	39.2	%
Medicare	733,335		26.8		610,009		27.7
Medicaid — skilled	182,394		6.7		146,355		6.6
Total Medicaid and Medicare	1,990,612		72.8		1,619,455		73.5
Managed care	488,511		17.9		389,036		17.7
Private and other(2)	254,220		9.3		194,895		8.8
SERVICE REVENUE	$	2,733,343	100.0	%	$	2,203,386	100.0	%

(1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $5,467 and $15,634, respectively, for the three and nine months ended September 30, 2023 and $4,122 and $12,550, respectively, for the three and nine months ended September 30, 2022.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

State relief funding

The Company receives state relief funding through Medicaid programs from various states, including healthcare relief funding under the American Rescue Plan Act (ARPA), increases in the Federal Medical Assistance Percentage (FMAP) under the Families First Coronavirus Response Act (FFCRA) and other state specific relief programs. The funding generally incorporates specific use requirements primarily for direct patient care including labor related expenses that are attributable to the COVID-19 pandemic or are associated with providing patient care.

Revenues from these additional payments are recognized in accordance with ASC 606, subject to variable consideration constraints. In certain operations where the Company received additional payments that exceeded expenses incurred related to specific qualifiers, the Company recorded deferred revenue for the excess amount until additional expenses are incurred for recognition. Accordingly, the amount of state relief revenue recognized is limited to the actual related expenses incurred. As of September 30, 2023 and December 31, 2022, the Company had $636 and $1,001 in unapplied state relief funds, respectively. During the three and nine months ended September 30, 2023, the Company received $9,900 and $54,744 in state relief funding and recognized $10,298 and $55,109, respectively, as revenue. During the three and nine months ended September 30, 2022, the Company received $20,293 and $64,955 in state relief funding and recognized $21,400 and $63,488, respectively, as revenue.

Balance Sheet Impact

Included in the Company’s condensed consolidated balance sheets are contract balances, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities and contract assets as of September 30, 2023 and December 31, 2022, or activity during the three and nine months ended September 30, 2023 and 2022.

Accounts receivable as of September 30, 2023 and December 31, 2022, is summarized in the following table:




	September 30, 2023		December 31, 2022
Medicaid	$	188,572	$	157,878
Managed care	118,756		95,940
Medicare	75,717		76,526
Private and other payors	98,500		85,890
	481,545		416,234
Less: allowance for doubtful accounts	(9,422)		(7,802)
ACCOUNTS RECEIVABLE, NET	$	472,123	$	408,432

4. COMPUTATION OF NET INCOME PER COMMON SHARE

Basic net income per share is computed by dividing income from operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
NUMERATOR:
Net income	$	63,968	$	56,242	$	188,027	$	164,133
Less: net income (loss) attributable to noncontrolling interests	105		63		319		(77)
Net income attributable to The Ensign Group, Inc.	$	63,863	$	56,179	$	187,708	$	164,210





DENOMINATOR:
Weighted average shares outstanding for basic net income per share	55,829		54,882		55,582		54,819

Basic net income per common share:	$	1.14	$	1.02	$	3.38	$	3.00

A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
NUMERATOR:
Net income	$	63,968	$	56,242	$	188,027	$	164,133
Less: net income (loss) attributable to noncontrolling interests	105		63		319		(77)
Net income attributable to The Ensign Group, Inc.	$	63,863	$	56,179	$	187,708	$	164,210





DENOMINATOR:
Weighted average common shares outstanding	55,829		54,882		55,582		54,819
Plus: incremental shares from assumed conversion (1)	1,508		1,879		1,663		2,010
Adjusted weighted average common shares outstanding	57,337		56,761		57,245		56,829

Diluted net income per common share:	$	1.11	$	0.99	$	3.28	$	2.89

(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 1,475 and 1,389 for the three and nine months ended September 30, 2023, respectively, and 918 and 734 for the three and nine months ended September 30, 2022, respectively.

5. FAIR VALUE MEASUREMENTS

The Company's financial assets include the captive insurance subsidiary's deposits and investments designated to support long-term insurance subsidiary liabilities and are carried at a cost basis of $57,290 and $53,924 as of September 30, 2023 and December 31, 2022, respectively. Also included are contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans that are held in a rabbi trust. The cash surrender value of these contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. As of September 30, 2023, and December 31, 2022, the adjusted cost basis of the investment funds was $36,867 and $25,144, respectively.

As of September 30, 2023 and December 31, 2022, the cost basis of the Company's financial assets included in the captive insurance subsidiary's investments and deferred compensation plan investment funds are considered to approximate the fair value of these financial assets and are derived using Level 2 inputs. Additionally, the Company has other investments, which are not material, where the fair value is derived using Level 3 inputs. The Company believes its investments that were in an unrealized loss position as of September 30, 2023 and December 31, 2022 do not require an allowance for expected credit losses, nor has any event occurred through the filing date of this report that would indicate differently.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value.

6. STANDARD BEARER

Standard Bearer's real estate portfolio consists of 107 of the Company's 112 owned real estate properties, of which 78 are operated and managed by the Company and 30 are leased to and operated by third party operators. Of those 30 operations, one senior living facility is located on the same real estate property as a skilled nursing facility that the Company owns and operates. Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022.

During the nine months ended September 30, 2023, Standard Bearer acquired the real estate of three stand-alone skilled nursing facilities and one campus operation for an aggregate purchase price of $52,802. Of these additions, the three skilled nursing facilities acquired are operated by the Company's affiliated operating subsidiaries and the campus operation is leased to a third party operator. During the nine months ended September 30, 2022, Standard Bearer acquired the real estate of eight skilled nursing facilities for an aggregate purchase price of $65,619, three of which were previously operated and managed by Ensign's affiliated operations. Refer to Note 7, Operation Expansions, for additional information.

As part of the formation of Standard Bearer, certain of the Company's operating subsidiaries, Standard Bearer and Standard Bearer's subsidiaries entered into several agreements that include leasing, management services and debt arrangements between the operations. All intercompany transactions have been eliminated in consolidation. Refer to Note 8, Business Segments, for additional information related to these intercompany eliminations as well as Standard Bearer as a reportable segment.

Intercompany master lease agreements

Certain of the Company's operating subsidiaries and the 78 Standard Bearer subsidiaries have entered into five triple-net master lease agreements (collectively, the Standard Bearer Master Leases). The lease periods range from 15 to 19 years with three five-year renewal options beyond the initial term, on the same terms and conditions. The rent structure under the Standard Bearer Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the operating subsidiaries are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties; (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Rental revenue generated from Ensign affiliated operations was $16,976 and $49,035 for the three and nine months ended September 30, 2023, respectively, and $15,024 and $42,343 for the three and nine months ended September 30, 2022, respectively.

Intercompany management agreement

Standard Bearer has no employees. The Service Center provides personnel and services to Standard Bearer pursuant to the management agreement between Standard Bearer and the Service Center. The management agreement provides for a base management fee that is equal to 5% of total rental revenue and an incentive management fee that is equal to 5% of funds from operations (FFO) and is capped at 1% of total rental revenue, for a total of 6%. Management fee generated between Standard Bearer and the Service Center for the three and nine months ended September 30, 2023 was $1,259 and $3,636, respectively. Management fees generated between Standard Bearer and the Service Center for the three and nine months ended September 30, 2022 was $1,124 and $3,202, respectively.

Intercompany debt arrangements

Standard Bearer obtains its funding through various sources including operating cash flows, access to debt arrangements and intercompany loans. The intercompany debt arrangements include mortgage loans and the Credit Facility to fund acquisitions and working capital needs. The interest rate under the Amended Credit Agreement is a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

In addition, as the Department of Housing and Urban Development (HUD) mortgage loans and promissory note are entered into by real estate subsidiaries of Standard Bearer, the interest expense incurred from these debts are included in Standard Bearer's segment income. Refer to Note 15, Debt, for additional information related to these debts.

Equity Instrument Denominated in the Shares of a Subsidiary

As part of the formation of Standard Bearer in January of 2022, the Company established the Standard Bearer Healthcare REIT, Inc. 2022 Omnibus Incentive Plan (Standard Bearer Equity Plan). The Company may grant stock options and restricted stock awards under the Standard Bearer Equity Plan to employees and management of Ensign's affiliated subsidiaries. These awards generally vest over a period of five years or upon the occurrence of certain prescribed events. The value of the stock options and restricted stock awards is tied to the value of the common stock of Standard Bearer, which is determined based on an independent valuation of Standard Bearer. The awards can be put to Standard Bearer at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination. In the second quarter of 2022, Standard Bearer sold fully vested common shares from the Standard Bearer Equity Plan to shareholders for cash of $6,544. During the nine months ended September 30, 2023 and 2022, the Company did not grant any stock options nor restricted shares under the Standard Bearer Equity Plan.

Also in the second quarter of 2022, Standard Bearer established shareholders of its preferred shares through contributions of cash of $149. These preferred shares were fully vested at the time of the contributions by the shareholders. The value of Standard Bearer common and preferred shares held by the Company are eliminated in consolidation and the value held by other shareholders are classified as noncontrolling interests on the Company's condensed consolidated balance sheets.

7. OPERATION EXPANSIONS

The expansion focus of the Company's subsidiaries is to purchase or lease operations that are complementary to the current affiliated operations, accretive to the business, or otherwise advance the Company's strategy. The results of all operating subsidiaries are included in the Interim Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's affiliated operations also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, a real estate affiliated subsidiary will acquire the property of facilities that have previously been operated under third-party leases.

2023 Expansions

During the nine months ended September 30, 2023, the Company expanded its operations and real estate portfolio through a combination of long-term leases and real estate purchases, with the addition of 24 stand-alone skilled nursing operations. Of these additions, Standard Bearer acquired the real estate of three of the stand-alone skilled nursing operations, which were leased back to Ensign affiliated entities. Refer to Note 6, Standard Bearer, for additional information on the purchase of real estate properties. These new operations added a total of 2,340 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses.

In connection with the new operations obtained through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with each prior operator as part of each transaction.

Subsequent to September 30, 2023, the Company expanded its operations through a long-term lease, with the addition of one stand-alone skilled nursing operation. This new operation added 45 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

2022 Expansions

During the nine months ended September 30, 2022, the Company expanded its operations and real estate portfolio through a combination of long-term leases and real estate purchases, with the addition of 11 stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of five of the stand-alone skilled nursing operations, which was leased back to Ensign affiliated entities. Refer to Note 6, Standard Bearer, for additional information on the purchases of real estate properties. In addition, the Company added five senior living operations that were transferred from The Pennant Group, Inc. (Pennant), three of which are part of campuses operated by the Company's affiliated operating subsidiaries. These new operations added a total of 1,553 operational skilled nursing beds and 674 operational senior living units to be operated by the Company's affiliated operating subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses.

Of the new operations acquired during the nine months ended September 30, 2022, $16,400 was concentrated in goodwill and accordingly, the transactions were classified as business combinations.

The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operations added by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operations, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired operating subsidiaries. The assets added during the nine months ended September 30, 2023 were not material operations to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These additions have been included in the September 30, 2023 condensed consolidated balance sheets of the Company, and the operating results have been included in the condensed consolidated statements of operations of the Company since the date the Company gained effective control.

8. BUSINESS SEGMENTS

The Company has two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators.

As of September 30, 2023, the skilled services segment includes 258 skilled nursing operations and 26 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. The Company's Standard Bearer segment consists of 107 owned real estate properties.

The Company also reports an “All Other” category that includes results from its senior living operations, which includes eleven stand-alone senior living operations and the senior living operations at 26 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. In addition, the "All Other" category includes mobile diagnostics, medical transportation, other real estate and other ancillary operations. Services included in the “All Other” category are insignificant individually, and therefore do not constitute a reportable segment.

The Company’s reportable segments are significant operating segments that offer differentiated services. The Company's CODM reviews financial information for each operating segment to evaluate performance and allocate capital resources. This structure reflects its current operational and financial management and provides the best structure to maximize the quality of care and investment strategy provided, while maintaining financial discipline. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.

The accounting policies of the reportable segments are the same as those described in Note 2, Summary of Significant Accounting Policies. Intercompany revenue is eliminated in consolidation, along with corresponding intercompany expenses. Segment income and loss is defined as profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate, real estate insurance recoveries and losses and impairment charges from operations. Included in segment income for Standard Bearer is expense for intercompany services provided by the Service Center as described in Note 6, Standard Bearer, as it is part of the CODM financial information.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The following tables set forth financial information for the segments:



	Three Months Ended September 30, 2023
	Skilled Services		Standard Bearer		All Other(1)		Intercompany Elimination		Total
Service revenue(2)	$	902,967	$	—	$	36,254	$	(3,897)	$	935,324
Rental revenue(3)	—		20,980		2,870		(18,383)		5,467
TOTAL REVENUE	$	902,967	$	20,980	$	39,124	$	(22,280)	$	940,791
Segment income (loss)	117,816		7,165		(42,936)		—		82,045

Income before provision for income taxes									$	82,045
Depreciation and amortization	9,936		6,429		2,081		—		18,446
Interest expense(4)	$	—	$	5,139	$	312	$	(3,427)	$	2,024

(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.

(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.

(3) All Other rental revenue includes rental revenue associated with the Company's subleases to third parties of $1,063 for the three months ended September 30, 2023. Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.

(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column.


	Three Months Ended September 30, 2022
	Skilled Services		Standard Bearer		All Other (1)		Intercompany Elimination		Total
Service revenue(2)	$	739,318	$	—	$	30,002	$	(3,437)	$	765,883
Rental revenue(3)	—		18,732		1,842		(16,452)		4,122
TOTAL REVENUE	$	739,318	$	18,732	$	31,844	$	(19,889)	$	770,005
Segment income (loss)	101,750		6,941		(37,036)		—		71,655
Gain on sale of assets, net									800
Income before provision for income taxes									$	72,455
Depreciation and amortization	8,397		5,561		1,983		—		15,941
Interest expense(4)	$	—	$	4,080	$	310	$	(2,282)	$	2,108

(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.

(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.



	Nine Months Ended September 30, 2023
	Skilled Services		Standard Bearer		All Other (1)		Intercompany Elimination		Total
Service revenue(2)	$	2,638,090	$	—	$	106,322	$	(11,069)	$	2,733,343
Rental revenue(3)	—		60,611		8,252		(53,229)		15,634
TOTAL REVENUE	$	2,638,090	$	60,611	$	114,574	$	(64,298)	$	2,748,977
Segment income (loss)	348,169		21,517		(128,106)		—		241,580
Loss on real estate insurance recoveries									(100)
Income before provision for income taxes									$	241,480
Depreciation and amortization	28,417		18,528		6,209		—		53,154
Interest expense(4)	$	—	$	14,283	$	927	$	(9,127)	$	6,083

(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(3) All Other rental revenue includes rental revenue associated with the Company's subleases to third parties of $2,834 for the nine months ended September 30, 2023. Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.



	Nine Months Ended September 30, 2022
	Skilled Services		Standard Bearer		All Other (1)		Intercompany Elimination		Total
Service revenue(2)	$	2,128,567	$	—	$	84,256	$	(9,437)	$	2,203,386
Rental revenue(3)	—		53,523		5,537		(46,510)		12,550
TOTAL REVENUE	$	2,128,567	$	53,523	$	89,793	$	(55,947)	$	2,215,936
Segment income (loss)	302,272		20,679		(114,580)		—		208,371
Gain on sale of assets, net									3,267
Income before provision for income taxes									$	211,638
Depreciation and amortization	24,411		15,798		5,266		—		45,475
Interest expense	$	—	$	11,385	$	1,557	$	(6,078)	$	6,864

(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.

Service revenue by major payor source were as follows:


	Three Months Ended September 30, 2023
	Skilled Services		All Other (3)		Total Service Revenue		Revenue %
Medicaid(1)	$	367,079	$	7,759	$	374,838	40.1	%
Medicare	237,531		—		237,531		25.4
Medicaid-skilled	62,452		—		62,452		6.6
Subtotal	667,062		7,759		674,821		72.1
Managed care	170,747		—		170,747		18.3
Private and other(2)	65,158		24,598		89,756		9.6
TOTAL SERVICE REVENUE	$	902,967	$	32,357	$	935,324	100.0	%

(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

(3) All Other incorporates intercompany eliminations.


	Three Months Ended September 30, 2022
	Skilled Services		All Other (3)		Total Service Revenue		Revenue %
Medicaid(1)	$	295,927	$	6,688	$	302,615	39.5	%
Medicare	211,104		—		211,104		27.6
Medicaid-skilled	50,643		—		50,643		6.6
Subtotal	557,674		6,688		564,362		73.7
Managed care	132,663		—		132,663		17.3
Private and other(2)	48,981		19,877		68,858		9.0
TOTAL SERVICE REVENUE	$	739,318	$	26,565	$	765,883	100.0	%

(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

(3) All Other incorporates intercompany eliminations.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)



	Nine Months Ended September 30, 2023
	Skilled Services		All Other (3)		Total Service Revenue		Revenue %
Medicaid(1)	$	1,052,904	$	21,979	$	1,074,883	39.3	%
Medicare	733,335		—		733,335		26.8
Medicaid-skilled	182,394		—		182,394		6.7
Subtotal	1,968,633		21,979		1,990,612		72.8
Managed care	488,511		—		488,511		17.9
Private and other(2)	180,946		73,274		254,220		9.3
TOTAL SERVICE REVENUE	$	2,638,090	$	95,253	$	2,733,343	100.0	%

(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

(3) All Other incorporates intercompany eliminations.



	Nine Months Ended September 30, 2022
	Skilled Services		All Other (3)		Total Service Revenue		Revenue %
Medicaid(1)	$	845,341	$	17,750	$	863,091	39.2	%
Medicare	610,009		—		610,009		27.7
Medicaid-skilled	146,355		—		146,355		6.6
Subtotal	1,601,705		17,750		1,619,455		73.5
Managed care	389,036		—		389,036		17.7
Private and other(2)	137,826		57,069		194,895		8.8
TOTAL SERVICE REVENUE	$	2,128,567	$	74,819	$	2,203,386	100.0	%

(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

(3) All Other incorporates intercompany eliminations.

9. PROPERTY AND EQUIPMENT - NET

Property and equipment, net consists of the following:




	September 30, 2023		December 31, 2022
Land	$	140,239	$	134,864
Buildings and improvements	790,333		728,231
Leasehold improvements	166,984		150,903
Equipment	334,999		295,739
Furniture and fixtures	4,868		4,544
Construction in progress	21,993		17,521
	1,459,416		1,331,802
Less: accumulated depreciation	(391,514)		(339,792)
PROPERTY AND EQUIPMENT, NET	$	1,067,902	$	992,010

The Company completed the sale of assets for a sale price of $8,607 and recorded a gain of $3,467 within the Company's condensed consolidated statement of income as cost of services during the nine months ended September 30, 2022. See also Note 6, Standard Bearer and Note 7, Operation Expansions for information on acquisitions during the nine months ended September 30, 2023.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

10. INTANGIBLE ASSETS - NET




	Weighted Average Life (Years)	September 30, 2023						December 31, 2022

		Gross Carrying Amount		Accumulated Amortization				Gross Carrying Amount		Accumulated Amortization
Intangible Assets						Net						Net


Assembled occupancy	0.3	$	702	$	(570)	$	132	$	435	$	(388)	$	47
Facility trade name	30.0	733		(433)		300		733		(415)		318
Customer relationships	18.4	4,582		(2,639)		1,943		4,582		(2,482)		2,100
TOTAL		$	6,017	$	(3,642)	$	2,375	$	5,750	$	(3,285)	$	2,465

During the three and nine months ended September 30, 2023, amortization expense was $495 and $1,256, respectively, of which $303 and $899 was related to the amortization of right-of-use assets, respectively. During the three and nine months ended September 30, 2022, amortization expense was $432 and $1,254, respectively, of which $289 and $866 was related to the amortization of right-of-use assets, respectively.

Estimated amortization expense for each of the years ending December 31 is as follows:


Year	Amount
2023 (remainder)	$	192
2024	234
2025	234
2026	234
2027	234
2028	234
Thereafter	1,013
	$	2,375

Other indefinite-lived intangible assets consist of the following:



	September 30, 2023		December 31, 2022

Trade name	$	889	$	889
Medicare and Medicaid licenses	3,083		3,083
TOTAL	$	3,972	$	3,972

11. GOODWILL

The Company anticipates that the majority of goodwill recognized will be fully deductible for tax purposes as of September 30, 2023. Provided that goodwill corresponds to the acquisition of a business and not merely the acquisition of real estate property, the Company's Standard Bearer segment appropriately does not carry a goodwill balance. The following table represents activity in goodwill by skilled service segment and "all other" category as of September 30, 2023 and December 31, 2022:



	Skilled Services		All Other		Total










Goodwill	$	67,886	$	8,983	$	76,869


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

12. RESTRICTED AND OTHER ASSETS

Restricted and other assets consist of the following:



	September 30, 2023		December 31, 2022

Debt issuance costs, net	$	3,104	$	3,753
Long-term insurance losses recoverable asset	13,439		10,512

Capital improvement reserves with landlords and lenders	5,051		6,446

Deposits with landlords	2,657		2,527
Escrow deposits	325		—
Other	11,403		14,053

RESTRICTED AND OTHER ASSETS	$	35,979	$	37,291

Included in restricted and other assets as of September 30, 2023 and December 31, 2022 are anticipated insurance recoveries related to the Company's workers' compensation and general and professional liability claims that are recorded on a gross, rather than net, basis.

13. OTHER ACCRUED LIABILITIES

Other accrued liabilities consists of the following:


	September 30, 2023		December 31, 2022

Quality assurance fee	$	8,786	$	7,701
Refunds payable	46,274		40,783
Resident advances	5,920		9,698
Unapplied state relief funds	636		1,001
Cash held in trust for patients	6,357		6,400

Dividends payable	3,243		3,201
Property taxes	15,371		10,926
Income tax payable	40,781		—
Legal finding accrued	3,734		4,553
Other	17,026		13,046
OTHER ACCRUED LIABILITIES	$	148,128	$	97,309

Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the condensed consolidated balance sheets.

14. INCOME TAXES

The Company recorded income tax expense of $53,453 and $47,505 during the nine months ended September 30, 2023 and 2022, respectively, or 22.1% of earnings before income taxes for the nine months ended September 30, 2023, compared to 22.4% for the nine months ended September 30, 2022. The effective tax rate for both periods is driven by the impact of excess tax benefits from stock-based compensation, offset by non-deductible expenses including non-deductible compensation.

The Company is not currently under examination by any major income tax jurisdiction. During 2023, the statutes of limitations will lapse on the Company's 2019 federal tax year and certain 2018 and 2019 state tax years. The Company does not believe the federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the Interim Financial Statements for the nine months ended September 30, 2023 and 2022.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

15. DEBT

Debt consists of the following:




	September 30, 2023		December 31, 2022


Mortgage loans and promissory note	$	153,354	$	156,271

Less: current maturities	(3,916)		(3,883)
Less: debt issuance costs, net	(2,985)		(3,119)
LONG-TERM DEBT LESS CURRENT MATURITIES	$	146,453	$	149,269

Credit Facility with a Lending Consortium Arranged by Truist

The Company maintains a revolving credit facility between the Company and its subsidiaries, including Standard Bearer as co-borrowers, and Truist Securities (Truist) (the Credit Facility) with a revolving line of credit of up to $600,000 in aggregate principal amount with a maturity date of April 8, 2027. Borrowings are supported by a lending consortium arranged by Truist. The interest rates applicable to loans under the Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the credit agreement). In addition, there is a commitment fee on the unused portion of the commitments that ranges from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio. When the Company amended the Credit Facility in 2022 with the terms and conditions described above, it wrote off deferred financing costs of $566 and additional deferred financing costs of $3,197 were capitalized during the nine months ended September 30, 2022.

Borrowings made under the Credit Facility are guaranteed, jointly and severally, by certain of the Company’s wholly owned subsidiaries, and are secured by a pledge of stock of the Company's material operating subsidiaries as well as a first lien on substantially all of such operating subsidiaries' personal property. The credit agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. The Company must comply with financial maintenance covenants to be tested quarterly, consisting of (i) a maximum consolidated total net debt to consolidated EBITDA ratio (which shall not be greater than 3.00:1.00; provided that if the aggregate consideration for approved acquisitions in a six month period is greater than $50,000, then the ratio can be increased at the election of the Company with notice to the administrative agent to 3.50:1.00 for the first fiscal quarter and the immediately following three fiscal quarters), and (ii) a minimum interest/rent coverage ratio (which cannot be less than 1.50:1.00). As of September 30, 2023, there was no outstanding debt under the Credit Facility. The Company was in compliance with all loan covenants as of September 30, 2023.

Mortgage Loans and Promissory Note

The Company has 23 subsidiaries that have mortgage loans insured with HUD in the aggregate amount of $151,063, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates in a range of 3.1% to 4.2%, including fixed interest rates in a range of 2.4% to 3.3% per annum. In addition to the interest rate, the Company incurs other fees for HUD placement, including but not limited to audit fees. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees based on the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10.0% and is reduced by 3.0% in the fourth year of the loan, and reduced by 1.0% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms for all the mortgage loans are 25 to 35 years.

In addition to the HUD mortgage loans above, the Company has a promissory note of $2,291 that bears a fixed interest rate of 5.3% per annum and has a term of 12 years. The note, which was assumed as part of an acquisition, is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility.

Based on Level 2 inputs, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Off-Balance Sheet Arrangements

As of September 30, 2023, the Company had approximately $6,710 of borrowing capacity under the Credit Facility pledged as collateral to secure outstanding letters of credit.

16. OPTIONS AND AWARDS

Stock-based compensation expense consists of stock-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s condensed consolidated statements of income for the three and nine months ended September 30, 2023 and 2022 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.

2022 Omnibus Incentive Plan (2022 Plan) — The Company has one active stock incentive plan, the 2022 Omnibus Incentive Plan (the 2022 Plan). Including the shares rolled over from the 2017 Plan, the 2022 Plan provides for the issuance of 3,452 shares of common stock. The number of shares available to be issued under the 2022 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) two shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Non-employee director options, to the extent granted, will vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years from the date of grant. At September 30, 2023, the total number of shares available for issuance under the 2022 Plan was 1,856.

The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for stock option awards. Determining the appropriate fair-value model and calculating the fair value of stock option awards at the grant date requires judgment, including estimating stock price volatility, expected option life, and forfeiture rates. The fair-value of the restricted stock awards at the grant date is based on the market price on the grant date, adjusted for forfeiture rates. The Company develops estimates based on historical data which can change significantly over time.

Stock Options

The Company granted 193 and 606 stock options during the three and nine months ended September 30, 2023, respectively. The Company used the following assumptions for stock options granted during the three months ended September 30, 2023 and 2022:



Grant Year	Options Granted	Weighted Average Risk-Free Rate	Expected Life	Weighted Average Volatility	Weighted Average Dividend Yield
2023	193	4.4%	6.1 years	41.3%	0.2%
2022	145	3.1%	6.3 years	41.8%	0.2%

The Company used the following assumptions for stock options granted during the nine months ended September 30, 2023 and 2022:



Grant Year	Options Granted	Weighted Average Risk-Free Rate	Expected Life	Weighted Average Volatility	Weighted Average Dividend Yield
2023	606	4.0%	6.2 years	41.4%	0.3%
2022	463	2.5%	6.2 years	42.1%	0.3%

For the nine months ended September 30, 2023 and 2022, the following represents the exercise price and fair value displayed at grant date for stock option grants:


Grant Year	Granted	Weighted Average Exercise Price		Weighted Average Fair Value of Options
2023	606	$	92.54	$	42.50
2022	463	$	83.41	$	36.22


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the nine month periods ended September 30, 2023 and 2022 and therefore, the intrinsic value was $0 at the date of grant.

The following table represents the employee stock option activity during the nine months ended September 30, 2023:


	Number of Options Outstanding	Weighted Average Exercise Price		Number of Options Vested	Weighted Average Exercise Price of Options Vested












January 1, 2023	3,833	$	46.72	2,069	$	28.87
Granted	606	92.54
Forfeited	(77)	69.64
Exercised	(578)	21.99
September 30, 2023	3,784	$	57.37	1,960	$	37.69

The aggregate intrinsic value of options outstanding, vested and expected to vest as of September 30, 2023 and December 31, 2022 is as follows:



Options	September 30, 2023		December 31, 2022


Outstanding	$	135,648	$	183,593
Vested	108,275		136,000
Expected to vest	25,910		43,232

The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options. The aggregate intrinsic value of options that vested during the nine months ended September 30, 2023 and 2022 was $16,856 and $15,810, respectively. The total intrinsic value of options exercised during the nine months ended September 30, 2023 and 2022 was $43,299 and $36,151, respectively.

Restricted Stock Awards

The Company granted 49 and 215 restricted stock awards during the three and nine months ended September 30, 2023, respectively. The Company granted 41 and 199 restricted stock awards during the three and nine months ended September 30, 2022, respectively. All awards were granted at an issue price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the nine months ended September 30, 2023 and 2022 ranged from $89.83 to $98.31 and $73.17 to $90.50, respectively. The fair value per share includes quarterly stock awards to non-employee directors.

A summary of the status of the Company's non-vested restricted stock awards as of September 30, 2023 and changes during the nine months ended September 30, 2023 is presented below:


	Non-Vested Restricted Awards	Weighted Average Grant Date Fair Value








Nonvested at January 1, 2023	487	$	64.92
Granted	215	91.96
Vested	(225)	64.29
Forfeited	(19)	70.64
Nonvested at September 30, 2023	458	$	77.81

During the three and nine months ended September 30, 2023, the Company granted 4 and 13 automatic quarterly stock awards to non-employee directors for their service on the Company's board of directors, respectively. The fair value per share of these stock awards ranged from $89.94 to $98.31 based on the market price on the grant date.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Long-Term Incentive Plan

On August 27, 2019, the Board approved the Long-Term Incentive Plan (the 2019 LTI Plan). The 2019 LTI Plan provides that certain employees of the Company who assisted in the consummation of the spin-off of Pennant from the Company in 2019 (spin-off transaction) were granted shares of restricted stock upon successful completion of the spin-off transaction. The 2019 LTI Plan provides for the issuance of 500 shares of Pennant restricted stock. The shares are vested over five years at 20% per year on the anniversary of the grant date. If a recipient is terminated or voluntarily leaves the Company, all shares subject to restriction or not yet vested shall be entirely forfeited. The total stock-based compensation related to the 2019 LTI Plan was approximately $218 and $620 for the three and nine months ended September 30, 2023, respectively, compared to $248 and $638 for the three and nine months ended September 30, 2022, respectively.

Stock-based compensation expense

Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the three and nine months ended September 30, 2023 and 2022 was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Stock-based compensation expense related to stock options	$	4,051	$	2,983	$	12,439	$	8,289
Stock-based compensation expense related to restricted stock awards	2,774		2,579		8,983		7,337
Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors	405		336		1,262		1,055
TOTAL	$	7,230	$	5,898	$	22,684	$	16,681

In future periods, the Company expects to recognize approximately $54,532 and $32,210 in stock-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of September 30, 2023. Future stock-based compensation expense will be recognized over 3.8 and 3.6 weighted average years for unvested options and restricted stock awards, respectively. There were 1,824 unvested and outstanding options as of September 30, 2023, of which 1,667 shares are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest as of September 30, 2023 was 6.5 years.

17. LEASES

The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 affiliated skilled nursing and senior living facilities used in the Company’s operations, 96 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and been continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024.

The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense under the Master Leases was approximately $16,741 and $49,698 for the three and nine months ended September 30, 2023, respectively, and $16,259 and $47,911 for the three and nine months ended September 30, 2022, respectively.

Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of September 30, 2023.

In connection with the spin-off transaction that occurred in 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued.

The Company leases certain affiliated operations and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $50,480 and $147,126 for the three and nine months ended September 30, 2023, respectively, and $38,940 and $111,976 for the three and nine months ended September 30, 2022, respectively.

Eighty of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under 13 separate master lease arrangements. In the first quarter of 2023, the Company expanded its operations through two separate master lease arrangements for 20 stand-alone skilled nursing operations, of which 17 are operated by the Company's affiliated operating subsidiaries and the remaining three are subleased to a third-party operator. These two master leases increased the lease liabilities and right-of-use assets by $325,369 to reflect the new lease obligations and have initial lease terms of 18 and 20 years. In the third quarter of 2023, the Company expanded its operations through one separate master lease arrangement for two stand-alone skilled nursing operations. This master lease increased the lease liabilities and right-of-use assets by $21,420 to reflect the new lease obligations and has an initial lease terms of 20 years. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.

The components of operating lease expense are as follows:




	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Rent - cost of services(1)	$	50,357	$	38,907	$	146,754	$	111,897
General and administrative expense	123		33		372		79
Depreciation and amortization(2)	303		289		899		866
Variable lease costs(3)	5,376		4,121		15,362		13,256
	$	56,159	$	43,350	$	163,387	$	126,098

(1) Rent- cost of services includes deferred rent expense adjustments of $211 and $692 for the three and nine months ended September 30, 2023, respectively, and $111 and of $351 for the three and nine months ended September 30, 2022, respectively. Additionally, rent- cost of services includes other variable lease costs such as CPI increases and short-term leases of $2,859 and $7,317 for the three and nine months ended September 30, 2023, respectively, and $1,758 and $3,997 for the three and nine months ended September 30, 2022, respectively.

(2) Depreciation and amortization is related to the amortization of favorable and direct lease costs.

(3) Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Future minimum lease payments for all leases as of September 30, 2023 are as follows:


Year	Amount
2023 (remainder)	$	47,730
2024	191,035
2025	190,946
2026	190,729
2027	190,147
2028	188,906
Thereafter	1,719,921
TOTAL LEASE PAYMENTS	2,719,414
Less: present value adjustment	(980,503)
PRESENT VALUE OF TOTAL LEASE LIABILITIES	1,738,911
Less: current lease liabilities	(80,956)
LONG-TERM OPERATING LEASE LIABILITIES	$	1,657,955

Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of September 30, 2023, the weighted average remaining lease term is 15.1 years and the weighted average discount rate used to determine the operating lease liabilities is 6.5%.

Subsequent to September 30, 2023, the Company expanded its operations through a long-term lease arrangement with the addition of one stand-alone skilled nursing facility, adding a total of 45 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries.

Lessor Activities

The Company leases its owned real estate properties to third party operators, of which 29 senior living operations are operated by The Pennant Group, Inc. (Pennant). All of these properties are triple-net leases, whereby the respective tenants are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range between 14 to 16 years.

During the first quarter of 2023, the Company entered into a sublease agreement for three stand-alone skilled nursing operations with a third-party operator with an initial lease term of 18 years. Additionally, during the three months ended September 30, 2023, the Company entered into a lease agreement with a third-party operator for one campus operation with an initial lease term of 15 years.

Total rental income from all third-party sources for the three and nine months ended September 30, 2023 and 2022 is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Pennant(1)	$	3,740	$	3,664	$	11,224	$	11,169
Other third-party	1,727		458		4,410		1,381
TOTAL	$	5,467	$	4,122	$	15,634	$	12,550

(1) Pennant rental income includes variable rent such as property taxes of $324 and $974 during the three and nine months ended September 30, 2023, respectively, and $331 and $988 for the three and nine months ended September 30, 2022, respectively. In addition, the number of senior living operations leased to and operated by Pennant was 29 during the nine months ended September 30, 2023 and decreased from 32 to 29 during the nine months ended September 30, 2022.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Future annual rental income for all leases as of September 30, 2023 were as follows:


Year	Amount(1)
2023 (remainder)	$	5,493
2024	21,526
2025	21,023
2026	20,788
2027	20,762
2028	20,737
Thereafter	128,013
TOTAL	$	238,342

(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of September 30, 2023.

18. DEFINED CONTRIBUTION PLANS

The Company has a 401(k) defined contribution plan (the 401(k) Plan), whereby eligible employees may contribute up to 90% of their annual basic earnings, subject to applicable annual Internal Revenue Code limits. Additionally, the 401(k) Plan provides for discretionary matching contributions (as defined in the 401(k) Plan) by the Company.

The Company has a non-qualified deferred compensation plan (the DCP), whereby certain highly compensated employees who are otherwise ineligible to participate in the Company's 401(k) plan, may defer the receipt of a portion of their base compensation and, for certain employees, up to 100% of their eligible bonuses. Additionally, the DCP allows for the employee deferrals to be deposited into a rabbi trust and the funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to fund savings plans of this nature. The Company paid for related administrative costs, which were not significant during three and nine months ended September 30, 2023 and 2022.

As of September 30, 2023 and December 31, 2022, the Company accrued $42,613 and $33,017, respectively, as long term deferred compensation in other long term liabilities on the consolidated balance sheet. Cash surrender value of the contracts is based on investment funds that shadow the investment allocations specified by participants in the deferred compensation plan. Refer to Note 5, Fair Value Measurements for more information on the funds.

For the three months ended September 30, 2023, the Company recorded a loss related to its DCP of $1,424, which is included in other income (expense), net, and recorded an offsetting reduction in expense of $1,352, which is allocated between cost of services and general and administrative expenses. For the nine months ended September 30, 2023, the company recorded a gain related to its DCP of $1,065, which is included in other income (expense), net, and recorded an offsetting expense of $1,261, which is allocated between cost of services and general and administrative expenses.

For the three and nine months ended September 30, 2022, the Company recorded a loss related to its DCP of $1,135 and $5,650, respectively, which is included in other income (expense), net. During the same periods, the Company recorded an offsetting reduction in expense of $1,055 and $5,566, respectively, which is allocated between cost of services and general and administrative expenses.

19. COMMITMENTS AND CONTINGENCIES

Regulatory Matters — Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is monitoring performed by the Office of Civil Rights which covers the Health Insurance Portability and Accountability Act of 1996, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.

Cost-Containment Measures — Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Indemnities — From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental obligations or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent operating subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and others, under which the Company may be required to indemnify such persons for liabilities arising out of the nature of their relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s condensed consolidated balance sheets for any of the periods presented.

In connection with the spin-off transaction in 2019, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the transaction. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties.

U.S. Department of Justice Civil Investigative Demand — On May 31, 2018, the Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice (DOJ) stating that it was investigating whether there had been a violation of the False Claims Act (FCA) and/or the Anti-Kickback Statute (AKS) with respect to relationships between certain of the Company’s independently operated skilled nursing facilities and persons who serve or have served as medical directors. The Company fully cooperated with the DOJ and promptly responded to its requests for information. In April 2020, the Company was advised that the DOJ declined to intervene in any subsequent action filed in connection with the subject matter of this investigation. Despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator has moved forward with the lawsuit. The Company is vigorously defending this lawsuit, but expects the costs of defense to be significant given the nature of the allegations and the date range contemplated by the complaint. At this time, the Company is unable to estimate the range of loss and cannot predict the final outcome of this lawsuit. If this lawsuit is ultimately resolved against the Company, the amounts owed, including fines, penalties and other consequences relating to the lawsuit, could have a material adverse effect on the Company's results of operations, financial condition and cash flows. As a general matter, the Company’s independent operating entities have established and maintain policies and procedures to promote compliance with the FCA, the AKS, and other applicable regulatory requirements.

U.S. House of Representatives Select Subcommittee Request — In 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company received a document and information request from the House Select Subcommittee in connection with its investigation. The Company cooperated in responding to this inquiry. In July 2022 and thereafter, the Company received follow up requests for additional documents and information. The Company responded to these requests and continued to cooperate with the House Select Subcommittee in connection with its investigation. On December 9, 2022, the House Select Subcommittee issued its final report summarizing its investigation and related recommendations designed "to strengthen the nation's ability to prevent and respond to public health and economic emergencies." According to the information provided by the House Select Subcommittee, the issuance of this report was the House Select Subcommittee's final official act.

Litigation — The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents served by the Company's independent operating subsidiaries. The Company, its independent operating subsidiaries, and others in the industry are subject to an increasing number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. In addition, the Company, its independent operating subsidiaries, and others in the industry are subject to claims and lawsuits in connection with COVID-19 and a facility's preparation for and/or response to COVID-19. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

In addition to the potential lawsuits and claims described above, the Company and its independent operating subsidiaries are also subject to potential lawsuits under the FCA and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from federally funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Under the qui tam or "whistleblower" provisions of the FCA, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the federal Government and receive a percentage of the federal Government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. For example, and despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator has moved forward with the lawsuit and is pursuing claims that the Company and certain of its independent operating subsidiaries allegedly violated the FCA and/or AKS. The Company is vigorously defending this lawsuit, but expects the costs of defense to be significant given the nature of the allegations and the date range contemplated by the complaint.

In addition to the FCA, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the FCA. As such, the Company and its independent operating subsidiaries could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent operating subsidiaries do business.

In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) which made significant changes to the FCA and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a FCA violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.

Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent operating subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements, and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations.

Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent operating subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and related causes of action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company’s business, cash flows, financial condition or results of operations.

The Company and its independent operating subsidiaries have been, and continue to be, subject to claims, findings and legal actions that arise in the ordinary course of the various businesses, including healthcare and non-healthcare services. These claims include, but are not limited to, potential claims filed by residents, customers, patients and responsible parties related to patient care and treatment (professional negligence claims); non-care based activities of certain of the subsidiaries; and employment related claims filed by current or former employees. A significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. In addition, these claims could impact the Company's ability to procure insurance to cover its exposure related to the various services provided by its independent operating subsidiaries to their residents, customers and patients.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The Company and its independent operating subsidiaries are also subject to requests for information and investigations by other state and federal governmental entities (e.g., Offices of the Attorney General and Offices of the Inspector General). The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent operating subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under federal Medicare statutes, the FCA, or similar state and federal statutes and related regulations, or if the Company or its independent operating subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations, and may also include the assumption of specific procedural and financial obligations by the Company or its independent operating subsidiaries under a Corporate Integrity Agreement and/or other such arrangement.

Medicare Revenue Recoupments — The Company's independent operating subsidiaries are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate (TPE) Program. Beginning in August 2020, CMS resumed TPE Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. The Company anticipates that these Reviews could increase in frequency in the future. As of September 30, 2023 and through the filing date of this report, 41 of the Company's independent operating subsidiaries had Reviews scheduled or in process.

CMS announced a new nationwide audit, the “SNF 5-Claim Probe & Educate Review”, in which the Medicare Administrative Contractors (MACs) will review five claims from each SNF to check for compliance. In implementing this SNF 5-Claim Probe & Educate Review, CMS acknowledged that the increase in observed improper payments from 2021 to 2022 may have arisen from a "misunderstanding" by SNFs about how to appropriately bill for claims of service after October 1, 2019. All facilities that are not undergoing TPE reviews, or have not recently passed a TPE review, will be subject to the nationwide audit. MACs will complete only one round of probe-and-educate for each SNF, rather than three rounds that typically occur in the TPE Program. Additionally, CMS's education for each SNF will be individualized and based on observed claim review errors, with rationales for denial explained to the SNF on a claim-by-claim basis. This program applies only to claims submitted after October 1, 2019, and will exclude claims containing a COVID-19 diagnosis.

Concentrations

Credit Risk — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary.

The Company’s receivables from Medicare and Medicaid payor programs accounted for 54.9% and 56.3% of its total accounts receivable as of September 30, 2023 and December 31, 2022, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 72.1% and 72.8% of the Company's revenue for the three and nine months ended September 30, 2023, respectively, and 73.7% and 73.5% for the three and nine months ended September 30, 2022.

Cash in Excess of FDIC Limits — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of September 30, 2023, the Company's uninsured cash deposits are not material. All uninsured bank deposits are held at high quality credit institutions.

20. COMMON STOCK REPURCHASE PROGRAM

On August 29, 2023, the Board of Directors approved a stock repurchase program pursuant to which the Company may repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from September 1, 2023. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The Company did not purchase any shares pursuant to this stock repurchase program during the three months ended September 30, 2023.


Table of Contents			THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company may repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from August 2, 2022. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program does not obligate the Company to acquire any specific number of shares. The stock repurchase program expired on August 2, 2023 and is no longer in effect. The Company did not purchase any shares pursuant to this stock repurchase program.

On February 9, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from February 10, 2022. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the three months ended June 30, 2022, the Company repurchased 271 shares of its common stock for $20,000. This repurchase program expired in 2022 upon the repurchase of the fully authorized amount under the plan and is no longer in effect.

On October 21, 2021, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from October 29, 2021. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the first quarter of 2022, the Company repurchased 133 shares of its common stock for $9,882 pursuant to this stock repurchase program. This repurchase program expired in 2022 upon the repurchase of the fully authorized amount under the plan and is no longer in effect.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the Interim Financial Statements and accompanying notes, which appear elsewhere in this Quarterly Report on Form 10-Q. We urge you to carefully review and consider the various disclosures made by us in this Quarterly Report and in our other reports filed with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2022 (Annual Report), which discusses our business and related risks in greater detail, as well as subsequent reports we may file from time to time on Form 10-Q and Form 8-K, for additional information. The section entitled “Risk Factors” contained in Part II, Item 1A of this Quarterly Report on Form 10-Q, and similar discussions in our other SEC filings, also describe some of the important risk factors that may affect our business, financial condition, results of operations and/or liquidity. You should carefully consider those risks, in addition to the other information in this Quarterly Report on Form 10-Q and in our other filings with the SEC, before deciding to purchase, hold or sell our common stock.

This Quarterly Report on Form 10-Q contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, which include, but are not limited to our expected future financial position, results of operations, cash flows, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities, and plans and objectives of management. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” similar expressions, and variations or negatives of these words. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results could differ materially from those expressed in any forward-looking statements as a result of various factors, some of which are listed under the section “Risk Factors” contained in Part II, Item 1A of this Quarterly Report on Form 10-Q. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q, and are based on our current expectations, estimates and projections about our industry and business, management’s beliefs, and certain assumptions made by us, all of which are subject to change. We undertake no obligation to revise or update publicly any forward-looking statement for any reason, except as otherwise required by law.

Table of Contents

As used in this Management’s Discussion and Analysis of Financial Condition and Results of Operations, the words, "Ensign," "Company," “we,” “our” and “us” refer to The Ensign Group, Inc. and its consolidated subsidiaries. All of our affiliated operations, the Service Center, our wholly owned captive insurance subsidiary and our captive real estate investment trust (REIT) called Standard Bearer Healthcare REIT, Inc. (Standard Bearer) are operated by separate, wholly owned, independent subsidiaries that have their own management, employees and assets. The use of "Ensign," "Company," “we,” “us,” “our” and similar verbiage in this Quarterly Report on Form 10-Q is not meant to imply that any of our affiliated operations, the Service Center, the captive insurance subsidiary or Standard Bearer are operated by the same entity. This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our Interim Financial Statements included in this Quarterly Report.

Overview

We are a provider of health care services across the post-acute care continuum. We engage in the operation, ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare related properties and other ancillary businesses located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Our operating subsidiaries, each of which strives to be the operation of choice in the community it serves, provide a broad spectrum of skilled nursing, senior living and other ancillary services. As of September 30, 2023, we offered skilled nursing, senior living and rehabilitative care services through 295 skilled nursing and senior living facilities. Our real estate portfolio includes 112 owned real estate properties, which includes 82 facilities operated and managed by us, 30 operations leased to and operated by third party operators, and the Service Center location. Of the 30 real estate operations leased to third party operators, one senior living facility is located on the same real estate property as a skilled nursing facility that we own and operate.

The following table summarizes our affiliated facilities and operational skilled nursing beds and senior living units by ownership status as of September 30, 2023:


	Owned and Operated		Leased (with a Purchase Option)		Leased (without a Purchase Option)		Total for Facilities Operated
Number of facilities	82		11		202		295
Percentage of total	27.8	%	3.7	%	68.5	%	100.0	%
Operational skilled nursing beds	8,128		1,145		21,196		30,469
Percentage of total	26.7	%	3.8	%	69.5	%	100.0	%
Senior living units	1,682		178		1,143		3,003
Percentage of total	56.0	%	5.9	%	38.1	%	100.0	%

Ensign is a holding company with no direct operating assets, employees or revenues. Our operating subsidiaries are operated by separate, independent entities, each of which has its own management, employees and assets. In addition, certain of our wholly owned subsidiaries, referred to collectively as the Service Center, provide centralized accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. We also have a wholly owned captive insurance subsidiary that provides some claims-made coverage to our operating subsidiaries for general and professional liability, as well as coverage for certain workers’ compensation insurance liabilities and our captive real estate trust owns and operates our real estate portfolio. Our captive real estate investment trust, Standard Bearer, owns and manages our real estate business. References herein to the consolidated “Company” and “its” assets and activities, as well as the use of the terms “we,” “us,” “our” and similar terms in this Quarterly Report, are not meant to imply, nor should they be construed as meaning, that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries are operated by The Ensign Group.

Recent Activities

Operational Update — On May 11, 2023, the United States Department of Health and Human Services (HHS) ended the public health emergency (PHE). Our primary focus has always been and continues to be the health and safety of our patients, residents, employees and their respective families. Even with the end of the PHE, we continue to implement new measures and maintain existing ones to provide the safest possible environment within our sites of service, taking into consideration the vulnerable nature of our patients.

Table of Contents

We continue to execute on key initiatives to rebuild occupancy lost due to the pandemic. Our combined Same Facilities and Transitioning Facilities occupancy is 79.2%, which represents a 2.9% increase compared to the prior year quarter and is closer to our pre-pandemic occupancy levels, which was 80.1% in March 2020. As we shift to an endemic, we anticipate the return of our seasonal occupancy and skilled mix. Throughout most of our history, our seasonality trends for skilled nursing occupancy and skilled mix typically included the greatest growth during the first and fourth quarters and softening in the second and third quarters. The seasonal impact coupled with certain Emergency Waivers expiring have contributed to shift our acuity towards pre-pandemic levels. Nevertheless, the innovative approaches and strategic partnerships developed during the pandemic have supported our occupancy improvements and continue to enable us to gain additional market share. These key initiatives together with our dedication to our cultural and operational fundamentals resulted in a strong third quarter.

We receive state relief funding from various states, including healthcare relief funding under the American Rescue Plan Act (ARPA), increases in the Federal Medical Assistance Percentage (FMAP) under the Families First Coronavirus Response Act (FFCRA) and other state specific relief programs. We use this funding, which reimburses the recipient, for healthcare and labor related patient care services and expenses that are attributable to the COVID-19 pandemic. The end of the PHE created a gradual phase down of the temporary increase in FMAP funding until it is completely phased out at the end of 2023. State specific approaches have been developed including various states having increased their base rates to account for increases in expenses in the post-pandemic environment.

During the three and nine months ended September 30, 2023, we recognized $10.3 million and $55.1 million, respectively, of combined state relief funding as revenue. During the three and nine months ended September 30, 2022, we recognized $21.4 million and $63.5 million, respectively, of combined state relief funding as revenue.

Common Stock Repurchase Program — On August 29, 2023, the Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from September 1, 2023. We did not repurchase any shares during the third quarter of 2023.

Facility Information

The following table sets forth the location of our operated and owned facilities by type as well as the number of beds and units located at operated and owned facilities as of September 30, 2023:

Table of Contents


	TX	CA	AZ	UT	CO	WA	ID	SC	NE	IA	KS	NV	WI	Total
Number of operated facilities
Skilled nursing operations	77	67	30	18	19	15	11	9	4	4	—	2	2	258
Senior living operations	1	—	1	2	5	1	—	—	1	—	—	—	—	11
Campuses(1)	4	3	5	1	1	—	1	—	2	2	7	—	—	26
Number of owned and operated facilities
Skilled nursing properties	18	10	9	7	5	4	5	5	1	—	—	—	2	66
Senior living communities	1	—	—	—	3	—	—	—	1	—	—	—	—	5
Campuses(1)	2	1	4	—	—	—	—	—	—	—	4	—	—	11
Number of operated beds/units
Operational skilled nursing beds	9,856	6,764	4,517	1,976	1,986	1,436	999	1,126	413	368	570	358	100	30,469
Senior living units	509	197	735	163	723	98	21	—	313	31	213	—	—	3,003
Number of owned and operated beds/units
Owned skilled nursing beds	2,279	1,185	1,596	669	457	413	468	544	88	—	329	—	100	8,128
Owned Senior living units	443	42	335	—	459	—	—	—	274	—	129	—	—	1,682
Real estate properties leased to third party(2)
Skilled nursing and senior living properties	6	2	1	—	—	1	—	—	—	—	—	1	19	30
(1) Campuses represent facilities that offer both skilled nursing and senior living services. (2) Excludes three subleases to third parties in California.

During the nine months ended September 30, 2023, we expanded our operations through long-term leases, with the addition of 24 stand-alone skilled nursing operations. Of these additions, Standard Bearer acquired the real estate of three of the stand-alone skilled nursing operations, which were leased back to Ensign affiliated entities. These new operations added a total of 2,340 operational skilled nursing beds to be operated by our affiliated operating subsidiaries. We also invested in new ancillary services that are complementary to our existing businesses. Additionally, Standard Bearer acquired the real estate of one campus operation, which is leased to a third party operator.

Subsequent to September 30, 2023, we expanded our operations through a long-term lease, with the addition of one stand-alone skilled nursing operation. This new operation added 45 operational skilled nursing beds to be operated by our affiliated operating subsidiaries. For further discussion of our real estate properties and expansions, see Note 6 and 7, Standard Bearer and Operation Expansions in the Notes to the Interim Financial Statements.

Key Performance Indicators

We manage the fiscal aspects of our business by monitoring key performance indicators that affect our financial performance. Revenue associated with these metrics is generated based on contractually agreed-upon amounts or rate, excluding the estimates of variable consideration under the revenue recognition standard, Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606. These indicators and their definitions include the following:

Skilled Services

•Routine revenue — Routine revenue is generated by the contracted daily rate charged for all contractually inclusive skilled nursing services. The inclusion of therapy and other ancillary treatments varies by payor source and by contract. Services provided outside of the routine contractual agreement are recorded separately as ancillary revenue, including Medicare Part B therapy services, and are not included in the routine revenue definition.

Table of Contents

•Skilled revenue - The amount of routine revenue generated from patients in the skilled nursing facilities who are receiving higher levels of care under Medicare, managed care, Medicaid, or other skilled reimbursement programs. The other skilled patients who are included in this population represent very high acuity patients who are receiving high levels of nursing and ancillary services which are reimbursed by payors other than Medicare or managed care. Skilled revenue excludes any revenue generated from our senior living services.

•Skilled mix — The amount of our skilled revenue as a percentage of our total skilled nursing routine revenue. Skilled mix (in days) represents the number of days our Medicare, managed care, or other skilled patients are receiving skilled nursing services at the skilled nursing facilities divided by the total number of days patients from all payor sources are receiving skilled nursing services at the skilled nursing facilities for any given period.

•Average daily rates — The routine revenue by payor source for a period at the skilled nursing facilities divided by actual patient days for that revenue source for that given period. These rates exclude additional state relief funding, which includes ARPA, FFCRA and other state relief programs.

•Occupancy percentage (operational beds) — The total number of patients occupying a bed in a skilled nursing facility as a percentage of the beds in a facility which are available for occupancy during the measurement period.

•Number of facilities and operational beds — The total number of skilled nursing facilities that we own or operate and the total number of operational beds associated with these facilities.

Skilled Mix — Like most skilled nursing providers, we measure both patient days and revenue by payor. Medicare, managed care and other skilled patients, whom we refer to as high acuity patients, typically require a higher level of skilled nursing and rehabilitative care. Accordingly, Medicare and managed care reimbursement rates are typically higher than from other payors. In most states, Medicaid reimbursement rates are generally the lowest of all payor types. Changes in the payor mix can significantly affect our revenue and profitability.

The following table summarizes our overall skilled mix from our skilled nursing services for the periods indicated as a percentage of our total skilled nursing routine revenue and as a percentage of total skilled nursing patient days:


	Three Months Ended September 30,				Nine Months Ended September 30,
Skilled Mix:	2023		2022		2023		2022
Days	29.1	%	31.6	%	30.7	%	32.1	%
Revenue	48.4	%	51.6	%	50.6	%	52.3	%

Occupancy — We define occupancy derived from our skilled services as the ratio of actual patient days (one patient day equals one patient occupying one bed for one day) during any measurement period to the number of beds in facilities which are available for occupancy during the measurement period. The number of beds in a skilled nursing facility that are actually operational and available for occupancy may be less than the total official licensed bed capacity. This sometimes occurs due to the permanent dedication of bed space to alternative purposes, such as enhanced therapy treatment space or other desirable uses calculated to improve service offerings and/or operational efficiencies in a facility. In some cases, three- and four-bed wards have been reduced to two-bed rooms for resident comfort, and larger wards have been reduced to conform to changes in Medicare requirements. These beds are seldom expected to be placed back into service. We believe that reporting occupancy based on operational beds is consistent with industry practices and provides a more useful measure of actual occupancy performance from period to period.

The following table summarizes our overall occupancy statistics for skilled nursing operations for the periods indicated:


	Three Months Ended September 30,				Nine Months Ended September 30,
Occupancy for skilled services:	2023		2022		2023		2022
Operational beds at end of period	30,469		26,630		30,469		26,630
Available patient days	2,778,007		2,440,900		8,128,137		7,047,179
Actual patient days	2,190,540		1,846,699		6,363,107		5,287,690
Occupancy percentage (based on operational beds)	78.9	%	75.7	%	78.3	%	75.0	%

Table of Contents

Segments

We have two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of select properties owned by us through our captive REIT and leased to skilled nursing and senior living operations, including our own operating subsidiaries and third-party operators.

We also reported an “all other” category that includes operating results from our senior living operations, mobile diagnostics, transportation, other real estate and other ancillary operations. These businesses are neither significant individually, nor in aggregate and therefore do not constitute a reportable segment. Our Chief Executive Officer, who is our chief operating decision maker, or CODM, reviews financial information at the operating segment level.

Revenue Sources

The following table sets forth our total service revenue by payor source generated by our skilled services segment and our "All Other" category and as a percentage of total revenue for the periods indicated (dollars in thousands):



	Three Months Ended September 30,
	Skilled Services				All Other (3)				Total Service Revenue
	2023		2022		2023		2022		2023		2022
Medicaid(1)	$	367,079	$	295,927	$	7,759	$	6,688	$	374,838	$	302,615
Medicare	237,531		211,104		—		—		237,531		211,104
Medicaid-skilled	62,452		50,643		—		—		62,452		50,643
Subtotal	667,062		557,674		7,759		6,688		674,821		564,362
Managed care	170,747		132,663		—		—		170,747		132,663
Private and other(2)	65,158		48,981		24,598		19,877		89,756		68,858
TOTAL SERVICE REVENUE	$	902,967	$	739,318	$	32,357	$	26,565	$	935,324	$	765,883


	Three Months Ended September 30,
	Skilled Services				All Other (3)				Total Service Revenue
	2023		2022		2023		2022		2023		2022
Medicaid(1)	40.7	%	40.0	%	24.0	%	25.2	%	40.1	%	39.5	%
Medicare	26.3		28.6		—		—		25.4		27.6
Medicaid-skilled	6.9		6.8		—		—		6.6		6.6
Subtotal	73.9		75.4		24.0		25.2		72.1		73.7
Managed care	18.9		17.9		—		—		18.3		17.3
Private and other(2)	7.2		6.7		76.0		74.8		9.6		9.0
TOTAL SERVICE REVENUE	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%

(1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.

(2) Private and other payors in our "all other" category includes revenue from senior living operations and all payors generated in our other ancillary operations.

(3) All Other incorporates intercompany eliminations.


	Nine Months Ended September 30,
	Skilled Services				All Other (3)	Total Service Revenue
	2023		2022			2023		2022		2023		2022
Medicaid(1)	$	1,052,904	$	845,341		$	21,979	$	17,750	$	1,074,883	$	863,091
Medicare	733,335		610,009			—		—		733,335		610,009
Medicaid-skilled	182,394		146,355			—		—		182,394		146,355
Subtotal	1,968,633		1,601,705			21,979		17,750		1,990,612		1,619,455
Managed care	488,511		389,036			—		—		488,511		389,036
Private and other(2)	180,946		137,826			73,274		57,069		254,220		194,895
TOTAL SERVICE REVENUE	$	2,638,090	$	2,128,567		$	95,253	$	74,819	$	2,733,343	$	2,203,386

Table of Contents


	Nine Months Ended September 30,
	Skilled Services				All Other (3)					Total Service Revenue
	2023		2022			2023		2022			2023		2022
Medicaid(1)	39.9	%	39.7	%		23.1	%	23.7	%		39.3	%	39.2	%
Medicare	27.8		28.7			—		—			26.8		27.7
Medicaid-skilled	6.9		6.8			—		—			6.7		6.6
Subtotal	74.6		75.2			23.1		23.7			72.8		73.5
Managed care	18.5		18.3			—		—			17.9		17.7
Private and other(2)	6.9		6.5			76.9		76.3			9.3		8.8
TOTAL SERVICE REVENUE	100.0	%	100.0	%		100.0	%	100.0	%		100.0	%	100.0	%

(1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.

(2) Private and other payors in our "all other" category includes revenue from senior living operations and all payors generated in our other ancillary operations.

(3) All Other incorporates intercompany eliminations.

Skilled Services

Within our skilled nursing operations, we generate revenue from Medicaid, private pay, managed care and Medicare payors. We believe that our skilled mix, which we define as the number of days Medicare, managed care and other skilled patients are receiving services at our skilled nursing operations divided by the total number of days patients are receiving services at our skilled nursing operations, from all payor sources (less days from senior living services) for any given period, is an important indicator of our success in attracting high-acuity patients because it represents the percentage of our patients who are reimbursed by Medicare, managed care and other skilled payors, for whom we receive higher reimbursement rates.

We are participating in supplemental payment programs in various states that provide supplemental Medicaid payments for skilled nursing facilities that are licensed to non-state government-owned entities such as city and county hospital districts. Numerous operating subsidiaries entered into transactions with various hospital districts providing for the transfer of the licenses for those skilled nursing facilities to the hospital districts. Each affected operating subsidiary agreement between the hospital district and our subsidiary is terminable by either party to fully restore the prior license status.

Standard Bearer

We generate rental revenue primarily by leasing post-acute care properties that we acquired, to healthcare operators under triple-net lease arrangements, whereby the tenant is solely responsible for the costs related to the property, including property taxes, insurance and maintenance and repair costs, subject to certain exceptions. As of September 30, 2023, our real estate portfolio within Standard Bearer is comprised of 107 real estate properties. Of these properties, 78 are leased to affiliated skilled nursing facilities wholly owned and managed by us and 30 are leased to facilities wholly owned and managed by third party operators. During the three and nine months ended September 30, 2023, we generated rental revenues of $21.0 million and $60.6 million, respectively, of which $17.0 million and $49.0 million, respectively, was derived from affiliated wholly owned healthcare operators and therefore eliminated in consolidation.

Other

Within our senior living operations, we generate revenue primarily from private pay sources, with a portion earned from Medicaid payors or through other state-specific programs. In addition, we hold majority membership interests in certain of our other ancillary operations. Payment for these services varies and is based upon the service provided. The payment is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk.

Critical Accounting Estimates

Our Interim Financial Statements included in this report have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The preparation of these financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, cash flows, revenues and expenses, and related disclosure of contingent assets and liabilities.

See Item 2., Management’s Discussion and Analysis of Financial Condition and Results of Operations, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 for further discussion of critical accounting estimates. There were no material changes to our critical accounting policies with which the estimates are developed since December 31, 2022.

Table of Contents

Industry Trends

The post-acute care industry has evolved to meet the growing demand for post-acute and custodial healthcare services generated by an aging population, increasing life expectancies and the trend toward shifting patient care to lower cost settings. The industry has evolved in recent years, which we believe has led to a number of favorable improvements in the industry, as described below:

•Shift of Patient Care to Lower Cost Alternatives — The growth of the senior population in the U.S. continues to increase healthcare costs, often faster than the available funding from government-sponsored healthcare programs. In response, federal and state governments have adopted cost-containment measures that encourage the treatment of patients in more cost-effective settings such as skilled nursing facilities, for which the staffing requirements and associated costs are often significantly lower than acute care hospitals and other post-acute care settings. As a result, skilled nursing facilities are generally serving a larger population of higher-acuity patients than in the past.

•Significant Acquisition and Consolidation Opportunities — The skilled nursing industry is large and highly fragmented, characterized predominantly by numerous local and regional providers. Due to the increasing demands from hospitals and insurance carriers to implement sophisticated and expensive reporting systems, we believe this fragmentation provides us with significant acquisition and consolidation opportunities.

•Improving Supply and Demand Balance — The number of skilled nursing facilities has declined modestly over the past several years. We expect that the supply and demand balance in the skilled nursing industry will continue to improve due to the shift of patient care to lower cost settings, an aging population and increasing life expectancies.

•Increased Demand Driven by Aging Populations — As seniors account for an increasing percentage of the total U.S. population, we believe the demand for skilled nursing and senior living services will continue to increase. According to the census projection released by the U.S. Census Bureau in early 2020, between 2016 and 2030, the number of individuals over 65 years old is projected to be one of the fastest growing segments of the United States population, growing from 15% to 21%. The Bureau expects this segment to increase nearly 50% to 73 million, as compared to the total U.S. population which is projected to increase by 10% over that time period. Furthermore, the generation currently retiring has accumulated less savings than prior generations, creating demand for more affordable senior housing and skilled nursing services. As a high-quality provider in lower cost settings, we believe we are well-positioned to benefit from this trend.

•Transition to Value-Based Payment Models — In response to rising healthcare spending in the United States, commercial, government and other payors are generally shifting away from fee-for-service (FFS) payment models towards value-based models, including risk-based payment models that tie financial incentives to quality, efficiency and coordination of care. We believe that patient-centered outcomes driven reimbursement models will continue to grow in prominence. Many of our operations already receive value-based payments, and as valued-based payment systems continue to increase in prominence, it is our view that our strong clinical outcomes will be increasingly rewarded.

•Accountable Care Organizations and Reimbursement Reform — A significant goal of U.S. federal health care reform is to transform the delivery of health care by changing reimbursement to reflect and support the quality and safety of care that providers deliver, increase efficiency and reduce growth in spending. Reimbursement models that provide financial incentives to encourage efficiency, affordability and high-quality care have been developed and implemented by government and commercial third-party payers. The most prolific of these models, the Accountable Care Organization (ACO) model, incentivizes groups of providers to share in savings that are achieved through the coordination of care and chronic disease management of an assigned patient population. Reimbursement methodology reform includes Value-Based Purchasing (VBP), in which a portion of provider reimbursement is redistributed based on relative performance, or improvement on designated economic, clinical quality and patient satisfaction metrics. In addition, the Centers for Medicare and Medicaid Services (CMS) has implemented Episode-based demonstration, voluntary and mandatory payment initiatives that bundle acute care and post-acute care reimbursement. These bundled payment models incentivize cross-continuum care coordination and include financial and performance accountability for episodes of care. These reimbursement methodologies and similar programs are likely to continue and expand, both in government and commercial health plans. Many of our operations already participate in ACOs. With our focus on quality care and strong clinical outcomes, Ensign is well-positioned to benefit from these outcome-based payment models.

We believe the post-acute industry has been and will continue to be impacted by several other trends. The use of long-term care insurance is increasing among seniors as a means of planning for the costs of skilled nursing services. In addition, as a result of increased mobility in society, reduction of average family size and the increased number of two-wage earner couples, more residents are looking for alternatives outside the family for their care.

Table of Contents

GOVERNMENT REGULATION

General

Healthcare is an area of extensive and frequent regulatory change. Changes in the law or new interpretations of existing laws may have a significant impact on our revenue, costs and business operations. Our independent operating subsidiaries that provide healthcare services are subject to federal, state and local laws relating to, among other things, licensure, quality and adequacy of care, physical plant requirements, life safety, personnel and operating policies. In addition, these same subsidiaries are subject to federal and state laws that govern billing and reimbursement, relationships with vendors, business relationships with physicians and workplace protection for healthcare staff. Such laws include (but are not limited to) the Anti-Kickback Statute (AKS), the federal False Claims Act (FCA), the Stark Law and state corporate practice of medicine statutes.

Governmental and other authorities periodically inspect the skilled nursing facilities (SNFs), senior living facilities and the outpatient rehabilitation agencies of our independent operating subsidiaries to verify continued compliance with applicable regulations and standards. The operations must pass these inspections to remain licensed under state laws and to comply with Medicare and Medicaid provider agreements and applicable Conditions of Participation. The operations can only participate in these third-party payment programs if inspections by regulatory authorities reveal that the operations are in substantial compliance with applicable state and federal requirements. In the ordinary course of business, federal or state regulatory authorities may issue notices to the operations alleging deficiencies in certain regulatory practices, which may require corrective action to regain and maintain compliance. In some cases, federal or state regulators may impose other remedies including imposition of civil monetary penalties, temporary payment bans, loss of certification as a provider in the Medicare or Medicaid program, or revocation of a state operating license.

We believe that the regulatory environment surrounding the healthcare industry subjects providers to intense scrutiny. In the ordinary course of business, providers are subject to inquiries, investigations and audits by federal and state agencies related to compliance with participation and payment rules under government payment programs. These inquiries may originate from HHS, Office of the Inspector General (OIG), state Medicaid agencies, state Attorney Generals, local and state ombudsman offices and CMS Recovery Audit Contractors, among other agencies. In response to the inquiries, investigations and audits, federal and state agencies continue to impose citations for regulatory deficiencies and other regulatory penalties, including demands for refund of overpayments, expanded civil monetary penalties that extend over long periods of time and date back to incidents prior to surveyor visits, Medicare and Medicaid payment bans and terminations from those programs, which may be temporary or permanent in nature. We vigorously contest each such regulatory outcome when appropriate; however, there are significant legal and other expenses involved that consume our financial and personnel resources. Expansion of enforcement activity could adversely affect our business, financial condition or the results of operations.

Proposed, Anticipated and Recently Issued Rulemaking and Administrative Actions

The federal government, through CMS rulemaking, Presidential executive actions or Congressional legislation, and state and local governments have recently released the following proposed rulemaking or administrative actions that may have an impact on our independent operating SNFs or assisted living facilities:

Biden-Harris Administration's Nursing Home Care Priorities — The Biden-Harris Administration is seeking reform around reimbursement, staffing levels, standards of care, increased transparency and public disclosure of ownership, and enhanced civil remedies as a means of enforcement against those facilities that do not satisfy CMS’s standards. Proposed rules based on these directives have already been published in 2023, including those highlighted below and observers expect additional rules to be issued this year and in the future. Final rules will follow publication of these proposed rules after a notice-and-comment period required by law.

Proposed Rule over Ownership Transparency — On February 13, 2023, CMS issued a proposed rule that, if finalized and implemented, would require SNFs to disclose certain information regarding their ownership and managerial relationships. The proposed rule would require disclosure to include the identity of any person or legal entity that: (1) exercises financial, operational, or managerial control over any facility or part of a facility, or provides services to a facility that include its policies and procedures or cash management services; (2) leases or subleases real property to the facility, or owns 5% or more of the real property’s total value; and (3) provides any management or administrative services (or consults regarding the same), or provides accounting or financial services to the SNF. A final rule concerning this subject has not yet been published. This proposed rule is different from, and farther-reaching than, the disclosure of Medicare-collected nursing facility ownership that has been published on the Nursing Home Compare website since April of 2022.

Table of Contents

Certain states have adopted laws reflecting their concerns regarding ownership transparency. For example, in July 2023, Iowa adopted laws requiring disclosure of ownership information not previously required for licensure to promote transparency. Additionally, in July of 2023, the California Department of Health Care Access and Information of the California Health and Human Services Agency issued a notice of proposed rulemaking containing regulations that would implement financial and ownership transparency requirements for California-licensed SNFs that are required by California law passed in 2021.

Federal Legislation — On March 9, 2023, the home and community-based services (HCBS) Access Act was introduced to expand access to and resources available for HCBS. This bill provides Medicaid funding to individuals who provide direct home- and community-based care to adults over the age of 60 or people who have disabilities. This bill also provides financial resources for the training of these direct care providers, who are intended to provide services to the elderly or disabled that range from advocacy and community integration to transportation and daily assistance tasks ranging from bathing and laundry to meal preparation and housekeeping. As of the date of filing, no further action has been taken on the HCBS Access Act since its introduction and referral to the aforementioned committees.

State Legislation — Many states in which our independent operating subsidiaries operate have introduced or passed legislation that would create or change laws and regulations related to our business and industry.

In the past, California had proposed a law on direct care spending requirements that may have affected our business and SNFs operating within that state. These proposals had included requirements for healthcare facilities certified by CMS, including SNFs, to report all annual revenues to the State of California by June 30 of each year and certify that a stated percentage of all non-Medicare revenues should be used for direct patient-related services, including staffing and operational costs.

On October 13, 2023, the California Governor signed into law a bill which impacts the minimum wages of healthcare workers. Effective June 1, 2024, the law raises the minimum wage for California healthcare employees and sets a new salary threshold for those who are considered exempt healthcare employees. The bill only becomes effective for SNFs if a patient care minimum spending requirement bill is also passed. We anticipate that a minimum spending bill will be proposed in the near future.

Final Rule Fiscal Year 2024 Skilled Nursing Facility Prospective Payment System (SNF PPS) — On July 31, 2023, CMS published its final rule updating the Medicare payment rates within the SNF PPS for FY 2024 (SNF PPS FY 2024 Final Rule). The SNF PPS FY 2024 Final Rule modifies the SNF Quality Reporting Program (QRP) and the SNF Value-Based Purchasing (VBP) Program. The SNF PPS FY 2024 Final Rule finalized the rates to be paid in the 2024 fiscal year.

The SNF PPS FY 2024 Final Rule increases the Medicare payment rate aggregate net market basket by 4.0%. The increase includes a 6.4% net market basket update to the payment rates of 3.0%, plus a 3.6% market basket forecast error adjustment, less a 0.2% productivity adjustment, as well as a negative 2.3% in the FY 2024 SNF PPS rates due to the second phase of the Patient Driven Payment Model (PDPM) parity adjustment recalibration. The net effect of these changes is expected to be an overall 4.0% increase in payments to SNFs in FY 2024. This final rule also updates the SNF QRP for FY 2024 and future years, including the adoption of two new quality reporting measures, modification of one measure and removal of three measures resulting in public reporting of four QRP measures. Additionally, the SNF PPS FY 2024 Final Rule makes changes to the SNF VBP Program. Specifically, this final rule adopts four new measures: the nursing staff turnover measure, the discharge function score measure, the long stay hospitalization measure per 1,000 resident days and the percent of residents experiencing one or more falls with a major injury (long stay); the existing SNF 30-day all-cause readmission measure (SNFRM) is replaced with the SNF within stay potentially preventable readmissions (SNF WS PPR) measure beginning in FY 2028.

SNF PPS FY 2024 Final Rule adopted the Nursing Staff Turnover (NST) measure for the SNF VBP program beginning with the FY 2026 program year. This is a structural measure that has been collected and publicly reported on Care Compare, and the measure assesses the stability of the staffing within a SNF using nursing staff turnover. The NST measure uses facility-reported, electronic data from CMS’ Payroll-Based Journal (PBJ) system to calculate annual turnover rates for nursing staff, including RNs, LPNs, and nurse assistants. Facilities would begin reporting this measure in FY 2024, with payment effects beginning in FY 2026.

The NST measure looks at six consecutive quarters of data. It starts with a baseline quarter and the first two quarters of the performance period to identify eligible employees. Then, it uses the next four quarters to find the number of employment spells that ended in turnover. Finally, it checks data from the sixth quarter to identify gaps in days worked that began in the last 60 days of the fifth quarter used for the measure. The measure score is then calculated by comparing the total number of eligible employees with 60-day gaps in working during the specified periods.

Table of Contents

Biden-Harris Administration Executive Order — In April of 2023, President Biden signed an executive order seeking to increase access to affordable, high-quality long-term care for adults who are older or disabled. This executive order articulated the Biden-Harris Administration’s policy to enable families to have access to affordable, high-quality care for older or disabled family members, and to support the workforce of individuals who would provide such care, including through adequate wages and the ability to unionize. This executive order directed HHS and CMS to take steps to use existing funding and resources to connect home- and community-based workers with education and training opportunities and to create greater opportunities for workers in those fields to obtain health insurance and retirement benefits.

Proposed CMS Minimum Staffing Mandate — On September 1, 2023, CMS issued its proposed rule that would establish minimum staffing standards for long-term care facilities. As a proposed rule, the comment period for this regulation is open for 60 days from the date of this proposed rule’s publication. This proposed rule contains three primary staffing proposals: 1) minimum staffing standards of 0.55 hours per resident per day (HPRD) for registered nurses (RNs) and 2.45 HPRD for nurse aids (NAs); 2) a requirement to have a RN on-site 24 hours per day, seven days per week; and 3) requirements for enhanced facility assessments. The proposed rule features a staggered implementation of these requirements, including a possible hardship exemption for select facilities. As this is a proposed rule, CMS has requested and received stakeholder feedback on all components of this regulation so that these comments may be considered prior to CMS's publication of a final rule. Additionally, the proposed rule would increase the reporting and transparency of Medicaid payments made to a facility for its direct care, including state-level reporting requirements and provisions for states and CMS to make public information about payments made to long-term care facilities.

Facility self-assessments would also be enhanced under this proposed rule. CMS proposes that the facility self-assessment be updated on the issue of staffing to contain or clarify: 1) that facilities must use evidence-based methods when planning for resident care, including accommodation of behavioral health needs; 2) requiring facilities to use the self-assessment to assess the specific needs of each resident, with adjustments made for changes in the resident population; 3) requiring that facilities include the input of staff, including leadership, management, nurse staff and other direct care providers who render other services to residents; 4) requiring that the staffing plan maximize recruitment and retention of staff in a manner consistent with the President’s April 2023 Executive Order on increasing access to high-quality care and supporting caregivers.

A hardship exemption for CMS’s proposed minimum staffing standards is also set forth in the proposed rule. Long-term care facilities could qualify for a temporary hardship exemption from new minimum staffing ratios upon meeting specific criteria that demonstrate: 1) workforce unavailability based on an absence of providers relative to individuals in the age group of recipients within a specific geographic location; 2) a facility’s good faith efforts to hire and retain staff through a recruitment and retention plan; and 3) a financial commitment to staffing by documenting the total annual amount spent on direct care staff. A survey would be required to assess the residents’ health and safety before CMS would consider granting such a hardship exemption. Any facility that received a hardship exemption from the minimum staffing requirement would have this exemption noted on the Care Compare website rating skilled nursing facilities. Further, facilities would not be eligible to receive an exemption if they: 1) failed to submit their data to the payroll-based journal system; 2) have been identified as a special focus facility; or 3) have been identified at any time within the preceding 12 months as having insufficient staffing that was either at a widespread or pattern level with resulting actual harm to residents, or receiving an immediate jeopardy citation regarding insufficient staffing. Even after receiving an exemption, a facility would still be required to maintain sufficient staff around-the-clock to provide care and monitor resident health.

If finalized, this proposed rule would have a staggered and phased implementation over a period of three years, with the phases differentiated between rural and non-rural facilities. For facilities in urban areas, the final rule’s facility assessment requirements would become effective within 60 days of the final rule’s publication, with the proposed rule’s round-the-clock on-site RN requirement becoming effective two years after the final rule’s publication; and the above-referenced minimum staffing of 0.55 HPRD for RNs and 2.45 HPRD for NAs would take effect three years after the final rule’s publication. For rural facilities, the final rule’s facility assessment requirements would still become effective within 60 days of the final rule’s publication but the proposed rule’s round-the-clock on-site RN requirement would become effective three years after the final rule’s publication, and the above-referenced minimum staffing of 0.55 HPRD for RNs and 2.45 HPRD for NAs would take effect five years after the final rule’s publication.

This minimum staffing proposed rule also seeks further information from stakeholders regarding alternative policies for establishing minimum nurse staffing standards. In particular, CMS seeks comment on an alternative total nurse staffing standard of 3.48 HPRD (among other alternatives), which would include minimum individual standards of 0.55 HPRD for RNs and 2.45 HPRD for NAs, in addition to other nurse staffing as needed to attain a total of 3.48 HPRD across all nurse types. CMS also seeks stakeholder comments regarding the benefits and trade-offs of using different standards, evidence, or methodologies used by states that have adopted minimum nursing standards to inform its own standard-setting.

Table of Contents

Coronavirus

In March of 2020, in an effort to promote efficient care delivery and to decrease the spread of COVID-19, federal, state and local regulators implemented new regulations and waived, (in some cases temporarily), certain existing regulations, including those discussed below. These new regulations and waivers of the other regulations expired on May 11, 2023.

Temporary suspension of certain patient coverage criteria and documentation and care requirements — CMS issued a series of temporary waivers, rules, and guidance, suspending various Medicare patient coverage criteria as it related to the COVID-19 pandemic to ensure patients continued to have adequate access to care, notwithstanding the burdens placed on healthcare providers HHS also waived requirements specific to SNFs. During this time, CMS also suspended and reduced the priority of standard audit activities in order to focus on patient care. While all of these waivers expired with the termination of the PHE on May 11, 2023, others were terminated at various points in 2021 and 2022 during the PHE. Certain rules, such as requirements for COVID-19 reporting, testing, and vaccination remained in place through the end of the PHE.

Testing requirements — Beginning in April 2020, authorities in several states in which our independent operating subsidiaries are located began to mandate widespread COVID-19 testing at all SNFs and assisted living facilities based on guidance from the Centers for Disease Control and Prevention (CDC). During the PHE, CMS issued revised parameters for testing, requiring routine testing of only unvaccinated staff and then further revised its guidance in September of 2022 to specify only symptomatic individuals and their close contacts, (including staff and residents), should be tested for COVID-19. On June 5, 2023, CMS published a final rule containing changes to COVID-19 vaccination, reporting, testing, and other requirements (Omnibus Final Rule), which takes effect 60 days after publication and ended the COVID-19 testing and reporting requirements for SNFs and assisted living facilities imposed during the PHE. All of the federal, state and local government vaccines mandates have been rescinded since the end of the PHE.

Changes to Medicaid Reimbursement — In March of 2020, the Families First Coronavirus Relief Act (FFCRA) provided a 6.2% increase to the Federal Medicaid Assistance Percentage (FMAP) during the PHE. The FFCRA also imposed conditions restricting the disenrollment and standards for re-enrolling Medicaid beneficiaries to promote continuous care of beneficiaries during the PHE. The Consolidated Appropriations Act of 2023 (CAA 2023) amended these Medicaid enrollment protections and increased FMAP funding provided in the FFCRA. In the first quarter of 2023, the FMAP increase CMS provides to the states remained elevated by 6.2%, but this amount decreased to 5% for April through June 2023, 2.5% for July through September 2023, and 1.5% for October through December 2023 before tapering to 0% by the end of 2023. The ultimate amount of Medicaid funding provided from each state will vary substantially based on each state's policies.

Under the CAA 2023, states were allowed to begin disenrolling Medicaid beneficiaries and resuming Medicaid eligibility determinations beginning on April 1, 2023 upon satisfying conditions that include reviewing Medicaid beneficiaries' eligibility and have begun doing so. On August 30, 2023, CMS advised all 50 states in a letter to their respective Medicaid administrators to observe federal Medicaid regulations in making these redeterminations, including requirements to make eligibility determinations on an individual basis rather than a per-household basis. CMS has worked with 12 states regarding their respective redetermination and disenrollment processes, and previously paused policy in six states. As a result of this activity, the redetermination and disenrollment period that began on April 1, 2023 has not proceeded as rapidly as some may have expected.

Medicare

Medicare presently accounts for approximately 27.8% of our skilled nursing services revenue year-to-date, being our second-largest payor. The Medicare program and its reimbursement rates and rules are subject to frequent change. These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which Medicare reimburses us for our services. Budget pressures often lead the federal government to reduce or place limits on reimbursement rates under Medicare. Implementation of these and other types of measures has in the past, and could in the future, result in substantial reductions in our revenue and operating margins.

Table of Contents

Patient-Driven Payment Model (PDPM)

The SNF PPS Rule became effective October 1, 2019. The SNF PPS Rule included a new case mix model that focuses on the patient’s condition (clinically relevant factors) and resulting care needs, rather than on the volume of care provided, to determine Medicare reimbursement. The case mix-model is called the PDPM, which utilizes clinically relevant factors for determining Medicare payment by using diagnosis codes and other patient characteristics as the basis for patient classification. PDPM utilizes five case-mix adjusted payment components: physician therapy, occupational therapy, speech language pathology, nursing and social services and non-therapy ancillary services. It also uses a sixth non-case mix component to cover utilization of SNFs' resources that do not vary depending on resident characteristics.

PDPM replaces the existing methodology, and is intended to achieve a more value-based, unified post-acute care payment system. For example, PDPM adjusts Medicare payments based on each aspect of a resident’s care. Under the SNF PPS PDPM system, the payment to SNFs and nursing homes is based heavily on the patient’s condition rather than the specific services provided by each SNF.

Skilled Nursing Facility - Quality Reporting Program (SNF QRP)

The Improving Medicare Post-Acute Care Transformation Act of 2014 (IMPACT Act) provided data reporting requirements for certain Post-Acute-Care (PAC) providers. If a SNF does not submit required quality data as required by the IMPACT Act, its payment rates are reduced by 2.0% for each such fiscal year, which may result in payment rates for a fiscal year being less than the preceding fiscal year.

The SNF QRP standardized patient assessment data elements. The SNF QRP applies to freestanding SNFs, SNFs affiliated with acute care facilities and all non-critical access hospital swing-bed rural hospitals. These data elements are the subject of frequent change and adjustment. CMS's rulemaking often identifies new data elements to be reported.

In July of 2022, CMS announced revisions to calculating its five-star ratings for the Nursing Home Compare website. Under this new calculation, points are assigned to a SNF based on its performance across six measures: (1) case-mix adjusted total nurse staffing levels (including registered nurses, licensed practical nurses, and nursing aides), measured by hours per resident per day; (2) case-mix adjusted registered nurse staffing levels, measured by hours per resident per day; (3) case-mix adjusted total nurse staffing levels (including registered nurses, licensed practical nurses, and nursing aides), measured by hours per resident day on the weekend; (4) total nurse turnover, defined as the percentage of nursing staff that left the nursing home over a 12-month period; (5) registered nurse turnover, defined as the percentage of registered nursing staff that left the nursing home over a 12-month period; and (6) administrator turnover, defined as the percentage of administrators that left the nursing home over a 12-month period. These six measures will be measured on a quarterly basis.

These six new measures were included in the five-star rating in October 2022. In addition, CMS also implemented a planned increase to the quality measure reporting thresholds, increasing each threshold by one-half of the average improvement of quality measure scores since CMS last set quality measure thresholds. Going forward, CMS plans to implement similar rating threshold increases every six months.

On July 29, 2022, CMS announced the adoption of a process measure for influenza vaccination coverage among healthcare personnel within SNFs. This measure will be determined by the percentage of SNF healthcare personnel who receive an influenza vaccine any time from when it first becomes available through March 31 of the following year. SNFs began submitting this data on October 1, 2022.

On July 31, 2023, CMS published the SNF PPS FY 2024 Final Rule, which included changes to the SNF QRP, including adopting, removing and modifying specific measures. The final rule also includes policy changes and the public reporting of four measures. The final rule adopts the Discharge Function Score (DC Function) measure, which determines the functional condition of residents by examining the proportion of SNF residents who achieve or surpass a projected discharge functionality score. The assessment includes consideration of mobility and self-care, utilizing data from the Minimum Data Set (MDS). The DC Function will replace the current process and is scheduled to go into effect for the FY 2025 SNF QRP.

CMS will adopt two measures for the SNF QRP starting in FY 2026. First, CMS will raise the Data Completion Thresholds for the MDS. SNFs must report required quality measure data and standardized resident assessment data gathered using the MDS for at least 90% of the assessments they submit to CMS. SNFs who fail to meet this requirement will be subject to a 2% reduction on their applicable fiscal year payment starting in FY 2026. Second, CMS will adopt the Patient/Resident COVID-19 Vaccine metric. This metric highlights the number of patient stays in which SNF patients received the COVID-19 vaccine.

Table of Contents

The SNF PPS FY 2024 Final Rule also modifies the SNF QRP’s Healthcare Professional (HCP) Covid Vaccine Measure. The measure will track the proportion of healthcare staff vaccinated for COVID-19 and have kept their vaccination status current per the CDC recommendations. Previously, SNFs were only obligated to disclose whether their healthcare workers had completed the initial vaccination series for COVID-19. Now, there is an added requirement to report the total count of healthcare employees who have maintained their COVID-19 vaccination status in line with CDC recommendations.

The SNF PPS FY 2024 Final Rule also removed the Application of Functional Assessment/Care Plan measures from the SNF QRP. CMS stated the decision stemmed from two primary reasons: first, the consistently high-performance levels among SNFs make it challenging for CMS to identify significant advancements; and second, the DC Function measure aligns more closely with the preferred functional outcomes for residents.

Medicare Annual Payment Rule

CMS is required to calculate an annual Medicare market-basket update to the payment rates. On July 31, 2023, CMS issued the SNF PPS FY 2024 Final Rule, which will result in a net increase of 4.0% in Medicare payments to SNFs in fiscal year 2024. This increase results from the 6.4% net market basket update to the payment rates, which is based on a 3.0% SNF market basket increase plus a 3.6% market basket forecast error adjustment, less a 0.2% productivity adjustment and a negative 2.3% adjustment as a result of the recalibrated parity adjustment.

On July 29, 2022, CMS issued a final rule for fiscal year 2023 that increased the Medicare payment rates to aggregate net market basket by 2.7%. The increase results from the 5.1% update to the market basket, which is based on a 3.9% current year market basket increase plus a 1.5% market basket error adjustment, less a 0.3% productivity adjustment and a negative 2.3% adjustment as a result of the recalibrated parity adjustment. The recalibrated parity adjustment is being phased in at a rate of 2.3% per year on both the SNF PPS FY 2024 and FY 2023 Final Rules.

Sequestration of Medicare Rates

The Budget Control Act of 2011 requires a mandatory, across the board reduction in federal spending, called a sequestration. Medicare FFS claims with dates of service or dates of discharge on or after April 1, 2013 incur a 2.0% reduction in Medicare payments through at least 2023, unless Congress takes further action. Under the CARES Act, there was a temporary suspension of the 2.0% reduction of Medicare claim reimbursements as a result of the COVID-19 pandemic which lasted until June 2022. Under the CAA 2023, a further 4% cut to Medicare spending that would have been required under the Statutory Pay-As-You-Go Act of 2010 (PAYGO) was waived for fiscal years 2023 and 2024. Instead, the CAA 2023 deferred any further Medicare sequestration under PAYGO until fiscal year 2025. The CAA 2023 also offset planned Medicare sequestrations that would have been as high as 4.0% and instead maintained fee schedule cuts of approximately 2%.

Skilled Nursing Facility Value-Based Purchasing (SNF-VBP) Program

The SNF-VBP Program rewards SNFs with incentive payments based on the quality of care they provide to Medicare beneficiaries, as measured by a hospital readmissions measure. CMS annually adjusts its payment rules for SNFs using the SNF-VBP Program. The program also introduced quality measures to assess how health information is shared and adopted a number of standardized patient assessment data elements that assess factors such as cognitive function and mental status, special services and social determinants of health. CMS uses regulations to specify how it measures the performance for SNFs as well as the data that SNFs are to report to CMS. The deadlines for baseline period quality measure quarterly reporting and performance periods and standards began in the 2023 program year. The final rule for the fiscal year 2023 SNF PPS also provided for SNF-VBP program expansion beyond the use of its single, all-cause hospital readmission measure to determine payment, with the inclusion of measures in fiscal year 2026 for SNF healthcare associated infections requiring hospitalization (SNF HAI) and total nursing hours per resident day measures and in fiscal year 2027, the discharge to community post-acute care measure for SNFs, which assess the rate of successful discharges to the community from a SNF setting.

Table of Contents

The SNF PPS FY 2024 Final Rule elected to replace the SNFRM measure with the SNF WS PPR measure beginning in the FY 2028 program year. The potentially preventable readmission (PPR) measure assesses the risk-standardized rate of unplanned and potentially avoidable readmissions during SNF stays for Medicare fee-for-service beneficiaries. The new SNF WS PPR measure refines the original Skilled Nursing Facility 30-Day Potentially Preventable Readmission (SNFPPR) measure, which followed the requirements of the Protecting Access to Medicare Act (PAMA) of 2014. The refinement in the SNF WS PPR measure shifts the observation window from a fixed 30-day post-hospital discharge to the duration of the SNF stay. Moreover, the time gap allowed between the prior inpatient discharge and the SNF admission has been extended from one day to 30 days. These changes, based on feedback from expert panels and a 2015 partnership, better align the measure with the IMPACT Act's provisions and enhance the reliability of tracking preventable readmissions. Additionally, the SNF WS PPR measure's calculations use two years of Medicare claims data to generate a provider-specific risk-standardized readmission rate.

Part B Rehabilitation Requirements

Some of our revenue is paid by the Medicare Part B program under a fee schedule. Part B services are limited with a payment cap by combined speech-language pathology services (SLP), physical therapy (PT) services and a separate annual cap for occupational therapy (OT) services. The Bipartisan Budget Act of 2018 (BBA) establishes coding modifier requirements to obtain payments beyond certain payment thresholds, discussed below and reaffirms the specific $3,000 claim audit threshold requirements for Medicare Administrative Contractors. For PT and SLP combined the threshold for coding modifier requirements was $2,230 for CY 2023 with the same threshold for OT services. The KX modifier is added to medical claims to indicate the providing clinician attests that the services corresponding to that claim were medically necessary and that the justification for those services is contained within the patient’s medical records. This modifier is intended for use where the services will exceed the threshold for those services set by the BBA and updated by annual fee schedule rules, yet are still appropriate and medically necessary, and thus should be compensated by Medicare.

Consistent with CMS’s “Patients over Paperwork” initiative, the agency has also been moving toward eliminating burdensome claims-based functional reporting requirements. Beginning in 2021, CMS rescinded 21 problematic National Correct Coding Initiative edits impacting outpatient therapy services, including services furnished under Medicare Part B primarily related to PT and OT services, removing a coding burden caused by requirements for additional documentation and claim modifier coding.

On November 1, 2022, CMS issued the calendar year 2023 PFS, resulting in a PFS conversion factor of $33.06, a decrease of $1.55 from the calendar year 2022 PFS conversion factor of $34.61. This is a 4.45% cut to the conversion factor for calendar year 2023.

Additionally, the Multiple Procedure Payment Reduction (MPPR) continues at a 50% reduction, which is applied to therapy procedures by reducing payments for practice expense of the second and subsequent procedures when services provided beyond one unit of one procedure are provided on the same day. The implementation of MPPR includes (1) facilities that provide Medicare Part B speech-language pathology, occupational therapy and physical therapy services and bill under the same provider number; and (2) providers in private practice, including speech-language pathologists, who perform and bill for multiple services in a single day.

Through the end of coverage year 2024, certain of our Part B services provided through telehealth will still qualify for Medicare reimbursement based on flexibility first provided under the Emergency Waivers, which added physical therapy, occupational therapy and speech-language pathology to the list of approved telehealth Providers for the Medicare Part B programs provided by a SNF. During the PHE, CMS added certain PT and OT services to the list of Medicare-covered telehealth services on a temporary basis, some of which were made permanent for use and new codes were added for PT, OT, or SLP telehealth services—including some “sometimes therapy” codes that were not subject to MPPR. The CAA 2023 extended certain, but not all, telehealth flexibilities until December 31, 2024, allowing certain telehealth flexibilities to continue after the PHE's expiration. On February 13, 2023, CMS extended the use of these codes for telehealth through the end of CY 2023.

On July 13, 2023, CMS issued the proposed CY 2024 PFS. Under this proposed rule, overall payment rates for Medicare Part B services are to be reduced by 1.25% compared to calendar year 2023. Additionally, acts of Congress may affect the ultimate conversion factor and amounts paid under Medicare for the Company’s services, as the CY 2023 PFS final rule reimbursement rates were scheduled to be lower than those that took effect until Congress passed spending legislation that reduced the amount of spending cut from CY 2022 to CY 2023.

Table of Contents

The proposed CY 2024 PFS contains provisions to make payments when physicians and certain non-physician practitioners, such as physician assistants, nurse practitioners, physical therapists, occupational therapists and clinical psychologists, involve caregivers in implementing an individualized plan of treatment or therapy. The purpose of this proposed provision is to incentivize the training of caregivers and provide additional funds to offset the costs of training these caregivers through participation in licensed healthcare providers’ course of care for patients and residents.

The proposed CY 2024 PFS also solicits information regarding changing the requirements for supervision of physical therapist assistants and occupational therapist assistants in private practice from “direct” supervision to broader “general” supervision. The comments and data CMS receives from this request for information may affect the rate of reimbursement for PT and OT services in the future and may affect the desirability and utilization of physical therapy assistants and occupational therapy assistants for certain patient services. Additionally, the proposed CY 2024 PFS would add certain health maintenance and well-being coaching to the services for which Medicare will reimburse telehealth services through December 31, 2024. This proposed rule also proposes adding risk assessments for social determinants of health to the list of telehealth services Medicare will reimburse on a permanent basis.

Programs of All-Inclusive Care for the Elderly

The requirements under the Programs of All-Inclusive Care for the Elderly (PACE) provide greater operational flexibility and update information under the Medicare and Medicaid programs, including leniency in compliance with program requirements during and after a 3-year trial period and relieving restrictions placed on the team that assesses and provides for the needs of each PACE participant. Further, non-physician primary care providers can provide certain services in place of primary care physicians. On February 1, 2023, CMS issued its final rule, which takes effect on April 3, 2023, requiring the collection of data by Medicare Advantage organizations and their service providers and the submission of data to CMS for risk adjustment data validation (RADV) audits. The purpose of these RADV audits is to maintain the accuracy of risk-adjusted payments made to Medicare Advantage organizations.

Decisions Regarding Skilled Nursing Facility Payment

Reimbursement rates and rules are subject to frequent change that historically, have had a significant effect on our revenue. The federal government and state governments continue to focus on efforts to curb spending on healthcare programs such as Medicare and Medicaid. We are not able to predict the outcome of the legislative process. We also cannot predict the extent to which proposals will be adopted or, if adopted and implemented, what effect, if any, such proposals and existing new legislation will have on us. Efforts to impose reduced allowances, greater discounts and more stringent cost controls by government and other payors are expected to continue and could adversely affect our business, financial condition and results of operations.

These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions influenced by budgetary or political pressures, may materially adversely affect the rates at which Medicare reimburses us for our services. Implementation of these and other types of measures has in the past, and could in the future, result in substantial reductions in our revenue and operating margins. For a discussion of historic adjustments and recent changes to the Medicare program and other reimbursement rates, see Part II, Item 1A Risk Factors under the headings Risks Related to Our Business and Industry.

Patient Protection and Affordable Care Act

Various healthcare reform provisions became law upon enactment of the ACA. The reforms contained in the ACA have affected our operating subsidiaries in some manner and are directed in large part at increased quality and cost reductions. Several of the reforms are very significant and could ultimately change the nature of our services, the methods of payment for our services and the underlying regulatory environment.

The Inflation Reduction Act of 2022 (IRA), which continued and expanded certain provisions of the ACA, extended the premium subsidies paid by the federal government, until the end of 2024, resulting in subsidies being available to offset or reduce the costs of private health insurance policies for qualifying individuals. This may aid older patients in obtaining or keeping their health insurance in order to pay for long-term care services. The CAA 2023 revised the funds available to fund Medicare in 2023 and deferred the PAYGO sequestration of Medicare expenses, resulting in the CY 2023 PFS increasing its conversion factor from $33.06 to more than $33.89.

Table of Contents

The 2024 presidential election may significantly alter the current regulatory framework and impact our business and the health care industry, including any further extensions or expansions of certain ACA provisions, namely recent rulemaking activity regarding ACA Section 1557's anti-discrimination provisions. We continually monitor these developments so we can respond to the changing regulatory environment impacting our business.

Requirements of Participation

CMS has requirements that providers, including SNFs, must meet in order to participate in the Medicare and Medicaid Programs. Some of these requirements can be burdensome and costly.

One such requirement of participation in the Medicare and Medicaid programs involves limitations around the use of pre-dispute, binding arbitration agreements by SNFs. CMS has issued guidance and direction around arbitration that must be satisfied for any agreement to be enforceable and which may result in adverse consequences for our business if not followed. Congress has routinely introduced, but not passed, legislation addressing the issue of arbitration agreements used by SNFs. While legislative action is possible in the future, federal regulations and state/federal laws remain our primary source of authority over the use of pre-dispute binding arbitration agreements.

On June 29, 2022, CMS announced updated guidance for Phase 2 and 3 of the Requirements of Participation. CMS distributed these updates to surveyors and state agencies in order to, among other things, enhance responses to resident complaints and reported incidents. This guidance focuses on the following topics: (1) resident abuse and neglect (including reporting of abuse); (2) admission, transfer and discharge; (3) mental health and substance abuse disorders; (4) nurse staffing and reporting of payroll to evaluate staffing sufficiency; (5) residents’ rights (including visitation); (6) potential inaccurate diagnoses or assessments; (7) prescription and use of pharmaceuticals, including psychotropics and drugs that act like psychotropics; (8) infection prevention and control; (9) arbitration of disputes between facilities and residents; (10) psychosocial outcomes and related severity; and (11) the timeliness and completion of state investigations to improve consistency in the application of standards among various states.

On July 29, 2022, CMS updated the Medicare Requirements of Participation for SNFs, which includes the modification of requirements associated with a facility's physical environment to minimize unnecessary renovation expenses in order to avoid closure of SNFs due to the related expense. CMS "grandfathered" certain facilities and will allow SNFs that were participating in Medicare before July 5, 2016 and that previously used the Fire Safety Evaluation System (FSES) to continue using the 2001 FSES mandatory values when determining compliance with applicable standards. CMS also updated the Requirements of Participation to revise existing qualification requirements for directors of food and nutrition services in SNFs, while "grandfathering" in directors with two or more years of experience and certain minimum training in food safety so they may continue in that role without satisfying further educational requirements.

On February 17, 2023, CMS revised the survey resources that CMS and state surveyors use in evaluating SNFs’ compliance with federal Requirements for Participation. This revision incorporated the recent changes to CMS’ focused infection control survey item, which CMS had removed in favor of standard infection control survey measures. These changes were made to the most recent revision of long-term care facility survey documents that CMS had last revised in October of 2022. These updates provided more information for state surveyors to utilize when evaluating SNFs’ compliance with the Medicare Requirements of Participation, as well as included guidance for facilities on operationalizing compliance with these requirements based on how surveyors would measure and evaluate facility performance.

Civil and Criminal Fraud and Abuse Laws and Enforcement

Various complex federal and state laws exist which govern a wide array of referrals, relationships and arrangements, and prohibit fraud by healthcare providers. Governmental agencies are devoting increasing attention and resources to such anti-fraud efforts. The Balanced Budget Act of 1997 expanded the penalties for healthcare fraud. Additionally, the government or those acting on its behalf may bring an action under the FCA, alleging that a healthcare provider has defrauded the government by submitting a claim for items or services not rendered as claimed, which may include coding errors, billing for services not provided and submitting false or erroneous cost reports. The FCA clarifies that if an item or service is provided in violation of the AKS, the claim submitted for those items or services is a false claim that may be prosecuted under the FCA as a false claim. Under the qui tam or “whistleblower” provisions of the FCA, a private individual with knowledge of fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government’s recovery. The Biden-Harris Administration has also signaled an increasing focus on nursing home performance and the reimbursement nursing homes receive from federal healthcare payment programs. Many states also have a false claim prohibition that mirrors or closely tracks the federal FCA.

Table of Contents

Federal law also provides that the OIG has the authority to exclude individuals and entities from federally funded health care programs on a number of grounds, including, but not limited to, certain types of criminal offenses, licensure revocations or suspensions and exclusion from state or other federal healthcare programs. CMS can recover overpayments from health care providers up to six years following the year in which payment was made.

In 2021, the OIG released the result of an audit finding that Medicare overpaid millions of dollars for chronic care management (CCM) services. The OIG's 2021 report found that in calendar years 2017 and 2018, Medicare overpaid millions of dollars in CCM claims. In 2022, the OIG released an audit revealing that CMS had not collected $226 million, or 45%, of identified overpayments within that period, potentially affecting SNFs. These investigatory actions by OIG demonstrate its increased scrutiny into post-hospital SNF care provided to beneficiaries and may encourage additional oversight or stricter compliance standards. In 2023, representatives of the DOJ speaking at certain industry events, including the American Health Law Association’s Fraud and Compliance Forum, have indicated that its healthcare enforcement trends would emphasize opioid prescribing, Medicare Advantage and managed care plan fraud, and COVID-19 related fraud, including under various relief programs available during and in conjunction with the pandemic.

Our business model, like those of some other for-profit operators, is based in part on seeking out higher-acuity patients whom we believe are generally more profitable. Over time our overall patient mix has consistently shifted to higher-acuity in most facilities we operate. We also use specialized care-delivery software that assists our caregivers in more accurately capturing and recording services in order to, among other things, increase reimbursement to levels appropriate for the care actually delivered. These efforts may place us under greater scrutiny with the OIG, CMS, our fiscal intermediaries, recovery audit contractors and others.

Federal Healthcare Reform

Five-Star Quality Reporting Metrics — The Quality Payment Program (QPP) was created under the Medicare Access and Children's Health Insurance Program (CHIP) Reauthorization Act of 2015. This program was based on the Merit-based Incentive Payment System (MIPS) or the use of Alternative Payment Models (APM), which relied on quality data CMS gathered and evaluated using the Five-Star Quality Rating system, which includes a rating of one to five in various categories. These categories include (but are not limited to) the results of surveys conducted by state inspectors, other health inspection outcomes, staffing, spending, readmissions and stay durations; the data collected and its weighting in determining a rating on a scale of one to five stars is subject to periodic and ongoing revision, re-balancing and adjustment by CMS to reflect market conditions and CMS’s priorities in patient care. Since 2020, CMS’s measurement of the data reported by providers, including SNFs, has become more competitive and resulted in a reduction of four- and five-star rankings available under CMS’s Five-Star Quality Rating system.

The Five-Star Quality reporting system for nursing homes is displayed on CMS's consumer-based Nursing Home Compare website, along with a consumer alert icon next to nursing homes that have been cited for incidents of abuse, neglect, or exploitation on the Nursing Home Compare website. The Nursing Home Compare website is updated monthly with CMS’s refresh of survey inspection results on that website. Additionally, in April of 2022, the Nursing Home Compare website began publishing the ownership information for Medicare-enrolled nursing facilities based on disclosures made to CMS from 2016 through 2022 due to mergers, acquisitions, or other changes in ownership, to allow for the identification of common ownership of nursing facilities. In addition, the Five Star Quality Ratings incorporated staffing data such as staff tenure and SNF weekend staffing beginning with the October 2022 refresh of the Nursing Home Compare website.

In January of 2023, CMS updated the Nursing Home Five-Star Quality Rating System’s Technical Users’ Guide. As explained in the latest update to this guide, CMS will be auditing schizophrenia coding within the MDS reported to CMS, with adjustments to quality ratings based on any inaccuracies in this schizophrenia-related data. Additionally, CMS will not display citations that a facility has informally disputed on the Nursing Home Compare website, although the outcome of such citations will only be included in the calculation of a facility’s star rating once the dispute is completed and the underlying survey considered final.

Table of Contents

In September 2023, CMS announced that it will update the staffing level case-mix adjustment methodology and freeze four of the quality measures used in the Nursing Home Five-Star Quality Rating System beginning with the April 2024 refresh of the Nursing Home Compare website’s data. This freeze is implemented to accommodate changes to the MDS so that information that will be added to the MDS can be gathered. For three months, until the July 2024 refresh of the Nursing Home Compare website rankings, CMS will freeze the staffing level measures for all SNFs. Beginning with the July 2024 refresh, CMS will change the staffing case-mix adjustment methodology to a model based on PDPM, which is discussed above. The Nursing Home Compare website will then begin posting staffing level measures that use this PDPM methodology. To incentivize SNFs to submit accurate staffing data, CMS will revise the staffing methodology to penalize SNFs that fail to submit staffing data, or submit erroneous data, by awarding them the lowest possible score for those measures beginning in April of 2024.

State Legislation Concerning Nursing Home Supervision — California passed into law a bill which changes the limitations, or “caps,” on non-economic damages that can be awarded in medical negligence cases filed against healthcare providers (including skilled nursing and long-term care facilities). Beginning on January 1, 2023, non-economic damages (i.e. pain and suffering) available to plaintiffs suing healthcare providers in medical malpractice and professional negligence cases increased from $0.25 million to $0.35 million, and will then increase over the following ten years up to a $0.75 million cap. Once the limit reaches $0.75 million, a 2% annual inflationary adjustment will attach beginning on January 1, 2034. In wrongful death cases that arise from claims of medical malpractice and professional negligence, the cap on non-economic damages increased from $0.25 million to $0.50 million on January 1, 2023, and increase every year thereafter for ten years until the cap on non-economic damages in such cases is $1.0 million; thereafter, this cap will also be subject to an annual 2% increase. The caps are separate as to each claim, meaning that there is one cap for negligence and one cap for wrongful death. The new limits on non-economic damages apply prospectively to lawsuits filed on and after January 1, 2023.

On September 27, 2022, California’s Governor signed into law the Skilled Nursing Facility Ownership and Management Reform Act of 2022. This law increases the oversight authority of the California Department of Public Health, and changes several provisions regarding SNF licensing in the State of California. This includes eliminating previous regulatory provisions that permitted SNFs to operate in advance of receiving their formal license from the State. This law also requires SNF license applicants to disclose additional information in connection with a license application and evaluates more data regarding the applicant’s prior operations, including prior citations, CMS sanctions and legal proceedings against the applicant or other facilities owned or managed by the applicant before issuing a license.

United States Supreme Court Decisions – On June 8, 2023, the United States Supreme Court issued its opinion in Health and Hospital Corporation of Marion County, Indiana (HHC) v. Talevski, which pertained to claims of mistreatment in a nursing home. The nursing home was publicly owned by the government county where it operated, rather than privately owned. The question before the Supreme Court was whether the Nursing Home Reform Act, passed as part of the Omnibus Budget Reconciliation Act of 1987, gave Talevski the right to sue HHC for a violation of his civil rights under 42 U.S.C. § 1983, a specific statute that allows for claims against persons who act for and on behalf of any government entity. The Supreme Court held that Talevski’s civil rights claim against HHC could proceed. While the facts of this case are of limited precedential value to our independent operating subsidiaries, which are not owned by and do not act on behalf of any government entity, this decision may draw wider public interest into claims against SNFs and assisted living facilities generally.

Monitoring Compliance in Our Facilities

Governmental agencies and other authorities periodically inspect our independent operating facilities to assess compliance with various standards, rules and regulations, with potential fines, sanctions and other penalties for noncompliance. Unannounced surveys or inspections generally occur at least annually and may also follow a government agency's receipt of a complaint about a facility. Facilities must pass these inspections to maintain licensure under state law, to obtain or maintain certification under the Medicare and Medicaid programs, to continue participation in the Veterans Administration program at some facilities, and to comply with provider contracts with managed care clients at many facilities. From time to time, our independent operating subsidiaries, like others in the healthcare industry, may receive notices from federal and state regulatory agencies of an alleged failure to substantially comply with applicable standards, rules or regulations. These notices may require corrective action, may impose civil monetary penalties for noncompliance, and may threaten or impose other operating restrictions on SNFs such as admission holds, provisional skilled nursing license, or increased staffing requirements. If our independent operating subsidiaries fail to comply with these directives or otherwise fail to comply substantially with licensure and certification laws, rules and regulations, the facility could lose its certification as a Medicare or Medicaid provider, or lose its license permitting operation in the State.

Table of Contents

Facilities with otherwise acceptable regulatory histories generally are given an opportunity to correct deficiencies and continue their participation in the Medicare and Medicaid programs by a certain date, usually within six months of inspection; however, although where denial of payment remedies are asserted, such interim remedies go into effect much sooner. Facilities with deficiencies that immediately jeopardize patient health and safety and those that are classified as poor performing facilities, however, may not be given an opportunity to correct their deficiencies prior to the imposition of remedies and other enforcement actions. Moreover, facilities with poor regulatory histories continue to be classified by CMS as poor performing facilities notwithstanding any intervening change in ownership, unless the new owner obtains a new Medicare provider agreement instead of assuming the facility's existing agreement. However, new owners nearly always assume the existing Medicare provider agreement due to the difficulty and time delays generally associated with obtaining new Medicare certifications, especially in previously certified locations with sub-par operating histories. Accordingly, facilities that have poor regulatory histories before acquisition by our independent operating subsidiaries and that develop new deficiencies after acquisition are more likely to have sanctions imposed upon them by CMS or state regulators.

In addition, CMS has increased its focus on facilities with a history of serious or sustained quality of care problems through the special focus facility (SFF) initiative. SFFs receive heightened scrutiny and more frequent regulatory surveys. Failure to improve the quality of care can result in fines and termination from participation in Medicare and Medicaid. A facility “graduates” from the program once it demonstrates significant improvements in quality of care that are continued over a defined period of time.

On October 21, 2022, CMS issued a Memorandum identifying the changes it intends to make in connection with the oversight of those facilities that fall under the SFF Program, including increased penalties for SFFs that fail to improve their performance upon further inspection by CMS, increasing the standards SFFs must meet to graduate from the SFF program, maintaining heightened oversight of any SFF for a period of three years after it graduates and increasing the technical assistance CMS provides to SFFs.

Sanctions such as denial of payment for new admissions often are scheduled to go into effect before surveyors return to verify compliance. Generally, if the surveyors confirm that the facility is in compliance upon their return, the sanctions never take effect. However, if they determine that the facility is not in compliance, the denial of payment goes into effect retroactive to the date given in the original notice, leaving operators with the task of deciding whether to continue accepting patients after the potential denial of payment date--risking the retroactive denial of revenue. Some of our independent operating subsidiaries have been or will be in denial of payment status due to findings of continued regulatory deficiencies, resulting in an actual loss of revenue associated with patients admitted after the denial of payment date. Additional sanctions could ensue and, if imposed, could include various remedies up to and including decertification.

CMS has undertaken several initiatives to increase or intensify Medicaid and Medicare survey and enforcement activities, including federal oversight of state surveyors. CMS is taking steps to focus more survey and enforcement efforts on facilities with findings of substandard care or repeat violations of Medicaid and Medicare standards and to identify multi-facility providers with patterns of noncompliance. CMS is also increasing its oversight of state survey agencies and requiring state agencies to use enforcement sanctions and remedies more promptly when substandard care or repeat violations are identified, to investigate complaints more promptly, and to survey facilities more consistently.

Regulations Regarding Financial Arrangements

We are also subject to federal and state laws that regulate financial arrangement by and between healthcare providers, such as the federal and state anti-kickback laws, the Stark laws, and various state anti-referral laws.

The Social Security Act prohibits the knowing and willful offer, payment, solicitation, or receipt of any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce the referral of an individual, in return for recommending, or to arrange for, the referral of an individual for any item or service payable under any federal healthcare program, including Medicare or Medicaid. The OIG has issued regulations that create “safe harbors” for certain conduct and business relationships that are deemed protected under the Social Security Act. In order to receive safe harbor protection, all of the requirements of a safe harbor must be met. The fact that a given business arrangement does not fall within one of these safe harbors does not render the arrangement per se illegal. Business arrangements of healthcare service providers that fail to satisfy the applicable safe harbor criteria, if investigated, will be evaluated on a case-by-case basis based upon all facts and circumstances and risk increased scrutiny and possible sanctions by enforcement authorities.

Table of Contents

Violations of the Social Security Act can result in inflation-adjusted criminal penalties of more than $0.1 million and ten years imprisonment. It can also result in inflation-adjusted civil monetary penalties of more than $0.1 million per violation and an assessment of up to three times the total amount of remuneration offered, paid, solicited, or received. It may also result in an individual's or organization's exclusion from future participation in federal healthcare programs. State Medicaid programs are required to enact an anti-kickback statute. Many states in which our independent operating subsidiaries operate have adopted or are considering similar legislative proposals, some of which extend beyond that state's e-Medicaid program, to prohibit the payment or receipt of remuneration for the referral of patients regardless of the source of payment for the care.

Additionally, the "Stark Law" of the Social Security Act provides that a physician may not refer a Medicare or Medicaid patient for a “designated health service” to an entity with which the physician or an immediate family member has a financial relationship unless the financial arrangement meets an exception under the Stark Law or its regulations. Designated health services include, in relevant part, inpatient and outpatient hospital services, PT, OT, SLP, durable medical equipment, prosthetics, orthotics and supplies, diagnostic imaging, and home health services. Under the Stark Law, a “financial relationship” is defined as an ownership or investment interest or a compensation arrangement. If such a financial relationship exists and does not meet a Stark Law exception, the entity is disallowed from seeking payment under the Medicare or Medicaid programs or from collecting from the patient or other payor. Statutory and regulatory exceptions and exemptions to this exist and have specific rules that must be followed to qualify for such exception or exemption. Any funds collected for an item or service resulting from a referral that violates the Stark Law are not eligible for payment by federal healthcare programs and must be repaid. Violations of the Stark Law may result in the imposition of civil monetary penalties, including, treble damages. Individuals and organizations may also be excluded from participation in federal healthcare programs for Stark Law violations. Many states have enacted healthcare provider referral laws that go beyond physician self-referrals or apply to a greater range of services than just the designated health services under the Stark Law.

Regulations Regarding Patient Record Confidentiality

Health care providers are also subject to laws and regulations enacted to protect the confidentiality of patient health information and patients' right to access such information. For example, HHS has issued rules pursuant to HIPAA, including the Health Information Technology for Economic and Clinical Health (HITECH) Act which governs our use and disclosure of protected health information of patients. We and our independent operating subsidiaries have established policies and procedures to comply with HIPAA privacy and security requirements and our independent operating subsidiaries have adopted and implemented HIPAA compliance plans, which we believe comply with the HIPAA privacy and security regulations, which impose significant costs for ongoing compliance activities.

There are numerous other laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns. Our independent operating subsidiaries are also subject to any federal or state privacy-related laws that are more restrictive than the privacy regulations issued under HIPAA.

Antitrust Laws

We are also subject to federal and state antitrust laws. Enforcement of the antitrust laws against healthcare providers is common, and antitrust liability may arise in a wide variety of circumstances, including third party contracting, physician relations, joint venture, merger, affiliation and acquisition activities. On February 3, 2023, the DOJ’s Antitrust Division withdrew its support for three policies that had been jointly created by the DOJ and the Federal Trade Commission (FTC) in 1993, 1996, and 2011, announcing instead, without providing further alternative guidance, that the DOJ would take a case-by-case enforcement approach to evaluate conduct in the healthcare industry, citing that the previous policies were outdated and overly permissive. Similarly, on July 14, 2023, the FTC withdrew two antitrust policy statements related to enforcement in healthcare markets. Moving forward, the FTC will evaluate mergers and conduct in healthcare markets on a case-by-case basis using principles of antitrust enforcement and competition policy.

Table of Contents

On July 19, 2023, the DOJ and FTC released a draft joint statement of antitrust policy that outlines 13 guidelines to be used when determining if a merger is unlawfully anticompetitive under antitrust laws. These guidelines cover various aspects of antitrust enforcement relevant to SNF and senior living facilities, such as market concentration, competition between firms, risk of coordination, elimination of potential entrants, control of products or services, vertical mergers, dominant positions, trends toward concentration, series of multiple acquisitions, multi-sided platforms, competing buyers, partial ownership or minority interests and overall impact on competition. The draft joint statement also includes detailed sections on the application of the guidelines, defining relevant markets and approaches to rebuttal evidence. These proposed statements are not exhaustive and the DOJ and FTC may focus on one or multiple guidelines depending on the specific circumstances of each merger. These proposed general statements of antitrust policy, once finalized, may be a prelude to a new joint statement of healthcare antitrust policy of the DOJ and FTC, with the agencies’ finalized general statements providing insight into whether healthcare-specific statements will be issued. This development and potential new guidance regarding DOJ and FTC antitrust policy increases risk and uncertainty regarding transactions that may be subject to criminal and civil enforcement by federal and state agencies, as well as by private litigants.

Americans with Disabilities Act

Our independent operating subsidiaries must also comply with the ADA, and similar state and local laws to the extent that the facilities are "public accommodations" as defined in those laws. The obligation to comply with the ADA and other similar laws is an ongoing obligation, and the independent operating subsidiaries continue to assess their facilities relative to ADA compliance and make appropriate modifications as needed.

Real Estate Investment Trust (REIT) Qualification

We elected for Standard Bearer to be taxed as a REIT for U.S. federal income tax purposes beginning with its taxable year ended December 31, 2022. Standard Bearer's qualification as a REIT will depend upon its ability to meet, on a continuing basis, various complex requirements under the Internal Revenue Code, relating to, among other things, the sources of its gross income, the composition and value of its assets, distribution levels to its shareholders and the concentration of ownership of its capital stock. We believe that Standard Bearer is organized in conformity with the requirements for qualification and taxation as a REIT under the Code and that its manner of operation has and will enable it to continue to meet the requirements for qualification and taxation as a REIT.

REGULATIONS SPECIFIC TO SENIOR LIVING COMMUNITIES

As previously mentioned, senior living services revenue (approximately 2.1% of total revenue) is primarily derived from private pay residents, with a small portion of senior living revenue derived from Medicaid funds. Thus, some of the regulations discussed above applicable to Medicaid providers, also apply to senior living.

A majority of states provide, or are approved to provide, Medicaid payments for personal care and medical services to some residents in licensed senior living communities. As rates paid to senior living community operators are generally lower than rates paid to SNF operators, some states use Medicaid funding of senior living services as a means of lowering the cost of services for residents who may not need the higher level of health services provided in SNFs. States that administer Medicaid programs for services in senior living communities are responsible for monitoring the participating communities and, as a result of the growth of senior living in recent years, these states have adopted licensing standards applicable to senior living communities.

CMS has continued to commence a series of actions to increase its oversight of state quality assurance programs for senior living communities and has provided guidance and technical assistance to states to improve their ability to monitor and improve the quality of services paid through Medicaid waiver programs. CMS is encouraging state Medicaid programs to expand their use of home and community-based services as alternatives to facility-based services, pursuant to provisions of the ACA, and other authorities, through the use of several programs.

The types of laws and statutes affecting the regulatory landscape of the post-acute industry continue to expand and the pressure to enforce those laws by federal and state authorities continues to grow as well. In order to operate our businesses, we and our independent operating subsidiaries must comply with myriad federal, state and local laws from healthcare including provisions regarding patient safety, staffing, and prescription drugs to environmental issues. Changes in the law or new interpretations of existing laws may have an adverse impact on our methods and costs of doing business.

Table of Contents

RESULTS OF OPERATIONS

We believe we exist to dignify and transform post-acute care. We set out a strategy to achieve our goal of ensuring our patients are receiving the best possible care through our ability to acquire, integrate and improve our operations. Our results serve as a strong indicator that our strategy is working and our transformation is underway.

Our total revenue for the three months ended September 30, 2023 increased $170.8 million, or 22.2%, while our diluted GAAP earnings per share grew by 12.1%, from $0.99 to $1.11, compared to the three months ended September 30, 2022. Throughout 2023, we have continued to make progress on targeted initiatives related to increasing occupancy in our facilities, attracting and developing our people and acquiring new skilled nursing operations and integrating them with our proven cultural and operational principals.

Our combined Same Facilities and Transitioning Facilities occupancy increased by 2.9% compared to the three months ended September 30, 2022. As our census continues to return to pre-pandemic levels, we anticipate a return to our historical seasonality trends, which typically result in higher occupancy and skilled mix during the first and fourth quarters and softening in the second and third quarters. See Recent Activities for our operational update.

During the nine months ended September 30, 2023, we added 24 new operations, which included 17 operations in California. These California facilities include a group of highly skilled team members who will further our mission of dignifying long term care. We continue to work diligently with existing and recently acquired operations so that each can reach its full clinical and financial potential.

Our strength remains in our operating model, which empowers each operator to form their own market-specific strategy and adjust to the needs of their local medical communities, including methods for attracting new healthcare professionals into our workforce and retaining and developing existing staff. Despite continued labor pressures, there are positive trends on both turnover and agency usage in some of our markets.

The following table sets forth details of operating results for our revenue, expenses and earnings, and their respective components, as a percentage of total revenue for the periods indicated:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022

REVENUE:
Service revenue	99.4	%	99.5	%	99.4	%	99.4	%
Rental revenue	0.6		0.5		0.6		0.6
TOTAL REVENUE	100.0	%	100.0	%	100.0	%	100.0	%


Expenses:
Cost of services	78.8		78.1		78.6		77.7



Rent—cost of services	5.4		5.1		5.3		5.0
General and administrative expense	5.4		5.1		5.7		5.2
Depreciation and amortization	1.9		2.1		1.9		2.1
TOTAL EXPENSES	91.5		90.4		91.5		90.0
Income from operations	8.5		9.6		8.5		10.0
Other income (expense):
Interest expense	(0.2)		(0.2)		(0.2)		(0.3)
Other income (expense)	0.4		—		0.5		(0.2)
Other income (expense), net	0.2		(0.2)		0.3		(0.5)
Income before provision for income taxes	8.7		9.4		8.8		9.5
Provision for income taxes	1.9		2.1		2.0		2.1


NET INCOME	6.8		7.3		6.8		7.4
Less: net income attributable to noncontrolling interests	—		—		—		—

Net income attributable to The Ensign Group, Inc.	6.8	%	7.3	%	6.8	%	7.4	%

Table of Contents


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022

SEGMENT INCOME(1)	(In thousands)
Skilled services	$	117,816	$	101,750	$	348,169	$	302,272
Standard Bearer(2)	7,165		6,941		21,517		20,679
NON-GAAP FINANCIAL MEASURES:
PERFORMANCE METRICS

Adjusted EBT	92,091		78,964		266,906		230,922
EBITDA	98,133		90,165		285,376		267,181


Adjusted EBITDA	108,044		96,588		310,620		285,413

FFO for Standard Bearer	13,594		12,502		40,045		36,477

VALUATION METRICS
Adjusted EBITDAR	$	158,401			$	457,374

(1) Segment income represents operating results of the reportable segments excluding gain and loss on sale of assets, real estate insurance recoveries and losses, impairment charges and provision for income taxes. Included in segment income for Standard Bearer are expenses for intercompany management fees between Standard Bearer and the Service Center and intercompany interest expense. Segment income is reconciled to the Condensed Consolidated Statement of Income in Note 8, Business Segments in Notes to Interim Financial Statements of this Quarterly Report on Form 10-Q.

(2) Standard Bearer segment income includes rental revenue from Ensign affiliated tenants and expenses.

The following discussion includes references to Adjusted EBT, EBITDA, Adjusted EBITDA, Adjusted EBITDAR and Funds from Operations (FFO) which are non-GAAP financial measures (collectively, the Non-GAAP Financial Measures). Regulation G, Conditions for Use of Non-GAAP Financial Measures, and other provisions of the Securities Exchange Act of 1934, as amended (the Exchange Act), define and prescribe the conditions for use of certain non-GAAP financial information. These Non-GAAP Financial Measures are used in addition to and in conjunction with results presented in accordance with GAAP. These Non-GAAP Financial Measures should not be relied upon to the exclusion of GAAP financial measures. These Non-GAAP Financial Measures reflect an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting our business.

We believe the presentation of certain Non-GAAP Financial Measures are useful to investors and other external users of our financial statements regarding our results of operations because:

•they are widely used by investors and analysts in our industry as a supplemental measure to evaluate the overall performance of companies in our industry without regard to items such as other income (expense), net and depreciation and amortization, which can vary substantially from company to company depending on the book value of assets, capital structure and the method by which assets were acquired; and

•they help investors evaluate and compare the results of our operations from period to period by removing the impact of our capital structure and asset base from our operating results.

We use the Non-GAAP Financial Measures:

•as measurements of our operating performance to assist us in comparing our operating performance on a consistent basis;

•to allocate resources to enhance the financial performance of our business;

•to assess the value of a potential acquisition;

•to assess the value of a transformed operation's performance;

•to evaluate the effectiveness of our operational strategies; and

•to compare our operating performance to that of our competitors.

We use certain Non-GAAP Financial Measures to compare the operating performance of each operation. These measures are useful in this regard because they do not include such costs as other expense, income taxes, depreciation and amortization expense, which may vary from period-to-period depending upon various factors, including the method used to finance operations, the amount of debt that we have incurred, whether an operation is owned or leased, the date of acquisition of a facility or business, and the tax law of the state in which a business unit operates.

Table of Contents

We also establish compensation programs and bonuses for our leaders that are partially based upon the achievement of Adjusted EBITDAR targets.

Despite the importance of these measures in analyzing our underlying business, designing incentive compensation and for our goal setting, the Non-GAAP Financial Measures have no standardized meaning defined by GAAP. Therefore, certain of our Non-GAAP Financial Measures have limitations as analytical tools, and they should not be considered in isolation, or as a substitute for analysis of our results as reported in accordance with GAAP. Some of these limitations are:

•they do not reflect our current or future cash requirements for capital expenditures or contractual commitments;

•they do not reflect changes in, or cash requirements for, our working capital needs;

•they do not reflect the interest expense, or the cash requirements necessary to service interest or principal payments, on our debt;

•they do not reflect rent expenses, which are necessary to operate our leased operations, in the case of Adjusted EBITDAR;

•they do not reflect any income tax payments we may be required to make;

•although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and do not reflect any cash requirements for such replacements; and

•other companies in our industry may calculate these measures differently than we do, which may limit their usefulness as comparative measures.

We compensate for these limitations by using them only to supplement net income on a basis prepared in accordance with GAAP in order to provide a more complete understanding of the factors and trends affecting our business.

Management strongly encourages investors to review our consolidated financial statements in their entirety and to not rely on any single financial measure. Because these Non-GAAP Financial Measures are not standardized, it may not be possible to compare these financial measures with other companies’ Non-GAAP financial measures having the same or similar names. These Non-GAAP Financial Measures should not be considered a substitute for, nor superior to, financial results and measures determined or calculated in accordance with GAAP. We strongly urge you to review the reconciliation of income from operations to the Non-GAAP Financial Measures in the table below, along with our Interim Financial Statements and related notes included elsewhere in this document.

We use the following Non-GAAP financial measures that we believe are useful to investors as key valuation and operating performance measures:

PERFORMANCE MEASURES

Adjusted EBT

We adjust income before provision for income taxes (Adjusted EBT) when evaluating our performance because we believe that the exclusion of certain additional items described below provides useful supplemental information to investors regarding our ongoing operating performance, in the case of Adjusted EBT. We believe that the presentation of Adjusted EBT, when combined with income before provision for income taxes and GAAP net income attributable to The Ensign Group, Inc., is beneficial to an investor’s complete understanding of our operating performance. We use this performance measure as an indicator of business performance, as well as for operational planning, decision-making purposes and to determine compensation in our executive compensation plan.

Adjusted EBT is income before provision for income taxes adjusted for non-core business items, which for the reported periods includes, to the extent applicable:

•stock-based compensation expense;

•legal costs and adjustments;

•gain on business interruption of recoveries and sale of assets;

•write-off of deferred financing fees;

•acquisition related costs;

•costs incurred related to new systems implementation; and

Table of Contents

•depreciation and amortization of patient base intangible assets.

EBITDA

We believe EBITDA is useful to investors in evaluating our operating performance because it helps investors evaluate and compare the results of our operations from period to period by removing the impact of our asset base (depreciation and amortization expense) from our operating results.

We calculate EBITDA as net income, adjusted for net losses attributable to noncontrolling interest, before (a) other income (expense), net, (b) provision for income taxes, and (c) depreciation and amortization.

Adjusted EBITDA

We adjust EBITDA when evaluating our performance because we believe that the exclusion of certain additional items described below provides useful supplemental information to investors regarding our ongoing operating performance, in the case of Adjusted EBITDA. We believe that the presentation of Adjusted EBITDA, when combined with EBITDA and GAAP net income attributable to The Ensign Group, Inc., is beneficial to an investor’s complete understanding of our operating performance.

Adjusted EBITDA is EBITDA adjusted for the same non-core business items as listed in Adjusted EBT, except for depreciation and amortization of patient base intangible assets and write-off of deferred financing fees.

Funds from Operations (FFO)

We consider FFO to be a useful supplemental measure of the operating performance of Standard Bearer. Historical cost accounting for real estate assets in accordance with U.S. GAAP implicitly assumes that the value of real estate assets diminishes predictably over time as evidenced by the provision for depreciation. However, since real estate values have historically risen or fallen with market conditions, many real estate investors and analysts have considered presentations of operating results for real estate companies that use historical cost accounting to be insufficient. In response, the National Association of Real Estate Investment Trusts (NAREIT) created FFO as a supplemental measure of operating performance for REITs, which excludes historical cost depreciation from net income. We define (in accordance with the definition used by NAREIT) FFO to consist of Standard Bearer segment income, excluding depreciation and amortization related to real estate, gains or losses from the sale of real estate, insurance recoveries related to real estate and impairment of depreciable real estate assets.

VALUATION MEASURE

Adjusted EBITDAR

We use Adjusted EBITDAR as one measure in determining the value of prospective acquisitions. It is also a commonly used measure by our management, research analysts and investors, to compare the enterprise value of different companies in the healthcare industry, without regard to differences in capital structures and leasing arrangements. Adjusted EBITDAR is a financial valuation measure that is not specified in GAAP. This measure is not displayed as a performance measure as it excludes rent expense, which is a normal and recurring operating expense, and is therefore presented only for the current period.

The adjustments made and previously described in the computation of Adjusted EBITDA are also made when computing Adjusted EBITDAR. We calculate Adjusted EBITDAR by excluding rent-cost of services from Adjusted EBITDA.

We believe the use of Adjusted EBITDAR allows the investor to compare operational results of companies who have operating and capital leases. A significant portion of capital lease expenditures are recorded in interest, whereas operating lease expenditures are recorded in rent expense.

Table of Contents

The table below reconciles income before provision for income taxes to Adjusted EBT for the periods presented:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022

Consolidated statements of income data:	(In thousands)
Income before provision for income taxes	$	82,045	$	72,455	$	241,480	$	211,638

Stock-based compensation expense	7,237		5,898		22,691		16,681

Legal costs and adjustments(a)	2,783		859		1,965		4,485
Gain on business interruption recoveries and sale of assets	(259)		(900)		(1,009)		(3,467)


Write-off of deferred financing fees(b)	—		—		—		566
Acquisition related costs(c)	150		245		722		416
Costs incurred related to new systems implementation	—		321		875		390
Depreciation and amortization - patient base(d)	135		86		182		213
ADJUSTED EBT	$	92,091	$	78,964	$	266,906	$	230,922

(a) Legal costs incurred in connection with the medical directors related matter. Legal adjustments relate to findings attributable to our ancillary services subsidiary, which includes the portion attributable to non-controlling interests.

(b) Represents the write-off of deferred financing fees associated with the amendment of the credit facility.

(d) Included in depreciation and amortization are amortization expenses related to patient base intangible assets at newly acquired skilled nursing and senior living facilities.

The table below reconciles net income to EBITDA, Adjusted EBITDA and Adjusted EBITDAR for the periods presented:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022

Consolidated statements of income data:	(In thousands)
Net income	$	63,968	$	56,242	$	188,027	$	164,133
Less: net income (loss) attributable to noncontrolling interests	105		63		319		(77)

Add: Other (income) expense, net	(2,253)		1,832		(8,939)		9,991
Provision for income taxes	18,077		16,213		53,453		47,505
Depreciation and amortization	18,446		15,941		53,154		45,475


EBITDA	$	98,133	$	90,165	$	285,376	$	267,181

Stock-based compensation expense	7,237		5,898		22,691		16,681

Legal costs and adjustments(a)	2,783		859		1,965		4,212
Gain on business interruption recoveries and sale of assets	(259)		(900)		(1,009)		(3,467)


Acquisition related costs(b)	150		245		722		416
Costs incurred related to new systems implementation	—		321		875		390





ADJUSTED EBITDA	$	108,044	$	96,588	$	310,620	$	285,413
Rent—cost of services	50,357		38,907		146,754		111,897



ADJUSTED EBITDAR	$	158,401			$	457,374

(a) Legal costs incurred in connection with the medical directors related matter. Legal adjustments relate to findings attributable to our ancillary services subsidiary, which excludes the portion attributable to non-controlling interests.

(b) Costs incurred to acquire operations that are not capitalizable.

Table of Contents

Three Months Ended September 30, 2023 Compared to the Three Months Ended September 30, 2022

The following table sets forth details of operating results for our revenue and earnings, and their respective components, by our reportable segment for the periods indicated.


	Three Months Ended September 30, 2023
	Skilled services		Standard Bearer		All Other		Eliminations		Consolidated
Total Revenue	$	902,967	$	20,980	$	39,124	$	(22,280)	$	940,791
Total expenses, including other income, net	785,151		13,815		82,060		(22,280)		858,746
Segment income (loss)	117,816		7,165		(42,936)		—		82,045

Income before provision for income taxes									$	82,045


	Three Months Ended September 30, 2022
	Skilled services		Standard Bearer		All Other		Eliminations		Consolidated
Total Revenue	$	739,318	$	18,732	$	31,844	$	(19,889)	$	770,005
Total expenses, including other income, net	637,568		11,791		68,880		(19,889)		698,350
Segment income (loss)	101,750		6,941		(37,036)		—		71,655
Gain on sale of assets, net	—		—		—		—		800
Income before provision for income taxes									$	72,455

Our total revenue increased by $170.8 million, or 22.2%, compared to the three months ended September 30, 2022. The increase in revenue was driven by an increase in occupancy from Medicaid non-skilled services as well as the impact of acquisitions. Total revenue from operations acquired on or subsequent to October 1, 2022 increased our consolidated service revenue by $117.3 million during the three months ended September 30, 2023, when compared to the same period in 2022. These increases were offset by a decline in state relief funds. We recorded $10.3 million of state relief revenue in the third quarter of 2023 compared to $21.4 million in the same period in 2022. All state relief revenue is included in Medicaid revenue.

Skilled Services

REVENUE

The following table presents the skilled services revenue and key performance metrics by category during the three months ended September 30, 2023 and 2022:


	Three Months Ended September 30,
	2023			2022			Change		% Change

TOTAL FACILITY RESULTS:	(Dollars in thousands)
Skilled services revenue	$	902,967		$	739,318		$	163,649	22.1	%
Number of facilities at period end	258			222			36		16.2	%
Number of campuses at period end*	26			26			—		—	%
Actual patient days	2,190,540			1,846,699			343,841		18.6	%
Occupancy percentage — Operational beds	78.9		%	75.7		%			3.2	%
Skilled mix by nursing days	29.1		%	31.6		%			(2.5)	%
Skilled mix by nursing revenue	48.4		%	51.6		%			(3.2)	%

Table of Contents


	Three Months Ended September 30,
	2023			2022			Change		% Change

SAME FACILITY RESULTS:(1)	(Dollars in thousands)
Skilled services revenue	$	692,257		$	649,690		$	42,567	6.6	%
Number of facilities at period end	189			189			—		—	%
Number of campuses at period end*	24			24			—		—	%
Actual patient days	1,660,683			1,596,942			63,741		4.0	%
Occupancy percentage — Operational beds	79.5		%	76.6		%			2.9	%
Skilled mix by nursing days	30.7		%	33.0		%			(2.3)	%
Skilled mix by nursing revenue	49.8		%	53.1		%			(3.3)	%


	Three Months Ended September 30,
	2023			2022			Change		% Change

TRANSITIONING FACILITY RESULTS:(2)	(Dollars in thousands)
Skilled services revenue	$	62,979		$	59,773		$	3,206	5.4	%
Number of facilities at period end	22			22			—		—	%
Number of campuses at period end*	1			1			—		—	%
Actual patient days	165,645			158,856			6,789		4.3	%
Occupancy percentage — Operational beds	76.2		%	73.5		%			2.7	%
Skilled mix by nursing days	20.0		%	23.1		%			(3.1)	%
Skilled mix by nursing revenue	36.1		%	40.5		%			(4.4)	%


	Three Months Ended September 30,
	2023			2022			Change		% Change

RECENTLY ACQUIRED FACILITY RESULTS:(3)	(Dollars in thousands)
Skilled services revenue	$	147,731		$	29,855		$	117,876	NM
Number of facilities at period end	47			11			36		NM
Number of campuses at period end*	1			1			—		NM
Actual patient days	364,212			90,901			273,311		NM
Occupancy percentage — Operational beds	77.4		%	65.6		%			NM
Skilled mix by nursing days	26.1		%	22.6		%			NM
Skilled mix by nursing revenue	46.9		%	39.3		%			NM

*Campus represents a facility that offers both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective operating segment.

(1)Same Facility results represent all facilities purchased prior to January 1, 2020.

(2)Transitioning Facility results represent all facilities purchased from January 1, 2020 to December 31, 2021.

(3)Recently Acquired Facility (Acquisitions) results represent all facilities purchased on or subsequent to January 1, 2022.

Skilled services revenue increased by $163.6 million, or 22.1%, compared to the three months ended September 30, 2022. The increases in skilled services revenue were across all payer types including increases in Medicaid revenue of $83.0 million, or 23.9%, Medicare revenue of $26.4 million, or 12.5%, managed care revenue of $38.1 million, or 28.7% and private revenue of $16.1 million, or 33.0%.

The increase in skilled services revenue was primarily driven by strong performance across our skilled services operations as our occupancy continued to recover in the third quarter of 2023, as well as the favorable impact of skilled census from our recent acquisitions. Our consolidated occupancy increased by 3.2% during the three months ended September 30, 2023 compared to the same period in 2022. As our census continues to return to pre-pandemic levels, we anticipate a return to our historical seasonality trends, which typically result in higher occupancy and skilled mix during the first and fourth quarters and softening in the second and third quarters. See Recent Activities for our operational update.

Table of Contents

Revenue in our Same Facilities increased by $42.6 million, or 6.6% due to increased occupancy and a shift to higher Medicaid and private census. Our diligent efforts to strengthen our partnerships with various managed care organizations, hospitals and the local communities we operate in increased our managed care days by 6.9% and managed care revenue per patient day by 6.6%, resulting in an increase in managed care revenue of 15.9%. In addition, Medicaid revenue increased by $30.7 million or 10.3%, mainly from the increase in days and Medicaid revenue per patient day. With the ending of the PHE, we experienced a decrease in acuity due to the return of seasonal trends.

Revenue generated by our Transitioning Facilities increased by $3.2 million, or 5.4%, primarily due to improved occupancy growth and an increase in revenue per patient day. Our Medicaid days and private days increased by 9.0% and 5.6%, respectively, demonstrating our ability to focus on increasing occupancy across various payer types. We experienced a decrease in Medicare revenue and skilled days as our normal seasonality returns in the post-pandemic environment.

Skilled services revenue generated by Recently Acquired Facilities increased by $117.9 million compared to the three months ended September 30, 2022. We acquired 36 operations between October 1, 2022 and September 30, 2023 across six states.

In the future, if we acquire additional turnaround or start-up operations, we expect to see lower occupancy rates and skilled mix and these metrics are expected to vary from period to period based upon the maturity of the facilities within our portfolio. Historically, we have generally experienced lower occupancy rates and lower skilled mix at Recently Acquired Facilities and therefore, we anticipate generally lower overall occupancy during years of growth. Included in our metrics for Recently Acquired Facilities are 17 facilities we acquired that are mature and have higher occupancy rates, higher skilled mix days and higher skilled mix revenue than our typical acquisitions.

The following table reflects the change in skilled nursing average daily revenue rates by payor source, excluding services that are not covered by the daily rate (1):


	Three Months Ended September 30,
	Same Facility				Transitioning				Acquisitions				Total
	2023		2022		2023		2022		2023		2022		2023		2022

SKILLED NURSING AVERAGE DAILY REVENUE RATES:
Medicare	$	721.35	$	684.58	$	699.44	$	669.29	$	800.93	$	652.66	$	735.66	$	682.41
Managed care	544.85		511.35		539.53		487.16		560.44		422.21		546.36		508.13
Other skilled	584.77		566.00		518.59		514.55		433.72		425.91		562.61		552.31
Total skilled revenue	615.02		593.71		612.82		587.23		663.54		510.11		622.12		590.36
Medicaid	277.82		258.54		274.44		262.17		263.95		236.02		275.09		257.57
Private and other payors	263.19		251.48		251.08		244.55		267.56		180.79		262.97		248.01
Total skilled nursing revenue	$	379.79	$	368.27	$	339.42	$	335.24	$	368.46	$	293.23	$	374.85	$	361.74

(1) These rates exclude state relief funding.

Our Medicare daily rates at Same Facilities and Transitioning Facilities increased by 5.4% and 4.5%, respectively, compared to the three months ended September 30, 2022. The increase is attributable to the 2.7% net market basket increase that became effective in October 2022. In addition, we have seen a shift to higher acuity patients.

Our average Medicaid rates increased 6.8% due to state reimbursement increases and our participation in supplemental Medicaid payment programs and quality improvement programs in various states. Medicaid rates exclude the amount of state relief revenue we recorded.

Payor Sources as a Percentage of Skilled Nursing Services. We use our skilled mix as measures of the quality of reimbursements we receive at our affiliated skilled nursing facilities over various periods.

Table of Contents

The following tables set forth our percentage of skilled nursing patient revenue and days by payor source:


	Three Months Ended September 30,
	Same Facility				Transitioning				Acquisitions				Total
	2023		2022		2023		2022		2023		2022		2023		2022
PERCENTAGE OF SKILLED NURSING REVENUE
Medicare	20.8	%	26.1	%	19.6	%	24.6	%	28.9	%	18.9	%	22.0	%	25.7	%
Managed care	20.2		19.0		12.7		11.9		13.2		7.9		18.6		18.0
Other skilled	8.8		8.0		3.8		4.0		4.8		12.5		7.8		7.9
Skilled Mix	49.8		53.1		36.1		40.5		46.9		39.3		48.4		51.6
Private and other payors	7.9		7.2		8.7		8.4		8.2		5.2		8.0		7.2

Medicaid	42.3		39.7		55.2		51.1		44.9		55.5		43.6		41.2
TOTAL SKILLED NURSING	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%


	Three Months Ended September 30,
	Same Facility				Transitioning				Acquisitions				Total
	2023		2022		2023		2022		2023		2022		2023		2022
PERCENTAGE OF SKILLED NURSING DAYS
Medicare	10.9	%	14.0	%	9.5	%	12.3	%	13.3	%	8.5	%	11.2	%	13.6	%
Managed care	14.1		13.7		8.0		8.2		8.7		5.5		12.7		12.8
Other skilled	5.7		5.3		2.5		2.6		4.1		8.6		5.2		5.2
Skilled Mix	30.7		33.0		20.0		23.1		26.1		22.6		29.1		31.6
Private and other payors	11.5		10.5		11.8		11.6		11.2		8.5		11.5		10.5

Medicaid	57.8		56.5		68.2		65.3		62.7		68.9		59.4		57.9
TOTAL SKILLED NURSING	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%

Cost of Services

The following table sets forth total cost of services for our Skilled services segment for the periods indicated (dollars in thousands):



	Three Months Ended September 30,				Change
	2023			2022	$			%

Cost of service	$	713,290			$	579,199			$	134,091	23.2	%
Revenue percentage	79.0		%		78.3		%				0.7	%

Cost of services related to our skilled services segment increased by $134.1 million, or 23.2%. Cost of services as a percentage of revenue increased to 79.0% from 78.3% due to costs related to new acquisitions, increase in professional liabilities reserves and higher staffing expenses as a result of the challenging labor environment. The increase in wages and benefits is offset by the decrease in contract labor usage as we made progress on retention and hiring.

Standard Bearer


	Three Months Ended September 30,				Change
	2023		2022		$		%

	(Dollars in thousands)
Rental revenue generated from third-party tenants	$	4,004	$	3,708	$	296	8.0	%
Rental revenue generated from Ensign affiliated operations	16,976		15,024		1,952		13.0
TOTAL RENTAL REVENUE	$	20,980	$	18,732	$	2,248	12.0	%
Segment income	7,165		6,941		224		3.2
Depreciation and amortization	6,429		5,561		868		15.6

FFO	$	13,594	$	12,502	$	1,092	8.7	%

Table of Contents

Rental revenue — Our rental revenue, including revenue generated from our affiliated facilities, increased by $2.2 million, or 12.0%, to $21.0 million, compared to the three months ended September 30, 2022. The increase in revenue is primarily attributable to six real estate purchases, as well as annual rent increases since the three months ended September 30, 2022.

FFO — Our FFO increased by $1.1 million, or 8.7%, to $13.6 million, compared to the three months ended September 30, 2022. The increase in rental revenue of $2.2 million is offset by increases in interest expense of $1.1 million associated with the intercompany agreements between Standard Bearer and the Service Center.

All Other Revenue

Our other revenue increased by $7.3 million, or 22.9%, to $39.1 million, compared to the three months ended September 30, 2022. Other revenue for 2023 includes senior living revenue of $18.9 million, revenue from other ancillary services of $17.3 million and rental income of $2.9 million. The increase in other revenue is primarily attributable to our other ancillary services.

Consolidated Financial Expenses

Rent-cost of services — Our rent-cost of services as a percentage of total revenue increased by 0.3% to 5.4%, primarily due to lease obligations acquired as part of our 31 operational expansions with long-term leases since the three months ended September 30, 2022.

General and administrative expense — General and administrative expense increased $11.9 million or 30.3%, to $51.1 million. General and administrative expense as a percentage of revenue increased by 0.3% to 5.4%. This increase was primarily due to increased legal costs and headcount due to acquisition activities. Excluding the legal costs, general and administrative expense as a percentage of revenue remained consistent at 5.1%.

Depreciation and amortization — Depreciation and amortization expense increased $2.5 million, or 15.7%, to $18.4 million. This increase was primarily related to the additional depreciation and amortization incurred as a result of our newly acquired operations and capital expenditures. Depreciation and amortization decreased 0.2%, to 1.9%, as a percentage of revenue.

Other income (expense), net — Other income (expense), net as a percentage of revenue increased by 0.4%. Other income primarily includes interest income from our investments offset by interest expense related to our debt. Additionally our deferred investment program incurs gains or losses depending on market performance. During the three months ended September 30, 2023 and 2022, the deferred compensation investment program had a loss of $1.4 million and $1.1 million, respectively. There is an offsetting reduction in expense allocated between cost of services and general and administrative expenses.

Provision for income taxes — Our effective tax rate was 22.0% for the three months ended September 30, 2023, compared to 22.4% for the same period in 2022. The effective tax rate for both periods is driven by the impact of excess tax benefits from stock-based compensation, partially offset by non-deductible expenses including non-deductible compensation. See Note 14, Income Taxes, in the Notes to the Interim Financial Statements for further discussion.

Nine Months Ended September 30, 2023 Compared to the Nine Months Ended September 30, 2022

The following table sets forth details of operating results for our revenue and earnings, and their respective components, by our reportable segment for the periods indicated.


	Nine Months Ended September 30, 2023
	Skilled Services		Standard Bearer		All Other		Eliminations		Consolidated
Total revenue	$	2,638,090	$	60,611	$	114,574	$	(64,298)	$	2,748,977
Total expenses, including other expense, net	2,289,921		39,094		242,680		(64,298)		2,507,397
Segment income (loss)	348,169		21,517		(128,106)		—		241,580
Loss on real estate insurance recoveries									(100)
Income before provision for income taxes									$	241,480

Table of Contents


	Nine Months Ended September 30, 2022
	Skilled Services		Standard Bearer		All Other		Eliminations		Consolidated
Total revenue	$	2,128,567	$	53,523	$	89,793	$	(55,947)	$	2,215,936
Total expenses, including other expense, net	1,826,295		32,844		204,373		(55,947)		2,007,565
Segment income (loss)	302,272		20,679		(114,580)		—		208,371
Gain from sale of real estate									3,267
Income before provision for income taxes									$	211,638

Our total revenue increased $533.0 million, or 24.1%, compared to the nine months ended September 30, 2022. The increase in revenue was primarily driven by an increase in occupancy and patient days from our skilled services operations and the impact of acquisitions. Total revenue from operations acquired on or subsequent to October 1, 2022 increased our consolidated service revenue by $300.1 million during the nine months ended September 30, 2023, when compared to the same period in 2022. In addition, we recorded $55.1 million of state relief revenue during the nine months ended September 30, 2023 compared to $63.5 million in 2022, which directly correlated to the additional COVID-19 related labor expenses incurred. All state relief revenue is included in Medicaid revenue.

Skilled Services Segment

Revenue

The following table presents the skilled services revenue and key performance metrics by category during the nine months ended September 30, 2023 and 2022:


	Nine Months Ended September 30,
	2023			2022		Change		% Change

TOTAL FACILITY RESULTS:	(Dollars in thousands)
Skilled services revenue	$	2,638,090		2,128,567		$	509,523	23.9	%
Number of facilities at period end	258			222		36		16.2	%
Number of campuses at period end*	26			26		—		—	%
Actual patient days	6,363,107			5,287,690		1,075,417		20.3	%
Occupancy percentage — Operational beds	78.3		%	75.0	%			3.3	%
Skilled mix by nursing days	30.7		%	32.1	%			(1.4)	%
Skilled mix by nursing revenue	50.6		%	52.3	%			(1.7)	%


	Nine Months Ended September 30,
	2023			2022			Change		% Change

SAME FACILITY RESULTS:(1)	(Dollars in thousands)
Skilled services revenue	$	2,058,291		$	1,909,387		$	148,904	7.8	%
Number of facilities at period end	189			189			—		—	%
Number of campuses at period end*	24			24			—		—	%
Actual patient days	4,895,304			4,680,168			215,136		4.6	%
Occupancy percentage — Operational beds	78.9		%	75.5		%			3.4	%
Skilled mix by nursing days	32.2		%	33.1		%			(0.9)	%
Skilled mix by nursing revenue	51.8		%	53.4		%			(1.6)	%

Table of Contents


	Nine Months Ended September 30,
	2023			2022			Change		% Change

TRANSITIONING FACILITY RESULTS:(2)	(Dollars in thousands)
Skilled services revenue	$	186,948		$	171,428		$	15,520	9.1	%
Number of facilities at period end	22			22			—		—	%
Number of campuses at period end*	1			1			—		—	%
Actual patient days	489,310			462,848			26,462		5.7	%
Occupancy percentage — Operational beds	76.0		%	72.1		%			3.9	%
Skilled mix by nursing days	21.8		%	23.4		%			(1.6)	%
Skilled mix by nursing revenue	38.9		%	41.8		%			(2.9)	%


	Nine Months Ended September 30,
	2023			2022			Change		% Change

RECENTLY ACQUIRED FACILITY RESULTS:(3)	(Dollars in thousands)
Skilled services revenue	$	392,851		$	47,752		$	345,099	NM
Number of facilities at period end	47			11			36		NM
Number of campuses at period end*	1			1			—		NM
Actual patient days	978,493			144,674			833,819		NM
Occupancy percentage — Operational beds	76.4		%	69.1		%			NM
Skilled mix by nursing days	27.5		%	28.0		%			NM
Skilled mix by nursing revenue	49.7		%	45.8		%			NM

(1)Same Facility results represent all facilities purchased prior to January 1, 2020.

(2)Transitioning Facility results represent all facilities purchased from January 1, 2020 to December 31, 2021.

(3)Recently Acquired Facility (Acquisitions) results represent all facilities purchased on or subsequent to January 1, 2022.

Skilled services revenue increased $509.5 million, or 23.9%, compared to the nine months ended September 30, 2022. The increases in skilled services revenue were across all payer types including increases in Medicaid revenue of $243.6 million, or 24.6%, Medicare revenue of $123.3 million, or 20.2%, managed care revenue of $99.5 million, or 25.6% and private revenue of $43.1 million, or 31.3%.

The increase in skilled services revenue was primarily driven by strong performance across our existing skilled services operations as our census continued to recover during the first nine months of 2023, continued growth in skilled census and the impact of acquisitions. Our consolidated occupancy increased by 3.3% during the nine months ended September 30, 2023 compared to the same period in 2022.

Revenue in our Same Facilities increased $148.9 million, or 7.8%, compared to the same period in 2022, due to increases in occupancy and revenue per patient day. Our diligent efforts to strengthen our partnership with various managed care organizations, hospitals and the local communities we operate in, increased our managed care revenue by $49.5 million, or 13.6%, mainly due to increases in managed care days of 8.2% and revenue per patient day of 4.2%. In addition, Medicaid revenue increased by $87.3 million or 10.0%, mainly from the increases in Medicaid days and revenue per patient day.

Revenue generated by our Transitioning Facilities increased $15.5 million, or 9.1%, primarily due to improved occupancy growth and an increase in revenue per patient day. Our private days, Medicaid days and managed care skilled days increased by 11.4%, 7.3% and 4.2%, respectively, demonstrating our ability to focus on increasing occupancy across payer types.

Skilled services revenue generated by Recently Acquired Facilities increased by approximately $345.1 million compared to the nine months ended September 30, 2022. The increases were primarily due to the expansion of 36 operations between October 1, 2022 and September 30, 2023 across six states.

Table of Contents

In the future, if we acquire additional turnaround or start-up operations, we expect to see lower occupancy rates and skilled mix, and these metrics are expected to vary from period to period based upon the maturity of the facilities within our portfolio. Historically, we have generally experienced lower occupancy rates and lower skilled mix at Recently Acquired Facilities and therefore, we anticipate generally lower overall occupancy during years of growth. Included in our metrics for Recently Acquired Facilities are 17 facilities we acquired that are mature and have higher occupancy rates, higher skilled mix days and higher skilled mix revenue than our typical acquisitions.

The following table reflects the change in skilled nursing average daily revenue rates by payor source, excluding services that are not covered by the daily rate (1):


	Nine Months Ended September 30,
	Same Facility				Transitioning				Acquisitions				Total
	2023		2022		2023		2022		2023		2022		2023		2022

SKILLED NURSING AVERAGE DAILY REVENUE RATES
Medicare	$	715.73	$	690.28	$	688.45	$	666.01	$	776.42	$	673.95	$	724.85	$	688.09
Managed care	530.73		509.18		527.77		492.19		548.39		439.40		532.41		507.32
Other skilled	594.85		570.37		522.06		533.80		468.14		428.56		576.60		558.30
Total skilled revenue	612.20		595.47		608.25		589.74		659.01		498.57		618.43		592.79
Medicaid	273.04		258.77		268.26		250.64		251.06		234.47		269.05		257.20
Private and other payors	263.13		249.86		253.81		249.37		260.58		181.23		261.99		248.66
Total skilled nursing revenue	$	381.33	$	369.26	$	340.74	$	329.84	$	364.26	$	305.09	$	375.58	$	364.06

(1) These rates exclude state relief funding and include sequestration reversal of 1% for the second quarter in 2022 and 2% for the first quarter of 2022.

Our Medicare daily rates at Same Facilities and Transitioning Facilities increased by 3.7% and 3.4%, respectively, compared to the nine months ended September 30, 2022. The increase is attributable to the 2.7% net market basket increase that became effective in October 2022, offset by the phased reinstatement of the sequestration. During the nine months ended September 30, 2022, Medicare daily rates included three months of sequestration suspension of 1%, three months of sequestration suspension of 2% and three months of no sequestration suspension. In addition, we have seen a shift to higher acuity patients.

Our average Medicaid rates increased 4.6% due to state reimbursement increases and our participation in supplemental Medicaid payment programs and quality improvement programs in various states. Medicaid rates exclude the amount of state relief revenue we recorded.

Payor Sources as a Percentage of Skilled Nursing Services — We use our skilled mix as a measure of the quality of reimbursements we receive at our affiliated skilled nursing facilities over various periods.

The following tables set forth our percentage of skilled nursing patient revenue and days by payor source:


	Nine Months Ended September 30,
	Same Facility				Transitioning				Acquisitions				Total
	2023		2022		2023		2022		2023		2022		2023		2022

PERCENTAGE OF SKILLED NURSING REVENUE
Medicare	23.0	%	26.2	%	22.3	%	25.3	%	31.4	%	17.0	%	24.2	%	25.9	%
Managed care	20.1		19.2		12.7		12.4		13.1		9.3		18.5		18.4
Other skilled	8.7		8.0		3.9		4.1		5.2		19.5		7.9		8.0
Skilled mix	51.8		53.4		38.9		41.8		49.7		45.8		50.6		52.3
Private and other payors	7.5		7.0		8.5		8.2		7.9		3.8		7.6		7.0

Medicaid	40.7		39.6		52.6		50.0		42.4		50.4		41.8		40.7
TOTAL SKILLED NURSING	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%

Table of Contents


	Nine Months Ended September 30,
	Same Facility				Transitioning				Acquisitions				Total
	2023		2022		2023		2022		2023		2022		2023		2022

PERCENTAGE OF SKILLED NURSING DAYS
Medicare	12.3	%	14.0	%	11.0	%	12.5	%	14.8	%	7.7	%	12.6	%	13.7	%
Managed care	14.4		13.9		8.2		8.3		8.7		6.5		13.1		13.2
Other skilled	5.5		5.2		2.6		2.6		4.0		13.8		5.0		5.2
Skilled mix	32.2		33.1		21.8		23.4		27.5		28.0		30.7		32.1
Private and other payors	10.9		10.4		11.4		10.8		11.0		6.4		10.9		10.3

Medicaid	56.9		56.5		66.8		65.8		61.5		65.6		58.4		57.6
TOTAL SKILLED NURSING	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%

Cost of Services

The following table sets forth total cost of services for our skilled services segment for the periods indicated (dollars in thousands):



	Nine Months Ended September 30,				Change
	2023			2022	$			%

Cost of service	$	2,081,107			$	1,658,124			$	422,983	25.5	%
Revenue percentage	78.9		%		77.9		%				1.0	%

Cost of services related to our skilled services segment increased by $423.0 million, or 25.5%. Cost of services as a percentage of revenue increased to 78.9% from 77.9%, due to costs related to new acquisitions, increase in professional liabilities reserves and higher wage expenses as a result of the labor shortage environment, resulting in additional overtime, benefits and bonuses to our staff.

Standard Bearer


	Nine Months Ended September 30,			Change
	2023		2022	$		%

	(Dollars in thousands)
Rental revenue generated from third-party tenants	$	11,576		$	11,180		$	396	3.5	%
Rental revenue generated from Ensign affiliated operations	49,035			42,343			6,692		15.8
TOTAL RENTAL REVENUE	$	60,611		$	53,523		$	7,088	13.2	%
Segment income	21,517			20,679			838		4.1
Depreciation and amortization	18,528			15,798			2,730		17.3

FFO	$	40,045		$	36,477		$	3,568	9.8	%

Rental revenue — Our rental revenue, including revenue generated from our affiliated facilities, increased by $7.1 million, or 13.2%, to $60.6 million, compared to the nine months ended September 30, 2022. The increase in revenue is primarily attributable to six real estate purchases as well as annual rent increases since the nine months ended September 30, 2022.

FFO — Our FFO increased by $3.6 million, or 9.8%, to $40.0 million, compared to the nine months ended September 30, 2022. The increase in rental revenue of $7.1 million is offset by increases in interest expense of $3.0 million associated with the intercompany agreements between Standard Bearer and the Service Center.

Table of Contents

All Other Revenue

Our other revenue increased by $24.8 million, or 27.6%, to $114.6 million, compared to the nine months ended September 30, 2022. Other revenue for 2023 includes senior living revenue of $56.4 million, revenue from other ancillary services of $49.9 million and rental income of $8.3 million. The increase in other revenue is primarily attributable to our other ancillary services as well as senior living operations' starting to rebound from COVID-19.

Consolidated Financial Expenses

Rent-cost of services — Our rent-cost of services as a percentage of total revenue increased by 0.3% to 5.3%, primarily due to lease obligations acquired as part of our 31 operational expansions with long-term leases since the nine months ended September 30, 2022.

General and administrative expense — General and administrative expense increased $40.4 million or 34.8%, to $156.4 million. General and administrative expense as a percentage of revenue increased by 0.5% to 5.7%. This increase was primarily due to increases in legal costs, system implementation costs, bonuses due to enhanced performance and headcount due to acquisition activity. Excluding the legal costs, general and administrative expense as a percentage of revenue decreased 0.1%.

Depreciation and amortization — Depreciation and amortization expense increased $7.7 million, or 16.9%, to $53.2 million. This increase was primarily related to the additional depreciation and amortization incurred as a result of our newly acquired operations and capital expenditures. Depreciation and amortization decreased 0.2%, to 1.9%, as a percentage of revenue.

Other income (expense), net — Other income (expense), net as a percentage of revenue increased by 0.8%. Other income primarily includes interest income from our investments offset by interest expense related to our debt. Additionally, our deferred investment program may incur gains or losses depending on market performance. During the nine months ended September 30, 2023, the deferred compensation investment program had a gain of $1.1 million. During the nine months ended September 30, 2022, the deferred compensation investment program had a loss of $5.7 million. There is an equal offsetting reduction in expense allocated between cost of services and general and administrative expenses.

Provision for income taxes — Our effective tax rate was 22.1% for the nine months ended September 30, 2023, compared to 22.4% for the same period in 2022. The effective tax rate for both periods is driven by the impact of excess tax benefits from stock-based compensation, partially offset by non-deductible expenses, including non-deductible compensation. See Note 14, Income Taxes, in the Interim Financial Statements for further discussion.

Liquidity and Capital Resources

Our primary sources of liquidity have historically been derived from our cash flows from operations and long-term debt secured by our real property and our Credit Facility. Our liquidity as of September 30, 2023 is impacted by cash generated from strong operational performance and increased acquisition and share repurchase activities.

The U.S. Internal Revenue Service and California have provided disaster-area tax relief for the deferral of federal and California estimated tax payments until the fourth quarter of 2023. As of the third quarter of 2023, the Company has deferred approximately $50.0 million of 2023 federal and California estimated tax payments. The Company subsequently made an estimated tax payment of $69.4 million in October of 2023 for federal and California taxes that had been incurred through the third quarter of 2023.

Historically, we have primarily financed the majority of our acquisitions through mortgages on our properties, our Credit Facility and cash generated from operations. Cash paid to fund acquisitions was $54.0 million and $90.4 million for the nine months ended September 30, 2023 and 2022, respectively. Total capital expenditures for property and equipment were $77.4 million and $59.7 million for the nine months ended September 30, 2023 and 2022, respectively. We currently have approximately $100.0 million budgeted for renovation projects in 2023. We believe our current cash balances, our cash flow from operations and the amounts available for borrowing under our Credit Facility will be sufficient to cover our operating needs for at least the next 12 months.

We may, in the future, seek to raise additional capital to fund growth, capital renovations, operations and other business activities, but such additional capital may not be available on acceptable terms, on a timely basis, or at all.

Table of Contents

As mentioned above, our primary source of cash is from our ongoing operations. Our positive cash flows have supported our business and have allowed us to pay regular dividends to our stockholders. We currently anticipate that existing cash and total investments as of September 30, 2023, along with projected operating cash flows and available financing, will support our normal business operations for the foreseeable future.

On August 29, 2023, the Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from September 1, 2023. Under this program, we are authorized to repurchase our issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program does not obligate us to acquire any specific number of shares. We did not purchase any shares pursuant to this stock repurchase program during the three months ended September 30, 2023.

The following table presents selected data from our condensed consolidated statement of cash flows for the periods presented:


	Nine Months Ended September 30,
	2023		2022


NET CASH PROVIDED BY/(USED IN):	(In thousands)
Operating activities	$	291,397	$	222,337
Investing activities	(137,754)		(143,771)
Financing activities	(2,043)		(31,903)

Net increase in cash and cash equivalents	151,600		46,663
Cash and cash equivalents beginning of period	316,270		262,201


Cash and cash equivalents at end of period	$	467,870	$	308,864

Operating Activities

Cash provided by operating activities is net income adjusted for certain non-cash items and changes in operating assets and liabilities.

The $69.1 million increase in cash provided by operating activities for the nine months ended September 30, 2023 compared to the same period in 2022 was primarily due to higher net income offset by changes in working capital. Changes in working capital were driven by deferral of income tax payments of $55.5 million and accrued wages offset by timing of accounts receivable collections.

Investing Activities

Investing cash flows consist primarily of capital expenditures, investment activities, insurance proceeds and cash used for acquisitions.

The $6.0 million decrease in cash used in investing activities for the nine months ended September 30, 2023 compared to the same period in 2022, was primarily due to a decrease in cash used for operational expansions of $36.4 million offset by an increase in cash used for capital expenditures of $17.6 million and investments of $4.8 million. In addition, in the prior year, we had cash proceeds from the sale of fixed assets and insurance proceeds of $8.6 million that did not recur in current year.

Financing Activities

Financing cash flows consist primarily of payment of dividends to stockholders, issuance and repayment of short-term and long-term debt, payment for share repurchases and sale of subsidiary shares.

Table of Contents

The $29.9 million decrease in cash used in financing activities for the nine months ended September 30, 2023 compared to the same period in 2022, was primarily due to $29.9 million of share repurchases as part of our stock repurchase program in 2022.

Credit Facility with a Lending Consortium Arranged by Truist

We maintain a revolving credit facility with Truist Securities (Truist) (the Credit Facility) with availability up to $600.0 million in aggregate principal amount. The maturity date of the Credit Facility is April 8, 2027. Borrowings are supported by a lending consortium arranged by Truist. The interest rates applicable to loans under the Credit Facility are, at our option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the credit agreement). In addition, there is a commitment fee on the unused portion of the commitments that ranges from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio.

Mortgage Loans and Promissory Note

As of September 30, 2023, 23 of our subsidiaries have mortgage loans insured with HUD for an aggregate amount of $151.1 million, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates at a range of 3.1% to 4.2%, including fixed interest rates at a range of 2.4% to 3.3% per annum. In addition to the interest rate, we incur other fees for HUD placement, including but not limited to audit fees. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees of the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10.0%, and is reduced by 3.0% in the fourth year of the loan, and reduced by 1.0% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms for all the mortgage loans are 25 to 35 years.

In addition to the HUD mortgage loans, one of our subsidiaries has a promissory note that bears a fixed interest rate of 5.3% per annum and has a term of 12 years. The note, which was used for an acquisition, is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility.

Operating Leases

As of September 30, 2023, 213 of our facilities are under long-term lease arrangements, of which 96 of the operations are under nine triple-net Master Leases and one stand-alone lease with CareTrust REIT, Inc. (CareTrust). The Master Leases consist of multiple leases, each with its own pool of properties, that have varying maturities and diversity in property geography. Under each master lease, our individual subsidiaries that operate those properties are the tenants and CareTrust's individual subsidiaries that own the properties subject to the Master Leases are the landlords. The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of the percentage change in the Consumer Price Index (but not less than zero) or 2.5%. At our option, we can extend the Master Leases for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. If we elect to renew the term of a Master Lease, the renewal will be effective as to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that we can exercise starting on December 1, 2024.

We also lease certain affiliated facilities and our administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, we lease certain of our equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases.

Eighty of our affiliated facilities, excluding the facilities that are operated under the Master Leases from CareTrust, are operated under 13 separate master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other affiliated facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of our leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in our outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.

Table of Contents

U.S. Department of Justice Civil Investigative Demand

On May 31, 2018, we received a Civil Investigative Demand (CID) from the U.S. Department of Justice (DOJ) stating that it was investigating whether there had been a violation of the FCA and/or the AKS with respect to the relationships between certain of our independently operated skilled nursing facilities and persons who serve or have served as medical directors. We have fully cooperated with the DOJ and promptly responded to its requests for information. In April 2020, we were advised that the DOJ declined to intervene in any subsequent action filed in connection with the subject matter of this investigation. Despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator has moved forward with the lawsuit. We are vigorously defending this lawsuit, but expects the costs of defense to be significant given the nature of the allegations and the date range contemplated by the complaint. As a general matter, our independent operating entities have established and maintain policies and procedures to promote compliance with the FCA, the AKS, and other applicable regulatory requirements.

Inflation

We have historically derived a substantial portion of our revenue from the Medicare program. We also derive revenue from state Medicaid and similar reimbursement programs. Payments under these programs generally provide for reimbursement levels that are adjusted for inflation annually based upon the state’s fiscal year for the Medicaid programs and in each October for the Medicare program. These adjustments may not continue in the future, and even if received, such adjustments may not reflect the actual increase in our costs for providing healthcare services.

Labor, supply expenses and capital expenditures make up a substantial portion of our cost of services. Those expenses can be subject to increase in periods of rising inflation and when labor shortages occur in the marketplace. To date, we have generally been able to implement cost control measures or obtain increases in reimbursement sufficient to offset increases in these expenses. There can be no assurance that we will be able to anticipate fully or otherwise respond to any future inflationary pressures.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Interest Rate Risk — We are exposed to risks associated with market changes in interest rates through our borrowing arrangements and investments. In particular, our Credit Facility exposes us to variability in interest payments due to changes in SOFR interest rates. We manage our exposure to this market risk by monitoring available financing alternatives. Our mortgages and promissory note require principal and interest payments through maturity pursuant to amortization schedules.

Our mortgages generally contain provisions that allow us to make repayments earlier than the stated maturity date. In some cases, we are not allowed to make early repayment prior to a cutoff date. Where prepayment is permitted, we are generally allowed to make prepayments only at a premium which is often designed to preserve a stated yield to the note holder. These prepayment rights may afford us opportunities to mitigate the risk of refinancing our debts at maturity at higher rates by refinancing prior to maturity.

We have a revolving line of credit with Truist of up to $600.0 million in aggregate principal amount. We have no outstanding borrowings under our Credit Facility as of September 30, 2023 and through the filing date of this report. In addition, we have outstanding indebtedness under mortgage loans insured with HUD and a promissory note to third parties of $153.4 million, all of which are at fixed interest rates.

Our cash and cash equivalents as of September 30, 2023 consisted of bank term deposits, money market funds and U.S. Treasury bill related investments. In addition, as of September 30, 2023, we held investments of approximately $103.3 million. We believe our investments that were in an unrealized loss position as of September 30, 2023 do not require an allowance for expected credit losses, nor has any event occurred subsequent to that date that would indicate so. Our market risk exposure is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. The primary objective of our investment activities is to preserve principal, while at the same time maximizing the income we receive from our investments without significantly increasing risk. Due to the low risk profile of our investment portfolio, an immediate 10.0% change in interest rates would not have a material effect on the fair market value of our portfolio. Accordingly, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our securities portfolio.

Table of Contents

The above only incorporates those exposures that exist as of September 30, 2023 and does not consider those exposures or positions which could arise after that date. If we diversify our investment portfolio into securities and other investment alternatives, we may face increased risk and exposures as a result of interest risk and the securities markets in general.

Item 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures are effective.

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended September 30, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II.

Item 1. LEGAL PROCEEDINGS

Regulatory Matters — Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action with fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations are rules requiring vaccination of employees and HIPAA, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.

Indemnities — From time to time, we enter into certain types of contracts that contingently require us to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which we may be required to indemnify property owners or prior facility operators for post-transfer environmental or other liabilities and other claims arising from our use of the applicable premises, (ii) operations transfer agreements, in which we agree to indemnify past operators of facilities we acquire against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to our independent operating subsidiary, (iii) certain lending agreements, under which we may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with our officers, directors and others, under which we may be required to indemnify such persons for liabilities arising out of the nature of their relationship to us. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on our balance sheets for any of the periods presented.

In connection with the spin-off transaction in 2019, certain landlords required, in exchange for their consent to the transaction, that our lease guarantees remain in place for a certain period of time following the spin-off. These guarantees could result in significant additional liabilities and obligations for us if Pennant were to default on their obligations under their leases with respect to these properties.

U.S. Department of Justice Civil Investigative Demand — On May 31, 2018, we received a Civil Investigative Demand (CID) from the U.S. Department of Justice (DOJ) stating that it was investigating to determine whether there had been a violation of the False Claims Act (FCA) and/or the Anti-Kickback Statute (AKS) with respect to the relationships between certain of our independently operated skilled nursing facilities and persons who serve or have served as medical directors. We have fully cooperated with the DOJ and promptly responded to its requests for information. In April 2020, we were advised that the DOJ declined to intervene in any subsequent action filed in connection with the subject matter of this investigation. Despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator has moved forward with the lawsuit. We are vigorously defending this litigation, but expect the costs of defense to be significant given nature of the allegations and the date range contemplated by the complaint. At this

Table of Contents

time, we are unable to estimate the range of loss and cannot predict the final outcome of this lawsuit. If this lawsuit is ultimately resolved against us, the amounts owed, including fines, penalties and other consequences relating to the lawsuit, could have a material adverse effect on our results of operations, financial condition and cash flows. As a general matter, our independent operating entities have established and maintain policies and procedures to promote compliance with the FCA, the AKS, and other applicable regulatory requirements.

Litigation — We and our independent operating entities are party to various legal actions and administrative proceedings, and are subject to various claims arising in the ordinary course of business, including claims that services provided to patients by our independent operating entities have resulted in injury or death, and claims related to employment and commercial matters. Although we intend to vigorously defend against these claims, there can be no assurance that the outcomes of these matters will not have a material adverse effect on operational results and financial condition. In certain states in which we have or have had independent operating entities, insurance coverage for the risk of punitive damages arising from general and professional liability litigation may not be available due to state law and/or public policy prohibitions. There can be no assurance that our independent operating entities will not be liable for punitive damages awarded in litigation arising in states for which punitive damage insurance coverage is not available.

The skilled nursing and post-acute care industry is heavily regulated. As such, we and our independent operating subsidiaries are continuously subject to state and federal regulatory scrutiny, supervision and control in the ordinary course of business. Such regulatory scrutiny often includes inquiries, investigations, examinations, audits, site visits and surveys, some of which are non-routine. In addition to being subject to direct regulatory oversight from state and federal agencies, the skilled nursing and post-acute care industry is also subject to regulatory requirements which could result in civil, administrative or criminal fines, penalties or restitutionary relief, and reimbursement; authorities could also seek the suspension or exclusion of the provider or individual from participation in their programs. We believe that there has been, and will continue to be, an increase in governmental investigations of long-term care providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Adverse determinations in legal proceedings or governmental investigations, whether currently asserted or arising in the future, could have a material adverse effect on our financial position, results of operations, and cash flows.

Additionally, and in 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, we and our independent operating subsidiaries received a document and information request from the House Select Subcommittee. We and our independent operating subsidiaries cooperated in responding to this inquiry. In July 2022 and thereafter, we and our independent operating subsidiaries received follow up requests for additional documents and information. We and our independent operating subsidiaries responded to these requests, and cooperated with the House Select Subcommittee in connection with its investigation. On December 9, 2022, the House Select Subcommittee issued its final report summarizing its investigation and related recommendations designed "to strengthen the nation's ability to prevent and respond to public health and economic emergencies." According to the information provided by the House Select Subcommittee, the issuance of this report was the House Select Subcommittee's final official act in connection with their assigned responsibilities.

In addition to the potential lawsuits and claims described above, we and our independent operating subsidiaries are also subject to potential lawsuits under the FCA and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from federally funded healthcare programs. Such exclusions could have a correlative negative impact on our financial performance. Under the qui tam or "whistleblower" provisions of the FCA, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. For example, and despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued Civil Investigative Demand, the involved qui tam relator is continuing on with the lawsuit and pursuing claims that one or more of our independent operating entities have allegedly violated the FCA and/or the AKS. We are vigorously defending this lawsuit, but expects the costs of defense to be significant given the nature of the allegations and the date range contemplated by the complaint.

In addition to the FCA, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the FCA. As such, we and our independent operating subsidiaries could face increased scrutiny, potential liability, and legal expenses and costs based on claims under state false claims acts in markets where our independent operating subsidiaries do business.

Table of Contents

In May 2009, Congress passed the FERA which made significant changes to the FCA and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that an FCA violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.

Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and our independent operating entities are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements. We expect the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims.

We and our independent operating subsidiaries have been, and continue to be, subject to claims, findings and legal actions that arise in the ordinary course of the various businesses, including healthcare and non-healthcare services. These claims include, but are not limited to potential claims related to patient care and treatment (professional negligence claims) as well as employment related claims. In addition, we and our independent operating subsidiaries, and others in the industry, are subject to claims and lawsuits in connection with COVID-19 and facility preparation for and/or response to the COVID-19 pandemic. While we have been able to settle or otherwise resolve many of these types of claims without an ongoing material adverse effect on our business, a significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of future claims, could materially adversely affect our business, financial condition, results of operations and cash flows. In addition, these claims could impact our ability to procure insurance to cover our exposure related to the various services provided by our independent operating subsidiaries to their residents, customers and patients.

Claims and suits, including class actions, continue to be filed against our independent operating subsidiaries and other companies in the post-acute care industry. We and our independent operating entities have been subjected to, and/or are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour law as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and other such similar causes of action. We do not believe that the ultimate resolution of these actions will have a material adverse effect on our business, cash flows, financial condition or results of operations.

Medicare Revenue Recoupments — We and our independent operating subsidiaries are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments resulting from reviews conducted via RAC, Program Safeguard Contractors, and Medicaid Integrity Contractors (collectively referred to as Reviews). For several months during the COVID-19 pandemic, CMS suspended its Targeted Probe and Educate (TPE) Program. Beginning in August 2020, CMS resumed TPE Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. We anticipate that these Reviews could increase in frequency in the future. As of September 30, 2023 and through the filing date of this report, 41 of our independent operating subsidiaries had Reviews scheduled or in process.

CMS announced a new nationwide audit, the “SNF 5-Claim Probe & Educate Review”, in which the Medicare Administrative Contractors will review five claims from each SNF to check for compliance. In implementing this SNF 5-Claim Probe & Educate Review, CMS acknowledged that the increase in observed improper payments from 2021 to 2022 may have arisen from a “misunderstanding” by SNFs about how to appropriately bill for claims of service after October 1, 2019. All facilities that are not undergoing TPE reviews, or have not recently passed a TPE review, will be subject to the nationwide audit. MACs will complete only one round of probe-and-educate for each SNF, rather than the three rounds that typically occur in the TPE Program. Additionally, CMS’s education for each SNF will be individualized and based on observed claim review errors, with rationales for denial explained to the SNF on a claim-by-claim basis. This program will apply only to claims submitted after October 1, 2019, and will exclude claims containing a COVID-19 diagnosis.

Table of Contents

Item 1A. RISK FACTORS

We are providing the following summary of the risk factors contained in our Form 10-Q to enhance the readability and accessibility of our risk factor disclosures. We encourage our stockholders to carefully review the risk factors contained in this Form 10-Q in their entirety for additional information regarding the risks and uncertainties that could cause our actual results to vary materially from recent results or from our anticipated future results.

Risks Related to our Business and Industry

•The rules of Medicare and Medicaid, including reductions of reimbursement rates, changes to spending requirements, data reporting, measurement and evaluation standards could have a material, adverse effect on our revenues, financial condition and results of operations.

•Reforms to the U.S. healthcare system, including new regulations under the ACA, potential federal and state standards for minimum nurse staffing levels, continue to impose new requirements upon us that could materially impact our business.

•The changes in Congress due to midterm elections in 2022 and actions in anticipation of the 2024 Presidential election, may result in significant changes to the regulatory framework, enforcement, and reimbursements in our industry.

•We are subject to various government reviews, audits and investigations that could adversely affect our business, including an obligation to refund amounts previously paid to us, potential criminal charges, loss of licensure, the imposition of fines and sanctions.

•Public and government calls for increased enforcement efforts toward SNFs, potential rulemaking that may result in enhanced enforcement and penalties, and new guidance for surveyors regarding the review of SNFs and enforcement of their Requirements of Participation, could result in increased scrutiny by state and federal survey agencies, including sanctions that could negatively affect our financial condition and results of operations.

•CMS’s changes to the SFF program and its look-back period may create greater risk of our facilities being subject to this program and subject to potential fines and sanctions, even after graduating from the SFF program.

•Federal minimum staffing mandates may adversely affect our labor costs, ability to maintain desired levels of patient or resident capacity, and profitability.

•Future cost containment initiatives undertaken by third-party payors may limit our revenue and profitability.

•We face numerous risks related to the COVID-19 PHE's expiration and surrounding wind-down and uncertainty, which could individually or in the aggregate have a material adverse effect on our business, financial condition, liquidity, results of operations and prospects.

•We may be subject to increased investigation and enforcement activities related to HIPAA violations if we fail to adopt and maintain business procedures and systems designed to protect the privacy, security and integrity of patients’ individual health information.

•Security breaches and other cyber-security incidents could violate security laws and subject us to significant liability.

•If our independent operating subsidiaries are not fully reimbursed for all services for which each facility bills through consolidated billing, our revenue, financial condition and results of operations could be adversely affected.

•Increased competition for, or a shortage of, nurses and other skilled personnel, could increase our staffing and labor costs and subject us to monetary fines resulting from a failure to maintain minimum staffing requirements, or may affect reimbursement.

•Annual caps, uncertainty regarding reimbursement and other cost-reductions for outpatient therapy services may reduce our future revenue and profitability or cause us to incur losses.

•Increased scrutiny of our billing practices by the OIG or other regulatory authorities may result in an increase in regulatory monitoring and oversight, decreased reimbursement rates, or otherwise adversely affect our business, financial condition and results of operations.

•State efforts to regulate or deregulate the healthcare services industry or the construction or expansion of healthcare facilities could impair our ability to expand our operations, or could result in increased competition.

•Newly enacted legislation in the States where our independently operating entities are located may impact the volume of cases filed and the overall cost of those cases from a defense and indemnity standpoint.

•Changes to federal and state employment-related laws and regulations could increase our cost of doing business.

•Required regulatory approvals could delay or prohibit transfers of our healthcare operations, which could result in periods in which we are unable to receive reimbursement for such properties.

•Compliance with federal and state fair housing, fire, safety, staffing, and other regulations may require us to incur unexpected expenses, which could be costly to us.

•We depend largely upon reimbursement from third-party payors, and our revenue, financial condition and results of operations could be negatively impacted by any changes in the acuity mix of patients in our affiliated facilities as well as payor mix and payment methodologies.

•We are subject to litigation that could result in significant legal costs and large settlement amounts or damage awards. Similarly, a change in the enforceability of arbitration provisions between SNFs and senior living facilities and residents and patients may affect the risks we face from claims and potential litigation.

•If our regular internal investigations into the care delivery, recordkeeping and billing processes of our operating subsidiaries detect instances of noncompliance, efforts to correct such non-compliance could materially decrease our revenue.

Table of Contents

•We may be unable to complete future facility or business acquisitions at attractive prices or at all, or may elect to dispose of underperforming or non-strategic operating subsidiaries, either of which could decrease our revenue.

•We may not be able to successfully integrate acquired facilities and businesses into our operations, or we may be exposed to costs, liabilities and regulatory issues that may adversely affect our operations.

•If we do not achieve or maintain competitive quality of care ratings from CMS or private organizations engaged in similar monitoring activities, our business may be negatively affected.

•If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, our business may be adversely affected, and our self-insurance programs may expose us to significant and unexpected costs and losses.

•The geographic concentration of our affiliated facilities could leave us vulnerable to economic downturn, regulatory changes or acts of nature in those areas.

•The actions of a national labor union that has pursued a negative publicity campaign criticizing our business in the past may adversely affect our revenue and our profitability.

•The risks associated with leased property where our operating subsidiaries operate could adversely affect our business, financial position or results of operations.

•Failure to generate sufficient cash flow to cover required payments or meet operating covenants under our long-term debt, mortgages and long-term operating leases could result in defaults under such agreements and cross-defaults under other debt, mortgage or operating lease arrangements, which could harm our operating subsidiaries and cause us to lose facilities or experience foreclosures.

•Move-in and occupancy rates may remain unpredictable even after the COVID-19 PHE's expiration.

•A continued housing slowdown or housing downturn could decrease demand for senior living services.

•As we continue to acquire and lease real estate assets, we may not be successful in identifying and consummating these transactions.

•As we expand our presence in other relevant healthcare industries, we would become subject to risks in a market in which we have limited experience.

•If our referral sources fail to view us as an attractive skilled nursing provider, or if our referral sources otherwise refer fewer patients, our patient base may decrease.

•We may need additional capital to fund our operating subsidiaries and finance our growth, and we may not be able to obtain it on terms acceptable to us, or at all, which may limit our ability to grow.

•The condition of the financial markets, including recent and expected future increases to the federal funds rate, inflation and the consumer price index, could limit the availability of debt and equity financing sources to fund the capital and liquidity requirements of our business, as well as negatively impact or impair the value of our current portfolio of cash, cash equivalents and investments.

•Delays in reimbursement may cause liquidity problems.

•The continued use and growth of managed care organizations may contribute to delays or reductions in our reimbursement, including Managed Medicaid.

•Compliance with the regulations of the Department of Housing and Urban Development may require us to make unanticipated expenditures which could increase our costs.

•Failure to safeguard our patient trust funds may subject us to citations, fines and penalties.

•We are a holding company with no operations and rely upon our multiple independent operating subsidiaries to provide us with the funds necessary to meet our financial obligations. Liabilities of any one or more of our subsidiaries could be imposed upon us or our other subsidiaries.

•We may be exposed to liabilities as a result of the separation of Pennant, including if the spin-off is not tax-free for U.S. federal income tax purposes.

•Certain directors who serve on our Board of Directors also serve as directors of Pennant, and ownership of shares of Pennant common stock by our directors and executive officers may create, or appear to create, conflicts of interest.

•Standard Bearer's failure to qualify as a REIT may cause it to be subject to U.S. federal income tax. Additionally, legislative or other actions affecting REITs could have a negative effect on Standard Bearer.

Risks Related to Ownership of our Common Stock

•We may not be able to pay or maintain dividends and the failure to do so would adversely affect our stock price.

•Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that could discourage transactions resulting in a change in control, which may negatively affect the market price of our common stock.

Table of Contents

Risks Related to Our Business and Industry

The rules of Medicare and Medicaid, including reductions of reimbursement rates, changes to spending requirements, data reporting, measurement and evaluation standards could have a material, adverse effect on our revenues, financial condition and results of operations.

We derived 25.4% and 26.8% of our service revenue from the Medicare programs for the three and nine months ended September 30, 2023, respectively, and 27.6% and 27.7% for the three and nine months ended September 30, 2022, respectively. In addition, many other payors may use published Medicare rates as a basis for reimbursements. Accordingly, if Medicare reimbursement rates are reduced or fail to increase as quickly as our costs, if there are changes in the rules governing the Medicare program that are disadvantageous to our business or industry, or if there are delays in Medicare payments, our business and results of operations will be adversely affected.

The Medicare program and its reimbursement rates and rules are subject to frequent change, including statutory and regulatory changes, rate adjustments (including retroactive adjustments), annual caps that limit the amount that can be paid (including deductible and coinsurance amounts), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which Medicare reimburses us for our services. See Item 2., under Government Regulation, Sequestration of Medicare Rates for further information. Implementation of these and other types of measures has in the past and could in the future result in substantial reductions in our revenue and operating margins.

Additionally, payments can be delayed or declined due to determinations that certain costs are not reimbursable or reasonable because either adequate or additional documentation was not provided or because certain services were not covered or considered medically necessary. Additionally, revenue from these payors can be retroactively adjusted after a new examination during the claims settlement process or as a result of post-payment audits. New legislation and regulatory proposals could impose further limitations on government payments to healthcare providers.

CMS often changes the rules governing the Medicare program, including those governing reimbursement. Changes to the Medicare program that could adversely affect our business include:

•administrative or legislative changes to base rates or the bases for payment;

•limits on the services or types of providers for which Medicare will provide reimbursement;

•changes in methodology for patient assessment and/or determination of payment levels;

•changes in staff requirements (i.e., requiring all workers to be vaccinated against COVID-19 and receive booster injections for those vaccinations) as a condition of payment or eligibility for Medicare reimbursement (See also, Item 2., under Government Regulation);

•the reduction or elimination of annual rate increases, or the end of the reduced payments deferment (See also, Item 2., under Government Regulation); and

•an increase in co-payments or deductibles payable by beneficiaries.

Among the changes being implemented by CMS are provisions of the IMPACT Act, which imposes a stringent timeline for implementing benchmark quality measures and data metrics across facilities that include SNFs. The enactment mandates specific actions to design a unified payment methodology for post-acute providers, which CMS implements through ongoing regulations. The costs of final implementation may be significant, with potential fines and payment reductions resulting from a failure to meet CMS's implementation requirements.

Reductions in reimbursement rates or the scope of services being reimbursed could have a material, adverse effect on our revenue, financial condition and results of operations or even result in reimbursement rates that are insufficient to cover our operating costs. Congress’s budgetary planning has also resulted in a difficulty to financially forecast, as the Medicare conversion factor paid under the CAA 2023 was 2.5% greater than the conversion factor provided for in the CY 2023 PFS final rule. Nonetheless, the 2023 conversion factor for CY 2023 was lower than CY 2022 PFS's conversion factor. The CY 2024 PFS conversion factor is proposed to have a decrease of 3.34% from the CY 2023 PFS factor. This decrease takes into account the expiration of the 2.5% statutory payment increase for 2023, the addition of a 1.25% statutory payment increase for 2024, a 0% conversion factor update, and a 2.17% budget-neutrality adjustment.

Table of Contents

On July 31, 2023, the CMS released its final rule for the SNF PPS for fiscal year 2024 which will increase payments by a net 4.0% in FY 2024 relative to FY 2023. The final rule includes updates to the SNF Quality Reporting Program and SNF Value-based Purchasing Program that assess staff turnover, discharge success, res-hospitalization, and resident falls with injuries, which may adversely affect revenues obtained through the Medicare program. The final rule may result in an increase in payments relative to FY 2023 depending on the performance of our individual operating subsidiaries as evaluated by CMS. The final rule will also replaces the SNF 30-day All-cause Readmission measure with the SNF Within Stay Potentially Reasonable Readmissions standard beginning in fiscal year 2025, which may also reduce the compensation our independent operating subsidiaries may receive under the SNF VBP program.

As discussed in more detail in Item 2., under Government Regulation, CMS implemented a final rule in October 2019 implementing a new case-mix classification system, PDPM, that focuses on the clinical condition of the patient. CMS may make future adjustments to reimbursement levels and underlying reimbursement formulae as it continues to monitor the impact of PDPM on patient outcomes and budget neutrality. The Biden-Harris Administration continues to study the nursing home industry and for HHS to issue proposed rules based on those studies, including changes to SNF facility reimbursement, including the SNF-VBP Program, may also adversely affect our reimbursement. These metrics potentially affecting our revenues and expenses in future government fiscal years include the SNF healthcare-associated infections (HAI) measurement, total nursing hours per resident day measures, and discharge to community - post acute care measure.

Loss of Medicare reimbursement, or a delay or default by the government in making Medicare payments, would also have a material adverse effect on our revenue. Non-compliance with Medicare regulations exist, and any penalty, suspension, termination, or other sanction under any state’s Medicaid program could lead to reciprocal and commensurate penalties being imposed under the Medicare program, up to termination or rescission of our Medicare participation and payor agreements as noted above.

A significant portion of reimbursement for skilled nursing services comes from Medicaid. In fact, Medicaid is our largest source of revenue, accounting for 46.7% and 46.0% of our revenue for the three and nine months ended September 30, 2023, respectively, and 46.1% and 45.8% for the three and nine months ended September 30, 2022, respectively. Medicaid is a state-administered program financed by both state funds and matching federal funds. Medicaid spending has increased rapidly in recent years, becoming a significant component of state budgets, which has led both the federal government and many states to institute measures aimed at controlling the growth of Medicaid spending, and in some instances reducing aggregate Medicaid spending. Since a significant portion of our revenue is generated from our skilled nursing operating subsidiaries in California, Texas and Arizona, any budget reductions or delays in these states could adversely affect our net patient service revenue and profitability. Despite present state budget surpluses in many of the states in which we operate, we can expect continuing cost containment pressures on Medicaid outlays for SNFs, and any such decline could adversely affect our financial condition and results of operations.

The Medicaid program and its reimbursement rates and rules are subject to frequent change at both the federal and state level, including through changes in laws, regulations, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which our services are reimbursed by state Medicaid plans or the amount of expense we incur.

To generate funds to pay for the increasing costs of the Medicaid program, many states utilize financial arrangements commonly referred to as provider taxes. Under provider tax arrangements, states collect taxes from healthcare providers and then use the revenue to pay the providers as a Medicaid expenditure, which allows the states to then claim additional federal matching funds on the additional reimbursements. Current federal law provides for a cap on the maximum allowable provider tax as a percentage of the providers' total revenue. There can be no assurance that federal law will continue to provide matching federal funds on state Medicaid expenditures funded through provider taxes, or that the current caps on provider taxes will not be reduced. Any discontinuance or reduction in federal matching of provider tax-related Medicaid expenditures could have a significant and adverse effect on states' Medicaid expenditures, and as a result could have a material and adverse effect on our business, financial condition or results of operations.

The CAA 2023 provided for the wind-down and termination of increased FMAP payments under the FFCRA, and also provided for the disenrollment of Medicaid beneficiaries who have participated in the program since early in the COVID-19 pandemic. CMS’s increased FMAP payments declined from 6.2% to 5% in the second quarter of 2023, 2.5% in the third quarter, and shall decline 1.5% in the fourth quarter before CMS’s increased FMAP spending ends entirely. The CAA 2023 grants CMS the authority to impose fines, penalties, and other sanctions upon states that do not comply with this law’s requirements for the unwinding of increased FMAP payments. As a result, these reductions may impose further burdens on the Medicaid programs in states where we operate in the form of fines and penalties, which may result in reduced payments.

Table of Contents

Beginning on April 1, 2023, states may begin disenrolling Medicaid beneficiaries. CMS guidance allowing for a return to Medicaid’s historical renewal, enrollment, and eligibility determination practices permits states up to 14 months to initiate and process traditional Medicaid renewals. The CAA 2023’s allowance of disenrollment and return to traditional Medicaid renewal processes, which will include pre-COVID eligibility determinations, may result in a reduction of the number of Medicaid beneficiaries and may result in a reduction of our current and potential patient population. As a result, there may be fewer current or potential patients able to pay for our operating subsidiaries’ services, and increased competition for Medicaid beneficiaries able to provide reimbursement for those services.

CMS is concerned that states are terminating people without definitively establishing their eligibility due to state residents not receiving eligibility forms or understanding instructions. CMS is monitoring states' compliance with federal requirements and is working with the affected states to address issues related to renewal requirements. States risk losing federal Medicaid matching funds for non-compliance with CMS’s instructions, which could result in reduced Medicaid funds available for timely reimbursement of the Company’s operating subsidiaries for their operations. Estimates suggest that roughly 17 million people may lose Medicaid coverage during the redetermination process through their scheduled completion in May of 2024.

Medicaid is an important source of funding for our independent operating subsidiaries. The Company may be adversely affected by the disenrollment of Medicaid beneficiaries, which may lead to a reduction in reimbursement that may adversely impact our revenue and profit. The temporary restoration of Medicaid benefits in states where redetermination has been paused can help relieve some of these economic concerns. The disruption caused by the temporary pauses and restoration of Medicaid coverage for beneficiaries can also create operational challenges for our independent operating subsidiaries, including adverse effects on cash flow, available funds to pay wages for staffing, and overall financial stability.

The ultimate impact of Medicaid disenrollment on the Company’s finances and operations will depend on individual states' specific circumstances and actions.

Reforms to the U.S. healthcare system, including new regulations under the ACA, continue to impose new requirements upon us that could materially impact our business

As discussed in greater detail in Item 2., under Government Regulation, the ACA has resulted in significant changes to our operations and reimbursement models for services we provide. CMS continues to issue rules to implement the ACA, including most recently, new rules regarding the implementation of the anti-discrimination provisions and proposed rules requiring the disclosure of SNF ownership, organization, management and the identity of the real property owners from which the SNF leases or subleases its operating space. With the passage of the IRA in August of 2022, Congress continues to expand and supplement the ACA, including through the continuation of federally funded insurance premium subsidies. This modification of the ACA by the IRA indicates that Congress may continue to change and expand the ACA in the future.

The efficacy of the ACA is the subject of much debate among members of Congress and the public and it has been the subject of extensive litigation before numerous courts, including the United States Supreme Court, with varying outcomes — some expanding and others limiting the ACA. In the event that the ACA is repealed or any elements of the ACA that are beneficial to our business are materially amended or changed, such as provisions regarding the health insurance industry, reimbursement and insurance coverage by payers, our business, operating results and financial condition could be harmed. Thus, the future impact of the ACA on our business is difficult to predict and its continued uncertain future may negatively impact our business. However, any material changes to the ACA or its implementing regulations may negatively impact our operations.

While it is not possible to predict whether and when any such changes will occur, specific proposals discussed during and after the midterm election in 2022, including a repeal or material amendment of the ACA, could harm our business, operating results and financial condition. The ACA continues to be a salient political topic and proposed changes to it may become the subject of campaign promises, litigation, administrative action, or legislation leading up to or following the 2024 Presidential election. In addition, even if the ACA is not amended or repealed, the President and the executive branch of the federal government, as well as CMS and HHS have a significant impact on the implementation of the provisions of the ACA, and a new administration could make changes impacting the implementation and enforcement of the ACA, which could harm our business, operating results and financial condition. We have already seen this with regulatory activity promulgating rules regarding anti-discrimination under Section 1557 of the ACA and most recently proposed rulemaking requiring the disclosure of SNF ownership and service providers under Section 6101 of the ACA. If we are slow or unable to adapt to any such changes, our business, operating results and financial condition could be adversely affected.

Table of Contents

Similarly, the Nursing Home Improvement Act proposed during the prior Congress may be re-introduced in the future and could ultimately have an impact on our business due to the proposed 2% decrease in payments to SNFs, as well as the staffing and reporting requirements contained within the bill. While it is difficult to determine whether the Nursing Home Improvement Act or an identical bill will even be reintroduced, if ultimately signed into law, this bill may negatively impact our business, with the scope and nature of its consequences unknown.

On February 13, 2023, CMS issued a proposed rule that, if finalized and implemented, would require SNFs to disclose certain information regarding their ownership and managerial relationships, which is more invasive and comprehensive than the ownership information already disclosed through Medicare's Nursing Home Compare website. Refer to Item 2., under Government Regulation, for additional information and may be adverse to our business interests and detrimental to our operations, revenue, and profitability.

We cannot predict what effect future reforms to the U.S. healthcare system will have on our business, including the demand for our services or the amount of reimbursement available for those services. However, it is possible these new laws may lower reimbursement or increase the cost of doing business and adversely affect our business.

The changes in Congress due to the most recent U.S. midterm elections in 2022 and actions in anticipation of the 2024 Presidential election may result in significant changes to regulatory framework, enforcements and reimbursements.

The most recent midterm elections in 2022 and resulting change in control of the House of Representatives could result in significant changes in, and has resulted in uncertainty with respect to, legislation, regulation, implementation or repeal of laws and rules related to government health programs, including Medicare and Medicaid. Democratic proposals for Medicare for All or significant expansion of Medicare, could significantly impact our business and the healthcare industry if implemented, although the implementation of such proposals remains unlikely under the political party currently holding a majority within the House of Representatives. Additionally, Congress’s passage of the IRA in August of 2022, which expanded upon and continued certain provisions of the ACA, indicates that additional legislative changes to the ACA may be forthcoming. If proposed policies specific to nursing facilities are implemented, these may result in significant regulatory changes, increased survey frequency and scope, and increased penalties for non-compliance. As both political parties begin their Presidential primaries and next congressional elections in 2024, each of them may seek to introduce or pass legislation that would either expand or reduce the scope of the ACA as a credential for future campaigning. Based on the IRA and inflationary pressures in the economy, the ACA and affordability of healthcare generally may be a campaign issue and lead to promises, administrative action, or legislation that could adversely affect our business. As a result, future legislation may be proposed or passed that may adversely affect our business, operating results and financial condition.

We continually monitor these developments in order to respond to the changing regulatory environment impacting our business. While it is not possible to predict whether and when any such changes will occur, specific proposals discussed during and after the election, including a repeal or material amendment of the ACA (whether to increase or decrease its scope), could harm our business, operating results and financial condition. If we are slow or unable to adapt to any such changes, our business, operating results and financial condition could be adversely affected.

We are subject to various government reviews, audits and investigations that could adversely affect our business, including an obligation to refund amounts previously paid to us, potential criminal charges, the imposition of fines, and/or the loss of our right to participate in Medicare and Medicaid programs.

As a result of our participation in the Medicaid and Medicare programs, we are subject to various governmental reviews, audits and investigations to verify our compliance with the rules associated with these programs and related applicable laws and regulations, including our claims for payments submitted to those programs, which are subject to reviews by Recovery Audit Contractors, Zone Program Integrity Contractors, Program Safeguard Contractors, Unified Program Integrity Contractors, Supplemental Medical Review Contractors and Medicaid Integrity Contractors programs, (collectively referred to as Reviews). In these Reviews, third party firms engaged by CMS conduct extensive analysis of claims data and medical and other records to identify potential improper payments under the federal and state programs. As discussed above, the Biden-Harris Administration has called for HHS and CMS to increase the level of scrutiny of SNF facilities and requested those agencies to adopt rules that would impose greater penalties upon non-compliant SNF operators. On February 17, 2023, CMS most recently updated the survey resources that CMS and state surveyors use in evaluating our SNFs’ compliance with federal Requirements for Participation, incorporating recent changes to CMS’s methods for surveying infection control procedures.

Table of Contents

On June 29, 2022, CMS announced updated guidance for Phase 2 and 3 of the requirements of participation, discussed in greater detail in Item 2., under Government Regulation. The application of CMS’s new guidance could result in more aggressive and stringent surveys, and potential fines, penalties, sanctions, or administrative actions taken against our independent operating subsidiaries.

CMS announced a new nationwide audit the “SNF 5-Claim Probe & Educate Review” in which the Medicare Administrative Contractors will review five claims from each of the facilities to check for compliance with PDPM billings, which could result in individual claim payment denials if errors are identified. All facilities that are not undergoing TPE reviews, or have not recently passed a TPE review, will be subject to the nationwide audit.

Private pay sources also reserve the right to conduct audits. We believe that billing and reimbursement errors and disagreements are common in our industry, and thus we are regularly engaged in reviews, audits and appeals of our claims for reimbursement due to the subjectivities inherent in the process related to patient diagnosis and care, record keeping, claims processing and other aspects of the patient service and reimbursement processes, and the errors and disagreements those subjectivities can produce. An adverse review, audit or investigation could result in:

•an obligation to refund amounts previously paid to us pursuant to the Medicare or Medicaid programs or from private payors, in amounts that could be material to our business;

•state or federal agencies imposing fines, penalties or other sanctions on us;

•temporary or permanent loss of our right to participate in the Medicare or Medicaid programs or one or more private payor networks;

•an increase in private litigation against us; and

•damage to our reputation in the geographies served by our independent operating subsidiaries.

Although we have always been subject to post-payment audits and reviews, more intensive “probe reviews” performed by Medicare administrative contractors in recent years appear to be a regular procedure with our fiscal intermediaries. All findings of overpayment from CMS contractors are eligible for appeal. With the exception of rare findings of overpayment related to objective errors in Medicare payment methodology or claims processing, we utilize all defenses reasonably available to us to demonstrate that the services provided meet all clinical and regulatory requirements for reimbursement.

In cases where claim and documentation review by a CMS contractor results in repeated unsatisfactory results, an operation can be subjected to protracted regulatory oversight. This CMS oversight may include education and sampling of claims, extended pre-payment review, referral of the operating business to recovery audit or integrity contractors, or extrapolation of an error rate to other reimbursement made outside of specifically reviewed claims. Ongoing failure to demonstrate improvement towards meeting all claim filing and documentation requirements could ultimately lead to Medicare decertification. As of September 30, 2023 and through the filing date of this report, 41 of our independent operating subsidiaries had reviews scheduled or in process, either pre- or post-payment. We anticipate that these reviews could increase in frequency in the future.

Additionally, both federal and state government agencies have heightened and coordinated civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies and, in particular, SNFs. The focus of these investigations includes, among other things, billing and cost reporting practices; quality of care provided; financial relationships with referral sources; and the medical necessity of rendered services.

On May 31, 2018, we received a Civil Investigative Demand (CID) from the U.S. Department of Justice (DOJ) stating that it is investigating our company to determine whether we have violated the False Claims Act (FCA) or the Anti-Kickback Statute (AKS) with respect to the relationships between certain of our SNFs and persons who served as medical directors. As a general matter, our operating entities maintain policies and procedures to promote compliance with the FCA, the AKS, and other applicable regulatory requirements. We fully cooperated with the DOJ. In April 2020, we were advised that the DOJ declined to intervene in any subsequent action filed by a relator in connection with the subject matter of this investigation.

If we should agree to a settlement of claims or obligations under Medicare statutes, the FCA, or similar federal or state statutes and related regulations, our business, financial condition and results of operations and cash flows could be materially and adversely affected, and our stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged civil violations and may also include our assumption of specific procedural and financial obligations going forward under a corporate integrity agreement or other arrangement with the government.

Table of Contents

If the government or a court were to conclude that errors and deficiencies constitute criminal violations and/or that such errors and deficiencies resulted in the submission of false claims to federal healthcare programs, or were to discover other problems in addition to the ones identified by the probe reviews that rose to actionable levels, we and certain of our officers might face potential criminal charges and civil claims, administrative sanctions and penalties for amounts that could be material to our business, results of operations and financial condition. In addition, we or some of the key personnel of our independent operating subsidiaries could be temporarily or permanently excluded from future participation in state and federal healthcare reimbursement programs such as Medicaid and Medicare.

If any of our independently operated subsidiary facilities is decertified or loses its licenses, our revenue, financial condition or results of operations would be adversely affected. In addition, the report of such issues at any of our independently operated subsidiary facilities could harm our reputation for quality care and lead to a reduction in the patient referrals to and ultimately a reduction in occupancy at these facilities. Also, responding to auditing and enforcement efforts diverts material time, resources and attention away from our management team and our staff, and could have a materially detrimental impact on our results of operations during and after any such investigation or proceedings, regardless of whether we prevail on the underlying claim.

We are subject to extensive and complex laws and government regulations. If we are not operating in compliance with these laws and regulations or if these laws and regulations change, we could be required to make significant expenditures or change our operations in order to bring our facilities and operations into compliance.

We, along with other companies in the healthcare industry, are required to comply with extensive and complex laws and regulations at the federal, state and local government levels relating to, among other things:

•licensure and certification;

•adequacy and quality of healthcare services;

•qualifications of healthcare and support personnel;

•state-specified and potential federal mandates for specific nurse staffing levels;

•quality and maintenance of medical equipment and facilities;

•confidentiality, maintenance and security issues associated with medical records and claims processing;

•relationships with physicians and other referral sources and recipients;

•constraints on protective contractual provisions with patients and third-party payors;

•operating policies and procedures;

•addition of facilities and services; and

•billing for services.

The laws and regulations governing our operations, along with the terms of participation in various government programs, regulate how we conduct our business, the services we offer, and our interactions with patients and other healthcare providers. These laws and regulations are subject to frequent change. As noted above, the Biden-Harris Administration has called upon HHS and CMS to study and propose new rules regarding staffing requirements and reimbursement for the nursing home industry, including tying reimbursement to staffing levels, salary, benefits, and retention. The recently proposed CMS rule over ownership transparency discussed above may provide an additional basis for further investigation, administrative action and ultimately fines, penalties, or sanctions if finalized.

We believe that such regulations that may adversely affect our business, operation and profitability may increase in the future and we cannot predict the ultimate content, timing or impact on us of any healthcare reform legislation. If we fail to comply with these applicable laws and regulations, or their interpretations as determined by courts or enforced by regulators, we could suffer civil or criminal penalties and other detrimental consequences, including denial of reimbursement, imposition of fines, temporary suspension of admission of new patients, suspension or decertification from the Medicaid and Medicare programs, restrictions on our ability to acquire new facilities or expand or operate existing facilities, the loss of our licenses to operate and the loss of our ability to participate in federal and state reimbursement programs. Additionally, in the future, different interpretations or enforcement of these laws and regulations could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our facilities, equipment, personnel, services, capital expenditure programs and operating expenses.

Table of Contents

As discussed in greater detail in Item 2., under Government Regulation, we are subject to federal and state laws intended to prevent healthcare fraud and abuse. Possible sanctions for violation of any of these laws and regulations include loss of eligibility to participate in federal and state reimbursement programs and civil and criminal penalties. If we fail to comply, even inadvertently, with any of these requirements, we could be required to alter our operations, refund payments to the government, enter into a corporate integrity agreement, deferred prosecution or similar agreements with state or federal government agencies, and become subject to significant civil and criminal penalties.

These anti-fraud and abuse laws and regulations are complex, and we do not always have the benefit of significant regulatory or judicial interpretation of these laws and regulations. While we do not believe we are in violation of these prohibitions, we cannot assure you that governmental officials charged with the responsibility for enforcing these prohibitions will not assert that we are violating the provisions of such laws and regulations. Our company is currently aware of litigation filed by an individual related to allegations that certain of our affiliated SNFs may have violated the FCA or the AKS with respect to the relationships between certain SNFs and persons who served as medical directors. While our operating entities maintain policies and procedures to promote compliance with the FCA, the AKS, and other applicable regulatory requirements, we cannot predict when the investigation will be resolved, the outcome of the investigation or its potential impact on our company.

On September 1, 2023, CMS issued a proposed rule setting forth proposed minimum nurse staffing requirements for SNFs. As discussed in more detail in Item 2., under Government Regulation, this proposed rule contains three primary staffing proposals: 1) minimum nurse staffing standards of 0.55 HPRD for RNs and 2.45 HPRD for NAs; 2) a requirement to have a RN on-site 24 hours per day, seven days per week; and 3) requirements for enhanced facility assessments. The proposed rule features a staggered implementation of these requirements, with potential accommodations for facilities that can demonstrate financial hardship and a delayed implementation schedule for rural facilities. Within this proposed rule, CMS also seeks comments about other staffing models, including alternate, higher standards for imposing staffing minimums, which will have a potentially adverse effect on our operations and profitability, the extent of which currently is not known.

We are unable to predict the future course of federal, state and local regulation or legislation, including as it pertains to Medicare, Medicaid, or fraud and abuse laws, and how they are enforced. Changes in the regulatory framework, our failure to obtain or renew required regulatory approvals, credentials, qualifications, or licenses or to comply with applicable regulatory requirements, or the imposition of other enforcement sanctions, fines or penalties could have a material adverse effect upon our business, financial condition or results of operations. Furthermore, should we lose licenses or certifications for a number of our facilities or other businesses as a result of regulatory action or legal proceedings, we could be deemed to be in default under some of our agreements, including agreements governing outstanding indebtedness.

Public and government calls for increased survey and enforcement efforts toward SNFs, and potential rulemaking that may result in enhanced enforcement and penalties, could result in increased scrutiny by state and federal survey agencies. In addition, potential sanctions and remedies based upon alleged regulatory deficiencies could negatively affect our financial condition and results of operations.

As CMS turns its attention to enhancing enforcement activities towards SNFs, as discussed in Item 2., under Government Regulation, state survey agencies will have more accountability for their survey and enforcement efforts. The Biden-Harris Administration’s fact sheet regarding enhanced penalties against SFFs, discussed in greater detail in Item 2., under Government Regulation, represents further federal calls for oversight and penalties for low-ranked and underperforming SNFs. This fact sheet precedes greater focus by CMS in obtaining oversight over SFFs, and continuing that oversight even after those SFFs improve, and subjecting them to more exacting and routine oversight. The likely result may be more frequent surveys of our affiliated facilities, with more substantial penalties, fines and consequences if they do not perform well. For low-performing facilities in the SFF program, the standards for successfully emerging from that program and not being subject to ongoing and enhanced government oversight will be higher and measured over a longer period of time, prolonging the risks of monetary penalties, fines and potential suspension or exclusion from the Medicare and Medicaid programs.

As discussed in Item 2., under Government Regulation, from time to time in the ordinary course of business, we receive deficiency reports from state and federal regulatory bodies resulting from such inspections or surveys. CMS's guidance to these surveyors was updated on February 17, 2023, incorporating recent changes to CMS’s methods for surveying infection control procedures. This guidance regarding SNFs has not been updated since February of 2023.

Table of Contents

Additionally, the recently proposed CMS rule requiring disclosure of ownership and financial relationships between nursing facilities and property owners or management entities, as well as other state rules over ownership transparency, may provide an additional basis for further investigation, administrative action, and ultimately fines, penalties, or sanctions if finalized.

Although most inspection deficiencies are resolved through an agreed-upon plan of corrective action, the reviewing agency typically has the authority to take further action against a licensed or certified facility. These remedial actions could result in the imposition of fines, imposition of a license to a conditional or provisional status, suspension or revocation of a license, suspension or denial of payment for new admissions, loss of certification as a provider under state or federal healthcare programs, or imposition of other sanctions, including criminal penalties. In the past, we have experienced inspection deficiencies that have resulted in the imposition of a provisional license and could experience these results in the future.

Furthermore, in some states, citation of one affiliated facility could negatively impact other affiliated facilities in the same state. Revocation of a license at a given facility could therefore impair our ability to obtain new licenses or to renew, or maintain, existing licenses at other facilities, which may also trigger defaults or cross-defaults under our leases and our credit arrangements, or adversely affect our ability to operate or obtain financing in the future. CMS’s proposed rules requiring disclosure of ownership, management and the owners of real property lessors or sublessors, which are greater and more intrusive than existing disclosure requirements heighten this risk. Our failure to comply with applicable legal and regulatory requirements in any single facility could negatively impact our financial condition and results of operations.

From time to time, we have opted to voluntarily stop accepting new patients pending completion of a new state survey, in order to avoid possible denial of payment for new admissions during the deficiency cure period, or simply to avoid straining staff and other resources while retraining staff, upgrading operating systems or making other operational improvements. If we elect to voluntary close any operations in the future or to opt to stop accepting new patients pending completion of a state or federal survey, it could negatively impact our financial condition and results of operation.

We have received notices of potential sanctions and remedies based upon alleged regulatory deficiencies from time to time, and such sanctions have been imposed on some of our affiliated facilities. We have had affiliated facilities placed on SFF status in the past and other operating subsidiaries may be identified for such status in the future. We currently have one facility placed on SFF status.

CMS’s changes to the SFF program and its look-back period may create greater risk of our facilities being subject to this program and subject to potential fines and sanctions, even after graduating from the SFF program.

As discussed in discussed in greater detail in Item 2., under Government Regulation, in October of 2022 CMS updated the SFF program with the intent to reduce the amount of time a SNF spends as an SFF and increase the number of nursing homes that progress through the SFF program. On September 27, 2023, CMS published technical corrections to this program to clarify certain details of the SFF program updates and how they are to be implemented by each state survey agency (SA). As noted in the October 2022 revisions to the SFF program, a priority in revising the SFF program was to address “yo-yo” noncompliance of SNFs that would graduate from the SFF program only to later see their compliance and quality measures regress after graduation, potentially requiring readmission to the SFF program. Among the measures implemented to avoid this issue of “yo-yo” noncompliance was a three-year lookback period for facilities that graduate from the SFF program to ensure that the quality and compliance improvements achieved through the SFF program were sustained. Facilities that graduate from the SFF program but continue to demonstrate poor compliance as evidenced by any SA’s survey, such as for actual harm, substandard quality of care, or immediate jeopardy deficiencies, may be subject to enhanced enforcement by CMS, up to and including termination from the Medicare and/or Medicaid programs.

Table of Contents

This three-year lookback for sustained improvements by facilities that graduate the SFF program poses risk for our independent operating facilities, specifically those that may be subject to the SFF program or that have been subject to the SFF program in the past. As of September 30, 2023, we have three facilities graduated from the SFF program within the past three years. First, for SNFs that are selected by CMS for participation in the SFF program, or which currently are in the SFF program, even graduation from the program is no longer an assurance that the SNF will be able to continue its operations. Even one survey with a significant compliance deficiency, such as actual harm or an immediate jeopardy deficiency, may result in CMS—acting solely within its discretion—terminating the SNF’s Medicare or Medicaid participation, likely triggering the termination of other payor contracts and rendering the facility economically unviable. Second, and relatedly, for SNFs that have graduated from the SFF program, they are subject to a three-year period of enhanced scrutiny where adverse findings by a SA and a single survey’s finding of poor compliance may result in CMS discretionarily terminating that facility’s Medicare and/or Medicaid participation, which would likely cause other payors to terminate their agreements with the facility as well. As a result, the financial and manpower resources needed for graduation from the SFF program may be for nothing if, in the three years following graduation from the SFF program, a SNF receives a poor survey result and permits CMS to impose fines and penalties up to the termination of the facility’s Medicare and Medicaid participation.

As discussed above, Medicare and Medicaid represent significant sources of payment for our independently operating subsidiaries. Any of our facilities’ loss of a Medicare or Medicaid contract would significantly harm the financial performance of that facility. Additionally, if CMS perceived there to be common upstream ownership of multiple facilities that were participants in or graduates of the SFF program, CMS may seek to take enforcement actions against those other facilities due to their common ownership based on another facility’s deficiencies after graduating the SFF program, with CMS imposing penalties up to and potentially including termination of those SNFs’ participation in the Medicare and/or Medicaid programs.

Federal minimum staffing mandates may adversely affect our labor costs, ability to maintain desired levels of patient or resident capacity, and profitability.

While the full effect of these proposed federal staff level minimums is not fully known at this time, likely will be studied by industry groups in the coming weeks and months to submit responsive comments while awaiting a final rule, and cannot be ascertained without a final rule that will specify the required number of staff for the Company’s operating subsidiaries to comply with such a regulation, we expect that such a mandate will have adverse financial consequences upon our business. Depending on the requirements of a final mandate and the time period over which its requirements are phased in, we may be required to hire substantially more staff members, particularly nurse practitioners, registered nurses, licensed practical nurses and nursing aides than currently staffed. Additionally, a federal mandate of this nature would place similar pressure on our competitors and result in sudden, expanded demand for nursing staff across the SNF industry. This sudden demand across the SNF industry may exacerbate an already difficult labor market, with demand for nursing staff far outstripping the supply of qualified individuals, and the salary requirements of both current and prospective staff increasing markedly to increase the likelihood of recruiting and retaining skilled caregivers.

Future cost containment initiatives undertaken by private third-party payors may limit our revenue and profitability.

Our non-Medicare and non-Medicaid revenue and profitability are affected by continuing efforts of third-party payors to maintain or reduce costs of healthcare, such as by lowering payment rates, narrowing the scope of covered services, increasing case management review of services and negotiating pricing. In addition, sustained unfavorable economic conditions may affect the number of patients enrolled in managed care programs and the profitability of managed care companies, which could result in reduced payment rates.

Third party payors may not make timely payments for our services, and we may be unable to maintain our current payor or revenue mix. We are continuing our efforts to develop our non-Medicare and non-Medicaid sources of revenue and any changes in payment levels from current or future third-party payors could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.

Table of Contents

Changes in Medicare reimbursements for physician and non-physician services could impact reimbursement for medical professionals.

As discussed in greater detail in Item 2., under Government Regulation, MACRA revised the payment system for physician and non-physician services. The changes to the therapy caps imposed on Medicare Part B outpatient therapy from this law have been changed by the BBA, and are subject to future budgetary changes through rulemaking and legislation, resulting in ongoing uncertainty regarding payment for these Medicare Part B services. Under the proposed CY 2024 PFS, reductions in payment and conditions imposed in exchange for higher payments may impose operational requirements and working conditions that further detract from and reduce our financial performance. Similarly, new final rules concerning the PACE program and the information it will collect from our operating subsidiaries may adversely affect the risk-adjusted reimbursement.

We face numerous risks related to the COVID-19 PHE’s expiration and surrounding wind-down and uncertainty, which could individually or in the aggregate have a material adverse effect on our business, financial condition, liquidity, results of operations and prospects.

The extent to which the COVID-19 PHE's termination will affect our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence. There remains uncertainty as to what changes will be made to HHS’s emergency response requirements for our SNFs and senior living facilities in order to better respond to the issues experienced during the COVID-19 PHE. Additionally, the expiration of the Emergency Waivers and other flexibilities allowed under the COVID-19 PHE create the risk of non-compliance and delays in operation as more attention is required to ensure that our operations comply with applicable laws and regulations.

As discussed in Item 2., under Government Regulation, federal, state and local regulators implemented new regulations and waived existing regulations to promote care delivery during the COVID-19 PHE, which ended as of May 11, 2023. The ending of the Emergency Waivers and wind-down of other flexibilities may require and continue to require operational change requirements on short notice. The reinstatement of waived state and federal regulations has not occurred simultaneously, requiring heightened monitoring to ensure compliance.

To the extent COVID-19 is endemic in nature, we and our independent operating subsidiaries may face continued challenges from ongoing infection control and emergency preparedness requirements made part of state laws or regulations. Additionally, the long-term effects of the COVID-19 pandemic may include long-term decline in demand for care in SNFs and senior living facilities, which will be borne out only through time. The extent and duration of the impact of the COVID-19 pandemic on our stock price is uncertain, our stock price may be more volatile, and our ability to raise capital could be impaired.

We may be subject to increased investigation and enforcement activities related to HIPAA violations.

HIPAA, as amended by the HITECH Act, requires us to adopt and maintain business procedures and systems designed to protect the privacy, security and integrity of patients' individual health information, in addition to state laws governing the privacy of patient information. We must comply with these state privacy laws to the extent that they are more protective of healthcare information or provide additional protections not afforded by HIPAA. The regulations enacting HIPAA periodically change and the last proposed change was issued in late 2022. This proposed rulemaking may be made final in 2023 and, if adopted as proposed, may require our operating subsidiaries to modify certain policies, procedures and practices regarding the disclosure of residents’ information. If we fail to comply with these state and federal laws, we could be subject to criminal penalties, civil sanctions, litigation, and be forced to modify our policies and procedures, in addition to undertaking costly breach notification and remediation efforts, as well as sustaining reputational harm.

In addition to breaches of protected patient information, under HIPAA and the 21st Century Cures Act (Cures Act) and other federal regulations, healthcare entities are also required to afford patients with certain rights of access to their health information and to promote sharing of patient data between and among healthcare providers involved in the same patient's course of care. Recently, the Office for Civil Rights, the agency responsible for HIPAA enforcement, has targeted investigative and enforcement efforts on violations of patients’ rights of access, imposing significant fines for violations largely initiated from patient complaints. If we fail to comply with our obligations under HIPAA, we could face significant fines. Likewise, if we fail to comply with our obligations under the Cures Act, we could face fines from the Office of the National Coordinator for Health Information Technology, the agency responsible for Cures Act enforcement.

Table of Contents

Security breaches and other cyber-security incidents could violate security laws and subject us to significant liability.

Healthcare businesses are increasingly the target of cyberattacks whereby hackers disrupt business operations or obtain protected health information, often demanding large ransoms. At the end of the first quarter of 2023, the healthcare sector saw a 60% increase in the average weekly number of cyberattacks over 2021. Our business is dependent on the proper functioning and availability of our computer systems and networks. While we have taken steps to protect the safety and security of our information systems and the patient health information and other data maintained within those systems, we cannot assure you that our safety and security measures and disaster recovery plan will prevent damage, interruption or breach of our information systems and operations. Additionally, we cannot control the safety and security of our information held by third-party vendors with whom we contract. The techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may be difficult to detect, and as such we (or third-party vendors) may be unable to anticipate these techniques or implement adequate preventive measures. In addition, hardware, software or applications we (or third-party vendors) develop or procure from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise the security of information systems. Unauthorized parties may attempt to gain access to our systems or facilities, or those of third parties with whom we do business, through fraud or other forms of deception.

On occasion, we have acquired additional information systems through our business acquisitions, and these acquired systems may expose us to risk. We also license certain third-party software to support our operations and information systems. Our inability, or the inability of third-party vendors, to continue to maintain and upgrade information systems and software could disrupt or reduce the efficiency of our operations. In addition, costs and potential problems and interruptions associated with the implementation of new or upgraded systems and technology or with maintenance or adequate support of existing systems also could disrupt or reduce the efficiency of our operations.

A cyber-attack or other incident that bypasses the security measures of our information systems could cause a security breach, which may lead to a material disruption to our information systems infrastructure or business, significant costs to remediate (e.g., data recovery) and may involve a significant loss of business or patient health information. If a cyber-attack or other unauthorized attempt to access our systems or facilities were successful, it could also result in the theft, destruction, loss, misappropriation or release of confidential information or intellectual property, and could cause operational or business delays that may materially impact our ability to provide various healthcare services. Any successful cyber-attack or other unauthorized attempt to access our systems or facilities also could result in negative publicity which could damage our reputation or brand with our patients, referral sources, payors or other third parties and could subject us to a number of adverse consequences, the vast majority of which are not insurable, including but not limited to, disruptions in our operations, regulatory and other civil and criminal penalties, fines, investigations and enforcement actions (including, but not limited to, those arising from the SEC, Federal Trade Commission, Office of Civil Rights, the OIG or state attorneys general), fines, private litigation with those affected by the data breach (including class action litigation), loss of customers, disputes with payors and increased operating expense, which either individually or in the aggregate could have a material adverse effect on our business, financial position, results of operations, liquidity, and stock price.

We may not be fully reimbursed for all services for which each facility bills through consolidated billing, which could adversely affect our revenue, financial condition and results of operations.

SNFs are required to perform consolidated billing for certain items and services furnished to patients and residents. The consolidated billing requirement requires the SNF to effectively bill for the entire package of care that its patients receive in these situations. Post-hospitalization skilled nursing services must be “bundled” into the hospital's diagnostic related group (DRG) payment in certain circumstances, in which case the hospital and SNF must effectively divide the payment that otherwise would have been made to the hospital. Although this practice is uncommon, it adversely affects SNF utilization and payments, whether due to the practical difficulty of this apportionment or hospitals being reluctant to lose revenue by discharging patients to a SNF. If more payments are required to be bundled in the future, this trend may continue, with our SNFs not receiving full reimbursement for all the services they provide, and have a further adverse effect on SNF utilization and revenue.

Table of Contents

Increased competition for, or a shortage of, nurses and other skilled personnel could increase our staffing and labor costs and subject us to monetary fines.

Our success depends upon our ability to retain and attract nurses and other skilled personnel, such as Certified Nurse Assistants, social workers and speech, physical and occupational therapists, as well as skilled management personnel responsible for day-to-day facility operation. Each facility has a facility leader responsible for the overall day-to-day operations of the facility, including quality of care, social services and financial performance. Depending upon the size of the facility, each facility leader is supported by facility staff who are directly responsible for day-to-day care of the patients, marketing and community outreach programs. Other key positions supporting each facility may include individuals responsible for physical, occupational and speech therapy, food service and maintenance. We compete with various healthcare service providers, including other skilled nursing providers, in retaining and attracting qualified and skilled personnel.

Our affiliated SNFs are located in the states of Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. All states follow the current federal regulation relative to staffing, which establishes that SNFs are required to staff to meet the needs of the residents present in the facility. In addition, California has established minimum staffing requirements for facilities operating in that state.

Failure to comply with these requirements can, among other things, jeopardize a facility's compliance with the conditions of participation under relevant state and federal healthcare programs. If a facility is determined to be out of compliance with these requirements, it may be subject to a notice of deficiency, a citation, or a significant fine or litigation risk, with penalties including the suspension of patient admissions and the termination of Medicaid participation, or the suspension, revocation or non-renewal of the SNF's license.

On September 1, 2023, CMS published a long-awaited proposed rule setting forth proposed SNF minimum staffing requirements at the federal level. In relevant part, these proposed federal standards require 1) minimum nurse staffing standards of 0.55 HPRD for RNs and 2.45 HPRD for NAs; and 2) a requirement to have a RN on-site 24 hours per day, seven days per week. This proposed rule contains numerous other provisions discussed in more detail in Item 2., under Government Regulation. Comments are still being submitted for this proposed rule, and the substance of both the comments and any revisions to the later-issued final rule setting forth minimum staffing requirements may influence the effect that this rule has on our business and its financial performance.

Nonetheless, for the federal government or any state government to materially change the way compliance with the minimum staffing standard is calculated or enforced, our labor costs could increase and the current shortage of healthcare workers could impact us more significantly. The broader labor market where we compete is in a state of disequilibrium where the needs of businesses such as ours outstrip the supply of available and willing workers. There is additional upward pressure on wages from different industries and more generally due to the current rate of inflation. Some of these industries compete with us for labor and others that do not, which makes it difficult to make significant hourly wage and salary increases due to the fixed nature of our reimbursement under insurance contracts as well as Medicare and Medicaid, in addition to our increasing variable costs. Due to the limited supply of qualified applicants who seek or are willing to accept employment, these broader concerns, may increase our labor costs or lead to potential staffing shortages, reduced operations to comply with applicable laws and regulations, or difficulty complying with those laws and regulations at current operational levels.

Federal laws and regulations, including the proposed minimum nurse staffing levels if they are made final, may increase our costs of maintaining qualified nursing and skilled personnel, or make it more difficult for us to attract or retain qualified nurses and skilled staff members. Proposed legislation, such as the previously proposed Nursing Home Improvement Act and the proposed HCBS Access Act, may make it more expensive to compete for, hire, and retain nursing staff, if passed into law in substantially the same form as previously introduced to Congress. The Biden-Harris Administration's desire to increase staffing level requirements for the nursing home industry and to tie reimbursement to the salary, benefits, and retention of staff also may increase our labor costs. CMS has published guidance to surveyors addressing topics that specifically include nurse staffing and collection of payroll data to evaluate appropriate staffing levels, which may lead to future regulation that increase our staffing requirements and labor costs or lower revenues.

Similar state-level requirements in the states where our affiliated SNFs operate, whether such requirements are passed by statute, regulation, or executive order, may result in a shortage or inability to obtain nurses and skilled staff. Prior concerns about the COVID-19 vaccination IFR may be abated by the Omnibus Final Rule’s withdrawal of that IFR. The withdrawal of the COVID-19 vaccination IFR may allow for nursing and other personnel unwilling to receive the COVID-19 vaccination to re-enter the workforce for Medicare-certified facilities and increase the pool of hirable talent.

Table of Contents

Increased competition for, or a shortage of, nurses or other trained personnel, or general ongoing inflationary pressures may require that we enhance our pay and benefits packages to compete effectively for such personnel. Turnover rates and the magnitude of the shortage of nurses or other trained personnel vary substantially from facility to facility, and may adversely affect those facilities' quality ratings based on data reported to CMS. In addition, state laws regarding minimum wage increases, such as California’s minimum wage increases for both health care and fast-food workers, may intensify competition for unskilled labor in both skilled and unskilled settings. For skilled workers within the skilled care market where we operate, the costs of skilled labor, which are already greater than unskilled labor, could increase further. Similarly, the increased minimum wage of unskilled labor will not only increase the cost of unskilled labor, but may also have effects that dissuade workers from training to join the skilled workforce to earn higher wage growth, resulting in a smaller pool of available skilled workers and further increased competition—and higher wages—for them. If we fail to attract and retain qualified and skilled personnel, our ability to conduct our business operations could be harmed.

Annual caps and other cost-reductions for outpatient therapy services may reduce our future revenue and profitability or cause us to incur losses.

As discussed in detail in Item 2., under Government Regulation, sub-heading Part B Rehabilitation Requirements, several government actions have been taken in recent years to try and contain the costs of rehabilitation therapy services provided under Medicare Part B, including the MPPR, institution of annual caps, mandatory medical reviews for annual claims beyond a certain monetary threshold, and a reduction in reimbursement rates for therapy assistant claim modifiers. Of specific concern has been CMSs efforts to lower Medicare Part B reimbursement rates for outpatient therapy services in 2021, 2022, and 2023. Such cost-containment measures and ongoing payment changes could have an adverse effect on our revenue.

The Office of the Inspector General or other regulatory authorities may choose to more closely scrutinize billing practices in areas where we operate or propose to expand, which could result in an increase in regulatory monitoring and oversight, decreased reimbursement rates, or otherwise adversely affect our business, financial condition and results of operations.

As discussed in greater detail in Item 2., under Government Regulation, Civil and Criminal Fraud and Abuse Laws and Enforcement, the OIG regularly conducts investigations regarding certain payment or compliance issues within the healthcare industry. The OIG identified SNF compliance as an issue of concern in its 2021 and 2022 semi-annual reports to Congress, and its January 2023 study regarding SNF emergency preparedness identified the need for further oversight and addition of SNF emergency readiness to the OIG's 2023 work plan. Nursing homes were also a topic of discussion in the OIG’s 2023 semiannual report to Congress, which emphasized the continued protection and oversight of care that nursing facilities provide to residents. Among other things, the OIG recommended a reduction in the use of psychotropic drugs in nursing homes and urged CMS to evaluate the appropriateness of psychotropic drug use among residents, including the use of data to identify nursing homes with higher rates of use for potential further scrutiny and action. Based on this information, SNFs in particular are potential targets for more robust scrutiny and examination by regulators. Recent publications and statements by the Biden-Harris Administration have also called for greater scrutiny of SNF facilities.

Our business model, like those of some other for-profit operators, is based in part on seeking out higher-acuity patients whom we believe are generally more profitable, and over time our overall patient mix has consistently shifted to higher-acuity and higher-resource utilization patients in most facilities we operate. We also use specialized care-delivery software that assists our caregivers in more accurately capturing and recording activities of daily living services, among other things. These efforts may place us under greater scrutiny with the OIG, CMS, our fiscal intermediaries, recovery audit contractors and others.

State efforts to regulate or deregulate the healthcare services industry or the construction or expansion of healthcare facilities could impair our ability to expand our operations, or could result in increased competition.

Some states require healthcare providers, including SNFs, to obtain prior approval, known as a certificate of need, for: (1) the purchase, construction or expansion of healthcare facilities; (2) capital expenditures exceeding a prescribed amount; or (3) changes in services or bed capacity.

Other states that do not require certificates of need have effectively barred the expansion of existing facilities and the establishment of new ones by placing partial or complete moratoria on the number of new Medicaid beds those states will certify in certain areas or throughout the entire state. Still other states have established such stringent development standards and approval procedures for constructing new healthcare facilities that the construction of new facilities, or the expansion or renovation of existing facilities, may become cost-prohibitive or extremely time-consuming. In addition, some states require the approval of the state Attorney General for acquisition of a facility being operated by a non-profit organization.

Table of Contents

Our ability to acquire or construct new facilities or expand or provide new services at existing facilities would be adversely affected if we are unable to obtain the necessary approvals, if there are changes in the standards applicable to those approvals, or if we experience delays and increased expenses associated with obtaining those approvals. We may not be able to obtain licensure, certificate of need approval, Medicaid certification, state Attorney General approval or other necessary approvals for future expansion projects. Conversely, the elimination or reduction of state regulations that limit the construction, expansion or renovation of new or existing facilities could result in increased competition to us or result in overbuilding of facilities in some of our markets. If overbuilding in the skilled nursing industry in the markets in which we operate were to occur, it could reduce the occupancy rates of existing facilities and, in some cases, might reduce the private rates that we charge for our services.

Newly enacted and proposed legislation in the States where our independently operating entities are located may affect our operations in terms of individual litigation and the broader regulatory environment.

A bill in the State of California was recently signed into law which increases the cap of non-economic damages awarded to plaintiffs who are successful in medical malpractice litigation. The cap increases from $0.25 million to $0.35 million beginning on January 1, 2023, then increases over the following 10 years until the cap reaches a maximum of $0.75 million, with further adjustments for inflation. In wrongful death cases, the cap increases from $0.25 million to $0.5 million on January 1, 2023, with incremental increases over the following 10 years until the cap reaches a maximum of $1 million, with adjustments for inflation. Due to California's influence on other states, other jurisdictions where we operate may enact similar laws. Similar to the potential incentive of increased damages caps, the Supreme Court’s recent decision in certain case may increase public interest in potential claims against SNFs and senior living facilities, particularly pertaining to specific civil rights claims against governmental actors rather than general liability claims against privately owned SNFs such as those operated by our independent operating subsidiaries. While there may be additional claims and litigation that arise from the Supreme Court's decision that have an adverse impact on our cash flow, it is not expected that the decision will have a significant impact on our business.

Another example, California’s adoption of the Skilled Nursing Facility Ownership and Management Reform Act of 2022, discussed in Item 2., Government Regulation, imposes new requirements for obtaining licenses to operate SNFs. These new requirements may delay or limit the ability to obtain new SNF licenses within that state, whether through acquisition of existing facilities or opening a new facility. This new law's obligations may increase the costs of obtaining licensure, make applications more time-consuming and complex, and may result in civil penalties and other sanctions against our affiliated facilities in the event they are not compliant with these new licensure application requirements. As a result, this new law may delay or impede growth within California. As with the bill that increases the cap of non-economic damages for medical malpractice litigation, California’s influence on other states may result in this legislation becoming a model for other states and having similar, potentially adverse effects within those jurisdictions as well.

More recently, California’s legislature has proposed bills related to increasing the minimum wage for workers, spending requirements and increased disclosure. As discussed in Item 2., Government Regulation, these proposed bills would create new and costly obligations on our independent operating subsidiaries if they became law and if enacted, would adversely affect our business, operations, and profitability.

As another example, Texas passed a bill which partially restored Medicaid state relief funding for SNFs through August 31, 2023, while it also considered legislation that contained direct care spending requirements and ownership, similar to proposed federal rulemaking discussed in Item 2., Government Regulation. While this bill provided financial relief to our independent operating subsidiaries in Texas, other proposed bills may impose the same regulatory requirements and limitations inherent in both the proposed legislation in other states and the federally proposed rule requiring disclosure of such information in applications and change-of-ownership disclosures, which may adversely affect our business, operations, and profitability.

Changes to federal and state employment-related laws and regulations could increase our cost of doing business.

Our operating subsidiaries are subject to a variety of federal and state employment-related laws and regulations, including, but not limited to, the U.S. Fair Labor Standards Act that governs such matters as minimum wages, overtime and other working conditions, the ADA and similar state laws that provide civil rights protections to individuals with disabilities in the context of employment, public accommodations and other areas, the National Labor Relations Act, regulations of the EEOC, regulations of the Office of Civil Rights, regulations of state attorney generals, family leave mandates and a variety of similar laws enacted by the federal and state governments that govern these and other employment law matters.

Table of Contents

On June 5, 2023, CMS published the Omnibus Final Rule, withdrawing the COVID-19 vaccination IFR 60 days after the rule's publication. Previously in November of 2022, a coalition of 22 states formally called on the Biden-Harris Administration to withdraw the COVID-19 vaccination IFR. At present, there is no nationally significant litigation concerning such mandates. The effects of the COVID-19 vaccination IFR's withdrawal on our operations and the labor pool for nursing and administrative staff is unknown, but may have an impact on our business, operations, and profitability.

Furthermore, the Biden-Harris Administration has requested HHS and CMS study and issue proposed rules regarding care-based careers, including improving access to training, increasing the attractiveness of compensation in care-based positions, and improving the retention and career progression of care workers. The Biden-Harris Administration has sought proposed rules that tie some of these issues, such as wages and retention, to Medicare reimbursement for facilities. Other pending legislation, such as the HCBS Access Act, indicate a legislative priority of providing funding for care-based careers that may affect our pool of desired workers. Rising operating costs due to labor shortages, greater compensation and incentives required to attract and retain qualified personnel and higher-than-usual inflation on items including energy, utilities, food and other goods used in our facilities and the costs for transporting these items could increase our cost and decrease our profits.

The compliance costs associated with these laws and evolving regulations could be substantial. By way of example, all of our affiliated facilities are required to comply with the ADA, which has separate compliance requirements for “public accommodations” and “commercial properties,” but generally requires that buildings be made accessible to people with disabilities. Compliance with ADA requirements could require removal of access barriers and non-compliance could result in imposition of government fines or an award of damages to private litigants. Further legislation may impose additional burdens or restrictions with respect to access by disabled persons. In addition, federal proposals to introduce a system of mandated health insurance and flexible work time and other similar initiatives could, if implemented, adversely affect our operations. We also may be subject to employee-related claims such as wrongful discharge, discrimination or violation of equal employment law. While we are insured for these types of claims, we could be subject to damages that are not covered by our insurance policies or that exceed our insurance limits, and we may be required to pay such damages directly, which would negatively impact our cash flow from operations.

Required regulatory approvals could delay or prohibit transfers of our healthcare operations, which could result in periods in which we are unable to receive reimbursement for such properties.

The operations of our operating subsidiaries must be licensed under applicable state law and, depending upon the type of operation, certified or approved as providers under the Medicare and/or Medicaid programs. In the process of acquiring or transferring operating assets, our operations must receive change of ownership approvals from state licensing agencies, Medicare and Medicaid as well as third party payors. Proposed rules regarding the disclosure of SNF facility ownership, if made effective, may increase the scrutiny placed on companies that operate, directly or indirectly, multiple SNFs, and may subject our licensing and approval process to additional scrutiny or delays. If there are any delays in receiving regulatory approvals from the applicable federal, state or local government agencies, or the inability to receive such approvals, such delays or denials could result in delayed or lost reimbursement related to periods of service prior to the receipt of such approvals, which could negatively impact our cash position.

Compliance with federal and state fair housing, fire, safety and other regulations may require us to make unanticipated expenditures, which could be costly to us.

We must comply with the federal Fair Housing Act and similar state laws, which prohibit us from discriminating against individuals if it would cause such individuals to face barriers in gaining residency in any of our affiliated facilities. Additionally, the Fair Housing Act and other similar state laws require that we advertise our services in such a way that we promote diversity and not limit it. We may be required, among other things, to change our marketing techniques to comply with these requirements.

Table of Contents

In addition, our affiliated facilities are required to operate in compliance with applicable fire and safety regulations, building codes and other land use regulations and food licensing or certification requirements as they may be adopted by governmental agencies and bodies from time to time. Like other healthcare facilities, our affiliated SNFs are subject to periodic surveys or inspections by governmental authorities to assess and assure compliance with regulatory requirements. Surveys occur on a regular (often annual or biannual) schedule, and special surveys may result from a specific complaint filed by a patient, a family member or one of our competitors. We may be required to make substantial capital expenditures to comply with these requirements.

We depend largely upon reimbursement from third-party payors, and our revenue, financial condition and results of operations could be negatively impacted by any changes in the acuity mix of patients in our affiliated facilities as well as payor mix and payment methodologies.

Our revenue is affected by the percentage of the patients of our operating subsidiaries who require a high level of skilled nursing and rehabilitative care, whom we refer to as high acuity patients, and by our mix of payment sources. Changes in the acuity level of patients we attract, as well as our payor mix among Medicaid, Medicare, private payors and managed care companies, significantly affect our profitability. We generally receive higher reimbursement rates for high acuity patients, and payors reimburse us at different rates. For the three and nine months ended September 30, 2023, 72.1% and 72.8%, of our revenue was provided by government payors that reimburse us at predetermined rates, respectively. If our labor or other operating costs increase, we will be unable to recover such increased costs from government payors. Accordingly, if we fail to maintain our proportion of high acuity patients or if there is any significant increase in the percentage of the patients of our operating subsidiaries for whom we receive Medicaid reimbursement, our results of operations may be adversely affected.

Initiatives undertaken by major insurers and managed care companies to contain healthcare costs may adversely affect our business. These tactics include contracting with healthcare providers to obtain services on a discounted basis. We believe that this trend will continue and may limit reimbursements for healthcare services. If insurers or managed care companies from whom we receive substantial payments were to reduce the amounts they pay for services and we did not wish to accept such reductions, we may lose patients if we choose not to renew our contracts with these insurers at lower rates. Additionally, trade publications within the healthcare industry have reported on the trend of payors using the No Surprises Act as a means to force re-negotiation of reimbursement rates for providers and facilities, leading to litigation between these providers and/or facilities against payors and it may adversely affect us as well.

As discussed under Item 2., Government Regulation, the Biden-Harris Administration has requested HHS and CMS conduct studies to evaluate potential staffing, data reporting, employee compensation and retention, and resident experience regulations that may result in a reduction of our revenue from Medicare and Medicaid. CMS first requested information regarding these priorities in 2022 and subsequently published further requests for information from the public in the Federal Register to aid in studies and anticipated rulemaking. CMS's proposed rule regarding disclosure of significant information regarding their ownership, operations, management and the owners of real property leased or subleased by our operating subsidiaries, may result in additional regulatory requirements for participation in those programs.

We are subject to litigation that could result in significant legal costs and large settlement amounts or damage awards.

The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents of our operating subsidiaries and the services we provide. The industry has experienced an increased trend in the number and severity of litigation claims, due in part to the number of large verdicts, including large punitive damage awards. These claims are filed based upon a wide variety of claims and theories, including deficiencies under conditions of participation under certain state and federal healthcare programs. Plaintiffs' attorneys have become increasingly more aggressive in their pursuit of claims against healthcare providers, including skilled nursing providers, employing a wide variety of advertising and solicitation activities to generate more claims. The increased caps on damages awarded in such actions, as discussed above, may trigger a larger number of these lawsuits against our independent operating subsidiaries in California and other states that adopt similar legislation. The defense of lawsuits has in the past, and may in the future, result in significant legal costs, regardless of the outcome. Additionally, increases to the frequency and/or severity of losses from such claims and suits may result in increased liability insurance premiums or a decline in available insurance coverage levels, which could materially and adversely affect our business, financial condition and results of operations.

Table of Contents

We have in the past been subject to class action litigation involving claims of violations of various regulatory requirements and been able to settle these claims without an ongoing material adverse effect on our business. Future claims could be brought that may materially affect our business, financial condition and results of operations. Other claims and suits, including class actions, continue to be filed against us and other companies in our industry. For example, there has been a general increase in the number of wage and hour class action claims filed in several of the jurisdictions where we operate, typically based on alleged failures to permit or properly compensate for meal and rest periods, or failure to pay for time worked. If there were a significant increase in the number of these claims against us or an increase in amounts owing should plaintiffs be successful in their claims, this could have a material adverse effect to our business, financial condition, results of operations and cash flows.

We are subject to potential lawsuits under the FCA and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. Under the qui tam or "whistleblower" provisions of the FCA, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. For example, and despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its CID issued on May 31, 2018, the involved qui tam relator has moved forward with the lawsuit and is pursuing claims that we allegedly violated the FCA and/or the AKS. We are vigorously defending this lawsuit, but the costs of defense may be significant given the nature of the allegations and the date range contemplated by the complaint.

Beyond our skilled nursing business, we engage in numerous ancillary businesses through one or more of our subsidiaries. These ancillary businesses generally support and provide services complementary to our operations, including but not limited to non-emergent ground transportation for patients and residents. Our ancillary businesses may also be the subject of claims, lawsuits, and regulatory oversight that are specific to the particular services they offer. Noncompliance with the laws and regulations that may apply to our ancillary businesses may result in fines, penalties, and civil claims paid by our affected independent subsidiaries. Specific to our non-emergent ground transportation business, the drivers employed by this business may be subject to additional state-specific regulations regarding working time allowed to be spent driving, waiting time, and break or rest periods, and violations of these rules may lead to regulatory fines, penalties, or claims to be paid to individual drivers, in addition to the general employment risks described above.

Our ancillary businesses also are susceptible to general liability claims based on facts and circumstances that are specific to their activities and operations, such as claims for automobile-involved accidents against our non-emergent ground transportation business. The defense of claims and lawsuits relating to our ancillary businesses in the past, and may in the future, result in significant legal costs, regardless of the outcome. As our ancillary businesses grow, the independent subsidiaries may be subject to increased frequency and/or severity of losses from such claims and suits which may result in increased liability insurance premiums and decline in available coverage as described above, which could materially and adversely affect our business, financial condition and results of operations.

In addition, we contract with a variety of landlords, lenders, vendors, suppliers, consultants and other individuals and businesses. These contracts typically contain covenants and default provisions. If the other party to one or more of our contracts were to allege that we have violated the contract terms, we could be subject to civil liabilities which could have a material adverse effect on our financial condition and results of operations.

If litigation is instituted against one or more of our subsidiaries, a successful plaintiff might attempt to hold us or another subsidiary liable for the alleged wrongdoing of the subsidiary principally targeted by the litigation. If a court in such litigation decided to disregard the corporate form, the resulting judgment could increase our liability and adversely affect our financial condition and results of operations.

Congress has repeatedly considered, without passage, a bill that would require, among other things, that agreements to arbitrate nursing home disputes be made after the dispute has arisen rather than before prospective patients move in, to prevent nursing home operators and prospective patients from mutually entering into a pre-admission pre-dispute arbitration agreement. This bill, known as the Fairness in Nursing Home Arbitration Act, was introduced in the House of Representatives in 2021; the bill and its analogue introduced in the Senate have never made it out of the committees to which they were referred for discussion. This legislation or similar bills have not yet been introduced in the current session of Congress, which commenced at the beginning of 2023.

Table of Contents

Our independently operating subsidiaries use arbitration agreements, which have generally been favored by the courts, to streamline the dispute resolution process and reduce our exposure to legal fees and excessive jury awards. CMS has identified these arbitration agreements as an area of focus and issued guidance to state surveyors regarding federal requirements for the use of arbitration agreements in nursing home care, with non-compliance potentially resulting in fines and other sanctions. If we are not able to secure pre-admission arbitration agreements, our litigation exposure and costs of defense in patient liability actions could increase, our liability insurance premiums could increase, and our business may be adversely affected.

We conduct regular internal investigations into the care delivery, recordkeeping and billing processes of our operating subsidiaries. These reviews sometimes detect instances of noncompliance which we attempt to correct, which can decrease our revenue.

As an operator of healthcare facilities, we have a program to help us comply with various requirements of federal and private healthcare programs. Our compliance program includes, among other things, (1) policies and procedures modeled after applicable laws, regulations, sub-regulatory guidance and industry practices and customs that govern the clinical, reimbursement and operational aspects of our subsidiaries; (2) training about our compliance process for all of the employees of our operating subsidiaries, our directors and officers, and training about Medicare and Medicaid laws, fraud and abuse prevention, clinical standards and practices, and claim submission and reimbursement policies and procedures for appropriate employees; and (3) internal controls that monitor, among other things, the accuracy of claims, reimbursement submissions, cost reports and source documents, provision of patient care, services, and supplies as required by applicable standards and laws, accuracy of clinical assessment and treatment documentation, and implementation of judicial and regulatory requirements (i.e., background checks, licensing and training).

From time to time our systems and controls highlight potential compliance issues, which we investigate as they arise. Historically, we have, and will continue to do so in the future, initiated internal inquiries into possible recordkeeping and related irregularities at our affiliated SNFs, which were detected by our internal compliance team in the course of its ongoing reviews.

Through these internal inquiries, we have identified potential deficiencies in the assessment of and recordkeeping for small subsets of patients. We have assisted in implementing, targeted improvements in the assessment and recordkeeping practices to make them consistent with the existing standards and policies applicable to our affiliated SNFs. We continue to monitor the measures implemented for effectiveness and perform follow-up reviews to ensure compliance. Consistent with healthcare industry accounting practices, we record any charge for refunded payments against revenue in the period in which the claim adjustment becomes known.

If additional reviews result in identification and quantification of additional amounts to be refunded, we will accrue additional liabilities for claim costs and interest, and repay any amounts due in normal course and within the time permitted by law. Failure to refund overpayments within required time frames (as described in greater detail above) could result in FCA liability and our business, financial condition and results of operations could be materially and adversely affected and our stock price could decline.

We may be unable to complete future facility or business acquisitions at attractive prices or at all, which may adversely affect our revenue; we may also elect to dispose of underperforming or non-strategic operating subsidiaries, which would also decrease our revenue.

To date, our revenue growth has been significantly impacted by our acquisition of new facilities and businesses. Subject to general market conditions and the availability of essential resources and leadership within our company, we continue to seek both single-and multi-facility acquisition and business acquisition opportunities that are consistent with our geographic, financial and operating objectives.

We face competition for the acquisition of facilities and businesses and expect this competition to increase. Based upon factors such as our ability to identify suitable acquisition candidates, future regulations affecting our ability to purchase facilities, the purchase price of the facilities, increasing interest rates for debt-financed purchases, prevailing market conditions, the availability of leadership to manage new facilities and our own willingness to take on new operations, the rate at which we have historically acquired facilities has fluctuated significantly. In the future, we anticipate the rate at which we may acquire facilities will continue to fluctuate, which may affect our revenue.

Table of Contents

We have also previously acquired a few facilities, which were or have proven to be non-strategic or less desirable, and we may consider disposing of such facilities or exchanging them for facilities that are more desirable, either because they were included in larger, indivisible groups of facilities or under other circumstances. To the extent we dispose of such a facility without simultaneously acquiring a facility in exchange, our revenue may decrease.

We may not be able to successfully integrate acquired facilities and businesses into our operations, and we may not achieve the benefits we expect from any of our facility acquisitions.

We may not be able to successfully or efficiently integrate new acquisitions of facilities and businesses with our existing operating subsidiaries, culture and systems. The process of integrating acquisitions into our existing operations may result in unforeseen operating difficulties, divert management's attention from existing operations, or require an unexpected commitment of staff and financial resources, and may ultimately be unsuccessful. Existing operations available for acquisition frequently serve or target different markets than those that we currently serve. We also may determine that renovations of acquired facilities and changes in staff and operating management personnel are necessary to successfully integrate those acquisitions into our existing operations. We may not be able to recover the costs incurred to reposition or renovate newly operating subsidiaries. The financial benefits we expect to realize from many of our acquisitions are largely dependent upon our ability to improve clinical performance, overcome regulatory deficiencies, rehabilitate or improve the reputation of the operations in the community, increase and maintain occupancy, control costs, and in some cases change the patient acuity mix. If we are unable to accomplish any of these objectives at the operating subsidiaries we acquire, we will not realize the anticipated benefits and we may experience lower than anticipated profits, or even losses.

During the nine months ended September 30, 2023, we expanded our operations and real estate portfolio through a combination of long-term leases and real estate purchases, with the addition of 24 stand-alone skilled nursing operations. This growth has placed and will continue to place significant demands on our current management resources. Our ability to manage our growth effectively and to successfully integrate new acquisitions into our existing business will require us to continue to expand our operational, financial and management information systems and to continue to retain, attract, train, motivate and manage key employees, including facility-level leaders and our local directors of nursing. We may not be successful in attracting qualified individuals necessary for future acquisitions to be successful, and our management team may expend significant time and energy working to attract qualified personnel to manage facilities we may acquire in the future. Also, the newly acquired facilities may require us to spend significant time improving services that have historically been substandard, and if we are unable to improve such facilities quickly enough, we may be subject to litigation and/or loss of licensure or certification. If we are not able to successfully overcome these and other integration challenges, we may not achieve the benefits we expect from any of our acquisitions, and our business may suffer.

In undertaking acquisitions, we may be adversely impacted by costs, liabilities and regulatory issues that may adversely affect our operations.

In undertaking acquisitions, we also may be adversely impacted by unforeseen liabilities attributable to the prior providers who operated those facilities, against whom we may have little or no recourse. Many facilities we have historically acquired were underperforming financially and had clinical and regulatory issues prior to and at the time of acquisition. Even where we have improved operating subsidiaries and patient care at facilities that we have acquired, we still may face post-acquisition regulatory issues related to pre-acquisition events. These may include, without limitation, payment recoupment related to our predecessors' prior noncompliance, the imposition of fines, penalties, operational restrictions or special regulatory status. Further, we may incur post-acquisition compliance risk due to the difficulty or impossibility of immediately or quickly bringing non-compliant facilities into full compliance. Diligence materials pertaining to acquisition targets, especially the underperforming facilities that often represent the greatest opportunity for return, are often inadequate, inaccurate or impossible to obtain, sometimes requiring us to make acquisition decisions with incomplete information. Despite our due diligence procedures, facilities that we have acquired or may acquire in the future may generate unexpectedly low returns, may cause us to incur substantial losses, may require unexpected levels of management time, expenditures or other resources, or may otherwise not meet a risk profile that our investors find acceptable.

In addition, we might encounter unanticipated difficulties and expenditures relating to any of the acquired facilities, including contingent liabilities. For example, when we acquire a facility, we generally assume the facility's existing Medicare provider number for purposes of billing Medicare for services. If CMS later determines that the prior owner of the facility had received overpayments from Medicare for the period of time during which it operated the facility, or had incurred fines in connection with the operation of the facility, CMS could hold us liable for repayment of the overpayments or fines. We may be unable to improve every facility that we acquire. In addition, operation of these facilities may divert management time and attention from other operations and priorities, negatively impact cash flows, result in adverse or unanticipated accounting charges, or otherwise damage other areas of our company if they are not timely and adequately improved.

Table of Contents

We also incur regulatory risk in acquiring certain facilities due to the licensing, certification and other regulatory requirements affecting our right to operate the acquired facilities. For example, in order to acquire facilities on a predictable schedule, or to acquire declining operations quickly to prevent further pre-acquisition declines, we frequently acquire such facilities prior to receiving license approval or provider certification. We operate such facilities as the interim manager for the outgoing licensee, assuming financial responsibility, among other obligations for the facility. To the extent that we may be unable or delayed in obtaining a license, we may need to operate the facility under a management agreement from the prior operator. Any inability in obtaining consent from the prior operator of a target acquisition to utilizing its license in this manner could impact our ability to acquire additional facilities. Further, anticipated future regulations may cause delays in acquiring the required licenses and certifications, if it is possible to do so at all. If we were subsequently denied licensure or certification for any reason, we might not realize the expected benefits of the acquisition and would likely incur unanticipated costs and other challenges which could cause our business to suffer.

If we do not achieve or maintain competitive quality of care ratings from CMS or private organizations engaged in similar monitoring activities, our business may be negatively affected.

As discussed in Item 2., under Government Regulation, CMS provides comparative public data, rating every SNF operating in each state based upon quality-of-care indicators. Certain private organizations engage in similar monitoring and ranking activities. CMS’s system is the Five-Star Quality Rating System which gives each nursing home a rating of between one and five stars in various categories, with five-star ratings harder to obtain over time. The ratings are available on a consumer-facing website, Nursing Home Compare. In cases of acquisitions, the previous operator's clinical ratings are included in our overall Five-Star Quality Rating and the rating may not reflect the improvements we were able to make until it is recalculated. Based on CMS's guidance and regulations, we expect more data to be collected by CMS and reported on the Nursing Home Compare website in the future.

CMS continues to increase quality measure thresholds, making it more difficult to achieve upward and five-star ratings. CMS increased its quality measure thresholds in October of 2022, making it more difficult for facilities to obtain or maintain four- and five-star ratings, which were most recently re-calculated in July of 2023, allowing only 10% of nursing facilities within a state to receive a five-star rating. CMS discloses the increasing standards for four- and five-star ratings in its star rating cut point table, which discloses the points needed for each star rating within every state. CMS has indicated that it will increase these quality measure thresholds every six months. Some facilities may see a decline in their overall five-star rating absent any new inspection information, and as a result the five-star ratings of our affiliated facilities may decline even as their quality measures remain unchanged or improve. Additionally, on the Nursing Home Compare website, CMS recently began displaying a consumer alert icon next to nursing homes that have been cited on inspection reports for incidents of abuse, neglect, or exploitation. In July of 2022, CMS updated the scoring measures used for SNFs to include six dimensions of staffing and turnover, which may adversely affect the rating of our facilities on the Nursing Home Compare website.

In July 2023, CMS revised the nursing-home level exclusion criteria used on the administrator turnover measure, adding information regarding its calculation of the staff turnover measure and publishing an updated ratings table, which identifies the points needed for each nursing facility to obtain certain star ratings within its state. This change made it more competitive to obtain a five-star rating, and more difficult to maintain such a rating once achieved. Only 10% of nursing facilities can receive a five-star rating in the state where it operates. The July 2023 change also increases the pressure on our independent operating subsidiaries to obtain a smaller number of available five-star ratings, as lower ratings may make it more difficult to attract prospective residents to receive our services.

In September 2023, CMS announced that it will update the staffing level case-mix adjustment methodology and freeze four of the quality measures used in the Nursing Home Five-Star Quality Rating System beginning with the April 2024 refresh of the Nursing Home Compare website data. In July 2024, CMS will change the staffing case-mix adjustment methodology to a model based on PDPM. The Nursing Home Compare website will then begin posting staffing level measures that use this methodology. CMS will revise the staffing rating thresholds to maintain the same distribution of points for staffing measures that will be affected by this freeze and replacement. Further, CMS will penalize SNFs that submit erroneous data, or fail to submit data, by awarding them the lowest possible rating on that measure. We may be significantly affected if any of our independent operating subsidiaries fail to submit information for the MDS in 2024, or if CMS deems their MDS submissions to be erroneous. In addition to the uncertainty created by coming changes to CMS’s five-star ratings that currently are unknown, the potential negative consequences of freezing unfavorable data may adversely affect our star rating and negatively impact our ability to attract residents.

Table of Contents

Providing quality patient care is the cornerstone of our business. We believe that hospitals, physicians and other referral sources refer patients to us in large part because of our reputation for delivering quality care. If we should fail to achieve our internal rating goals or fail to exceed the national average rating on the Five-Star Quality Rating System, including due to nursing and administrative staffing and turnover, or have facilities displaying a consumer alert icon for incidents of abuse, neglect, or exploitation, it may affect our ability to generate referrals, which could have a material adverse effect upon our business and consolidated financial condition, results of operations and cash flows.

If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, our business may be adversely affected.

It may become more difficult and costly for us to obtain coverage for resident care liabilities and other risks, including property, automobile and casualty insurance. For example, the following circumstances may adversely affect our ability to obtain insurance at favorable rates:

•we experience higher-than-expected professional liability, property and casualty, or other types of claims or losses;

•we receive survey deficiencies or citations of higher-than-normal scope or severity;

•we acquire especially troubled operations or facilities that present unattractive risks to current or prospective insurers;

•insurers choose to stop operating or offering policies in certain states due to changes in economic conditions or laws;

•insurers tighten underwriting standards applicable to us or our industry; or

•insurers or reinsurers are unable or unwilling to insure us or the industry at historical premiums and coverage levels.

If any of these potential circumstances were to occur, our insurance carriers may cancel or not renew our policies, or require us to significantly increase our self-insured retention levels or pay substantially higher premiums for the same or reduced coverage for insurance, including workers compensation, property and casualty, automobile, employment practices liability, directors and officers liability, employee healthcare and general and professional liability coverages.

In some states, the law prohibits or limits insurance coverage for the risk of punitive damages arising from professional liability and general liability claims or litigation. Other states where we operate have experienced a withdrawal of insurers from the marketplace due to prior losses, or are at risk of insurers leaving the market due to changes in the law that make it difficult for those insurers to operate within the state. Coverage for punitive damages is also excluded under some insurance policies. As a result, we may be liable for punitive damage awards in these states that either are not covered or are in excess of our insurance policy limits. Claims against us, regardless of their merit or eventual outcome, could also inhibit our ability to attract patients or expand our business and could require our management to devote time to matters unrelated to the day-to-day operation of our business.

With few exceptions, workers compensation and employee health insurance costs have also increased markedly in recent years. To partially offset these increases, we have increased the amounts of our self-insured retention and deductibles in connection with general and professional liability claims. We also have implemented a self-insurance program for workers compensation in all states, and elected non-subscriber status for workers compensation in Texas. Due to the nature of our business and the residents we serve, including the risk of claims from residents as well as potential governmental action, it may be difficult to complete the underwriting process and obtain insurance at commercially reasonable rates. If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, or if the coverage levels we can economically obtain decline, our business may be adversely affected.

Our self-insurance programs may expose us to significant and unexpected costs and losses.

We have maintained general and professional liability insurance since 2002 and workers compensation insurance since 2005 through a wholly owned captive insurance subsidiary to insure our self-insurance reimbursements and deductibles as part of a continually evolving overall risk management strategy. We establish the insurance loss reserves based on an estimation process that uses information obtained from both company-specific and industry data. The estimation process requires us to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and our assumptions about emerging trends, we, along with an independent actuary, develop information about the size of ultimate claims based on our historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damages with respect to unpaid claims. It is possible, however, that the actual liabilities may exceed our estimates of loss. We may also experience an unexpectedly large number of successful claims or claims that result in costs or liability significantly in excess of our projections. For these and other reasons, our self-insurance reserves could prove to be inadequate, resulting in liabilities in excess of our available insurance and self-insurance. If a

Table of Contents

successful claim is made against us and it is not covered by our insurance or exceeds the insurance policy limits, our business may be negatively and materially impacted.

Further, because our self-insurance reimbursements under our general and professional liability and workers compensation programs applies on a per claim basis, there is no limit to the maximum number of claims or the total amount for which we could incur liability in any policy period.

We also self-insure our employee health benefits. With respect to our health benefits self-insurance, our reserves and premiums are computed based on a mix of company specific and general industry data that is not specific to our own company. Even with a combination of limited company-specific loss data and general industry data, our loss reserves are based on actuarial estimates that may not correlate to actual loss experience in the future. Therefore, our reserves may prove to be insufficient and we may be exposed to significant and unexpected losses.

The geographic concentration of our affiliated facilities could leave us vulnerable to an economic downturn, regulatory changes or acts of nature in those areas.

Our affiliated facilities located in Arizona, California, and Texas account for the majority of our total revenue. As a result of this concentration, the conditions of local economies, changes in governmental rules, presence and participation of insurers, regulations and reimbursement rates or criteria, changes in demographics, state funding, acts of nature and other factors that may result in a decrease in demand and/or reimbursement for skilled nursing services in these states could have a disproportionately adverse effect on our revenue, costs and results of operations. Moreover, since over 24% of our affiliated facilities are located in California, we are particularly susceptible to revenue loss, cost increase or damage caused by natural disasters such as electrical power shortages, fires, earthquakes or mudslides, or increased liabilities that may arise from regulations as discussed within Item 2., under Government Regulation.

In addition, our affiliated facilities in Iowa, Nebraska, Kansas, South Carolina, Washington and Texas are more susceptible to revenue loss, cost increases or damage caused by natural disasters including hurricanes, tornadoes and flooding. These acts of nature may cause disruption to us, the employees of our operating subsidiaries and our affiliated facilities, which could have an adverse impact on the patients of our operating subsidiaries and our business. In order to provide care for the patients of our operating subsidiaries, we are dependent on consistent and reliable delivery of food, pharmaceuticals, utilities and other goods to our affiliated facilities, and the availability of employees to provide services. If the delivery of goods or the ability of employees to reach our affiliated facilities were interrupted in any material respect due to a natural disaster or other reasons, it would have a significant impact on our affiliated facilities and our business. Furthermore, the impact, or impending threat, of a natural disaster may require that we evacuate one or more facilities, which would be costly and would involve risks, including potentially fatal risks, for the patients. The impact of disasters and similar events is inherently uncertain. Such events could harm the patients and employees of our operating subsidiaries, severely damage or destroy one or more of our affiliated facilities, harm our business, reputation and financial performance, or otherwise cause our business to suffer in ways that we currently cannot predict.

The actions of a national labor union that has pursued a negative publicity campaign criticizing our business in the past may adversely affect our revenue and our profitability.

We continue to maintain our right to inform the employees of our operating subsidiaries about our views of the potential impact of unionization upon the workplace generally and upon individual employees. Historically, the staff at our affiliated facilities that have been approached to unionize have uniformly rejected union organizing efforts. Forthcoming proposed rules from CMS, which, based on the Biden-Harris Administration's executive orders discussed under Government Regulation in Item 2., as well as potential legislation such as the HCBS Access Act aimed toward providing more resources to those considering care-based careers, may increase the likelihood of employee unionization due to increased emphasis on care-based careers in SNF facilities. If employees decide to unionize, our cost of doing business could increase, and we could experience contract delays, difficulty in adapting to a changing regulatory and economic environment, cultural conflicts between unionized and non-unionized employees, strikes and work stoppages, and we may conclude that affected facilities or operations would be uneconomical to continue operating.

Table of Contents

Because we lease the majority of our affiliated facilities, we are subject to risks associated with leased real property, including risks relating to lease termination, lease extensions and special charges, any of which could adversely affect our business, financial position or results of operations.

As of September 30, 2023, we leased 213 of our 295 affiliated facilities. Most of our leases are triple-net leases, which means that, in addition to rent, we are required to pay for the costs related to the property (including property taxes, insurance, and maintenance and repair costs). We are responsible for paying these costs notwithstanding the fact that some of the benefits associated with paying these costs accrue to the landlords as owners of the associated facilities.

Each lease provides that the landlord may terminate the lease for a variety of reasons, including the default in any payment of rent, taxes or other payment obligations or the breach of any other covenant or agreement in the lease. Termination of a lease could result in a default under our debt agreements and could adversely affect our business, financial position or results of operations. There can be no assurance that we will be able to comply with all of our obligations under the leases in the future.

Failure to generate sufficient cash flow to cover required payments or meet operating covenants under our long-term debt, mortgages and long-term operating leases could result in defaults under such agreements and cross-defaults under other debt, mortgage or operating lease arrangements, which could harm our operating subsidiaries and cause us to lose facilities or experience foreclosures.

Our Credit Facility has a borrowing capacity of up to $600.0 million in aggregate principal amount. As of September 30, 2023 and through the filing date of this report, we had no outstanding borrowings under our Credit Facility. Twenty-three of our subsidiaries have mortgage loans insured with the Department of Housing and Urban Development (HUD) for an aggregate amount of $151.1 million, which subjects these subsidiaries to HUD oversight and periodic inspections. The terms of the mortgage loans range from 25- to 35-years.

We also have one outstanding promissory note with an aggregate principal amount of approximately $2.3 million as of September 30, 2023. The term of the note is 12 years. Because this mortgage loan is insured with HUD, our borrower subsidiary under the loan is subject to HUD oversight and periodic inspections.

In addition, we had $2.7 billion of future operating lease obligations as of September 30, 2023. We intend to continue financing our operating subsidiaries through mortgage financing, long-term operating leases and other types of financing, including borrowings under our lines of credit and future credit facilities we may obtain.

We may not generate sufficient cash flow from operations to cover required interest, principal and lease payments. In addition, our outstanding Credit Facility and mortgage loans contain restrictive covenants and require us to maintain or satisfy specified coverage tests on a consolidated basis and on a facility or facilities basis. These restrictions and operating covenants include, among other things, requirements with respect to occupancy, debt service coverage, project yield, net leverage ratios, minimum interest coverage ratios and minimum asset coverage ratios. These restrictions may interfere with our ability to obtain additional advances under our Credit Facility or to obtain new financing or to engage in other business activities, which may inhibit our ability to grow our business and increase revenue.

From time to time, the financial performance of one or more of our mortgaged facilities may not comply with the required operating covenants under the terms of the mortgage. Any non-payment, noncompliance or other default under our financing arrangements could, subject to cure provisions, cause the lender to foreclose upon the facility or facilities securing such indebtedness or, in the case of a lease, cause the lessor to terminate the lease, each with a consequent loss of revenue and asset value to us or a loss of property. Furthermore, in many cases, indebtedness is secured by both a mortgage on one or more facilities, and a guaranty by us. In the event of a default under one of these scenarios, the lender could avoid judicial procedures required to foreclose on real property by declaring all amounts outstanding under the guaranty immediately due and payable, and requiring us to fulfill our obligations to make such payments. If any of these scenarios were to occur, our financial condition would be adversely affected. For tax purposes, a foreclosure on any of our properties would be treated as a sale of the property for a price equal to the outstanding balance of the debt secured by the mortgage. If the outstanding balance of the debt secured by the mortgage exceeds our tax basis in the property, we would recognize taxable income on foreclosure, but would not receive any cash proceeds, which would negatively impact our earnings and cash position. Further, because our mortgages and operating leases generally contain cross-default and cross-collateralization provisions, a default by us related to one facility could affect a significant number of other facilities and their corresponding financing arrangements and operating leases.

100

Table of Contents

Because our term loans, promissory note, bonds, mortgages and lease obligations are fixed expenses and secured by specific assets, and because our revolving loan obligations are secured by virtually all of our assets, if reimbursement rates, patient acuity mix or occupancy levels decline, or if for any reason we are unable to meet our loan or lease obligations, we may not be able to cover our costs and some or all of our assets may become at risk. Our ability to make payments of principal and interest on our indebtedness and to make lease payments on our operating leases depends upon our future performance, which will be subject to general economic conditions, industry cycles and financial, business and other factors affecting our operating subsidiaries, many of which are beyond our control. If we are unable to generate sufficient cash flow from operations in the future to service our debt or to make lease payments on our operating leases, we may be required, among other things, to seek additional financing in the debt or equity markets, refinance or restructure all or a portion of our indebtedness, sell selected assets, reduce or delay planned capital expenditures or delay or abandon desirable acquisitions. Such measures might not be sufficient to enable us to service our debt or to make lease payments on our operating leases. The failure to make required payments on our debt or operating leases or the delay or abandonment of our planned growth strategy could result in an adverse effect on our future ability to generate revenue and sustain profitability. In addition, any such financing, refinancing or sale of assets might not be available on terms that are economically favorable to us, or at all.

Move-in and occupancy rates may remain unpredictable even after the COVID-19 pandemic is over.

Occupancy levels at SNFs are likely to remain vulnerable to the effects of COVID-19 even after the pandemic is over. Facilities experiencing decreases in move-in rates cite resident or family member concerns as the basis for such decreases. These and other similar concerns may continue to impact our ability to attract new residents and our ability to retain existing residents.

A housing downturn could decrease demand for senior living services.

Seniors often use the proceeds of home sales to fund their admission to senior living facilities. A downturn in the housing markets, including reductions in sales prices caused by increasing mortgage interest rates, economic uncertainty, recession, or a reduction in activity in the market for residential real estate, could adversely affect seniors’ ability to afford our resident fees and entrance fees. If national or local housing markets enter a persistent decline, our occupancy rates, revenues, results of operations and cash flow could be negatively impacted.

As we continue to acquire and lease real estate assets, we may not be successful in identifying and consummating these transactions.

We lease 30 of our properties to third party operators. In the future, we might expand our leasing property portfolio to additional tenants. We have very limited control over the success or failure of our tenants’ and operators’ businesses and, at any time, a tenant or operator may experience a downturn in its business that weakens its financial condition. If that happens, the tenant or operator may fail to make its payments to us when due. Although our lease agreements give us the right to exercise certain remedies in the event of default on the obligations owing to us, we may determine not to do so if we believe that enforcement of our rights would be more detrimental to our business than seeking alternative approaches.

An important part of our business strategy is to continue to expand and diversify our real estate portfolio through accretive acquisition and investment opportunities in healthcare properties. Our execution of this strategy by successfully identifying, securing and consummating beneficial transactions is made more challenging by increased competition and can be affected by many factors, including our relationships with current and prospective tenants, our ability to obtain debt and equity capital at costs comparable to or better than our competitors and our ability to negotiate favorable terms with property owners seeking to sell and other contractual counterparties. Our competitors for these opportunities include healthcare REITs, real estate partnerships, healthcare providers, healthcare lenders and other investors, including developers, banks, insurance companies, pension funds, government-sponsored entities and private equity firms, some of whom may have greater financial resources and lower costs of capital than we do. Potential regulations may affect the ability of these entities, as well as ourselves, to compete for these opportunities or enter into transactions for real estate related to our business. If we are unsuccessful at identifying and capitalizing on investment or acquisition opportunities, our growth and profitability in our real estate investment portfolio may be adversely affected.

101

Table of Contents

Investments in and acquisitions of healthcare properties entail risks associated with real estate investments generally, including risks that the investment will not achieve expected returns, that the cost estimates for necessary property improvements will prove inaccurate or that the tenant or operator will fail to meet performance expectations. Income from properties and yields from investments in our properties may be affected by many factors, including changes in governmental regulation (such as licensing and government payment), general or local economic conditions (such as fluctuations in interest rates, senior savings, and employment conditions), the available local supply of and demand for improved real estate, a reduction in rental income as the result of an inability to maintain occupancy levels, natural disasters (such as hurricanes, earthquakes and floods) or similar factors. Furthermore, healthcare properties are often highly customized, and the development or redevelopment of such properties may require costly tenant-specific improvements. As a result, we cannot assure you that we will achieve the economic benefit we expect from acquisition or investment opportunities.

As we expand our presence in other relevant healthcare industries, we would become subject to risks in a market in which we have limited experience.

The majority of our affiliated facilities have historically been SNFs. As we expand our presence in other relevant healthcare industries, our existing overall business model will continue to change and expose our company to risks in markets in which we have limited experience, such as the Eliminating Kickbacks in Recovery Act and other state laws that are not as well-developed in regulation and decisional authority as their federal equivalents. We expect that we will have to adjust certain elements of our existing business model, which could have an adverse effect on our business.

If our referral sources fail to view us as an attractive skilled nursing provider, or if our referral sources otherwise refer fewer patients, our patient base may decrease.

We rely significantly on appropriate referrals from hospitals, physicians, and other healthcare providers in the communities in which we deliver our services to attract appropriate residents and patients to our affiliated facilities. Our referral sources are not obligated to refer business to us and may refer business to other healthcare providers. We believe many of our referral sources refer business to us as a result of the quality of our patient care and our efforts to establish and build a relationship with our referral sources. If we lose, or fail to maintain, existing relationships with our referral resources, fail to develop new relationships, or if we are perceived by our referral sources as not providing high quality patient care, our occupancy rate and the quality of our patient mix could suffer. In addition, if any of our referral sources have a reduction in patients whom they can refer due to a decrease in their business, our occupancy rate and the quality of our patient mix could suffer.

We may need additional capital to fund our operating subsidiaries and finance our growth, and we may not be able to obtain it on terms acceptable to us, or at all, which may limit our ability to grow.

Our ability to maintain and enhance our operating subsidiaries and equipment in a suitable condition to meet regulatory standards, operate efficiently and remain competitive in our markets requires us to commit substantial resources to continued investment in our affiliated facilities and equipment. We are sometimes more aggressive than our competitors in capital spending to address issues that arise in connection with aging and obsolete facilities and equipment. In addition, continued expansion of our business through the acquisition of existing facilities, expansion of our existing facilities and construction of new facilities may require additional capital, particularly if we were to accelerate our acquisition and expansion plans. Financing may not be available to us or may be available to us only on terms that are not favorable, including being subject to interest rates that are higher than those incurred in the recent past. In addition, some of our outstanding indebtedness and long-term leases restrict, among other things, our ability to incur additional debt. If we are unable to raise additional funds or obtain additional funds on terms acceptable to us, we may have to delay or abandon some or all of our growth strategies. Further, if additional funds are raised through the issuance of additional equity securities, the percentage ownership of our stockholders would be diluted. Any newly issued equity securities may have rights, preferences or privileges senior to those of our common stock.

102

Table of Contents

The condition of the financial markets, including volatility and deterioration in the capital and credit markets, could limit the availability of debt and equity financing sources to fund the capital and liquidity requirements of our business, as well as negatively impact or impair the value of our current portfolio of cash, cash equivalents and investments, including U.S. Treasury securities and U.S.-backed investments.

Our cash, cash equivalents and investments are held in a variety of interest-bearing instruments, including U.S. treasury securities. As a result of the uncertain domestic and global political, economic, credit and financial market conditions, including the significant increases in the federal funds rate since 2021, an increase in the Consumer Price Index of 7% in 2022, which has continued at a slightly slower rate in 2023 that still exceeds target inflation, investments in these types of financial instruments pose risks arising from liquidity and credit concerns. Given that future deterioration in the U.S. and global credit and financial markets is a possibility, no assurance can be made that losses or significant deterioration in the fair value of our cash, cash equivalents, or investments will not occur. Uncertainty surrounding the trading market for U.S. government securities or impairment of the U.S. government's ability to satisfy its obligations under such treasury securities could impact the liquidity or valuation of our current portfolio of cash, cash equivalents, and investments, a substantial portion of which were invested in U.S. treasury securities. Further, continued domestic and international political uncertainty, along with credit, and financial market uncertainty, may make it difficult for us to liquidate our investments prior to their maturity without incurring a loss, which would have a material adverse effect on our consolidated financial position, results of operations or cash flows.

We may need additional capital if a substantial acquisition or other growth opportunity becomes available or if unexpected events occur or opportunities arise. U.S. capital markets can be volatile. We cannot assure you that additional capital will be available or available on terms acceptable to us. If capital is not available, we may not be able to fund internal or external business expansion or respond to competitive pressures or other market conditions.

Delays in reimbursement may cause liquidity problems.

If we experience problems with our billing information systems or if issues arise with Medicare, Medicaid or other payors, we may encounter delays in our payment cycle. From time to time, we have experienced such delays as a result of government payors instituting planned reimbursement delays for budget balancing purposes or as a result of prepayment reviews.

Some states in which we operate are operating with budget deficits or could have budget deficit in the future, which may delay reimbursement in a manner that would adversely affect our liquidity. In addition, from time to time, procedural issues require us to resubmit or appeal claims before payment is remitted, which contributes to our aged receivables. Unanticipated delays in receiving reimbursement from state programs or commercial payors due to changes in their policies or billing or audit procedures may adversely impact our liquidity and working capital.

The continued use and growth of managed care organizations (MCOs) may contribute to delays or reductions in our reimbursement, including Managed Medicaid.

In forty-one states, including some of the largest where we operate, state Medicaid benefits are administered through MCOs. Typically, these MCOs manage commercial health and federal Medicare Advantage benefits under a managed care contract. Nationally, MCOs cover approximately 57 million and 30 million Medicaid and Medicare Advantage beneficiaries, respectively. MCOs may be more aggressive than state Medicaid and federal Medicare agencies in denying claims or seeking recoupment of payments so that their services under these managed contracts are profitable. The additional steps created by the use of MCOs in disbursement of funds creates more risk of delayed, reduced, or recouped payments for our independent operating subsidiaries, and additional avenues for risks that include fines and other sanctions, including suspension or exclusion from participation in various governmental programs.

Compliance with the regulations of the Department of Housing and Urban Development may require us to make unanticipated expenditures which could increase our costs.

Twenty-three of our affiliated facilities are currently subject to regulatory agreements with HUD that give the Commissioner of HUD broad authority to require us to be replaced as the operator of those facilities in the event that the Commissioner determines there are operational deficiencies at such facilities under HUD regulations. Compliance with HUD's requirements can often be difficult because these requirements are not always consistent with the requirements of other federal and state agencies. Appealing a failed inspection can be costly and time-consuming and, if we do not successfully remediate the failed inspection, we could be precluded from obtaining HUD financing in the future or we may encounter limitations or prohibitions on our operation of HUD-insured facilities.

103

Table of Contents

If we fail to safeguard the monies held in our patient trust funds, we will be required to reimburse such monies, and we may be subject to citations, fines and penalties.

Each of our affiliated facilities is required by federal law to maintain a patient trust fund to safeguard certain assets of their residents and patients. If any money held in a patient trust fund is misappropriated, we are required to reimburse the patient trust fund for the amount of money that was misappropriated. If any monies held in our patient trust funds are misappropriated in the future and are unrecoverable, we will be required to reimburse such monies, and we may be subject to citations, fines and penalties pursuant to federal and state laws.

We are a holding company with no operations and rely upon our multiple independent operating subsidiaries to provide us with the funds necessary to meet our financial obligations. Liabilities of any one or more of our subsidiaries could be imposed upon us or our other subsidiaries.

We are a holding company with no direct operating assets, employees or revenue. Each of our affiliated facilities is operated through a separate, wholly owned, independent subsidiary, which has its own management, employees and assets. Our principal assets are the equity interests we directly or indirectly hold in our multiple operating and real estate holding subsidiaries. As a result, we are dependent upon distributions from our subsidiaries to generate the funds necessary to meet our financial obligations and pay dividends. Our subsidiaries are legally distinct from us and have no obligation to make funds available to us. The ability of our subsidiaries to make distributions to us will depend substantially on their respective operating results and will be subject to restrictions under, among other things, the laws of their jurisdiction of organization, which may limit the amount of funds available for distribution to investors or stockholders, agreements of those subsidiaries, the terms of our financing arrangements and the terms of any future financing arrangements of our subsidiaries.

If the separation of Pennant fails to qualify as generally tax-free for U.S. federal income tax purposes, we and our stockholders could be subject to significant tax liabilities.

The spin-off in 2019 is intended to qualify for tax-free treatment to us and our stockholders for U.S. federal income tax purposes. Accordingly, completion of the transaction was conditioned upon, among other things, our receipt of opinions from outside tax advisors that the distributions would qualify as a transaction that is intended to be tax-free to both us and our stockholders for U.S. federal income tax purposes under Sections 355 and 368(a)(1)(D) of the Internal Revenue Code. The opinions were based on and relied on, among other things, certain facts and assumptions, as well as certain representations, statements and undertakings, including those relating to the past and future conduct. If any of these facts, assumptions, representations, statements or undertakings is, or becomes, inaccurate or incomplete, or if any of the parties breach any of their respective covenants relating to the transactions, the tax opinions may be invalid. Moreover, the opinions are not binding on the IRS or any courts. Accordingly, notwithstanding receipt of the opinion, the IRS could determine that the distribution and certain related transactions should be treated as taxable transactions for U.S. federal income tax purposes.

If the spin-off fails to qualify as a transaction that is generally tax-free under Sections 355 and 368(a)(1)(D) of the Internal Revenue Code, in general, for U.S. federal income tax purposes, we would recognize taxable gain with respect to the distributed securities and our stockholders who received securities in such distribution would be subject to tax as if they had received a taxable distribution equal to the fair market value of such shares.

We also have obligations to provide indemnification to a number of parties as a result of the transaction. Any indemnity obligations for tax issues or other liabilities related to the spin-off, could be significant and could adversely impact our business.

Certain directors who serve on our Board of Directors also serve as directors of Pennant, and ownership of shares of Pennant common stock by our directors and executive officers may create, or appear to create, conflicts of interest.

Certain of our directors who serve on our Board of Directors also serve on the board of directors of Pennant. This may create, or appear to create, conflicts of interest when our, or Pennant's management and directors face decisions that could have different implications for us and Pennant, including the resolution of any dispute regarding the terms of the agreements governing the spin-off transaction and the relationship between us and Pennant after the spin-off transaction or any other commercial agreements entered into in the future between us and Pennant and the allocation of such directors’ time between us and Pennant.

104

Table of Contents

All of our executive officers and some of our non-employee directors own shares of the common stock of Pennant. The continued ownership of such common stock by our directors and executive officers following the spin-off creates, or may create, the appearance of a conflict of interest when these directors and executive officers are faced with decisions that could have different implications for us and Pennant.

If Standard Bearer fails to qualify or remain qualified as a REIT, it will be subject to U.S. federal income tax as a regular corporation and could face substantial tax liability.

Standard Bearer currently operates, and intends to continue to operate, in a manner that allows it to qualify to be taxed as a REIT for U.S. federal income tax purposes. Standard Bearer elected to be taxed as a REIT for U.S. federal income tax purposes beginning with its taxable year ended December 31, 2022.

If Standard Bearer fails to qualify to be taxed as a REIT in any year, it would be subject to U.S. federal income tax, including any applicable alternative minimum tax, on our taxable income at regular corporate rates, and dividends paid to its shareholders would not be deductible by it in computing its taxable income. Any resulting corporate liability could be substantial and would reduce the amount of cash available for distribution to its shareholders. Unless it was entitled to relief under certain Code provisions, it also would be disqualified from re-electing to be taxed as a REIT for the four taxable years following the year in which it failed to qualify to be taxed as a REIT.

Legislative or other actions affecting REITs could have a negative effect on Standard Bearer.

The rules dealing with U.S. federal income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Department of the Treasury (Treasury). Changes to the tax laws or interpretations thereof, with or without retroactive application, could materially and adversely affect Standard Bearer's investors or Standard Bearer. We cannot predict how changes in the tax laws, including any tax reform called for by the current presidential administration, might affect Standard Bearer or its investors. New legislation, Treasury regulations, administrative interpretations or court decisions could significantly and negatively affect its ability to qualify to be taxed as a REIT or the U.S. federal income tax consequences to Standard Bearer or its investors of such qualification. For instance, the Tax Cuts and Jobs Act (TCJA) significantly changed the U.S. federal income tax laws applicable to businesses and their owners, including REITs and their shareholders. Technical corrections or other amendments to the TCJA or administrative guidance interpreting the TCJA may be forthcoming at any time. We cannot predict the long-term effect of the TCJA or any future law changes on REITs or their shareholders. Changes to the U.S. federal tax laws and interpretations thereof, whether under the TCJA or otherwise, could adversely affect an investment in our stock.

No prediction can be made regarding whether new legislation or regulation (including new tax measures) will be enacted by legislative bodies or governmental agencies, nor can we predict what consequences would result from this legislation or regulation. Accordingly, no assurance can be given that the currently anticipated tax treatment of an investment will not be modified by legislative, judicial or administrative changes, possibly with retroactive effect.

Standard Bearer could fail to qualify to be taxed as a REIT if income it receives from our tenants is not treated as qualifying income.

Under applicable provisions of the Code, Standard Bearer will not be treated as a REIT unless it satisfies various requirements, including requirements relating to the sources of its gross income. Rents received or accrued by it from its tenants will not be treated as qualifying rent for purposes of these requirements if the leases are not respected as true leases for U.S. federal income tax purposes and are instead treated as service contracts, joint ventures or other arrangements. If the leases are not respected as true leases for U.S. federal income tax purposes, Standard Bearer will likely fail to qualify to be taxed as a REIT.

Even if Standard Bearer remains qualified as a REIT, it may face other tax liabilities that reduce its cash flow.

Even if Standard Bearer remain qualified for taxation as a REIT, it may be subject to certain U.S. federal, state, and local taxes on its income and assets, including taxes on any undistributed income and state or local income, property and transfer taxes. For example, Standard Bearer may hold some of its assets or conduct certain of its activities through one or more taxable REIT subsidiaries (each, a TRS) or other subsidiary corporations that will be subject to U.S. federal, state, and local corporate-level income taxes as regular C corporations. In addition, it may incur a 100% excise tax on transactions with a TRS if they are not conducted on an arm’s-length basis. Any of these taxes would decrease cash available for distribution to its shareholders.

105

Table of Contents

Risks Related to Ownership of our Common Stock

We may not be able to pay or maintain dividends and the failure to do so would adversely affect our stock price.

Our ability to pay and maintain cash dividends is based on many factors, including our ability to make and finance acquisitions, our ability to negotiate favorable lease and other contractual terms, anticipated operating cost levels, the level of demand for occupancy at our facilities, the rates we charge and actual results that may vary substantially from estimates. Some of the factors are beyond our control and a change in any such factor could affect our ability to pay or maintain dividends. The Amended Credit Agreement restricts our ability to pay dividends to stockholders if we receive notice that we are in default under the agreement. The failure to pay or maintain dividends could adversely affect our stock price.

Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that could discourage transactions resulting in a change in control, which may negatively affect the market price of our common stock.

Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that may enable our Board of Directors to resist a change in control. These provisions may discourage, delay or prevent a change in the ownership of our company or a change in our management, even if doing so might be beneficial to our stockholders. In addition, these provisions could limit the price that investors would be willing to pay in the future for shares of our common stock. Such provisions set forth in our amended and restated certificate of incorporation or our amended and restated bylaws include:

•our Board of Directors is authorized, without prior stockholder approval, to create and issue preferred stock, commonly referred to as “blank check” preferred stock, with rights senior to those of common stock;

•advance notice requirements for stockholders to nominate individuals to serve on our Board of Directors or to submit proposals that can be acted upon at stockholder meetings;

•our Board of Directors is classified so not all members of our board are elected at one time, which may make it more difficult for a person who acquires control of a majority of our outstanding voting stock to replace our directors;

•stockholder action by written consent is limited;

•special meetings of the stockholders are permitted to be called only by the chairman of our Board of Directors, our chief executive officer or by a majority of our Board of Directors;

•stockholders are not permitted to cumulate their votes for the election of directors;

•newly created directorships resulting from an increase in the authorized number of directors or vacancies on our Board of Directors are filled only by majority vote of the remaining directors;

•our Board of Directors is expressly authorized to make, alter or repeal our bylaws; and

•stockholders are permitted to amend our bylaws only upon receiving the affirmative vote of at least a majority of our outstanding common stock.

We are also subject to the anti-takeover provisions of Section 203 of the General Corporation Law of the State of Delaware. Under these provisions, if anyone becomes an “interested stockholder,” we may not enter into a “business combination” with that person for three years without special approval, which could discourage a third party from making a takeover offer and could delay or prevent a change of control. For purposes of Section 203, “interested stockholder” means, generally, someone owning more than 15% or more of our outstanding voting stock or an affiliate of ours that owned 15% or more of our outstanding voting stock during the past three years, subject to certain exceptions as described in Section 203.

These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could discourage acquisition proposals and make it more difficult or expensive for stockholders or potential acquirers to obtain control of our Board of Directors or initiate actions that are opposed by our then-current Board of Directors, including delaying or impeding a merger, tender offer or proxy contest involving us. Any delay or prevention of a change of control transaction or changes in our Board of Directors could cause the market price of our common stock to decline.

106

Table of Contents

Item 5. OTHER INFORMATION

Rule 10b5-1 Plan Elections

Spencer W. Burton, President & Chief Operations Officer, entered into a Rule 10b5-1 trading arrangement on September 12, 2023 (the "Rule 10b5-1 Plan"). Mr. Burton's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 8,280 shares of the Company's common stock between December 14, 2023 and August 30, 2024. Pursuant to the 10b5-1 Plan, Mr. Burton may also make a gift of up to 2,380 shares of the Company's common stock starting on December 14, 2023.

This Rule 10b5-1 trading arrangement was entered into during an open trading window and is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (c) under the Securities Exchange Act of 1934, as amended, and the Company's policies regarding transactions in Company securities.

107

Table of Contents

Item 6. EXHIBITS

EXHIBIT INDEX


Exhibit						Description

3.1						Fifth Amended and Restated Certificate of Incorporation of The Ensign Group, Inc., filed with the Delaware Secretary of State on November 15, 2007 (attached as Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-33757) filed with the SEC on December 21, 2007)

3.2						Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation of The Ensign Group, Inc., filed with the Delaware Secretary of State on February 4, 2020 (attached as Exhibit 3.2 to the Company’s Annual Report on Form 10-K (File No. 001-33757) filed with the SEC on February 5, 2020)

3.3						Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation of The Ensign Group, Inc., filed with the Delaware Secretary of State on May 18, 2023.

3.4						Amended and Restated Bylaws of The Ensign Group, Inc. (attached as Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-33757) filed with the SEC on December 21, 2007)





3.5						Amendment to the Amended and Restated Bylaws, dated August 5, 2014 (attached as Exhibit 3.2 to the Company’s Current Report on Form 8-K (File No. 001-33757) filed with the SEC on August 8, 2014)

31.1						Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2						Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1						Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2						Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS						XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH						Inline XBRL Taxonomy Extension Schema Document

101.CAL						Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF						Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB						Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE						Inline XBRL Taxonomy Extension Presentation Linkbase Document

104						Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

* Documents not filed herewith are incorporated by reference to the prior filings identified in the table above.

108

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	THE ENSIGN GROUP, INC.

October 25, 2023	BY:	/s/ SUZANNE D. SNAPPER
		Suzanne D. Snapper
		Chief Financial Officer, Executive Vice President and Director (Principal Financial Officer and Accounting Officer and Duly Authorized Officer)

109

EX-31.1 2 ensgq32023ex311.htm EX-31.1 Document

EXHIBIT 31.1

I, Barry R. Port, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of The Ensign Group, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 25, 2023

/s/ Barry R. Port

Name:

Barry R. Port

Title:

Chief Executive Officer and Director (principal executive officer)

EX-31.2 3 ensgq32023ex312.htm EX-31.2 Document

EXHIBIT 31.2

I, Suzanne D. Snapper, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of The Ensign Group, Inc.;

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 25, 2023

/s/ Suzanne D. Snapper

Name:

Suzanne D. Snapper

Title:

Chief Financial Officer, Executive Vice President and Director (principal financial officer and accounting officer and duly authorized officer)

EX-32.1 4 ensgq32023ex321.htm EX-32.1 Document

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of The Ensign Group, Inc. (the Company) on Form 10-Q for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Barry R. Port, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d))); and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Barry R. Port

Name:

Barry R. Port

Title:

Chief Executive Officer and Director (principal executive officer)

October 25, 2023

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 ensgq32023ex322.htm EX-32.2 Document

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of The Ensign Group, Inc. (the Company) on Form 10-Q for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Suzanne D. Snapper, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d))); and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Suzanne D. Snapper

Name:

Suzanne D. Snapper

Title:

Chief Financial Officer, Executive Vice President and Director (principal financial officer and accounting officer and duly authorized officer)

October 25, 2023

EX-101.SCH 6 ensg-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - STANDARD BEARER link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - OPERATION EXPANSIONS link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - BUSINESS SEGMENTS link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - PROPERTY AND EQUIPMENT— NET link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - INTANGIBLE ASSETS — NET link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - GOODWILL link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - RESTRICTED AND OTHER ASSETS link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - OTHER ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - OPTIONS AND AWARDS link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - DEFINED CONTRIBUTION PLANS link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - COMMON STOCK REPURCHASE PROGRAM link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - BUSINESS SEGMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - PROPERTY AND EQUIPMENT— NET (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - INTANGIBLE ASSETS — NET (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - GOODWILL (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - RESTRICTED AND OTHER ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - OTHER ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - OPTIONS AND AWARDS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - DESCRIPTION OF BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Revenue from Medicare and Medicaid Programs and State Relief Funding (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - STANDARD BEARER (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - OPERATION EXPANSIONS (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - BUSINESS SEGMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - PROPERTY AND EQUIPMENT— NET - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - PROPERTY AND EQUIPMENT— NET - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - INTANGIBLE ASSETS — NET - Schedule of Finite Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - INTANGIBLE ASSETS — NET - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - INTANGIBLE ASSETS — NET - Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - INTANGIBLE ASSETS — NET - Schedule of Indefinite-lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - GOODWILL (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - RESTRICTED AND OTHER ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - OTHER ACCRUED LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - DEBT - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - OPTIONS AND AWARDS - Stock Options, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - OPTIONS AND AWARDS - Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - OPTIONS AND AWARDS - Exercise Price and Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - OPTIONS AND AWARDS - Options Outstanding Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - OPTIONS AND AWARDS - Intrinsic Values (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - OPTIONS AND AWARDS - Restricted Award Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - OPTIONS AND AWARDS - Long-Term Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - OPTIONS AND AWARDS - Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - LEASES - Lessee Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - LEASES - Lessee Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - LEASES - Lessee Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - LEASES - Lessee Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - LEASES - Lessor Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - LEASES - Lessor Rental Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - LEASES - Lessor Future Minimum Lease Payments Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - DEFINED CONTRIBUTION PLANS (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - COMMON STOCK REPURCHASE PROGRAM (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 ensg-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 ensg-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 ensg-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] All States Except Colorado All States Except Colorado [Member] All States Except Colorado [Domain] Schedule of Other Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Other third-party Third Party Tenants [Member] Third Party Tenants [Member] Cash held in trust for patients Cash Held in Trust for Residents Cash held in trust for residents reflects monies received from, or on behalf of, residents. Maintaining a trust account for residents is a regulatory requirement and, while the trust assets offset the liability, the Company assumes a fiduciary responsibility for these funds. Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Change in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Management fees, as a percentage of funds from operations Property Management Fee, Percent Fee of Funds from Operations Property Management Fee, Percent Fee of Funds from Operations October 21, 2021 Repurchase Program October 21, 2021 Repurchase Program [Member] October 21, 2021 Repurchase Program February 9, 2022 Repurchase Program February 9, 2022 Repurchase Program [Member] February 9, 2022 Repurchase Program Health Liability Insurance Health Liability Insurance [Member] Health Liability Insurance [Member] STANDARD BEARER Standard Bearer [Text Block] Standard Bearer Purchases of investments Payments to Acquire Investments Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Skilled Nursing Operations Skilled Nursing Operations [Member] Skilled Nursing Operations Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Five Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] COMMON STOCK REPURCHASE PROGRAM Equity [Text Block] Leases To Third Party Operators Leases To Third Party Operators [Member] Leases To Third Party Operators Weighted Average Dividend Yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Issuance of restricted stock, net of forfeitures (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Diluted (in dollars per share) Diluted net income per common share (in dollars per share) Earnings Per Share, Diluted Restricted and other assets RESTRICTED AND OTHER ASSETS Restricted And Other Assets, Noncurrent Restricted And Other Assets, Noncurrent Capital improvement reserves with landlords and lenders Other Restricted Assets Accounts receivable—less allowance for doubtful accounts of $9,422 and $7,802 at September 30, 2023 and December 31, 2022, respectively ACCOUNTS RECEIVABLE, NET Accounts Receivable, after Allowance for Credit Loss, Current Texas TEXAS Assembled occupancy Assembled Occupancy Acquired [Member] Assembled occupancy acquired [Member] Other income (expense): Other Nonoperating Income (Expense) [Abstract] Trading Symbol Trading Symbol Letters of credit outstanding, pledged amount Letters of Credit Outstanding, Amount Weighted Average Exercise Price (in dollars per share) Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic Net Income Per Common Share Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] TOTAL Lessor, Operating Lease, Payment to be Received Ensign Group, Inc. stockholders' equity: Equity, Attributable to Parent [Abstract] Series of Individually Immaterial Asset Acquisitions Series of Individually Immaterial Asset Acquisitions [Member] Base Management Fee Management Service, Base [Member] Executive Category: Executive Category [Axis] 2027 Lessor, Operating Lease, Payment to be Received, Year Four Sublease Of Stand Along Skilled Nursing Operations Sublease Of Stand Along Skilled Nursing Operations [Member] Sublease Of Stand Along Skilled Nursing Operations Non-Vested Restricted Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Prepayment Fee, Period [Axis] Prepayment Fee, Period [Axis] Prepayment Fee, Period Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Granted (in shares) Options Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Schedule of Service Revenue by Major Payor Source Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Noncontrolling Interest Noncontrolling Interest [Policy Text Block] The noncontrolling interest in a subsidiary initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. Entity Small Business Entity Small Business Weighted Average Volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Accounts Receivable Accounts Receivable [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Reduction in prepayment penalty Reduction In Prepayment Penalty Percentage that the prepayment penalty percentage is reduced during the fourth year. Retirement Benefits [Abstract] Retirement Benefits [Abstract] Lessor, Lease, Description [Table] Lessor, Lease, Description [Table] Self-Insurance Retention Per Claim Self-insurance Retention Per Claim [Member] Self-insurance retention per claim [Member] Owned Properties Wholly Owned Properties [Member] Schedule of Debt Schedule of Long-Term Debt Instruments [Table Text Block] Shares of common stock used to satisfy tax withholding obligations Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation After Year Ten After Year Ten [Member] After Year Ten Cash, uninsured amount Cash, Uninsured Amount Cost of Sales and General and Administrative Expense Cost of Sales and General and Administrative Expense [Member] Primary financial statement caption encompassing cost of services and general and administrative expense Management fees Management Fee Expense Grantee Status [Axis] Grantee Status [Axis] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Award Type [Axis] Award Type [Axis] Antidilutive securities excluded from computation of earnings per share, amount (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Granted restricted shares (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] General and administrative expense General and Administrative Expense [Member] Goodwill [Line Items] Goodwill [Line Items] Property and equipment Property, Plant and Equipment, Gross Right-of-use assets obtained in exchange for new and modified operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Less: present value adjustment Lessee, Operating Lease, Liability, Undiscounted Excess Amount Number of real estate properties leased with an option to purchase Number of Real Estate Properties Leased with an Option to Purchase Number of Real Estate Properties Leased with an Option to Purchase PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Lease liabilities—current Less: current lease liabilities Operating Lease, Liability, Current Schedule of Restricted and Other Assets Schedule of Other Assets [Table Text Block] Cash surrender value of life insurance policy premiums Life Insurance, Corporate or Bank Owned, Change in Value 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Net Finite-Lived Intangible Assets, Net Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Less: Net Income (Loss) Attributable to Noncontrolling Interest [Abstract] Long-term debt, threshold for EBITDA ratio increase election Long-Term Debt, Threshold For EBITDA Ratio Increase Election Long-Term Debt, Threshold For EBITDA Ratio Increase Election Counterparty Name [Domain] Counterparty Name [Domain] Segment Reporting, Revenue Reconciling Item [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Accounts receivable, gross Accounts Receivable, before Allowance for Credit Loss Rental revenue Rental [Member] Rental Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Resident advances Contract with Customer, Liability, Current Schedule of Assumptions for Stock Options Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Award vesting rights, percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Stock Options Stock-based compensation expense related to stock options Employee Stock Option [Member] TOTAL EXPENSES Costs and Expenses Maximum Maximum [Member] Various Landlords Various Landlords [Member] Various Landlords[Member] Share-based compensation, nonvested awards, cost not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Goodwill Goodwill, Acquired During Period Revenue, FMAP payments received Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized Tabular List, Table Tabular List [Table Text Block] Repurchase of common stock (Note 20) Repurchase of common stock, value Treasury Stock, Value, Acquired, Cost Method OPTIONS AND AWARDS Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Number of financing lease Number Of Financing Leases Number Of Financing Leases 2023 (remainder) Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year Business Acquisition [Axis] Business Acquisition [Axis] Allowance for doubtful accounts Less: allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Customer Concentration Risk Customer Concentration Risk [Member] Self-Insurance Self Insurance Reserve [Policy Text Block] Real Estate Properties [Domain] Real Estate Properties [Domain] Variable Rate [Axis] Variable Rate [Axis] 2024 Lessor, Operating Lease, Payment to be Received, Year One Expense: Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Sublease Income Sublease Income OPERATION EXPANSIONS Business Combination Disclosure [Text Block] Other indefinite-lived intangibles Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Operating Segments Operating Segments [Member] Nonvested at beginning of period (in dollars per share) Nonvested at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Purchase of property and equipment Payments To Acquire Property And Equipment Payments To Acquire Property And Equipment Non-controlling interest distribution Payments to Noncontrolling Interests Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Accounts Receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Lease, cost Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Qualified Plan Qualified Plan [Member] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Term of operating lease Lessor, Operating Lease, Term of Contract Intangible Assets and Goodwill Goodwill and Intangible Assets, Policy [Policy Text Block] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Standard Bearer Master Leases Standard Bearer Master Leases [Member] Standard Bearer Master Leases Lease Of Campus Operation Lease Of Campus Operation [Member] Lease Of Campus Operation Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Service and Rental Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Total net debt ratio, minimum Total Net Debt Ratio, Minimum Total Net Debt Ratio, Minimum Deposits with landlords Security Deposit Counterparty Name [Axis] Counterparty Name [Axis] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Lease liabilities Operating Lease, Payments Common shares outstanding Balance at beginning of period (in shares) Balance at end of period (in shares) Common Stock, Shares, Outstanding HUD Insured Mortgages HUD Insured Mortgages [Member] HUD Insured Mortgages Dividends declared Dividends New Master Lease Agreeement New Master Lease Agreeement [Member] New Master Lease Agreeement Accrued self-insurance liabilities—current Self Insurance Reserve, Current PEO PEO [Member] Schedule of Annual Rental Income Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block] General Liability General Liability [Member] Schedule of Employee Stock Option Roll Forward Schedule of Common Stock Outstanding Roll Forward [Table Text Block] Defined Contribution Plan Disclosure [Line Items] Defined Contribution Plan Disclosure [Line Items] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Number of stand-alone leases Lessee, Operating Lease, Number Of Leases Lessee, Operating Lease, Number Of Leases NET CASH USED IN INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities Debt Instrument [Axis] Debt Instrument [Axis] Segment income (loss) Segment Income (Loss) Segment Income (Loss) Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Other long-term liabilities Deferred rent and other long-term liabilities Rental expense in excess of actual rental payments and other long-term liabilities Credit Facility [Axis] Credit Facility [Axis] TOTAL LIABILITIES Liabilities Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] PROPERTY AND EQUIPMENT— NET Property, Plant and Equipment Disclosure [Text Block] 2026 Lessor, Operating Lease, Payment to be Received, Year Three EX-101.PRE 10 ensg-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 ensg-20230930_g1.jpg GRAPHIC begin 644 ensg-20230930_g1.jpg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htm IDEA: XBRL DOCUMENT

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2023	Oct. 20, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-33757
Entity Registrant Name	ENSIGN GROUP, INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-0861263
Entity Address, Address Line One	29222 Rancho Viejo Road, Suite 127
Entity Address, City or Town	San Juan Capistrano
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92675
City Area Code	949
Local Phone Number	487-9500
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	ENSG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		56,452,238
Entity Central Index Key	0001125376
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false
Current Fiscal Year End Date	--12-31

XML 13 R2.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 467,870	$ 316,270
Accounts receivable—less allowance for doubtful accounts of $9,422 and $7,802 at September 30, 2023 and December 31, 2022, respectively	472,123	408,432
Investments—current	16,433	15,441
Prepaid expenses and other current assets	37,921	40,982
Total current assets	994,347	781,125
Property and equipment, net	1,067,902	992,010
Right-of-use assets	1,773,751	1,450,995
Insurance subsidiary deposits and investments	86,818	67,652
Deferred tax assets	39,968	39,643
Restricted and other assets	35,979	37,291
Intangible assets, net	6,347	6,437
Goodwill	76,869	76,869
TOTAL ASSETS	4,081,981	3,452,022
Current liabilities:
Accounts payable	77,091	77,087
Accrued wages and related liabilities	311,509	289,810
Lease liabilities—current	80,956	65,796
Accrued self-insurance liabilities—current	50,197	48,187
Other accrued liabilities	148,128	97,309
Current maturities of long-term debt	3,916	3,883
Total current liabilities	671,797	582,072
Long-term debt—less current maturities	146,453	149,269
Long-term lease liabilities—less current portion	1,657,955	1,355,113
Accrued self-insurance liabilities—less current portion	97,502	83,495
Other long-term liabilities	42,832	33,273
TOTAL LIABILITIES	2,616,539	2,203,222
Commitments and contingencies (Notes 15, 17 and 19)
Ensign Group, Inc. stockholders' equity:
Common stock: $0.001 par value; 150,000, 59,803 and 56,413 shares authorized, shares issued and shares outstanding at September 30, 2023, respectively, and 100,000, 59,029 and 55,661 shares authorized, shares issued and shares outstanding at December 31, 2022, respectively	60	59
Additional paid-in capital	451,883	415,560
Retained earnings	1,124,358	946,339
Common stock in treasury, at cost, 3,390 and 3,368 shares at September 30, 2023 and December 31, 2022, respectively	(116,555)	(114,626)
Total Ensign Group, Inc. stockholders' equity	1,459,746	1,247,332
Non-controlling interest	5,696	1,468
Total equity	1,465,442	1,248,800
TOTAL LIABILITIES AND EQUITY	$ 4,081,981	$ 3,452,022

XML 14 R3.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 9,422	$ 7,802
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common shares authorized	150,000	100,000
Common shares issued	59,803	59,029
Common shares outstanding	56,413	55,661
Common shares in treasury, at cost	3,390	3,368

XML 15 R4.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
TOTAL REVENUE	$ 940,791	$ 770,005	$ 2,748,977	$ 2,215,936
Expense:
Cost of services	741,069	601,623	2,160,080	1,720,905
Rent—cost of services	50,357	38,907	146,754	111,897
General and administrative expense	51,127	39,247	156,448	116,030
Depreciation and amortization	18,446	15,941	53,154	45,475
TOTAL EXPENSES	860,999	695,718	2,516,436	1,994,307
Income from operations	79,792	74,287	232,541	221,629
Other income (expense):
Interest expense	(2,024)	(2,108)	(6,083)	(6,864)
Other income (expense)	4,277	276	15,022	(3,127)
Other income (expense), net	2,253	(1,832)	8,939	(9,991)
Income before provision for income taxes	82,045	72,455	241,480	211,638
Provision for income taxes	18,077	16,213	53,453	47,505
NET INCOME	63,968	56,242	188,027	164,133
Less:
Net income (loss) attributable to noncontrolling interest	105	63	319	(77)
Net income attributable to The Ensign Group, Inc.	$ 63,863	$ 56,179	$ 187,708	$ 164,210
NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC.
Basic (in dollars per share)	$ 1.14	$ 1.02	$ 3.38	$ 3.00
Diluted (in dollars per share)	$ 1.11	$ 0.99	$ 3.28	$ 2.89
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic (in shares)	55,829	54,882	55,582	54,819
Diluted (in shares)	57,337	56,761	57,245	56,829
Service revenue
TOTAL REVENUE	$ 935,324	$ 765,883	$ 2,733,343	$ 2,203,386
Rental revenue
TOTAL REVENUE	$ 5,467	$ 4,122	$ 15,634	$ 12,550

XML 16 R5.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Treasury Stock	Non-Controlling Interest
Balance at beginning of period (in shares) at Dec. 31, 2021		55,190
Balance at beginning of period at Dec. 31, 2021	$ 1,021,714	$ 58	$ 369,760	$ 733,992	$ (83,042)	$ 946
Balance at beginning of period (in shares) at Dec. 31, 2021					2,944
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock to employees and directors resulting from the exercise of stock options (in shares)		147
Issuance of common stock to employees and directors resulting from the exercise of stock options	2,768		2,768
Issuance of restricted stock, net of forfeitures (in shares)		104
Issuance of restricted stock, net of forfeitures	5,241		5,241
Shares of common stock used to satisfy tax withholding obligations	(15)				$ (15)
Dividends declared	(3,042)			(3,042)
Employee stock award compensation	5,167		5,167
Repurchase of common stock (in shares)		133			133
Repurchase of common stock (Note 20)	(9,882)				$ (9,882)
Acquisition of noncontrolling interest shares	(26)		245			(271)
Net income (loss) attributable to noncontrolling interest	(252)					(252)
Net income attributable to the Ensign Group, Inc.	50,340			50,340
Balance at end of period (in shares) at Mar. 31, 2022		55,308
Balance at end of period at Mar. 31, 2022	1,072,013	$ 58	383,181	781,290	$ (92,939)	423
Balance at end of period (in shares) at Mar. 31, 2022					3,077
Balance at beginning of period (in shares) at Dec. 31, 2021		55,190
Balance at beginning of period at Dec. 31, 2021	1,021,714	$ 58	369,760	733,992	$ (83,042)	946
Balance at beginning of period (in shares) at Dec. 31, 2021					2,944
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to noncontrolling interest	(77)
Net income attributable to the Ensign Group, Inc.	164,210
Balance at end of period (in shares) at Sep. 30, 2022		55,465
Balance at end of period at Sep. 30, 2022	1,181,748	$ 58	405,555	889,069	$ (114,626)	1,692
Balance at end of period (in shares) at Sep. 30, 2022					3,368
Balance at beginning of period (in shares) at Mar. 31, 2022		55,308
Balance at beginning of period at Mar. 31, 2022	1,072,013	$ 58	383,181	781,290	$ (92,939)	423
Balance at beginning of period (in shares) at Mar. 31, 2022					3,077
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock to employees and directors resulting from the exercise of stock options (in shares)		223
Issuance of common stock to employees and directors resulting from the exercise of stock options	3,303		3,303
Issuance of restricted stock, net of forfeitures (in shares)		38
Shares of common stock used to satisfy tax withholding obligations (in shares)		20			20
Shares of common stock used to satisfy tax withholding obligations	(1,687)				$ (1,687)
Dividends declared	(3,040)			(3,040)
Employee stock award compensation	5,616		5,616
Repurchase of common stock (in shares)		271			271
Repurchase of common stock (Note 20)	(20,000)				$ (20,000)
Net income (loss) attributable to noncontrolling interest	112					112
Noncontrolling interests attributable to subsidiary equity plan	(8)					(8)
Issuance of noncontrolling interests through subsidiary equity plan	6,693		6,693
Net income attributable to the Ensign Group, Inc.	57,691			57,691
Balance at end of period (in shares) at Jun. 30, 2022		55,278
Balance at end of period at Jun. 30, 2022	1,120,693	$ 58	398,793	835,941	$ (114,626)	527
Balance at end of period (in shares) at Jun. 30, 2022					3,368
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock to employees and directors resulting from the exercise of stock options (in shares)		151
Issuance of common stock to employees and directors resulting from the exercise of stock options	2,635		2,635
Issuance of restricted stock, net of forfeitures (in shares)		36
Dividends declared	(3,051)			(3,051)
Employee stock award compensation	5,898		5,898
Acquisition of noncontrolling interest shares	(669)		(1,774)			1,105
Net income (loss) attributable to noncontrolling interest	63					63
Issuance of noncontrolling interests through subsidiary equity plan	0		3			(3)
Net income attributable to the Ensign Group, Inc.	56,179			56,179
Balance at end of period (in shares) at Sep. 30, 2022		55,465
Balance at end of period at Sep. 30, 2022	$ 1,181,748	$ 58	405,555	889,069	$ (114,626)	1,692
Balance at end of period (in shares) at Sep. 30, 2022					3,368
Balance at beginning of period (in shares) at Dec. 31, 2022	55,661	55,661
Balance at beginning of period at Dec. 31, 2022	$ 1,248,800	$ 59	415,560	946,339	$ (114,626)	1,468
Balance at beginning of period (in shares) at Dec. 31, 2022	3,368				3,368
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock to employees and directors resulting from the exercise of stock options (in shares)		145
Issuance of common stock to employees and directors resulting from the exercise of stock options	$ 2,654	$ 1	2,653
Issuance of restricted stock, net of forfeitures (in shares)		102
Issuance of restricted stock, net of forfeitures	5,068		5,068
Shares of common stock used to satisfy tax withholding obligations (in shares)		1			1
Shares of common stock used to satisfy tax withholding obligations	(20)				$ (20)
Dividends declared	(3,215)			(3,215)
Employee stock award compensation	6,573		6,573
Acquisition of noncontrolling interest shares	(77)		(77)
Net income (loss) attributable to noncontrolling interest	117					117
Issuance of noncontrolling interests through subsidiary equity plan	2		6			(4)
Net income attributable to the Ensign Group, Inc.	59,852			59,852
Balance at end of period (in shares) at Mar. 31, 2023		55,907
Balance at end of period at Mar. 31, 2023	$ 1,319,754	$ 60	429,783	1,002,976	$ (114,646)	1,581
Balance at end of period (in shares) at Mar. 31, 2023					3,369
Balance at beginning of period (in shares) at Dec. 31, 2022	55,661	55,661
Balance at beginning of period at Dec. 31, 2022	$ 1,248,800	$ 59	415,560	946,339	$ (114,626)	1,468
Balance at beginning of period (in shares) at Dec. 31, 2022	3,368				3,368
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to noncontrolling interest	$ 319
Net income attributable to the Ensign Group, Inc.	$ 187,708
Balance at end of period (in shares) at Sep. 30, 2023	56,413	56,413
Balance at end of period at Sep. 30, 2023	$ 1,465,442	$ 60	451,883	1,124,358	$ (116,555)	5,696
Balance at end of period (in shares) at Sep. 30, 2023	3,390				3,390
Balance at beginning of period (in shares) at Mar. 31, 2023		55,907
Balance at beginning of period at Mar. 31, 2023	$ 1,319,754	$ 60	429,783	1,002,976	$ (114,646)	1,581
Balance at beginning of period (in shares) at Mar. 31, 2023					3,369
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock to employees and directors resulting from the exercise of stock options (in shares)		253
Issuance of common stock to employees and directors resulting from the exercise of stock options	5,905		5,905
Issuance of restricted stock, net of forfeitures (in shares)		54
Shares of common stock used to satisfy tax withholding obligations (in shares)		21			21
Shares of common stock used to satisfy tax withholding obligations	(1,909)				$ (1,909)
Dividends declared	(3,231)			(3,231)
Employee stock award compensation	8,881		8,881
Acquisition of noncontrolling interest shares	(100)		(100)
Net income (loss) attributable to noncontrolling interest	97					97
Issuance of noncontrolling interests through subsidiary equity plan	3		(3,937)			3,940
Net income attributable to the Ensign Group, Inc.	63,993			63,993
Balance at end of period (in shares) at Jun. 30, 2023		56,193
Balance at end of period at Jun. 30, 2023	1,393,393	$ 60	440,532	1,063,738	$ (116,555)	5,618
Balance at end of period (in shares) at Jun. 30, 2023					3,390
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock to employees and directors resulting from the exercise of stock options (in shares)		180
Issuance of common stock to employees and directors resulting from the exercise of stock options	4,148		4,148
Issuance of restricted stock, net of forfeitures (in shares)		40
Dividends declared	(3,243)			(3,243)
Employee stock award compensation	7,230		7,230
Acquisition of noncontrolling interest shares	(57)		(57)
Net income (loss) attributable to noncontrolling interest	105					105
Issuance of noncontrolling interests through subsidiary equity plan	3		30			(27)
Net income attributable to the Ensign Group, Inc.	$ 63,863			63,863
Balance at end of period (in shares) at Sep. 30, 2023	56,413	56,413
Balance at end of period at Sep. 30, 2023	$ 1,465,442	$ 60	$ 451,883	$ 1,124,358	$ (116,555)	$ 5,696
Balance at end of period (in shares) at Sep. 30, 2023	3,390				3,390

XML 17 R6.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Statement of Stockholders' Equity [Abstract]
Dividends declared	$ 0.0575	$ 0.0575	$ 0.0575	$ 0.0550	$ 0.0550	$ 0.0550

XML 18 R7.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net income	$ 188,027	$ 164,133
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	53,154	45,475
Amortization of deferred financing fees	802	770
Non-cash leasing arrangement	692	351
Write-off of deferred financing fees	0	566
Deferred income taxes	(325)	(585)
Provision for doubtful accounts	3,081	2,301
Stock-based compensation	22,691	16,681
Cash received from insurance proceeds	1,396	0
Gain on sale of assets	0	(3,467)
(Gain)/loss on insurance claims, legal adjustments and asset disposals	(1,813)	5,499
Change in operating assets and liabilities
Accounts receivable	(66,630)	(27,552)
Prepaid income taxes	4,643	(9,846)
Prepaid expenses and other assets	1,459	(8,479)
Cash surrender value of life insurance policy premiums	(11,723)	(5,378)
Deferred compensation liability	11,663	5,371
Operating lease obligations	(6,345)	215
Accounts payable	704	4,878
Accrued wages and related liabilities	24,700	14,307
Income taxes payable	40,781	0
Other accrued liabilities	11,387	5,163
Accrued self-insurance liabilities	13,090	11,968
Other long-term liabilities	(37)	(34)
NET CASH PROVIDED BY OPERATING ACTIVITIES	291,397	222,337
Cash flows from investing activities:
Purchase of property and equipment	(77,360)	(59,735)
Cash payments for business acquisitions (Note 7)	0	(16,400)
Cash payments for asset acquisitions (Note 7)	(53,684)	(65,699)
Escrow deposits	(325)	(8,287)
Cash from insurance proceeds	1,129	1,143
Cash proceeds from the sale of assets	48	8,626
Purchases of investments	(20,538)	(15,497)
Maturities of investments	12,103	11,905
Other restricted assets	873	173
NET CASH USED IN INVESTING ACTIVITIES	(137,754)	(143,771)
Cash flows from financing activities:
Proceeds from debt (Note 15)	0	211
Payments on debt (Note 15)	(2,917)	(2,908)
Issuance of common stock upon exercise of options	12,707	8,706
Repurchase of shares of common stock to satisfy tax withholding obligations	(1,929)	(1,702)
Repurchase of shares of common stock (Note 20)	0	(29,882)
Dividends paid	(9,647)	(9,118)
Proceeds from sale of subsidiary shares (Note 6)	0	6,693
Non-controlling interest distribution	(4)	(11)
Purchase of non-controlling interest	(234)	(695)
Payments of deferred financing costs	(19)	(3,197)
NET CASH USED IN FINANCING ACTIVITIES	(2,043)	(31,903)
Net increase in cash and cash equivalents	151,600	46,663
Cash and cash equivalents beginning of period	316,270	262,201
Cash and cash equivalents end of period	467,870	308,864
Cash paid during the period for:
Interest	5,287	5,800
Income taxes	8,480	57,880
Lease liabilities	146,162	110,942
Non-cash financing and investing activity
Accrued capital expenditures	4,100	4,200
Right-of-use assets obtained in exchange for new and modified operating lease obligations	$ 373,832	$ 254,742

XML 19 R8.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS	9 Months Ended
DESCRIPTION OF BUSINESS	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	DESCRIPTION OF BUSINESS The Company — The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company's independent operating subsidiaries provide health care services across the post-acute care continuum and engage in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties and other ancillary businesses. As of September 30, 2023, the Company's independent operating subsidiaries operated 295 facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The Company's independent operating subsidiaries have a collective capacity of approximately 30,500 operational skilled nursing beds and 3,000 senior living units. As of September 30, 2023, the Company's independent operating subsidiaries operated 213 facilities under long-term lease arrangements, and had options to purchase 11 of those 213 facilities. The Company's real estate portfolio includes 112 owned real estate properties, which includes 82 facilities operated and managed by the Company's independent operating subsidiaries, 30 operations leased to and operated by third party operators, and the Service Center location. Of those 30 operations, one senior living facility is located on the same real estate property as a skilled nursing facility that the Company owns and operates. Certain of the Company’s wholly owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly owned captive insurance subsidiary that provides some claims-made coverage to the Company’s operating subsidiaries for general and professional liabilities, as well as coverage for certain workers’ compensation insurance liabilities. In 2022, the Company formed a captive real estate investment trust (REIT), which owns and manages its real estate business, called Standard Bearer Healthcare REIT, Inc. (Standard Bearer). The REIT structure provides the Company with an efficient vehicle for future acquisitions of properties that could be operated by Ensign affiliates or other third parties. Refer to Note 6, Standard Bearer for additional information on Standard Bearer. Each of the Company's affiliated operations are operated by separate, wholly owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Quarterly Report is not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc. Other Information — The accompanying condensed consolidated financial statements as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 (collectively, the Interim Financial Statements) are unaudited. Certain information and note disclosures normally included in the annual consolidated financial statements have been condensed or omitted, as permitted under applicable rules and regulations. Readers of the Interim Financial Statements should refer to the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2022 which are included in the Company’s Annual Report on Form 10-K, File No. 001-33757 (the Annual Report) filed with the Securities and Exchange Commission (SEC). Management believes that the Interim Financial Statements reflect all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position and results of operations in all material respects. The results of operations presented in the Interim Financial Statements are not necessarily representative of operations for the entire year.

XML 20 R9.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation — The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interests in its condensed consolidated statements of income. The Interim Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Estimates and Assumptions — The preparation of the Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities and income taxes. Actual results could differ from those estimates. Fair Value of Financial Instruments —The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, deferred compensation investment funds, equity investments, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions. See Note 5, Fair Value Measurements for additional information. Service Revenue Recognition — The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606). The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to patients at the amount that reflects the consideration that the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services provided pursuant to skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services that are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered. Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration that is included in the transaction price may be constrained, and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known. Rental Revenue Recognition — The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue for operating leases is recognized on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, Leases (ASC 842). The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met. Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under the new lease standards. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s condensed consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis. Accounts Receivable — Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. Property and Equipment — Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. Leases and Leasehold Improvements — The Company leases skilled nursing facilities, senior living facilities and commercial office space. The Company determines if an arrangement is a lease and performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of September 30, 2023, the Company has one financing lease that is not material to the condensed consolidated balance sheets. Rights and obligations of these leases are included as right-of-use assets, current and long-term lease liabilities on the Company's condensed consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate. The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements. The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional ten to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company subleases skilled nursing facilities to third-party operators and considers the subleases to be separate contracts because the Company is not relieved of its primary obligation under its operating lease. The rental income from third-parties related to these subleases is presented on a gross basis from the rent expense associated with the Company's lease obligations and is not material to the condensed consolidated statements of income. Impairment of Long-Lived Assets — The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and determined there was no impairment during the three and nine months ended September 30, 2023 and 2022. Intangible Assets and Goodwill — Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years. The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year. Management has evaluated its intangible assets and determined there was no impairment during the three and nine months ended September 30, 2023 and 2022. Self-Insurance — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,250 for California affiliated operations and a separate, one-time, deductible of $1,250 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider. The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $90,811 and $79,781 as of September 30, 2023 and December 31, 2022, respectively. The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $28,733 and $27,301 as of September 30, 2023 and December 31, 2022, respectively. In addition, the Company has recorded an asset and corresponding liability of $13,439 and $10,512 as of September 30, 2023 and December 31, 2022, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12, Restricted and Other Assets. The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal year 2023. As of September 30, 2023 and December 31, 2022, the Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $14,716 and $14,088, respectively. The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected. Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ. Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer believes it has been organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions. Noncontrolling Interest — The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest. Stock-Based Compensation — The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.

XML 21 R10.htm IDEA: XBRL DOCUMENT

REVENUE AND ACCOUNTS RECEIVABLE

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

REVENUE AND ACCOUNTS RECEIVABLE

Disaggregation of Revenue

Revenue by Payor

Service revenue for the three and nine months ended September 30, 2023 and 2022 is summarized in the following tables:



	Three Months Ended September 30,
	2023				2022
	Revenue		% of Revenue		Revenue		% of Revenue
Medicaid(1)	$	374,838	40.1	%	$	302,615	39.5	%
Medicare	237,531		25.4		211,104		27.6
Medicaid — skilled	62,452		6.6		50,643		6.6
Total Medicaid and Medicare	674,821		72.1		564,362		73.7
Managed care	170,747		18.3		132,663		17.3
Private and other(2)	89,756		9.6		68,858		9.0
SERVICE REVENUE	$	935,324	100.0	%	$	765,883	100.0	%

(1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.



	Nine Months Ended September 30,
	2023				2022
	Revenue		% of Revenue		Revenue		% of Revenue
Medicaid(1)	$	1,074,883	39.3	%	$	863,091	39.2	%
Medicare	733,335		26.8		610,009		27.7
Medicaid — skilled	182,394		6.7		146,355		6.6
Total Medicaid and Medicare	1,990,612		72.8		1,619,455		73.5
Managed care	488,511		17.9		389,036		17.7
Private and other(2)	254,220		9.3		194,895		8.8
SERVICE REVENUE	$	2,733,343	100.0	%	$	2,203,386	100.0	%

(1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

State relief funding

Balance Sheet Impact

Accounts receivable as of September 30, 2023 and December 31, 2022, is summarized in the following table:




	September 30, 2023		December 31, 2022
Medicaid	$	188,572	$	157,878
Managed care	118,756		95,940
Medicare	75,717		76,526
Private and other payors	98,500		85,890
	481,545		416,234
Less: allowance for doubtful accounts	(9,422)		(7,802)
ACCOUNTS RECEIVABLE, NET	$	472,123	$	408,432

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent

+ Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

COMPUTATION OF NET INCOME PER COMMON SHARE

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

COMPUTATION OF NET INCOME PER COMMON SHARE

A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
NUMERATOR:
Net income	$	63,968	$	56,242	$	188,027	$	164,133
Less: net income (loss) attributable to noncontrolling interests	105		63		319		(77)
Net income attributable to The Ensign Group, Inc.	$	63,863	$	56,179	$	187,708	$	164,210





DENOMINATOR:
Weighted average shares outstanding for basic net income per share	55,829		54,882		55,582		54,819

Basic net income per common share:	$	1.14	$	1.02	$	3.38	$	3.00

A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
NUMERATOR:
Net income	$	63,968	$	56,242	$	188,027	$	164,133
Less: net income (loss) attributable to noncontrolling interests	105		63		319		(77)
Net income attributable to The Ensign Group, Inc.	$	63,863	$	56,179	$	187,708	$	164,210





DENOMINATOR:
Weighted average common shares outstanding	55,829		54,882		55,582		54,819
Plus: incremental shares from assumed conversion (1)	1,508		1,879		1,663		2,010
Adjusted weighted average common shares outstanding	57,337		56,761		57,245		56,829

Diluted net income per common share:	$	1.11	$	0.99	$	3.28	$	2.89

XML 23 R12.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS	9 Months Ended
FAIR VALUE MEASUREMENTS	Sep. 30, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The Company's financial assets include the captive insurance subsidiary's deposits and investments designated to support long-term insurance subsidiary liabilities and are carried at a cost basis of $57,290 and $53,924 as of September 30, 2023 and December 31, 2022, respectively. Also included are contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans that are held in a rabbi trust. The cash surrender value of these contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. As of September 30, 2023, and December 31, 2022, the adjusted cost basis of the investment funds was $36,867 and $25,144, respectively. As of September 30, 2023 and December 31, 2022, the cost basis of the Company's financial assets included in the captive insurance subsidiary's investments and deferred compensation plan investment funds are considered to approximate the fair value of these financial assets and are derived using Level 2 inputs. Additionally, the Company has other investments, which are not material, where the fair value is derived using Level 3 inputs. The Company believes its investments that were in an unrealized loss position as of September 30, 2023 and December 31, 2022 do not require an allowance for expected credit losses, nor has any event occurred through the filing date of this report that would indicate differently. The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

STANDARD BEARER	9 Months Ended
STANDARD BEARER	Sep. 30, 2023
Segment Reporting [Abstract]
STANDARD BEARER	STANDARD BEARER Standard Bearer's real estate portfolio consists of 107 of the Company's 112 owned real estate properties, of which 78 are operated and managed by the Company and 30 are leased to and operated by third party operators. Of those 30 operations, one senior living facility is located on the same real estate property as a skilled nursing facility that the Company owns and operates. Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. During the nine months ended September 30, 2023, Standard Bearer acquired the real estate of three stand-alone skilled nursing facilities and one campus operation for an aggregate purchase price of $52,802. Of these additions, the three skilled nursing facilities acquired are operated by the Company's affiliated operating subsidiaries and the campus operation is leased to a third party operator. During the nine months ended September 30, 2022, Standard Bearer acquired the real estate of eight skilled nursing facilities for an aggregate purchase price of $65,619, three of which were previously operated and managed by Ensign's affiliated operations. Refer to Note 7, Operation Expansions, for additional information. As part of the formation of Standard Bearer, certain of the Company's operating subsidiaries, Standard Bearer and Standard Bearer's subsidiaries entered into several agreements that include leasing, management services and debt arrangements between the operations. All intercompany transactions have been eliminated in consolidation. Refer to Note 8, Business Segments, for additional information related to these intercompany eliminations as well as Standard Bearer as a reportable segment. Intercompany master lease agreements Certain of the Company's operating subsidiaries and the 78 Standard Bearer subsidiaries have entered into five triple-net master lease agreements (collectively, the Standard Bearer Master Leases). The lease periods range from 15 to 19 years with three five-year renewal options beyond the initial term, on the same terms and conditions. The rent structure under the Standard Bearer Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the operating subsidiaries are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties; (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Rental revenue generated from Ensign affiliated operations was $16,976 and $49,035 for the three and nine months ended September 30, 2023, respectively, and $15,024 and $42,343 for the three and nine months ended September 30, 2022, respectively. Intercompany management agreement Standard Bearer has no employees. The Service Center provides personnel and services to Standard Bearer pursuant to the management agreement between Standard Bearer and the Service Center. The management agreement provides for a base management fee that is equal to 5% of total rental revenue and an incentive management fee that is equal to 5% of funds from operations (FFO) and is capped at 1% of total rental revenue, for a total of 6%. Management fee generated between Standard Bearer and the Service Center for the three and nine months ended September 30, 2023 was $1,259 and $3,636, respectively. Management fees generated between Standard Bearer and the Service Center for the three and nine months ended September 30, 2022 was $1,124 and $3,202, respectively. Intercompany debt arrangements Standard Bearer obtains its funding through various sources including operating cash flows, access to debt arrangements and intercompany loans. The intercompany debt arrangements include mortgage loans and the Credit Facility to fund acquisitions and working capital needs. The interest rate under the Amended Credit Agreement is a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum. In addition, as the Department of Housing and Urban Development (HUD) mortgage loans and promissory note are entered into by real estate subsidiaries of Standard Bearer, the interest expense incurred from these debts are included in Standard Bearer's segment income. Refer to Note 15, Debt, for additional information related to these debts. Equity Instrument Denominated in the Shares of a Subsidiary As part of the formation of Standard Bearer in January of 2022, the Company established the Standard Bearer Healthcare REIT, Inc. 2022 Omnibus Incentive Plan (Standard Bearer Equity Plan). The Company may grant stock options and restricted stock awards under the Standard Bearer Equity Plan to employees and management of Ensign's affiliated subsidiaries. These awards generally vest over a period of five years or upon the occurrence of certain prescribed events. The value of the stock options and restricted stock awards is tied to the value of the common stock of Standard Bearer, which is determined based on an independent valuation of Standard Bearer. The awards can be put to Standard Bearer at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination. In the second quarter of 2022, Standard Bearer sold fully vested common shares from the Standard Bearer Equity Plan to shareholders for cash of $6,544. During the nine months ended September 30, 2023 and 2022, the Company did not grant any stock options nor restricted shares under the Standard Bearer Equity Plan. Also in the second quarter of 2022, Standard Bearer established shareholders of its preferred shares through contributions of cash of $149. These preferred shares were fully vested at the time of the contributions by the shareholders. The value of Standard Bearer common and preferred shares held by the Company are eliminated in consolidation and the value held by other shareholders are classified as noncontrolling interests on the Company's condensed consolidated balance sheets.

XML 25 R14.htm IDEA: XBRL DOCUMENT

OPERATION EXPANSIONS

9 Months Ended

Sep. 30, 2023

Business Combination and Asset Acquisition [Abstract]

OPERATION EXPANSIONS

2023 Expansions

2022 Expansions

Of the new operations acquired during the nine months ended September 30, 2022, $16,400 was concentrated in goodwill and accordingly, the transactions were classified as business combinations.

XML 26 R15.htm IDEA: XBRL DOCUMENT

BUSINESS SEGMENTS

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

BUSINESS SEGMENTS

The following tables set forth financial information for the segments:



	Three Months Ended September 30, 2023
	Skilled Services		Standard Bearer		All Other(1)		Intercompany Elimination		Total
Service revenue(2)	$	902,967	$	—	$	36,254	$	(3,897)	$	935,324
Rental revenue(3)	—		20,980		2,870		(18,383)		5,467
TOTAL REVENUE	$	902,967	$	20,980	$	39,124	$	(22,280)	$	940,791
Segment income (loss)	117,816		7,165		(42,936)		—		82,045

Income before provision for income taxes									$	82,045
Depreciation and amortization	9,936		6,429		2,081		—		18,446
Interest expense(4)	$	—	$	5,139	$	312	$	(3,427)	$	2,024

(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.


	Three Months Ended September 30, 2022
	Skilled Services		Standard Bearer		All Other (1)		Intercompany Elimination		Total
Service revenue(2)	$	739,318	$	—	$	30,002	$	(3,437)	$	765,883
Rental revenue(3)	—		18,732		1,842		(16,452)		4,122
TOTAL REVENUE	$	739,318	$	18,732	$	31,844	$	(19,889)	$	770,005
Segment income (loss)	101,750		6,941		(37,036)		—		71,655
Gain on sale of assets, net									800
Income before provision for income taxes									$	72,455
Depreciation and amortization	8,397		5,561		1,983		—		15,941
Interest expense(4)	$	—	$	4,080	$	310	$	(2,282)	$	2,108

(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.



	Nine Months Ended September 30, 2023
	Skilled Services		Standard Bearer		All Other (1)		Intercompany Elimination		Total
Service revenue(2)	$	2,638,090	$	—	$	106,322	$	(11,069)	$	2,733,343
Rental revenue(3)	—		60,611		8,252		(53,229)		15,634
TOTAL REVENUE	$	2,638,090	$	60,611	$	114,574	$	(64,298)	$	2,748,977
Segment income (loss)	348,169		21,517		(128,106)		—		241,580
Loss on real estate insurance recoveries									(100)
Income before provision for income taxes									$	241,480
Depreciation and amortization	28,417		18,528		6,209		—		53,154
Interest expense(4)	$	—	$	14,283	$	927	$	(9,127)	$	6,083

(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.



	Nine Months Ended September 30, 2022
	Skilled Services		Standard Bearer		All Other (1)		Intercompany Elimination		Total
Service revenue(2)	$	2,128,567	$	—	$	84,256	$	(9,437)	$	2,203,386
Rental revenue(3)	—		53,523		5,537		(46,510)		12,550
TOTAL REVENUE	$	2,128,567	$	53,523	$	89,793	$	(55,947)	$	2,215,936
Segment income (loss)	302,272		20,679		(114,580)		—		208,371
Gain on sale of assets, net									3,267
Income before provision for income taxes									$	211,638
Depreciation and amortization	24,411		15,798		5,266		—		45,475
Interest expense	$	—	$	11,385	$	1,557	$	(6,078)	$	6,864

(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.

Service revenue by major payor source were as follows:


	Three Months Ended September 30, 2023
	Skilled Services		All Other (3)		Total Service Revenue		Revenue %
Medicaid(1)	$	367,079	$	7,759	$	374,838	40.1	%
Medicare	237,531		—		237,531		25.4
Medicaid-skilled	62,452		—		62,452		6.6
Subtotal	667,062		7,759		674,821		72.1
Managed care	170,747		—		170,747		18.3
Private and other(2)	65,158		24,598		89,756		9.6
TOTAL SERVICE REVENUE	$	902,967	$	32,357	$	935,324	100.0	%

(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

(3) All Other incorporates intercompany eliminations.


	Three Months Ended September 30, 2022
	Skilled Services		All Other (3)		Total Service Revenue		Revenue %
Medicaid(1)	$	295,927	$	6,688	$	302,615	39.5	%
Medicare	211,104		—		211,104		27.6
Medicaid-skilled	50,643		—		50,643		6.6
Subtotal	557,674		6,688		564,362		73.7
Managed care	132,663		—		132,663		17.3
Private and other(2)	48,981		19,877		68,858		9.0
TOTAL SERVICE REVENUE	$	739,318	$	26,565	$	765,883	100.0	%

(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

(3) All Other incorporates intercompany eliminations.



	Nine Months Ended September 30, 2023
	Skilled Services		All Other (3)		Total Service Revenue		Revenue %
Medicaid(1)	$	1,052,904	$	21,979	$	1,074,883	39.3	%
Medicare	733,335		—		733,335		26.8
Medicaid-skilled	182,394		—		182,394		6.7
Subtotal	1,968,633		21,979		1,990,612		72.8
Managed care	488,511		—		488,511		17.9
Private and other(2)	180,946		73,274		254,220		9.3
TOTAL SERVICE REVENUE	$	2,638,090	$	95,253	$	2,733,343	100.0	%

(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

(3) All Other incorporates intercompany eliminations.



	Nine Months Ended September 30, 2022
	Skilled Services		All Other (3)		Total Service Revenue		Revenue %
Medicaid(1)	$	845,341	$	17,750	$	863,091	39.2	%
Medicare	610,009		—		610,009		27.7
Medicaid-skilled	146,355		—		146,355		6.6
Subtotal	1,601,705		17,750		1,619,455		73.5
Managed care	389,036		—		389,036		17.7
Private and other(2)	137,826		57,069		194,895		8.8
TOTAL SERVICE REVENUE	$	2,128,567	$	74,819	$	2,203,386	100.0	%

(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

(3) All Other incorporates intercompany eliminations.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//280/tableOfContent

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-26

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-34

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

+ Details

XML 27 R16.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT— NET

9 Months Ended

Sep. 30, 2023

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT— NET

PROPERTY AND EQUIPMENT - NET

Property and equipment, net consists of the following:




	September 30, 2023		December 31, 2022
Land	$	140,239	$	134,864
Buildings and improvements	790,333		728,231
Leasehold improvements	166,984		150,903
Equipment	334,999		295,739
Furniture and fixtures	4,868		4,544
Construction in progress	21,993		17,521
	1,459,416		1,331,802
Less: accumulated depreciation	(391,514)		(339,792)
PROPERTY AND EQUIPMENT, NET	$	1,067,902	$	992,010

XML 28 R17.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS — NET

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS — NET

INTANGIBLE ASSETS - NET




	Weighted Average Life (Years)	September 30, 2023						December 31, 2022

		Gross Carrying Amount		Accumulated Amortization				Gross Carrying Amount		Accumulated Amortization
Intangible Assets						Net						Net


Assembled occupancy	0.3	$	702	$	(570)	$	132	$	435	$	(388)	$	47
Facility trade name	30.0	733		(433)		300		733		(415)		318
Customer relationships	18.4	4,582		(2,639)		1,943		4,582		(2,482)		2,100
TOTAL		$	6,017	$	(3,642)	$	2,375	$	5,750	$	(3,285)	$	2,465

Estimated amortization expense for each of the years ending December 31 is as follows:


Year	Amount
2023 (remainder)	$	192
2024	234
2025	234
2026	234
2027	234
2028	234
Thereafter	1,013
	$	2,375

Other indefinite-lived intangible assets consist of the following:



	September 30, 2023		December 31, 2022

Trade name	$	889	$	889
Medicare and Medicaid licenses	3,083		3,083
TOTAL	$	3,972	$	3,972

XML 29 R18.htm IDEA: XBRL DOCUMENT

GOODWILL

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL



	Skilled Services		All Other		Total










Goodwill	$	67,886	$	8,983	$	76,869

XML 30 R19.htm IDEA: XBRL DOCUMENT

RESTRICTED AND OTHER ASSETS

9 Months Ended

Sep. 30, 2023

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

RESTRICTED AND OTHER ASSETS

Restricted and other assets consist of the following:



	September 30, 2023		December 31, 2022

Debt issuance costs, net	$	3,104	$	3,753
Long-term insurance losses recoverable asset	13,439		10,512

Capital improvement reserves with landlords and lenders	5,051		6,446

Deposits with landlords	2,657		2,527
Escrow deposits	325		—
Other	11,403		14,053

RESTRICTED AND OTHER ASSETS	$	35,979	$	37,291

XML 31 R20.htm IDEA: XBRL DOCUMENT

OTHER ACCRUED LIABILITIES

9 Months Ended

Sep. 30, 2023

Payables and Accruals [Abstract]

OTHER ACCRUED LIABILITIES

Other accrued liabilities consists of the following:


	September 30, 2023		December 31, 2022

Quality assurance fee	$	8,786	$	7,701
Refunds payable	46,274		40,783
Resident advances	5,920		9,698
Unapplied state relief funds	636		1,001
Cash held in trust for patients	6,357		6,400

Dividends payable	3,243		3,201
Property taxes	15,371		10,926
Income tax payable	40,781		—
Legal finding accrued	3,734		4,553
Other	17,026		13,046
OTHER ACCRUED LIABILITIES	$	148,128	$	97,309

XML 32 R21.htm IDEA: XBRL DOCUMENT

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company recorded income tax expense of $53,453 and $47,505 during the nine months ended September 30, 2023 and 2022, respectively, or 22.1% of earnings before income taxes for the nine months ended September 30, 2023, compared to 22.4% for the nine months ended September 30, 2022. The effective tax rate for both periods is driven by the impact of excess tax benefits from stock-based compensation, offset by non-deductible expenses including non-deductible compensation. The Company is not currently under examination by any major income tax jurisdiction. During 2023, the statutes of limitations will lapse on the Company's 2019 federal tax year and certain 2018 and 2019 state tax years. The Company does not believe the federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the Interim Financial Statements for the nine months ended September 30, 2023 and 2022.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

XML 33 R22.htm IDEA: XBRL DOCUMENT

DEBT

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

DEBT

Debt consists of the following:




	September 30, 2023		December 31, 2022


Mortgage loans and promissory note	$	153,354	$	156,271

Less: current maturities	(3,916)		(3,883)
Less: debt issuance costs, net	(2,985)		(3,119)
LONG-TERM DEBT LESS CURRENT MATURITIES	$	146,453	$	149,269

Credit Facility with a Lending Consortium Arranged by Truist

Mortgage Loans and Promissory Note

Off-Balance Sheet Arrangements

As of September 30, 2023, the Company had approximately $6,710 of borrowing capacity under the Credit Facility pledged as collateral to secure outstanding letters of credit.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

XML 34 R23.htm IDEA: XBRL DOCUMENT

OPTIONS AND AWARDS

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

OPTIONS AND AWARDS

Stock Options



Grant Year	Options Granted	Weighted Average Risk-Free Rate	Expected Life	Weighted Average Volatility	Weighted Average Dividend Yield
2023	193	4.4%	6.1 years	41.3%	0.2%
2022	145	3.1%	6.3 years	41.8%	0.2%

The Company used the following assumptions for stock options granted during the nine months ended September 30, 2023 and 2022:



Grant Year	Options Granted	Weighted Average Risk-Free Rate	Expected Life	Weighted Average Volatility	Weighted Average Dividend Yield
2023	606	4.0%	6.2 years	41.4%	0.3%
2022	463	2.5%	6.2 years	42.1%	0.3%

For the nine months ended September 30, 2023 and 2022, the following represents the exercise price and fair value displayed at grant date for stock option grants:


Grant Year	Granted	Weighted Average Exercise Price		Weighted Average Fair Value of Options
2023	606	$	92.54	$	42.50
2022	463	$	83.41	$	36.22

The following table represents the employee stock option activity during the nine months ended September 30, 2023:


	Number of Options Outstanding	Weighted Average Exercise Price		Number of Options Vested	Weighted Average Exercise Price of Options Vested












January 1, 2023	3,833	$	46.72	2,069	$	28.87
Granted	606	92.54
Forfeited	(77)	69.64
Exercised	(578)	21.99
September 30, 2023	3,784	$	57.37	1,960	$	37.69

The aggregate intrinsic value of options outstanding, vested and expected to vest as of September 30, 2023 and December 31, 2022 is as follows:



Options	September 30, 2023		December 31, 2022


Outstanding	$	135,648	$	183,593
Vested	108,275		136,000
Expected to vest	25,910		43,232

Restricted Stock Awards

A summary of the status of the Company's non-vested restricted stock awards as of September 30, 2023 and changes during the nine months ended September 30, 2023 is presented below:


	Non-Vested Restricted Awards	Weighted Average Grant Date Fair Value








Nonvested at January 1, 2023	487	$	64.92
Granted	215	91.96
Vested	(225)	64.29
Forfeited	(19)	70.64
Nonvested at September 30, 2023	458	$	77.81

Long-Term Incentive Plan

Stock-based compensation expense

Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the three and nine months ended September 30, 2023 and 2022 was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Stock-based compensation expense related to stock options	$	4,051	$	2,983	$	12,439	$	8,289
Stock-based compensation expense related to restricted stock awards	2,774		2,579		8,983		7,337
Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors	405		336		1,262		1,055
TOTAL	$	7,230	$	5,898	$	22,684	$	16,681

XML 35 R24.htm IDEA: XBRL DOCUMENT

LEASES

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

LEASES

The components of operating lease expense are as follows:




	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Rent - cost of services(1)	$	50,357	$	38,907	$	146,754	$	111,897
General and administrative expense	123		33		372		79
Depreciation and amortization(2)	303		289		899		866
Variable lease costs(3)	5,376		4,121		15,362		13,256
	$	56,159	$	43,350	$	163,387	$	126,098

(2) Depreciation and amortization is related to the amortization of favorable and direct lease costs.

(3) Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.

Future minimum lease payments for all leases as of September 30, 2023 are as follows:


Year	Amount
2023 (remainder)	$	47,730
2024	191,035
2025	190,946
2026	190,729
2027	190,147
2028	188,906
Thereafter	1,719,921
TOTAL LEASE PAYMENTS	2,719,414
Less: present value adjustment	(980,503)
PRESENT VALUE OF TOTAL LEASE LIABILITIES	1,738,911
Less: current lease liabilities	(80,956)
LONG-TERM OPERATING LEASE LIABILITIES	$	1,657,955

Lessor Activities

Total rental income from all third-party sources for the three and nine months ended September 30, 2023 and 2022 is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Pennant(1)	$	3,740	$	3,664	$	11,224	$	11,169
Other third-party	1,727		458		4,410		1,381
TOTAL	$	5,467	$	4,122	$	15,634	$	12,550

Future annual rental income for all leases as of September 30, 2023 were as follows:


Year	Amount(1)
2023 (remainder)	$	5,493
2024	21,526
2025	21,023
2026	20,788
2027	20,762
2028	20,737
Thereafter	128,013
TOTAL	$	238,342

(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of September 30, 2023.

LEASES

The components of operating lease expense are as follows:




	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Rent - cost of services(1)	$	50,357	$	38,907	$	146,754	$	111,897
General and administrative expense	123		33		372		79
Depreciation and amortization(2)	303		289		899		866
Variable lease costs(3)	5,376		4,121		15,362		13,256
	$	56,159	$	43,350	$	163,387	$	126,098

(2) Depreciation and amortization is related to the amortization of favorable and direct lease costs.

(3) Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.

Future minimum lease payments for all leases as of September 30, 2023 are as follows:


Year	Amount
2023 (remainder)	$	47,730
2024	191,035
2025	190,946
2026	190,729
2027	190,147
2028	188,906
Thereafter	1,719,921
TOTAL LEASE PAYMENTS	2,719,414
Less: present value adjustment	(980,503)
PRESENT VALUE OF TOTAL LEASE LIABILITIES	1,738,911
Less: current lease liabilities	(80,956)
LONG-TERM OPERATING LEASE LIABILITIES	$	1,657,955

Lessor Activities

Total rental income from all third-party sources for the three and nine months ended September 30, 2023 and 2022 is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Pennant(1)	$	3,740	$	3,664	$	11,224	$	11,169
Other third-party	1,727		458		4,410		1,381
TOTAL	$	5,467	$	4,122	$	15,634	$	12,550

Future annual rental income for all leases as of September 30, 2023 were as follows:


Year	Amount(1)
2023 (remainder)	$	5,493
2024	21,526
2025	21,023
2026	20,788
2027	20,762
2028	20,737
Thereafter	128,013
TOTAL	$	238,342

(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of September 30, 2023.

XML 36 R25.htm IDEA: XBRL DOCUMENT

DEFINED CONTRIBUTION PLANS	9 Months Ended
DEFINED CONTRIBUTION PLANS	Sep. 30, 2023
Retirement Benefits [Abstract]
DEFINED CONTRIBUTION PLANS	DEFINED CONTRIBUTION PLANS The Company has a 401(k) defined contribution plan (the 401(k) Plan), whereby eligible employees may contribute up to 90% of their annual basic earnings, subject to applicable annual Internal Revenue Code limits. Additionally, the 401(k) Plan provides for discretionary matching contributions (as defined in the 401(k) Plan) by the Company. The Company has a non-qualified deferred compensation plan (the DCP), whereby certain highly compensated employees who are otherwise ineligible to participate in the Company's 401(k) plan, may defer the receipt of a portion of their base compensation and, for certain employees, up to 100% of their eligible bonuses. Additionally, the DCP allows for the employee deferrals to be deposited into a rabbi trust and the funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to fund savings plans of this nature. The Company paid for related administrative costs, which were not significant during three and nine months ended September 30, 2023 and 2022. As of September 30, 2023 and December 31, 2022, the Company accrued $42,613 and $33,017, respectively, as long term deferred compensation in other long term liabilities on the consolidated balance sheet. Cash surrender value of the contracts is based on investment funds that shadow the investment allocations specified by participants in the deferred compensation plan. Refer to Note 5, Fair Value Measurements for more information on the funds. For the three months ended September 30, 2023, the Company recorded a loss related to its DCP of $1,424, which is included in other income (expense), net, and recorded an offsetting reduction in expense of $1,352, which is allocated between cost of services and general and administrative expenses. For the nine months ended September 30, 2023, the company recorded a gain related to its DCP of $1,065, which is included in other income (expense), net, and recorded an offsetting expense of $1,261, which is allocated between cost of services and general and administrative expenses. For the three and nine months ended September 30, 2022, the Company recorded a loss related to its DCP of $1,135 and $5,650, respectively, which is included in other income (expense), net. During the same periods, the Company recorded an offsetting reduction in expense of $1,055 and $5,566, respectively, which is allocated between cost of services and general and administrative expenses.

XML 37 R26.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Regulatory Matters — Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is monitoring performed by the Office of Civil Rights which covers the Health Insurance Portability and Accountability Act of 1996, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information. Cost-Containment Measures — Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company. Indemnities — From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental obligations or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent operating subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and others, under which the Company may be required to indemnify such persons for liabilities arising out of the nature of their relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s condensed consolidated balance sheets for any of the periods presented. In connection with the spin-off transaction in 2019, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the transaction. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties. U.S. Department of Justice Civil Investigative Demand — On May 31, 2018, the Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice (DOJ) stating that it was investigating whether there had been a violation of the False Claims Act (FCA) and/or the Anti-Kickback Statute (AKS) with respect to relationships between certain of the Company’s independently operated skilled nursing facilities and persons who serve or have served as medical directors. The Company fully cooperated with the DOJ and promptly responded to its requests for information. In April 2020, the Company was advised that the DOJ declined to intervene in any subsequent action filed in connection with the subject matter of this investigation. Despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator has moved forward with the lawsuit. The Company is vigorously defending this lawsuit, but expects the costs of defense to be significant given the nature of the allegations and the date range contemplated by the complaint. At this time, the Company is unable to estimate the range of loss and cannot predict the final outcome of this lawsuit. If this lawsuit is ultimately resolved against the Company, the amounts owed, including fines, penalties and other consequences relating to the lawsuit, could have a material adverse effect on the Company's results of operations, financial condition and cash flows. As a general matter, the Company’s independent operating entities have established and maintain policies and procedures to promote compliance with the FCA, the AKS, and other applicable regulatory requirements. U.S. House of Representatives Select Subcommittee Request — In 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company received a document and information request from the House Select Subcommittee in connection with its investigation. The Company cooperated in responding to this inquiry. In July 2022 and thereafter, the Company received follow up requests for additional documents and information. The Company responded to these requests and continued to cooperate with the House Select Subcommittee in connection with its investigation. On December 9, 2022, the House Select Subcommittee issued its final report summarizing its investigation and related recommendations designed "to strengthen the nation's ability to prevent and respond to public health and economic emergencies." According to the information provided by the House Select Subcommittee, the issuance of this report was the House Select Subcommittee's final official act. Litigation — The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents served by the Company's independent operating subsidiaries. The Company, its independent operating subsidiaries, and others in the industry are subject to an increasing number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. In addition, the Company, its independent operating subsidiaries, and others in the industry are subject to claims and lawsuits in connection with COVID-19 and a facility's preparation for and/or response to COVID-19. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards. In addition to the potential lawsuits and claims described above, the Company and its independent operating subsidiaries are also subject to potential lawsuits under the FCA and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from federally funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Under the qui tam or "whistleblower" provisions of the FCA, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the federal Government and receive a percentage of the federal Government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. For example, and despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator has moved forward with the lawsuit and is pursuing claims that the Company and certain of its independent operating subsidiaries allegedly violated the FCA and/or AKS. The Company is vigorously defending this lawsuit, but expects the costs of defense to be significant given the nature of the allegations and the date range contemplated by the complaint. In addition to the FCA, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the FCA. As such, the Company and its independent operating subsidiaries could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent operating subsidiaries do business. In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) which made significant changes to the FCA and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a FCA violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing. Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent operating subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements, and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations. Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent operating subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and related causes of action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company’s business, cash flows, financial condition or results of operations. The Company and its independent operating subsidiaries have been, and continue to be, subject to claims, findings and legal actions that arise in the ordinary course of the various businesses, including healthcare and non-healthcare services. These claims include, but are not limited to, potential claims filed by residents, customers, patients and responsible parties related to patient care and treatment (professional negligence claims); non-care based activities of certain of the subsidiaries; and employment related claims filed by current or former employees. A significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. In addition, these claims could impact the Company's ability to procure insurance to cover its exposure related to the various services provided by its independent operating subsidiaries to their residents, customers and patients. The Company and its independent operating subsidiaries are also subject to requests for information and investigations by other state and federal governmental entities (e.g., Offices of the Attorney General and Offices of the Inspector General). The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent operating subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under federal Medicare statutes, the FCA, or similar state and federal statutes and related regulations, or if the Company or its independent operating subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations, and may also include the assumption of specific procedural and financial obligations by the Company or its independent operating subsidiaries under a Corporate Integrity Agreement and/or other such arrangement. Medicare Revenue Recoupments — The Company's independent operating subsidiaries are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate (TPE) Program. Beginning in August 2020, CMS resumed TPE Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. The Company anticipates that these Reviews could increase in frequency in the future. As of September 30, 2023 and through the filing date of this report, 41 of the Company's independent operating subsidiaries had Reviews scheduled or in process. CMS announced a new nationwide audit, the “SNF 5-Claim Probe & Educate Review”, in which the Medicare Administrative Contractors (MACs) will review five claims from each SNF to check for compliance. In implementing this SNF 5-Claim Probe & Educate Review, CMS acknowledged that the increase in observed improper payments from 2021 to 2022 may have arisen from a "misunderstanding" by SNFs about how to appropriately bill for claims of service after October 1, 2019. All facilities that are not undergoing TPE reviews, or have not recently passed a TPE review, will be subject to the nationwide audit. MACs will complete only one round of probe-and-educate for each SNF, rather than three rounds that typically occur in the TPE Program. Additionally, CMS's education for each SNF will be individualized and based on observed claim review errors, with rationales for denial explained to the SNF on a claim-by-claim basis. This program applies only to claims submitted after October 1, 2019, and will exclude claims containing a COVID-19 diagnosis. Concentrations Credit Risk — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s receivables from Medicare and Medicaid payor programs accounted for 54.9% and 56.3% of its total accounts receivable as of September 30, 2023 and December 31, 2022, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 72.1% and 72.8% of the Company's revenue for the three and nine months ended September 30, 2023, respectively, and 73.7% and 73.5% for the three and nine months ended September 30, 2022. Cash in Excess of FDIC Limits — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of September 30, 2023, the Company's uninsured cash deposits are not material. All uninsured bank deposits are held at high quality credit institutions.

XML 38 R27.htm IDEA: XBRL DOCUMENT

COMMON STOCK REPURCHASE PROGRAM	9 Months Ended
COMMON STOCK REPURCHASE PROGRAM	Sep. 30, 2023
Equity [Abstract]
COMMON STOCK REPURCHASE PROGRAM	COMMON STOCK REPURCHASE PROGRAMOn August 29, 2023, the Board of Directors approved a stock repurchase program pursuant to which the Company may repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from September 1, 2023. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The Company did not purchase any shares pursuant to this stock repurchase program during the three months ended September 30, 2023. On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company may repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from August 2, 2022. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program does not obligate the Company to acquire any specific number of shares. The stock repurchase program expired on August 2, 2023 and is no longer in effect. The Company did not purchase any shares pursuant to this stock repurchase program. On February 9, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from February 10, 2022. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the three months ended June 30, 2022, the Company repurchased 271 shares of its common stock for $20,000. This repurchase program expired in 2022 upon the repurchase of the fully authorized amount under the plan and is no longer in effect. On October 21, 2021, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from October 29, 2021. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the first quarter of 2022, the Company repurchased 133 shares of its common stock for $9,882 pursuant to this stock repurchase program. This repurchase program expired in 2022 upon the repurchase of the fully authorized amount under the plan and is no longer in effect.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

XML 39 R28.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 63,863	$ 63,993	$ 59,852	$ 56,179	$ 57,691	$ 50,340	$ 187,708	$ 164,210

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

XML 40 R29.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended	9 Months Ended
Insider Trading Arrangements	Sep. 30, 2023 shares	Sep. 30, 2023 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Spencer W. Burton [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		Spencer W. Burton, President & Chief Operations Officer, entered into a Rule 10b5-1 trading arrangement on September 12, 2023 (the "Rule 10b5-1 Plan"). Mr. Burton's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 8,280 shares of the Company's common stock between December 14, 2023 and August 30, 2024. Pursuant to the 10b5-1 Plan, Mr. Burton may also make a gift of up to 2,380 shares of the Company's common stock starting on December 14, 2023.
Name	Spencer W. Burton
Title	President & Chief Operations Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	September 12, 2023
Arrangement Duration	260 days
Aggregate Available	8,280	8,280

XML 41 R30.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation — The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interests in its condensed consolidated statements of income.The Interim Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest.
Estimates and Assumptions	Estimates and Assumptions — The preparation of the Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities and income taxes. Actual results could differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments —The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, deferred compensation investment funds, equity investments, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.
Service and Rental Revenue Recognition	Service Revenue Recognition — The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606). The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to patients at the amount that reflects the consideration that the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services provided pursuant to skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services that are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered. Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration that is included in the transaction price may be constrained, and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known. Rental Revenue Recognition — The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue for operating leases is recognized on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, Leases (ASC 842). The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met. Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under the new lease standards. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s condensed consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.
Accounts Receivable	Accounts Receivable — Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.
Property and Equipment	Property and Equipment — Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
Leases and Leasehold Improvements	Leases and Leasehold Improvements — The Company leases skilled nursing facilities, senior living facilities and commercial office space. The Company determines if an arrangement is a lease and performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of September 30, 2023, the Company has one financing lease that is not material to the condensed consolidated balance sheets. Rights and obligations of these leases are included as right-of-use assets, current and long-term lease liabilities on the Company's condensed consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate. The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements. The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional ten to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company subleases skilled nursing facilities to third-party operators and considers the subleases to be separate contracts because the Company is not relieved of its primary obligation under its operating lease. The rental income from third-parties related to these subleases is presented on a gross basis from the rent expense associated with the Company's lease obligations and is not material to the condensed consolidated statements of income.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets — The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset.
Intangible Assets and Goodwill	Intangible Assets and Goodwill — Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years. The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year.
Self-Insurance	Self-Insurance — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,250 for California affiliated operations and a separate, one-time, deductible of $1,250 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider. The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $90,811 and $79,781 as of September 30, 2023 and December 31, 2022, respectively. The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $28,733 and $27,301 as of September 30, 2023 and December 31, 2022, respectively. In addition, the Company has recorded an asset and corresponding liability of $13,439 and $10,512 as of September 30, 2023 and December 31, 2022, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12, Restricted and Other Assets. The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal year 2023. As of September 30, 2023 and December 31, 2022, the Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $14,716 and $14,088, respectively. The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.
Income Taxes	Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ. Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer believes it has been organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions.
Noncontrolling Interest	Noncontrolling Interest — The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.
Stock-Based Compensation	Stock-Based Compensation — The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.

XML 42 R31.htm IDEA: XBRL DOCUMENT

REVENUE AND ACCOUNTS RECEIVABLE (Tables)

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

Service revenue for the three and nine months ended September 30, 2023 and 2022 is summarized in the following tables:



	Three Months Ended September 30,
	2023				2022
	Revenue		% of Revenue		Revenue		% of Revenue
Medicaid(1)	$	374,838	40.1	%	$	302,615	39.5	%
Medicare	237,531		25.4		211,104		27.6
Medicaid — skilled	62,452		6.6		50,643		6.6
Total Medicaid and Medicare	674,821		72.1		564,362		73.7
Managed care	170,747		18.3		132,663		17.3
Private and other(2)	89,756		9.6		68,858		9.0
SERVICE REVENUE	$	935,324	100.0	%	$	765,883	100.0	%

(1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.



	Nine Months Ended September 30,
	2023				2022
	Revenue		% of Revenue		Revenue		% of Revenue
Medicaid(1)	$	1,074,883	39.3	%	$	863,091	39.2	%
Medicare	733,335		26.8		610,009		27.7
Medicaid — skilled	182,394		6.7		146,355		6.6
Total Medicaid and Medicare	1,990,612		72.8		1,619,455		73.5
Managed care	488,511		17.9		389,036		17.7
Private and other(2)	254,220		9.3		194,895		8.8
SERVICE REVENUE	$	2,733,343	100.0	%	$	2,203,386	100.0	%

(1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

Schedule of Accounts Receivable

Accounts receivable as of September 30, 2023 and December 31, 2022, is summarized in the following table:




	September 30, 2023		December 31, 2022
Medicaid	$	188,572	$	157,878
Managed care	118,756		95,940
Medicare	75,717		76,526
Private and other payors	98,500		85,890
	481,545		416,234
Less: allowance for doubtful accounts	(9,422)		(7,802)
ACCOUNTS RECEIVABLE, NET	$	472,123	$	408,432

XML 43 R32.htm IDEA: XBRL DOCUMENT

COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic Net Income Per Common Share

A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
NUMERATOR:
Net income	$	63,968	$	56,242	$	188,027	$	164,133
Less: net income (loss) attributable to noncontrolling interests	105		63		319		(77)
Net income attributable to The Ensign Group, Inc.	$	63,863	$	56,179	$	187,708	$	164,210





DENOMINATOR:
Weighted average shares outstanding for basic net income per share	55,829		54,882		55,582		54,819

Basic net income per common share:	$	1.14	$	1.02	$	3.38	$	3.00

Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Diluted Net Income Per Common Share

A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
NUMERATOR:
Net income	$	63,968	$	56,242	$	188,027	$	164,133
Less: net income (loss) attributable to noncontrolling interests	105		63		319		(77)
Net income attributable to The Ensign Group, Inc.	$	63,863	$	56,179	$	187,708	$	164,210





DENOMINATOR:
Weighted average common shares outstanding	55,829		54,882		55,582		54,819
Plus: incremental shares from assumed conversion (1)	1,508		1,879		1,663		2,010
Adjusted weighted average common shares outstanding	57,337		56,761		57,245		56,829

Diluted net income per common share:	$	1.11	$	0.99	$	3.28	$	2.89

XML 44 R33.htm IDEA: XBRL DOCUMENT

BUSINESS SEGMENTS (Tables)

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Schedule of Segment Financial Information

The following tables set forth financial information for the segments:



	Three Months Ended September 30, 2023
	Skilled Services		Standard Bearer		All Other(1)		Intercompany Elimination		Total
Service revenue(2)	$	902,967	$	—	$	36,254	$	(3,897)	$	935,324
Rental revenue(3)	—		20,980		2,870		(18,383)		5,467
TOTAL REVENUE	$	902,967	$	20,980	$	39,124	$	(22,280)	$	940,791
Segment income (loss)	117,816		7,165		(42,936)		—		82,045

Income before provision for income taxes									$	82,045
Depreciation and amortization	9,936		6,429		2,081		—		18,446
Interest expense(4)	$	—	$	5,139	$	312	$	(3,427)	$	2,024

(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.


	Three Months Ended September 30, 2022
	Skilled Services		Standard Bearer		All Other (1)		Intercompany Elimination		Total
Service revenue(2)	$	739,318	$	—	$	30,002	$	(3,437)	$	765,883
Rental revenue(3)	—		18,732		1,842		(16,452)		4,122
TOTAL REVENUE	$	739,318	$	18,732	$	31,844	$	(19,889)	$	770,005
Segment income (loss)	101,750		6,941		(37,036)		—		71,655
Gain on sale of assets, net									800
Income before provision for income taxes									$	72,455
Depreciation and amortization	8,397		5,561		1,983		—		15,941
Interest expense(4)	$	—	$	4,080	$	310	$	(2,282)	$	2,108

(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.



	Nine Months Ended September 30, 2023
	Skilled Services		Standard Bearer		All Other (1)		Intercompany Elimination		Total
Service revenue(2)	$	2,638,090	$	—	$	106,322	$	(11,069)	$	2,733,343
Rental revenue(3)	—		60,611		8,252		(53,229)		15,634
TOTAL REVENUE	$	2,638,090	$	60,611	$	114,574	$	(64,298)	$	2,748,977
Segment income (loss)	348,169		21,517		(128,106)		—		241,580
Loss on real estate insurance recoveries									(100)
Income before provision for income taxes									$	241,480
Depreciation and amortization	28,417		18,528		6,209		—		53,154
Interest expense(4)	$	—	$	14,283	$	927	$	(9,127)	$	6,083

(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.



	Nine Months Ended September 30, 2022
	Skilled Services		Standard Bearer		All Other (1)		Intercompany Elimination		Total
Service revenue(2)	$	2,128,567	$	—	$	84,256	$	(9,437)	$	2,203,386
Rental revenue(3)	—		53,523		5,537		(46,510)		12,550
TOTAL REVENUE	$	2,128,567	$	53,523	$	89,793	$	(55,947)	$	2,215,936
Segment income (loss)	302,272		20,679		(114,580)		—		208,371
Gain on sale of assets, net									3,267
Income before provision for income taxes									$	211,638
Depreciation and amortization	24,411		15,798		5,266		—		45,475
Interest expense	$	—	$	11,385	$	1,557	$	(6,078)	$	6,864

(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.

Schedule of Service Revenue by Major Payor Source

Service revenue by major payor source were as follows:


	Three Months Ended September 30, 2023
	Skilled Services		All Other (3)		Total Service Revenue		Revenue %
Medicaid(1)	$	367,079	$	7,759	$	374,838	40.1	%
Medicare	237,531		—		237,531		25.4
Medicaid-skilled	62,452		—		62,452		6.6
Subtotal	667,062		7,759		674,821		72.1
Managed care	170,747		—		170,747		18.3
Private and other(2)	65,158		24,598		89,756		9.6
TOTAL SERVICE REVENUE	$	902,967	$	32,357	$	935,324	100.0	%

(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

(3) All Other incorporates intercompany eliminations.


	Three Months Ended September 30, 2022
	Skilled Services		All Other (3)		Total Service Revenue		Revenue %
Medicaid(1)	$	295,927	$	6,688	$	302,615	39.5	%
Medicare	211,104		—		211,104		27.6
Medicaid-skilled	50,643		—		50,643		6.6
Subtotal	557,674		6,688		564,362		73.7
Managed care	132,663		—		132,663		17.3
Private and other(2)	48,981		19,877		68,858		9.0
TOTAL SERVICE REVENUE	$	739,318	$	26,565	$	765,883	100.0	%

(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

(3) All Other incorporates intercompany eliminations.



	Nine Months Ended September 30, 2023
	Skilled Services		All Other (3)		Total Service Revenue		Revenue %
Medicaid(1)	$	1,052,904	$	21,979	$	1,074,883	39.3	%
Medicare	733,335		—		733,335		26.8
Medicaid-skilled	182,394		—		182,394		6.7
Subtotal	1,968,633		21,979		1,990,612		72.8
Managed care	488,511		—		488,511		17.9
Private and other(2)	180,946		73,274		254,220		9.3
TOTAL SERVICE REVENUE	$	2,638,090	$	95,253	$	2,733,343	100.0	%

(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

(3) All Other incorporates intercompany eliminations.



	Nine Months Ended September 30, 2022
	Skilled Services		All Other (3)		Total Service Revenue		Revenue %
Medicaid(1)	$	845,341	$	17,750	$	863,091	39.2	%
Medicare	610,009		—		610,009		27.7
Medicaid-skilled	146,355		—		146,355		6.6
Subtotal	1,601,705		17,750		1,619,455		73.5
Managed care	389,036		—		389,036		17.7
Private and other(2)	137,826		57,069		194,895		8.8
TOTAL SERVICE REVENUE	$	2,128,567	$	74,819	$	2,203,386	100.0	%

(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.

(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

(3) All Other incorporates intercompany eliminations.

XML 45 R34.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT— NET (Tables)

9 Months Ended

Sep. 30, 2023

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment, Net

Property and equipment, net consists of the following:




	September 30, 2023		December 31, 2022
Land	$	140,239	$	134,864
Buildings and improvements	790,333		728,231
Leasehold improvements	166,984		150,903
Equipment	334,999		295,739
Furniture and fixtures	4,868		4,544
Construction in progress	21,993		17,521
	1,459,416		1,331,802
Less: accumulated depreciation	(391,514)		(339,792)
PROPERTY AND EQUIPMENT, NET	$	1,067,902	$	992,010

XML 46 R35.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS — NET (Tables)

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets




	Weighted Average Life (Years)	September 30, 2023						December 31, 2022

		Gross Carrying Amount		Accumulated Amortization				Gross Carrying Amount		Accumulated Amortization
Intangible Assets						Net						Net


Assembled occupancy	0.3	$	702	$	(570)	$	132	$	435	$	(388)	$	47
Facility trade name	30.0	733		(433)		300		733		(415)		318
Customer relationships	18.4	4,582		(2,639)		1,943		4,582		(2,482)		2,100
TOTAL		$	6,017	$	(3,642)	$	2,375	$	5,750	$	(3,285)	$	2,465

Schedule of Estimated Amortization Expense

Estimated amortization expense for each of the years ending December 31 is as follows:


Year	Amount
2023 (remainder)	$	192
2024	234
2025	234
2026	234
2027	234
2028	234
Thereafter	1,013
	$	2,375

Schedule of Indefinite-lived Intangible Assets

Other indefinite-lived intangible assets consist of the following:



	September 30, 2023		December 31, 2022

Trade name	$	889	$	889
Medicare and Medicaid licenses	3,083		3,083
TOTAL	$	3,972	$	3,972

XML 47 R36.htm IDEA: XBRL DOCUMENT

GOODWILL (Tables)

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The following table represents activity in goodwill by skilled service segment and "all other" category as of September 30, 2023 and December 31, 2022:



	Skilled Services		All Other		Total










Goodwill	$	67,886	$	8,983	$	76,869

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2

+ Details

XML 48 R37.htm IDEA: XBRL DOCUMENT

RESTRICTED AND OTHER ASSETS (Tables)

9 Months Ended

Sep. 30, 2023

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Restricted and Other Assets

Restricted and other assets consist of the following:



	September 30, 2023		December 31, 2022

Debt issuance costs, net	$	3,104	$	3,753
Long-term insurance losses recoverable asset	13,439		10,512

Capital improvement reserves with landlords and lenders	5,051		6,446

Deposits with landlords	2,657		2,527
Escrow deposits	325		—
Other	11,403		14,053

RESTRICTED AND OTHER ASSETS	$	35,979	$	37,291

XML 49 R38.htm IDEA: XBRL DOCUMENT

OTHER ACCRUED LIABILITIES (Tables)

9 Months Ended

Sep. 30, 2023

Payables and Accruals [Abstract]

Schedule of Other Accrued Liabilities

Other accrued liabilities consists of the following:


	September 30, 2023		December 31, 2022

Quality assurance fee	$	8,786	$	7,701
Refunds payable	46,274		40,783
Resident advances	5,920		9,698
Unapplied state relief funds	636		1,001
Cash held in trust for patients	6,357		6,400

Dividends payable	3,243		3,201
Property taxes	15,371		10,926
Income tax payable	40,781		—
Legal finding accrued	3,734		4,553
Other	17,026		13,046
OTHER ACCRUED LIABILITIES	$	148,128	$	97,309

XML 50 R39.htm IDEA: XBRL DOCUMENT

DEBT (Tables)

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Schedule of Debt

Debt consists of the following:




	September 30, 2023		December 31, 2022


Mortgage loans and promissory note	$	153,354	$	156,271

Less: current maturities	(3,916)		(3,883)
Less: debt issuance costs, net	(2,985)		(3,119)
LONG-TERM DEBT LESS CURRENT MATURITIES	$	146,453	$	149,269

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482949/835-30-55-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480848/942-470-50-3

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-6

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-7

+ Details

XML 51 R40.htm IDEA: XBRL DOCUMENT

OPTIONS AND AWARDS (Tables)

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

Schedule of Assumptions for Stock Options Granted

The Company used the following assumptions for stock options granted during the three months ended September 30, 2023 and 2022:



Grant Year	Options Granted	Weighted Average Risk-Free Rate	Expected Life	Weighted Average Volatility	Weighted Average Dividend Yield
2023	193	4.4%	6.1 years	41.3%	0.2%
2022	145	3.1%	6.3 years	41.8%	0.2%

The Company used the following assumptions for stock options granted during the nine months ended September 30, 2023 and 2022:



Grant Year	Options Granted	Weighted Average Risk-Free Rate	Expected Life	Weighted Average Volatility	Weighted Average Dividend Yield
2023	606	4.0%	6.2 years	41.4%	0.3%
2022	463	2.5%	6.2 years	42.1%	0.3%

Schedule of Exercise Price and Fair Value Displayed at Grant Date for Stock Option Grants

For the nine months ended September 30, 2023 and 2022, the following represents the exercise price and fair value displayed at grant date for stock option grants:


Grant Year	Granted	Weighted Average Exercise Price		Weighted Average Fair Value of Options
2023	606	$	92.54	$	42.50
2022	463	$	83.41	$	36.22

Schedule of Employee Stock Option Roll Forward

The following table represents the employee stock option activity during the nine months ended September 30, 2023:


	Number of Options Outstanding	Weighted Average Exercise Price		Number of Options Vested	Weighted Average Exercise Price of Options Vested












January 1, 2023	3,833	$	46.72	2,069	$	28.87
Granted	606	92.54
Forfeited	(77)	69.64
Exercised	(578)	21.99
September 30, 2023	3,784	$	57.37	1,960	$	37.69

Schedule of Aggregate Intrinsic Value of Options

The aggregate intrinsic value of options outstanding, vested and expected to vest as of September 30, 2023 and December 31, 2022 is as follows:



Options	September 30, 2023		December 31, 2022


Outstanding	$	135,648	$	183,593
Vested	108,275		136,000
Expected to vest	25,910		43,232

Schedule of Nonvested Restricted Stock Awards

A summary of the status of the Company's non-vested restricted stock awards as of September 30, 2023 and changes during the nine months ended September 30, 2023 is presented below:


	Non-Vested Restricted Awards	Weighted Average Grant Date Fair Value








Nonvested at January 1, 2023	487	$	64.92
Granted	215	91.96
Vested	(225)	64.29
Forfeited	(19)	70.64
Nonvested at September 30, 2023	458	$	77.81

Schedule of Stock-Based Compensation Expense

Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the three and nine months ended September 30, 2023 and 2022 was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Stock-based compensation expense related to stock options	$	4,051	$	2,983	$	12,439	$	8,289
Stock-based compensation expense related to restricted stock awards	2,774		2,579		8,983		7,337
Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors	405		336		1,262		1,055
TOTAL	$	7,230	$	5,898	$	22,684	$	16,681

XML 52 R41.htm IDEA: XBRL DOCUMENT

LEASES (Tables)

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

Schedule of Operating Lease Expenses

The components of operating lease expense are as follows:




	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Rent - cost of services(1)	$	50,357	$	38,907	$	146,754	$	111,897
General and administrative expense	123		33		372		79
Depreciation and amortization(2)	303		289		899		866
Variable lease costs(3)	5,376		4,121		15,362		13,256
	$	56,159	$	43,350	$	163,387	$	126,098

(2) Depreciation and amortization is related to the amortization of favorable and direct lease costs.

(3) Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.

Schedule of Future Minimum Lease Payments

Future minimum lease payments for all leases as of September 30, 2023 are as follows:


Year	Amount
2023 (remainder)	$	47,730
2024	191,035
2025	190,946
2026	190,729
2027	190,147
2028	188,906
Thereafter	1,719,921
TOTAL LEASE PAYMENTS	2,719,414
Less: present value adjustment	(980,503)
PRESENT VALUE OF TOTAL LEASE LIABILITIES	1,738,911
Less: current lease liabilities	(80,956)
LONG-TERM OPERATING LEASE LIABILITIES	$	1,657,955

Schedule of Rental Income from Third-Party Sources

Total rental income from all third-party sources for the three and nine months ended September 30, 2023 and 2022 is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Pennant(1)	$	3,740	$	3,664	$	11,224	$	11,169
Other third-party	1,727		458		4,410		1,381
TOTAL	$	5,467	$	4,122	$	15,634	$	12,550

Schedule of Annual Rental Income

Future annual rental income for all leases as of September 30, 2023 were as follows:


Year	Amount(1)
2023 (remainder)	$	5,493
2024	21,526
2025	21,023
2026	20,788
2027	20,762
2028	20,737
Thereafter	128,013
TOTAL	$	238,342

(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of September 30, 2023.

XML 53 R42.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS (Details) senior_living_unit in Thousands	Sep. 30, 2023 facility property senior_living_unit bed operation
Real Estate Properties [Line Items]
Health care facilities	295
Operational skilled nursing beds \| bed	30,500
Operational senior living units \| senior_living_unit	3
Number of real estate properties leased	213
Number of real estate properties leased with an option to purchase	11
Number of real estate properties \| property	112
Third Party Operators
Real Estate Properties [Line Items]
Number of operations lease and operated by third parties \| operation	30
Number of senior living operations sharing property with skilled nursing facilities	1
Owned Properties
Real Estate Properties [Line Items]
Number of facilities	82

XML 54 R43.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)	Sep. 30, 2023
Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	59 years

XML 55 R44.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details)	9 Months Ended
	Sep. 30, 2023 option lease
Real Estate Properties [Line Items]
Number of financing lease \| lease	1
Lessee, operating lease, term of contract	10 years
Lessee, operating lease, number of renewal options \| option	1
Minimum
Real Estate Properties [Line Items]
Lessee, operating lease, renewal term	10 years
Maximum
Real Estate Properties [Line Items]
Lessee, operating lease, renewal term	15 years

XML 56 R45.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details)	Sep. 30, 2023
Trade name
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	30 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	20 years
Minimum \| Assembled occupancy
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	4 months
Maximum \| Assembled occupancy
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	8 months

XML 57 R46.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Liability for Claims and Claims Adjustment Expense [Line Items]
Long-term insurance losses recoverable asset	$ 13,439	$ 10,512
General and Professional Liability
Liability for Claims and Claims Adjustment Expense [Line Items]
Malpractice loss contingency, accrual, undiscounted	90,811	79,781
Workers' Compensation
Liability for Claims and Claims Adjustment Expense [Line Items]
Self insurance reserve	28,733	27,301
Health
Liability for Claims and Claims Adjustment Expense [Line Items]
Self insurance reserve	14,716	$ 14,088
Workers' Compensation
Liability for Claims and Claims Adjustment Expense [Line Items]
Self insurance reserve	625
Workers' Compensation \| Texas
Liability for Claims and Claims Adjustment Expense [Line Items]
Self insurance reserve	750
Self-Insurance Retention Per Claim \| General Liability
Liability for Claims and Claims Adjustment Expense [Line Items]
Self insurance reserve	500
Self-Insurance Retention Per Claim \| Parent Company \| General Liability
Liability for Claims and Claims Adjustment Expense [Line Items]
Self insurance reserve	500
Aggregate Deductible \| Parent Company \| General Liability \| California
Liability for Claims and Claims Adjustment Expense [Line Items]
Self insurance reserve	1,250
Aggregate Deductible \| Parent Company \| General Liability \| Non-california
Liability for Claims and Claims Adjustment Expense [Line Items]
Self insurance reserve	1,250
Per Occurence \| Third-Party Payor \| General Liability \| All States Except Colorado
Liability for Claims and Claims Adjustment Expense [Line Items]
Self insurance reserve	1,000
Per Occurence \| Third-Party Payor \| General Liability \| Colorado
Liability for Claims and Claims Adjustment Expense [Line Items]
Self insurance reserve	1,000
Per Facility \| Third-Party Payor \| General Liability \| All States Except Colorado
Liability for Claims and Claims Adjustment Expense [Line Items]
Self insurance reserve	3,000
Per Facility \| Third-Party Payor \| General Liability \| Colorado
Liability for Claims and Claims Adjustment Expense [Line Items]
Self insurance reserve	3,000
Blanket Aggregate \| Third-Party Payor \| General Liability \| All States Except Colorado
Liability for Claims and Claims Adjustment Expense [Line Items]
Self insurance reserve	5,000
Loss-Sensitive Limit Per Claim \| Workers' Compensation \| Other States, Except California, Texas and Washington
Liability for Claims and Claims Adjustment Expense [Line Items]
Self insurance reserve	350
Stop-Loss Insurance Limit Per Claim \| Health Liability Insurance
Liability for Claims and Claims Adjustment Expense [Line Items]
Self insurance reserve	$ 525

XML 58 R47.htm IDEA: XBRL DOCUMENT

REVENUE AND ACCOUNTS RECEIVABLE - Revenue from Medicare and Medicaid Programs and State Relief Funding (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 940,791	$ 770,005	$ 2,748,977	$ 2,215,936
Unapplied state relief funds	636		636		$ 1,001
FMAP payments received	9,900	20,293	54,744	64,955
Revenue, FMAP payments received	10,298	21,400	55,109	63,488
Rental revenue
Disaggregation of Revenue [Line Items]
Revenue	$ 5,467	$ 4,122	$ 15,634	$ 12,550
Customer Concentration Risk \| Revenue \| Total Medicare and Medicaid
Disaggregation of Revenue [Line Items]
% of Revenue	72.10%	73.70%	72.80%	73.50%

XML 59 R48.htm IDEA: XBRL DOCUMENT

REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 940,791	$ 770,005	$ 2,748,977	$ 2,215,936
Total Medicaid and Medicare \| Customer Concentration Risk \| Revenue
Disaggregation of Revenue [Line Items]
% of Revenue	72.10%	73.70%	72.80%	73.50%
Service revenue
Disaggregation of Revenue [Line Items]
Revenue	$ 935,324	$ 765,883	$ 2,733,343	$ 2,203,386
Service revenue \| Customer Concentration Risk \| Revenue
Disaggregation of Revenue [Line Items]
% of Revenue	100.00%	100.00%	100.00%	100.00%
Service revenue \| Total Medicaid and Medicare
Disaggregation of Revenue [Line Items]
Revenue	$ 674,821	$ 564,362	$ 1,990,612	$ 1,619,455
Service revenue \| Total Medicaid and Medicare \| Customer Concentration Risk \| Revenue
Disaggregation of Revenue [Line Items]
% of Revenue	72.10%	73.70%	72.80%	73.50%
Service revenue \| Medicaid
Disaggregation of Revenue [Line Items]
Revenue	$ 374,838	$ 302,615	$ 1,074,883	$ 863,091
Service revenue \| Medicaid \| Customer Concentration Risk \| Revenue
Disaggregation of Revenue [Line Items]
% of Revenue	40.10%	39.50%	39.30%	39.20%
Service revenue \| Medicare
Disaggregation of Revenue [Line Items]
Revenue	$ 237,531	$ 211,104	$ 733,335	$ 610,009
Service revenue \| Medicare \| Customer Concentration Risk \| Revenue
Disaggregation of Revenue [Line Items]
% of Revenue	25.40%	27.60%	26.80%	27.70%
Service revenue \| Medicaid — skilled
Disaggregation of Revenue [Line Items]
Revenue	$ 62,452	$ 50,643	$ 182,394	$ 146,355
Service revenue \| Medicaid — skilled \| Customer Concentration Risk \| Revenue
Disaggregation of Revenue [Line Items]
% of Revenue	6.60%	6.60%	6.70%	6.60%
Service revenue \| Managed care
Disaggregation of Revenue [Line Items]
Revenue	$ 170,747	$ 132,663	$ 488,511	$ 389,036
Service revenue \| Managed care \| Customer Concentration Risk \| Revenue
Disaggregation of Revenue [Line Items]
% of Revenue	18.30%	17.30%	17.90%	17.70%
Service revenue \| Private and other
Disaggregation of Revenue [Line Items]
Revenue	$ 89,756	$ 68,858	$ 254,220	$ 194,895
Service revenue \| Private and other \| Customer Concentration Risk \| Revenue
Disaggregation of Revenue [Line Items]
% of Revenue	9.60%	9.00%	9.30%	8.80%

XML 60 R49.htm IDEA: XBRL DOCUMENT

REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 481,545	$ 416,234
Less: allowance for doubtful accounts	(9,422)	(7,802)
ACCOUNTS RECEIVABLE, NET	472,123	408,432
Medicaid
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	188,572	157,878
Managed care
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	118,756	95,940
Medicare
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	75,717	76,526
Private and other payors
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 98,500	$ 85,890

XML 61 R50.htm IDEA: XBRL DOCUMENT

COMPUTATION OF NET INCOME PER COMMON SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
NUMERATOR:
Net income	$ 63,968			$ 56,242			$ 188,027	$ 164,133
Less: net income (loss) attributable to noncontrolling interests	105			63			319	(77)
Net income attributable to The Ensign Group, Inc.	$ 63,863	$ 63,993	$ 59,852	$ 56,179	$ 57,691	$ 50,340	$ 187,708	$ 164,210
DENOMINATOR:
Weighted average shares outstanding for basic net income per share (in shares)	55,829			54,882			55,582	54,819
Plus: incremental shares from assumed conversion (in shares)	1,508			1,879			1,663	2,010
Adjusted weighted average common shares outstanding (in shares)	57,337			56,761			57,245	56,829
Basic net income per common share (in dollars per share)	$ 1.14			$ 1.02			$ 3.38	$ 3.00
Diluted net income per common share (in dollars per share)	$ 1.11			$ 0.99			$ 3.28	$ 2.89
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	1,475			918			1,389	734

XML 62 R51.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS (Details) - Fair Value, Inputs, Level 2 - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Deferred rent receivable	$ 36,867	$ 25,144
Captive Insurance Subsidiary
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Insurance subsidiary's deposits and investments	$ 57,290	$ 53,924

XML 63 R52.htm IDEA: XBRL DOCUMENT

STANDARD BEARER (Details) $ in Thousands		1 Months Ended	3 Months Ended			9 Months Ended
STANDARD BEARER (Details) $ in Thousands	Apr. 08, 2022	Jan. 31, 2022 lease renewal	Sep. 30, 2023 USD ($) operation property shares	Sep. 30, 2022 USD ($) shares	Jun. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) property operation shares	Sep. 30, 2022 USD ($) skilled_nursing_property property shares
Segment Reporting Information [Line Items]
Number of real estate properties \| property			112			112
Number of master lease arrangements \| lease		5
Lessee, operating lease, term of contract			10 years			10 years
Granted (in shares) \| shares			193,000	145,000		606,000	463,000
Restricted Stock Awards
Segment Reporting Information [Line Items]
Award vesting period						5 years
Granted restricted shares (in shares) \| shares			49,000	41,000		215,000	199,000
Standard Bearer Equity Plan
Segment Reporting Information [Line Items]
Award vesting period		5 years
Threshold event period after vesting of restricted awards or exercise of stock options		6 months
Proceeds from issuance of common stock					$ 6,544
Granted (in shares) \| shares						0	0
Proceeds from issuance of preferred shares					$ 149
Standard Bearer Equity Plan \| Restricted Stock Awards
Segment Reporting Information [Line Items]
Granted restricted shares (in shares) \| shares						0	0
Standard Bearer Master Leases
Segment Reporting Information [Line Items]
Rental revenue			$ 16,976	$ 15,024
Standard Bearer
Segment Reporting Information [Line Items]
Rental revenue						$ 49,035	$ 42,343
Minimum
Segment Reporting Information [Line Items]
Lessee, operating lease, renewal term			10 years			10 years
Minimum \| Revolving credit facility with Truist \| Truist \| Base Rate
Segment Reporting Information [Line Items]
Interest rate margin	0.25%
Minimum \| Revolving credit facility with Truist \| Truist \| Secured Overnight Financing Rate (SOFR)
Segment Reporting Information [Line Items]
Interest rate margin	1.25%
Maximum
Segment Reporting Information [Line Items]
Lessee, operating lease, renewal term			15 years			15 years
Maximum \| Revolving credit facility with Truist \| Truist \| Base Rate
Segment Reporting Information [Line Items]
Interest rate margin	1.25%
Maximum \| Revolving credit facility with Truist \| Truist \| Secured Overnight Financing Rate (SOFR)
Segment Reporting Information [Line Items]
Interest rate margin	2.25%
Standard Bearer Master Leases
Segment Reporting Information [Line Items]
Lessee leasing arrangements, operating leases, number of renewal terms \| renewal		3
Lessee, operating lease, renewal term		5 years
Operating leases of lessee, contingent rentals, basis spread on variable rate		2.50%
Standard Bearer Master Leases \| Total Management Fee
Segment Reporting Information [Line Items]
Management fees, as a percentage of total revenues			6.00%
Standard Bearer Master Leases \| Base Management Fee
Segment Reporting Information [Line Items]
Management fees, as a percentage of total revenues		5.00%
Management fees			$ 1,259	$ 1,124		$ 3,636	3,202
Standard Bearer Master Leases \| Incentive Management Fee
Segment Reporting Information [Line Items]
Management fees, as a percentage of total revenues		1.00%
Management fees, as a percentage of funds from operations		5.00%
Standard Bearer Master Leases \| Minimum
Segment Reporting Information [Line Items]
Lessee, operating lease, term of contract		15 years
Operating leases of lessee, contingent rentals, basis spread on variable rate		0.00%
Standard Bearer Master Leases \| Maximum
Segment Reporting Information [Line Items]
Lessee, operating lease, term of contract		19 years
Standard Bearer Healthcare REIT, Inc.
Segment Reporting Information [Line Items]
Number of real estate properties \| property			107			107
Standard Bearer Healthcare REIT, Inc. \| Series of Individually Immaterial Asset Acquisitions
Segment Reporting Information [Line Items]
Asset acquisition, purchase price						$ 52,802	$ 65,619
Standard Bearer Healthcare REIT, Inc. \| Skilled Nursing Operations
Segment Reporting Information [Line Items]
Number of real estate skilled nursing properties acquired \| skilled_nursing_property							3
Standard Bearer Healthcare REIT, Inc. \| Owned Properties
Segment Reporting Information [Line Items]
Number of real estate skilled nursing properties acquired \| property						3	8
Standard Bearer Healthcare REIT, Inc. \| Campus Operation
Segment Reporting Information [Line Items]
Number of real estate skilled nursing properties acquired \| operation						1
Standard Bearer Healthcare REIT, Inc. \| Third Parties
Segment Reporting Information [Line Items]
Number of real estate properties \| operation			30			30
Standard Bearer Healthcare REIT, Inc. \| Owned Properties
Segment Reporting Information [Line Items]
Number of real estate properties \| operation			78			78

XML 64 R53.htm IDEA: XBRL DOCUMENT

OPERATION EXPANSIONS (Details) $ in Thousands	1 Months Ended		9 Months Ended
OPERATION EXPANSIONS (Details) $ in Thousands	Oct. 25, 2023 bed operation	Jan. 31, 2022 lease	Sep. 30, 2023 operation bed senior_living_unit	Sep. 30, 2022 USD ($) bed operation senior_living_unit
Business Acquisition [Line Items]
Operational skilled nursing beds \| bed			30,500
Number of master lease arrangements \| lease		5
Operational senior living units \| senior_living_unit			3,000
Skilled Nursing Operations \| Subsequent Event
Business Acquisition [Line Items]
Operational skilled nursing beds \| bed	45
Skilled Nursing Operations \| Standard Bearer Healthcare REIT, Inc.
Business Acquisition [Line Items]
Number of asset acquisitions			3
Skilled Nursing Operations
Business Acquisition [Line Items]
Number of businesses acquired			24	11
Operational skilled nursing beds \| bed			2,340	1,553
Number of master lease arrangements				5
Skilled Nursing Operations \| Subsequent Event
Business Acquisition [Line Items]
Number of businesses acquired	1
Campus Operation
Business Acquisition [Line Items]
Number of businesses acquired				1
Senior Living Facilities
Business Acquisition [Line Items]
Number of businesses acquired				5
Number of operations transferred from third parties				3
Operational senior living units \| senior_living_unit				674
Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Goodwill \| $				$ 16,400

XML 65 R54.htm IDEA: XBRL DOCUMENT

BUSINESS SEGMENTS - Narrative (Details)	9 Months Ended
BUSINESS SEGMENTS - Narrative (Details)	Sep. 30, 2023 facility property segment operation
Segment Reporting Information [Line Items]
Number of reportable segments \| segment	2
Transitional and skilled service facilities \| operation	258
Transitional and skilled services and senior living campuses \| operation	26
Number of real estate properties \| property	112
Senior living facilities \| facility	11
Standard Bearer Healthcare REIT, Inc.
Segment Reporting Information [Line Items]
Number of real estate properties \| property	107

XML 66 R55.htm IDEA: XBRL DOCUMENT

BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
TOTAL REVENUE	$ 940,791	$ 770,005	$ 2,748,977	$ 2,215,936
Segment income (loss)	82,045	71,655	241,580	208,371
Gain (loss) on real estate insurance recoveries/sale of assets, net		800	(100)	3,267
Income before provision for income taxes	82,045	72,455	241,480	211,638
Depreciation and amortization	18,446	15,941	53,154	45,475
Interest expense	2,024	2,108	6,083	6,864
Service revenue
Segment Reporting Information [Line Items]
TOTAL REVENUE	935,324	765,883	2,733,343	2,203,386
Rental revenue
Segment Reporting Information [Line Items]
TOTAL REVENUE	5,467	4,122	15,634	12,550
Operating Segments \| Skilled Services
Segment Reporting Information [Line Items]
TOTAL REVENUE	902,967	739,318	2,638,090	2,128,567
Segment income (loss)	117,816	101,750	348,169	302,272
Depreciation and amortization	9,936	8,397	28,417	24,411
Interest expense	0	0	0	0
Operating Segments \| Skilled Services \| Service revenue
Segment Reporting Information [Line Items]
TOTAL REVENUE	902,967	739,318	2,638,090	2,128,567
Operating Segments \| Skilled Services \| Rental revenue
Segment Reporting Information [Line Items]
TOTAL REVENUE	0	0	0	0
Operating Segments \| Standard Bearer
Segment Reporting Information [Line Items]
TOTAL REVENUE	20,980	18,732	60,611	53,523
Segment income (loss)	7,165	6,941	21,517	20,679
Depreciation and amortization	6,429	5,561	18,528	15,798
Interest expense	5,139	4,080	14,283	11,385
Operating Segments \| Standard Bearer \| Service revenue
Segment Reporting Information [Line Items]
TOTAL REVENUE	0	0	0	0
Operating Segments \| Standard Bearer \| Rental revenue
Segment Reporting Information [Line Items]
TOTAL REVENUE	20,980	18,732	60,611	53,523
Operating Segments \| All Other
Segment Reporting Information [Line Items]
TOTAL REVENUE	39,124	31,844	114,574	89,793
Segment income (loss)	(42,936)	(37,036)	(128,106)	(114,580)
Depreciation and amortization	2,081	1,983	6,209	5,266
Interest expense	312	310	927	1,557
Operating Segments \| All Other \| Service revenue
Segment Reporting Information [Line Items]
TOTAL REVENUE	36,254	30,002	106,322	84,256
Operating Segments \| All Other \| Rental revenue
Segment Reporting Information [Line Items]
TOTAL REVENUE	2,870	1,842	8,252	5,537
Sublease Income	1,063		2,834
Intercompany Elimination
Segment Reporting Information [Line Items]
TOTAL REVENUE	(22,280)	(19,889)	(64,298)	(55,947)
Segment income (loss)	0	0	0	0
Depreciation and amortization	0	0	0	0
Interest expense	(3,427)	(2,282)	(9,127)	(6,078)
Intercompany Elimination \| Service revenue
Segment Reporting Information [Line Items]
TOTAL REVENUE	(3,897)	(3,437)	(11,069)	(9,437)
Intercompany Elimination \| Rental revenue
Segment Reporting Information [Line Items]
TOTAL REVENUE	$ (18,383)	$ (16,452)	$ (53,229)	$ (46,510)

XML 67 R56.htm IDEA: XBRL DOCUMENT

BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	$ 940,791	$ 770,005	$ 2,748,977	$ 2,215,936
Operating Segments \| Skilled Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	$ 902,967	$ 739,318	$ 2,638,090	$ 2,128,567
Total Medicaid and Medicare \| Revenue \| Customer Concentration Risk
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue %	72.10%	73.70%	72.80%	73.50%
Service revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	$ 935,324	$ 765,883	$ 2,733,343	$ 2,203,386
Service revenue \| Revenue \| Customer Concentration Risk
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue %	100.00%	100.00%	100.00%	100.00%
Service revenue \| Operating Segments \| Skilled Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	$ 902,967	$ 739,318	$ 2,638,090	$ 2,128,567
Service revenue \| All Other
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	32,357	26,565	95,253	74,819
Service revenue \| Total Medicaid and Medicare
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	$ 674,821	$ 564,362	$ 1,990,612	$ 1,619,455
Service revenue \| Total Medicaid and Medicare \| Revenue \| Customer Concentration Risk
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue %	72.10%	73.70%	72.80%	73.50%
Service revenue \| Total Medicaid and Medicare \| Operating Segments \| Skilled Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	$ 667,062	$ 557,674	$ 1,968,633	$ 1,601,705
Service revenue \| Total Medicaid and Medicare \| All Other
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	7,759	6,688	21,979	17,750
Service revenue \| Medicaid
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	$ 374,838	$ 302,615	$ 1,074,883	$ 863,091
Service revenue \| Medicaid \| Revenue \| Customer Concentration Risk
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue %	40.10%	39.50%	39.30%	39.20%
Service revenue \| Medicaid \| Operating Segments \| Skilled Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	$ 367,079	$ 295,927	$ 1,052,904	$ 845,341
Service revenue \| Medicaid \| All Other
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	7,759	6,688	21,979	17,750
Service revenue \| Medicare
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	$ 237,531	$ 211,104	$ 733,335	$ 610,009
Service revenue \| Medicare \| Revenue \| Customer Concentration Risk
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue %	25.40%	27.60%	26.80%	27.70%
Service revenue \| Medicare \| Operating Segments \| Skilled Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	$ 237,531	$ 211,104	$ 733,335	$ 610,009
Service revenue \| Medicare \| All Other
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	0	0	0	0
Service revenue \| Medicaid-skilled
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	$ 62,452	$ 50,643	$ 182,394	$ 146,355
Service revenue \| Medicaid-skilled \| Revenue \| Customer Concentration Risk
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue %	6.60%	6.60%	6.70%	6.60%
Service revenue \| Medicaid-skilled \| Operating Segments \| Skilled Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	$ 62,452	$ 50,643	$ 182,394	$ 146,355
Service revenue \| Medicaid-skilled \| All Other
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	0	0	0	0
Service revenue \| Managed care
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	$ 170,747	$ 132,663	$ 488,511	$ 389,036
Service revenue \| Managed care \| Revenue \| Customer Concentration Risk
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue %	18.30%	17.30%	17.90%	17.70%
Service revenue \| Managed care \| Operating Segments \| Skilled Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	$ 170,747	$ 132,663	$ 488,511	$ 389,036
Service revenue \| Managed care \| All Other
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	0	0	0	0
Service revenue \| Private and other
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	$ 89,756	$ 68,858	$ 254,220	$ 194,895
Service revenue \| Private and other \| Revenue \| Customer Concentration Risk
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue %	9.60%	9.00%	9.30%	8.80%
Service revenue \| Private and other \| Operating Segments \| Skilled Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	$ 65,158	$ 48,981	$ 180,946	$ 137,826
Service revenue \| Private and other \| All Other
Segment Reporting, Revenue Reconciling Item [Line Items]
Total Service Revenue	$ 24,598	$ 19,877	$ 73,274	$ 57,069

XML 68 R57.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT— NET - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment	$ 1,459,416	$ 1,331,802
Less: accumulated depreciation	(391,514)	(339,792)
PROPERTY AND EQUIPMENT, NET	1,067,902	992,010
Land
Property, Plant and Equipment [Line Items]
Property and equipment	140,239	134,864
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property and equipment	790,333	728,231
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment	166,984	150,903
Equipment
Property, Plant and Equipment [Line Items]
Property and equipment	334,999	295,739
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment	4,868	4,544
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment	$ 21,993	$ 17,521

XML 69 R58.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT— NET - Narrative (Details) - Senior Living Operations - Disposal Group, Disposed of by Sale, Not Discontinued Operations $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Property, Plant and Equipment [Line Items]
Proceeds from sale of real estate	$ 8,607
Gain on sales property, plant and equipment	$ 3,467

XML 70 R59.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS — NET - Schedule of Finite Lived Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 6,017	$ 5,750
Accumulated Amortization	(3,642)	(3,285)
Net	$ 2,375	2,465
Assembled occupancy
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (Years)	3 months 18 days
Gross Carrying Amount	$ 702	435
Accumulated Amortization	(570)	(388)
Net	$ 132	47
Facility trade name
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (Years)	30 years
Gross Carrying Amount	$ 733	733
Accumulated Amortization	(433)	(415)
Net	$ 300	318
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (Years)	18 years 4 months 24 days
Gross Carrying Amount	$ 4,582	4,582
Accumulated Amortization	(2,639)	(2,482)
Net	$ 1,943	$ 2,100

XML 71 R60.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS — NET - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 495	$ 432	$ 1,256	$ 1,254
Depreciation and Amortization
Finite-Lived Intangible Assets [Line Items]
Operating lease expense	$ 303	$ 289	$ 899	$ 866

XML 72 R61.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS — NET - Future Amortization (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2023 (remainder)	$ 192
2024	234
2025	234
2026	234
2027	234
2028	234
Thereafter	1,013
Net	$ 2,375	$ 2,465

XML 73 R62.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS — NET - Schedule of Indefinite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Indefinite-lived Intangible Assets [Line Items]
Other indefinite-lived intangibles	$ 3,972	$ 3,972
Trade name
Indefinite-lived Intangible Assets [Line Items]
Other indefinite-lived intangibles	889	889
Medicare and Medicaid licenses
Indefinite-lived Intangible Assets [Line Items]
Other indefinite-lived intangibles	$ 3,083	$ 3,083

XML 74 R63.htm IDEA: XBRL DOCUMENT

GOODWILL (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Goodwill [Line Items]
Goodwill	$ 76,869	$ 76,869
Operating Segments \| Skilled Services
Goodwill [Line Items]
Goodwill	67,886	67,886
All Other
Goodwill [Line Items]
Goodwill	$ 8,983	$ 8,983

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2

+ Details

XML 75 R64.htm IDEA: XBRL DOCUMENT

RESTRICTED AND OTHER ASSETS (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Debt issuance costs, net	$ 3,104	$ 3,753
Long-term insurance losses recoverable asset	13,439	10,512
Capital improvement reserves with landlords and lenders	5,051	6,446
Deposits with landlords	2,657	2,527
Escrow deposits	325	0
Other	11,403	14,053
RESTRICTED AND OTHER ASSETS	$ 35,979	$ 37,291

XML 76 R65.htm IDEA: XBRL DOCUMENT

OTHER ACCRUED LIABILITIES (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Quality assurance fee	$ 8,786	$ 7,701
Refunds payable	46,274	40,783
Resident advances	5,920	9,698
Unapplied state relief funds	636	1,001
Cash held in trust for patients	6,357	6,400
Dividends payable	3,243	3,201
Property taxes	15,371	10,926
Income tax payable	40,781	0
Legal finding accrued	3,734	4,553
Other	17,026	13,046
OTHER ACCRUED LIABILITIES	$ 148,128	$ 97,309

XML 77 R66.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 18,077	$ 16,213	$ 53,453	$ 47,505
Effective income tax rate			22.10%	22.40%

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 78 R67.htm IDEA: XBRL DOCUMENT

DEBT - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Less: current maturities	$ (3,916)	$ (3,883)
Less: debt issuance costs, net	(2,985)	(3,119)
LONG-TERM DEBT LESS CURRENT MATURITIES	146,453	149,269
Mortgage loans and promissory note
Debt Instrument [Line Items]
Mortgage loans and promissory note	$ 153,354	$ 156,271

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482900/835-30-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

XML 79 R68.htm IDEA: XBRL DOCUMENT

DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details)		9 Months Ended
	Apr. 08, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Debt Instrument [Line Items]
Write-off of deferred financing fees		$ 0	$ 566,000
Payments of deferred financing costs		19,000	$ 3,197,000
Revolving credit facility with Truist \| Truist
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity		600,000,000
Total net debt ratio, maximum	3.00
Long-term debt threshold for EBITDA ratio increase election period	6 months
Long-term debt, threshold for EBITDA ratio increase election	$ 50,000,000
Total net debt ratio, maximum after increase election	3.50
Total net debt ratio, minimum	1.50
Outstanding debt		$ 0
Revolving credit facility with Truist \| Truist \| Minimum
Debt Instrument [Line Items]
Line of credit facility, unused capacity, commitment fee percentage	0.20%
Revolving credit facility with Truist \| Truist \| Maximum
Debt Instrument [Line Items]
Line of credit facility, unused capacity, commitment fee percentage	0.40%
Revolving credit facility with Truist \| Truist \| Base Rate \| Minimum
Debt Instrument [Line Items]
Interest rate margin	0.25%
Revolving credit facility with Truist \| Truist \| Base Rate \| Maximum
Debt Instrument [Line Items]
Interest rate margin	1.25%
Revolving credit facility with Truist \| Truist \| Secured Overnight Financing Rate (SOFR) \| Minimum
Debt Instrument [Line Items]
Interest rate margin	1.25%
Revolving credit facility with Truist \| Truist \| Secured Overnight Financing Rate (SOFR) \| Maximum
Debt Instrument [Line Items]
Interest rate margin	2.25%

XML 80 R69.htm IDEA: XBRL DOCUMENT

DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($) subsidiary	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Letters of credit outstanding, pledged amount	$ 6,710
Mortgage loans and promissory note
Debt Instrument [Line Items]
Outstanding debt	$ 153,354	$ 156,271
Mortgage loans and promissory note \| HUD Insured Mortgages \| First Three Years
Debt Instrument [Line Items]
Prepayment penalty	10.00%
Mortgage loans and promissory note \| HUD Insured Mortgages \| In The Fourth Year
Debt Instrument [Line Items]
Reduction in prepayment penalty	3.00%
Mortgage loans and promissory note \| HUD Insured Mortgages \| Years Five Through Ten
Debt Instrument [Line Items]
Reduction in prepayment penalty	1.00%
Mortgage loans and promissory note \| HUD Insured Mortgages \| After Year Ten
Debt Instrument [Line Items]
Prepayment penalty	0.00%
Mortgage loans and promissory note \| HUD Insured Mortgages \| Minimum
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage	3.10%
Debt instrument, interest rate, stated percentage	2.40%
Debt instrument, term	25 years
Mortgage loans and promissory note \| HUD Insured Mortgages \| Maximum
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage	4.20%
Debt instrument, interest rate, stated percentage	3.30%
Debt instrument, term	35 years
Mortgage loans and promissory note \| HUD Insured Mortgages \| Twenty Three Subsidiaries
Debt Instrument [Line Items]
Number of operating subsidiaries \| subsidiary	23
Outstanding debt	$ 151,063
Mortgage loans and promissory note \| 5.3% Promissory Note
Debt Instrument [Line Items]
Outstanding debt	$ 2,291
Debt instrument, interest rate, stated percentage	5.30%
Debt instrument, term	12 years

XML 81 R70.htm IDEA: XBRL DOCUMENT

OPTIONS AND AWARDS - Stock Options, Narrative (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023 plan shares	Sep. 30, 2022 shares	Sep. 30, 2023 USD ($) plan installment $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option plans \| plan	1		1
Options Granted (in shares)	193	145	606	463
Grant date intrinsic value (in dollars per share) \| $ / shares			$ 0	$ 0
Intrinsic value of options exercised in period \| $			$ 43,299	$ 36,151
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value of options that vested in period \| $			$ 16,856	$ 15,810
2022 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)	3,452		3,452
Conversion to reduce shares availability			1
Other than options, conversion to reduce shares availability			2
Award vesting period			5 years
Award vesting rights, percentage			20.00%
Expiration period			10 years
Number of shares available for grant (in shares)	1,856		1,856
2022 Plan \| Non-employee Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of installments \| installment			3
Award requisite service period			3 years

XML 82 R71.htm IDEA: XBRL DOCUMENT

OPTIONS AND AWARDS - Valuation Assumptions (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Options Granted (in shares)	193	145	606	463
Weighted Average Risk-Free Rate	4.40%	3.10%	4.00%	2.50%
Expected Life	6 years 1 month 6 days	6 years 3 months 18 days	6 years 2 months 12 days	6 years 2 months 12 days
Weighted Average Volatility	41.30%	41.80%	41.40%	42.10%
Weighted Average Dividend Yield	0.20%	0.20%	0.30%	0.30%

XML 83 R72.htm IDEA: XBRL DOCUMENT

OPTIONS AND AWARDS - Exercise Price and Fair Value (Details) - $ / shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Granted (in shares)	193	145	606	463
Weighted Average Exercise Price (in dollars per share)			$ 92.54	$ 83.41
Weighted Average Fair Value of Options (in dollars per share)			$ 42.50	$ 36.22

XML 84 R73.htm IDEA: XBRL DOCUMENT

OPTIONS AND AWARDS - Options Outstanding Rollforward (Details) - $ / shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Number of Options Outstanding
Balance at beginning of period, (in shares)			3,833
Granted (in shares)	193	145	606	463
Forfeited (in shares)			(77)
Exercised (in shares)			(578)
Balance at end of period, (in shares)	3,784		3,784
Weighted Average Exercise Price
Balance at beginning of period (in dollars per share)			$ 46.72
Granted (in dollars per share)			92.54	$ 83.41
Forfeited (in dollars per share)			69.64
Exercised (in dollars per share)			21.99
Balance at end of period (in dollars per share)	$ 57.37		$ 57.37
Number of Options Vested (in shares)	1,960		1,960		2,069
Weighted Average Exercise Price of Options Vested (in dollars per share)	$ 37.69		$ 37.69		$ 28.87

XML 85 R74.htm IDEA: XBRL DOCUMENT

OPTIONS AND AWARDS - Intrinsic Values (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Outstanding	$ 135,648	$ 183,593
Vested	108,275	136,000
Expected to vest	$ 25,910	$ 43,232

XML 86 R75.htm IDEA: XBRL DOCUMENT

OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details) - $ / shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, restricted awards, exercise price (in dollars per share)			$ 0
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	49	41	215	199
Award vesting period			5 years
Granted (in dollars per share)			$ 91.96
Restricted Stock Awards \| Non-employee Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	4		13
Restricted Stock Awards \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in dollars per share)			$ 89.83	$ 73.17
Restricted Stock Awards \| Minimum \| Non-employee Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in dollars per share)			89.94
Restricted Stock Awards \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in dollars per share)			98.31	$ 90.50
Restricted Stock Awards \| Maximum \| Non-employee Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in dollars per share)			$ 98.31

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

XML 87 R76.htm IDEA: XBRL DOCUMENT

OPTIONS AND AWARDS - Restricted Award Rollforward (Details) - Restricted Stock Awards - $ / shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Non-Vested Restricted Awards
Nonvested at beginning of period (in shares)			487
Granted (in shares)	49	41	215	199
Vested (in shares)			(225)
Forfeited (in shares)			(19)
Nonvested at end of period (in shares)	458		458
Weighted Average Grant Date Fair Value
Nonvested at beginning of period (in dollars per share)			$ 64.92
Granted (in dollars per share)			91.96
Vested (in dollars per share)			64.29
Forfeited (in dollars per share)			70.64
Nonvested at end of period (in dollars per share)	$ 77.81		$ 77.81

XML 88 R77.htm IDEA: XBRL DOCUMENT

OPTIONS AND AWARDS - Long-Term Incentive Plan (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Aug. 27, 2019	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		$ 7,230	$ 5,898	$ 22,684	$ 16,681
Spinoff \| 2019 LTI Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)	500,000
Award vesting period	5 years
Award vesting rights, percentage	20.00%
Share-based compensation		$ 218	$ 248	$ 620	$ 638

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

XML 89 R78.htm IDEA: XBRL DOCUMENT

OPTIONS AND AWARDS - Compensation Expense (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense related to stock options	$ 7,230	$ 5,898	$ 22,684	$ 16,681
Share-based compensation, options outstanding, weighted average remaining contractual term			6 years 6 months
Stock-based compensation expense related to stock options
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense related to stock options	4,051	2,983	$ 12,439	8,289
Share-based compensation, nonvested awards, cost not yet recognized	$ 54,532		$ 54,532
Share-based compensation, nonvested awards, cost not yet recognized, period for recognition			3 years 9 months 18 days
Share-based compensation, nonvested awards (in shares)	1,824		1,824
Share-based compensation, options expected to vest, number (in shares)	1,667		1,667
Stock-based compensation expense related to restricted stock awards
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense related to stock options	$ 2,774	2,579	$ 8,983	7,337
Share-based compensation, nonvested awards, cost not yet recognized	32,210		$ 32,210
Share-based compensation, nonvested awards, cost not yet recognized, period for recognition			3 years 7 months 6 days
Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense related to stock options	$ 405	$ 336	$ 1,262	$ 1,055

XML 90 R79.htm IDEA: XBRL DOCUMENT

LEASES - Lessee Narrative (Details) $ in Thousands	1 Months Ended	3 Months Ended			9 Months Ended
LEASES - Lessee Narrative (Details) $ in Thousands	Oct. 25, 2023 bed operation	Sep. 30, 2023 USD ($) agreement bed facility operation renewal	Mar. 31, 2023 USD ($) operation agreement	Sep. 30, 2022 USD ($) bed	Sep. 30, 2023 USD ($) operation lease bed agreement facility renewal	Sep. 30, 2022 USD ($) bed operation
Lessee, Lease, Description [Line Items]
Lessee, operating lease, term of contract		10 years			10 years
Right-of-use assets obtained in exchange for new and modified operating lease obligations \| $					$ 373,832	$ 254,742
Operating lease, weighted average remaining lease term		15 years 1 month 6 days			15 years 1 month 6 days
Operating lease, weighted average discount rate, percent		6.50%			6.50%
Operational skilled nursing beds \| bed		30,500			30,500
Skilled Nursing Operations
Lessee, Lease, Description [Line Items]
Number of businesses acquired					24	11
Operational skilled nursing beds \| bed		2,340		1,553	2,340	1,553
Skilled Nursing Operations \| Subsequent Event
Lessee, Lease, Description [Line Items]
Number of businesses acquired	1
Cost of Sales and General and Administrative Expense
Lessee, Lease, Description [Line Items]
Rent expense \| $		$ 50,480		$ 38,940	$ 147,126	$ 111,976
Minimum
Lessee, Lease, Description [Line Items]
Lessee, operating lease, renewal term		10 years			10 years
Maximum
Lessee, Lease, Description [Line Items]
Lessee, operating lease, renewal term		15 years			15 years
Amended Master Lease Agreement
Lessee, Lease, Description [Line Items]
Amended of separate master leases \| agreement		1	2		1
Amended Master Lease Agreement \| Skilled Nursing Operations \| Subsequent Event
Lessee, Lease, Description [Line Items]
Number of businesses acquired	1
Operational skilled nursing beds \| bed	45
New Master Lease Agreeement
Lessee, Lease, Description [Line Items]
Right-of-use assets obtained in exchange for new and modified operating lease obligations \| $		$ 21,420	$ 325,369
Term of operating lease		20 years			20 years
New Master Lease Agreeement \| Skilled Nursing Operations
Lessee, Lease, Description [Line Items]
Number of businesses acquired		2	20
New Master Lease Agreeement \| Maximum
Lessee, Lease, Description [Line Items]
Term of operating lease			20 years
Amended Master Lease \| Skilled Nursing Operations
Lessee, Lease, Description [Line Items]
Number of businesses acquired			17
CareTrust REIT
Lessee, Lease, Description [Line Items]
Skilled nursing, assisted living and independent living facilities \| facility		97			97
Consumer price index		0.00%			0.00%
Operating leases of lessee, contingent rentals, basis spread on variable rate		2.50%			2.50%
Number of stand-alone leases \| lease					1
Rent expense \| $		$ 16,741		$ 16,259	$ 49,698	$ 47,911
CareTrust REIT \| Triple Net Lease Arrangements
Lessee, Lease, Description [Line Items]
Skilled nursing, assisted living and independent living facilities \| facility		96			96
Master lease agreements \| agreement		9			9
Lessee, operating lease, renewal term		5 years			5 years
CareTrust REIT \| Triple Net Lease Arrangements \| Minimum
Lessee, Lease, Description [Line Items]
Lessee, operating lease, term of contract		13 years			13 years
Lessee leasing arrangements, operating leases, number of renewal terms \| renewal		2			2
CareTrust REIT \| Triple Net Lease Arrangements \| Maximum
Lessee, Lease, Description [Line Items]
Lessee, operating lease, term of contract		20 years			20 years
Lessee leasing arrangements, operating leases, number of renewal terms \| renewal		3			3
CareTrust REIT \| Purchase Option
Lessee, Lease, Description [Line Items]
Skilled nursing, assisted living and independent living facilities \| facility		4			4
Various Landlords
Lessee, Lease, Description [Line Items]
Master lease agreements \| agreement		13			13
Facilities under master lease arrangement \| facility		80			80
Various Landlords \| Minimum
Lessee, Lease, Description [Line Items]
Lessee, operating lease, term of contract		5 years			5 years
Various Landlords \| Minimum \| Equipment
Lessee, Lease, Description [Line Items]
Lessee, operating lease, term of contract		3 years			3 years
Various Landlords \| Maximum
Lessee, Lease, Description [Line Items]
Lessee, operating lease, term of contract		20 years			20 years
Various Landlords \| Maximum \| Equipment
Lessee, Lease, Description [Line Items]
Lessee, operating lease, term of contract		5 years			5 years

XML 91 R80.htm IDEA: XBRL DOCUMENT

LEASES - Lessee Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Lessee, Lease, Description [Line Items]
Lease, cost	$ 56,159	$ 43,350	$ 163,387	$ 126,098
Amortization of deferred rent	211	111	692	351
Cost of Services
Lessee, Lease, Description [Line Items]
Operating lease expense	50,357	38,907	146,754	111,897
Variable lease, costs	5,376	4,121	15,362	13,256
CPI increases and short term-lease cost	2,859	1,758	7,317	3,997
General and administrative expense
Lessee, Lease, Description [Line Items]
Operating lease expense	123	33	372	79
Depreciation and Amortization
Lessee, Lease, Description [Line Items]
Operating lease expense	$ 303	$ 289	$ 899	$ 866

XML 92 R81.htm IDEA: XBRL DOCUMENT

LEASES - Lessee Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Year
2023 (remainder)	$ 47,730
2024	191,035
2025	190,946
2026	190,729
2027	190,147
2028	188,906
Thereafter	1,719,921
TOTAL LEASE PAYMENTS	2,719,414
Less: present value adjustment	(980,503)
PRESENT VALUE OF TOTAL LEASE LIABILITIES	1,738,911
Less: current lease liabilities	(80,956)	$ (65,796)
LONG-TERM OPERATING LEASE LIABILITIES	$ 1,657,955	$ 1,355,113

XML 93 R82.htm IDEA: XBRL DOCUMENT

LEASES - Lessor Narrative (Details) - lease	3 Months Ended		9 Months Ended		12 Months Ended
LEASES - Lessor Narrative (Details) - lease	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2021
Leases To Third Party Operators \| The Pennant Group, Inc.
Lessor, Lease, Description [Line Items]
Number of leases			29	29	32
Sublease Of Stand Along Skilled Nursing Operations
Lessor, Lease, Description [Line Items]
Number of leases		3
Term of operating lease		18 years
Lease Of Campus Operation
Lessor, Lease, Description [Line Items]
Number of leases	1
Term of operating lease	15 years		15 years
Minimum \| Leases To Third Party Operators
Lessor, Lease, Description [Line Items]
Term of operating lease	14 years		14 years
Maximum \| Leases To Third Party Operators
Lessor, Lease, Description [Line Items]
Term of operating lease	16 years		16 years

XML 94 R83.htm IDEA: XBRL DOCUMENT

LEASES - Lessor Rental Income (Details) - Leases To Third Party Operators $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) lease	Sep. 30, 2022 USD ($) lease	Dec. 31, 2021 lease
Lessor, Lease, Description [Line Items]
Rental revenue	$ 5,467	$ 4,122	$ 15,634	$ 12,550
Pennant
Lessor, Lease, Description [Line Items]
Rental revenue	3,740	3,664	11,224	11,169
Operating lease, variable lease income	324	331	$ 974	$ 988
Number of leases \| lease			29	29	32
Other third-party
Lessor, Lease, Description [Line Items]
Rental revenue	$ 1,727	$ 458	$ 4,410	$ 1,381

XML 95 R84.htm IDEA: XBRL DOCUMENT

LEASES - Lessor Future Minimum Lease Payments Receivable (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Leases [Abstract]
2023 (remainder)	$ 5,493
2024	21,526
2025	21,023
2026	20,788
2027	20,762
2028	20,737
Thereafter	128,013
TOTAL	$ 238,342

XML 96 R85.htm IDEA: XBRL DOCUMENT

DEFINED CONTRIBUTION PLANS (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Defined Contribution Plan Disclosure [Line Items]
Deferred compensation liability, noncurrent	$ 42,613		$ 42,613		$ 33,017
Gain (loss) on deferral investment	(1,424)	$ (1,135)	1,065	$ (5,650)
Offsetting expense (income)	$ (1,352)	$ (1,055)	$ 1,261	$ (5,566)
Qualified Plan
Defined Contribution Plan Disclosure [Line Items]
Maximum annual contributions per employee			90.00%
Nonqualified Plan
Defined Contribution Plan Disclosure [Line Items]
Maximum annual contributions per employee			100.00%

XML 97 R86.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details)	3 Months Ended		9 Months Ended		12 Months Ended
COMMITMENTS AND CONTINGENCIES (Details)	Sep. 30, 2023 USD ($) subsidiary	Sep. 30, 2022	Sep. 30, 2023 USD ($) subsidiary	Sep. 30, 2022	Dec. 31, 2022	Oct. 25, 2023 subsidiary
Concentration Risk [Line Items]
Facilities under medicare probe reviews	41		41
Cash, uninsured amount \| $	$ 0		$ 0
Customer Concentration Risk \| Total Medicaid and Medicare \| Accounts Receivable
Concentration Risk [Line Items]
Concentration percentage			54.90%		56.30%
Customer Concentration Risk \| Total Medicaid and Medicare \| Revenue
Concentration Risk [Line Items]
Concentration percentage	72.10%	73.70%	72.80%	73.50%
Subsequent Event
Concentration Risk [Line Items]
Facilities under medicare probe reviews						41

XML 98 R87.htm IDEA: XBRL DOCUMENT

COMMON STOCK REPURCHASE PROGRAM (Details) - USD ($) shares in Thousands					3 Months Ended
	Aug. 29, 2023	Jul. 28, 2022	Feb. 09, 2022	Oct. 21, 2021	Jun. 30, 2022	Mar. 31, 2022
Equity, Class of Treasury Stock [Line Items]
Repurchase of common stock, value					$ 20,000,000	$ 9,882,000
August 2023 Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount	$ 20,000,000
Stock repurchase program, period in force	12 months
July 2022 Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount		$ 20,000,000
Stock repurchase program, period in force		12 months
February 9, 2022 Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount			$ 20,000,000
Stock repurchase program, period in force			12 months
Repurchase of common stock (in shares)					271
Repurchase of common stock, value					$ 20,000,000
October 21, 2021 Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount				$ 20,000,000
Stock repurchase program, period in force				12 months
Repurchase of common stock (in shares)						133
Repurchase of common stock, value						$ 9,882,000

XML 99 ensg-20230930_htm.xml IDEA: XBRL DOCUMENT 0001125376 2023-01-01 2023-09-30 0001125376 2023-10-20 0001125376 2023-09-30 0001125376 2022-12-31 0001125376 us-gaap:ServiceMember 2023-07-01 2023-09-30 0001125376 us-gaap:ServiceMember 2022-07-01 2022-09-30 0001125376 us-gaap:ServiceMember 2023-01-01 2023-09-30 0001125376 us-gaap:ServiceMember 2022-01-01 2022-09-30 0001125376 ensg:RentalMember 2023-07-01 2023-09-30 0001125376 ensg:RentalMember 2022-07-01 2022-09-30 0001125376 ensg:RentalMember 2023-01-01 2023-09-30 0001125376 ensg:RentalMember 2022-01-01 2022-09-30 0001125376 2023-07-01 2023-09-30 0001125376 2022-07-01 2022-09-30 0001125376 2022-01-01 2022-09-30 0001125376 us-gaap:CommonStockMember 2022-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001125376 us-gaap:RetainedEarningsMember 2022-12-31 0001125376 us-gaap:TreasuryStockCommonMember 2022-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2022-12-31 0001125376 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001125376 2023-01-01 2023-03-31 0001125376 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001125376 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001125376 us-gaap:CommonStockMember 2023-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001125376 us-gaap:RetainedEarningsMember 2023-03-31 0001125376 us-gaap:TreasuryStockCommonMember 2023-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2023-03-31 0001125376 2023-03-31 0001125376 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001125376 2023-04-01 2023-06-30 0001125376 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0001125376 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001125376 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001125376 us-gaap:CommonStockMember 2023-06-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001125376 us-gaap:RetainedEarningsMember 2023-06-30 0001125376 us-gaap:TreasuryStockCommonMember 2023-06-30 0001125376 us-gaap:NoncontrollingInterestMember 2023-06-30 0001125376 2023-06-30 0001125376 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001125376 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001125376 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001125376 us-gaap:CommonStockMember 2023-09-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001125376 us-gaap:RetainedEarningsMember 2023-09-30 0001125376 us-gaap:TreasuryStockCommonMember 2023-09-30 0001125376 us-gaap:NoncontrollingInterestMember 2023-09-30 0001125376 us-gaap:CommonStockMember 2021-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001125376 us-gaap:RetainedEarningsMember 2021-12-31 0001125376 us-gaap:TreasuryStockCommonMember 2021-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2021-12-31 0001125376 2021-12-31 0001125376 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001125376 2022-01-01 2022-03-31 0001125376 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0001125376 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001125376 us-gaap:CommonStockMember 2022-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001125376 us-gaap:RetainedEarningsMember 2022-03-31 0001125376 us-gaap:TreasuryStockCommonMember 2022-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2022-03-31 0001125376 2022-03-31 0001125376 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001125376 2022-04-01 2022-06-30 0001125376 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0001125376 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001125376 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001125376 us-gaap:CommonStockMember 2022-06-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001125376 us-gaap:RetainedEarningsMember 2022-06-30 0001125376 us-gaap:TreasuryStockCommonMember 2022-06-30 0001125376 us-gaap:NoncontrollingInterestMember 2022-06-30 0001125376 2022-06-30 0001125376 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001125376 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001125376 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001125376 us-gaap:CommonStockMember 2022-09-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001125376 us-gaap:RetainedEarningsMember 2022-09-30 0001125376 us-gaap:TreasuryStockCommonMember 2022-09-30 0001125376 us-gaap:NoncontrollingInterestMember 2022-09-30 0001125376 2022-09-30 0001125376 us-gaap:WhollyOwnedPropertiesMember 2023-09-30 0001125376 ensg:ThirdPartyOperatorsMember 2023-09-30 0001125376 srt:MinimumMember 2023-09-30 0001125376 srt:MaximumMember 2023-09-30 0001125376 srt:MinimumMember ensg:AssembledOccupancyAcquiredMember 2023-09-30 0001125376 srt:MaximumMember ensg:AssembledOccupancyAcquiredMember 2023-09-30 0001125376 us-gaap:TradeNamesMember 2023-09-30 0001125376 us-gaap:CustomerRelationshipsMember 2023-09-30 0001125376 us-gaap:GeneralLiabilityMember ensg:SelfInsuranceRetentionPerClaimMember srt:ParentCompanyMember 2023-09-30 0001125376 us-gaap:GeneralLiabilityMember stpr:CA ensg:AggregateDeductibleMember srt:ParentCompanyMember 2023-09-30 0001125376 us-gaap:GeneralLiabilityMember ensg:NonCaliforniaMember ensg:AggregateDeductibleMember srt:ParentCompanyMember 2023-09-30 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember ensg:PerOccurenceMember naics:ZZ524292 2023-09-30 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember ensg:PerFacilityMember naics:ZZ524292 2023-09-30 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember ensg:BlanketAggregateMember naics:ZZ524292 2023-09-30 0001125376 us-gaap:GeneralLiabilityMember stpr:CO ensg:PerOccurenceMember naics:ZZ524292 2023-09-30 0001125376 us-gaap:GeneralLiabilityMember stpr:CO ensg:PerFacilityMember naics:ZZ524292 2023-09-30 0001125376 us-gaap:ProfessionalMalpracticeLiabilityMember 2023-09-30 0001125376 us-gaap:ProfessionalMalpracticeLiabilityMember 2022-12-31 0001125376 us-gaap:WorkersCompensationInsuranceMember 2023-09-30 0001125376 us-gaap:WorkersCompensationInsuranceMember stpr:TX 2023-09-30 0001125376 us-gaap:WorkersCompensationInsuranceMember ensg:OtherStatesExceptCaliforniaTexasAndWashingtonMember ensg:LossSensitiveLimitPerClaimMember 2023-09-30 0001125376 us-gaap:GeneralLiabilityMember ensg:SelfInsuranceRetentionPerClaimMember 2023-09-30 0001125376 us-gaap:WorkersCompensationInsuranceMember 2023-09-30 0001125376 us-gaap:WorkersCompensationInsuranceMember 2022-12-31 0001125376 ensg:HealthLiabilityInsuranceMember ensg:StopLossInsuranceLimitPerClaimMember 2023-09-30 0001125376 us-gaap:HealthInsuranceProductLineMember 2023-09-30 0001125376 us-gaap:HealthInsuranceProductLineMember 2022-12-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001125376 ensg:MedicaidMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0001125376 ensg:MedicaidMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001125376 ensg:MedicaidMember us-gaap:ServiceMember 2022-07-01 2022-09-30 0001125376 ensg:MedicaidMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001125376 ensg:MedicareMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0001125376 ensg:MedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001125376 ensg:MedicareMember us-gaap:ServiceMember 2022-07-01 2022-09-30 0001125376 ensg:MedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember 2022-07-01 2022-09-30 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2022-07-01 2022-09-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember 2022-07-01 2022-09-30 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2022-07-01 2022-09-30 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001125376 us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001125376 us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001125376 ensg:MedicaidMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0001125376 ensg:MedicaidMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001125376 ensg:MedicaidMember us-gaap:ServiceMember 2022-01-01 2022-09-30 0001125376 ensg:MedicaidMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001125376 ensg:MedicareMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0001125376 ensg:MedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001125376 ensg:MedicareMember us-gaap:ServiceMember 2022-01-01 2022-09-30 0001125376 ensg:MedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember 2022-01-01 2022-09-30 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2022-01-01 2022-09-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember 2022-01-01 2022-09-30 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2022-01-01 2022-09-30 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001125376 us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001125376 us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001125376 ensg:MedicaidMember 2023-09-30 0001125376 ensg:MedicaidMember 2022-12-31 0001125376 ensg:ManagedCareMember 2023-09-30 0001125376 ensg:ManagedCareMember 2022-12-31 0001125376 ensg:MedicareMember 2023-09-30 0001125376 ensg:MedicareMember 2022-12-31 0001125376 ensg:PrivatePayAndOtherMember 2023-09-30 0001125376 ensg:PrivatePayAndOtherMember 2022-12-31 0001125376 srt:SubsidiariesMember us-gaap:FairValueInputsLevel2Member 2023-09-30 0001125376 srt:SubsidiariesMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001125376 us-gaap:FairValueInputsLevel2Member 2023-09-30 0001125376 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001125376 ensg:StandardBearerHealthcareREITIncMember 2023-09-30 0001125376 us-gaap:WhollyOwnedPropertiesMember ensg:StandardBearerHealthcareREITIncMember 2023-09-30 0001125376 ensg:ThirdPartiesMember ensg:StandardBearerHealthcareREITIncMember 2023-09-30 0001125376 ensg:OwnedPropertiesMember ensg:StandardBearerHealthcareREITIncMember 2023-01-01 2023-09-30 0001125376 ensg:CampusOperationMember ensg:StandardBearerHealthcareREITIncMember 2023-01-01 2023-09-30 0001125376 us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember ensg:StandardBearerHealthcareREITIncMember 2023-01-01 2023-09-30 0001125376 ensg:OwnedPropertiesMember ensg:StandardBearerHealthcareREITIncMember 2022-01-01 2022-09-30 0001125376 us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember ensg:StandardBearerHealthcareREITIncMember 2022-01-01 2022-09-30 0001125376 ensg:SkilledNursingOperationsMember ensg:StandardBearerHealthcareREITIncMember 2022-01-01 2022-09-30 0001125376 2022-01-01 2022-01-31 0001125376 srt:MinimumMember ensg:StandardBearerMasterLeasesMember 2022-01-31 0001125376 srt:MaximumMember ensg:StandardBearerMasterLeasesMember 2022-01-31 0001125376 ensg:StandardBearerMasterLeasesMember 2022-01-31 0001125376 ensg:StandardBearerMasterLeasesMember 2023-07-01 2023-09-30 0001125376 ensg:StandardBearerSegmentMember 2023-01-01 2023-09-30 0001125376 ensg:StandardBearerMasterLeasesMember 2022-07-01 2022-09-30 0001125376 ensg:StandardBearerSegmentMember 2022-01-01 2022-09-30 0001125376 us-gaap:ManagementServiceBaseMember ensg:StandardBearerMasterLeasesMember 2022-01-01 2022-01-31 0001125376 us-gaap:ManagementServiceIncentiveMember ensg:StandardBearerMasterLeasesMember 2022-01-01 2022-01-31 0001125376 ensg:ManagementServiceTotalMember ensg:StandardBearerMasterLeasesMember 2023-07-01 2023-09-30 0001125376 us-gaap:ManagementServiceBaseMember ensg:StandardBearerMasterLeasesMember 2023-07-01 2023-09-30 0001125376 us-gaap:ManagementServiceBaseMember ensg:StandardBearerMasterLeasesMember 2023-01-01 2023-09-30 0001125376 us-gaap:ManagementServiceBaseMember ensg:StandardBearerMasterLeasesMember 2022-07-01 2022-09-30 0001125376 us-gaap:ManagementServiceBaseMember ensg:StandardBearerMasterLeasesMember 2022-01-01 2022-09-30 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:BaseRateMember 2022-04-08 2022-04-08 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:BaseRateMember 2022-04-08 2022-04-08 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember ensg:SecuredOvernightFinancingRateSOFRMember 2022-04-08 2022-04-08 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember ensg:SecuredOvernightFinancingRateSOFRMember 2022-04-08 2022-04-08 0001125376 ensg:StandardBearerEquityPlanMember 2022-01-01 2022-01-31 0001125376 ensg:StandardBearerEquityPlanMember 2022-04-01 2022-06-30 0001125376 us-gaap:RestrictedStockMember ensg:StandardBearerEquityPlanMember 2022-01-01 2022-09-30 0001125376 ensg:StandardBearerEquityPlanMember 2023-01-01 2023-09-30 0001125376 ensg:StandardBearerEquityPlanMember 2022-01-01 2022-09-30 0001125376 us-gaap:RestrictedStockMember ensg:StandardBearerEquityPlanMember 2023-01-01 2023-09-30 0001125376 ensg:SkilledNursingOperationsMember 2023-01-01 2023-09-30 0001125376 ensg:SkilledNursingOperationsMember ensg:StandardBearerHealthcareREITIncMember 2023-01-01 2023-09-30 0001125376 ensg:SkilledNursingOperationsMember 2023-09-30 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember 2023-10-01 2023-10-25 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember 2023-10-25 0001125376 ensg:SkilledNursingOperationsMember 2022-01-01 2022-09-30 0001125376 ensg:CampusOperationMember 2022-01-01 2022-09-30 0001125376 ensg:SeniorLivingFacilitiesMember 2022-01-01 2022-09-30 0001125376 ensg:SkilledNursingOperationsMember 2022-09-30 0001125376 ensg:SeniorLivingFacilitiesMember 2022-09-30 0001125376 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2022-01-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-07-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:StandardBearerSegmentMember 2023-07-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember us-gaap:AllOtherSegmentsMember 2023-07-01 2023-09-30 0001125376 srt:ConsolidationEliminationsMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:SkilledServicesSegmentMember 2023-07-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:StandardBearerSegmentMember 2023-07-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember us-gaap:AllOtherSegmentsMember 2023-07-01 2023-09-30 0001125376 srt:ConsolidationEliminationsMember ensg:RentalMember 2023-07-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2023-07-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:StandardBearerSegmentMember 2023-07-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2023-07-01 2023-09-30 0001125376 srt:ConsolidationEliminationsMember 2023-07-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-07-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:StandardBearerSegmentMember 2022-07-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember us-gaap:AllOtherSegmentsMember 2022-07-01 2022-09-30 0001125376 srt:ConsolidationEliminationsMember us-gaap:ServiceMember 2022-07-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:SkilledServicesSegmentMember 2022-07-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:StandardBearerSegmentMember 2022-07-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember us-gaap:AllOtherSegmentsMember 2022-07-01 2022-09-30 0001125376 srt:ConsolidationEliminationsMember ensg:RentalMember 2022-07-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2022-07-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:StandardBearerSegmentMember 2022-07-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2022-07-01 2022-09-30 0001125376 srt:ConsolidationEliminationsMember 2022-07-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:StandardBearerSegmentMember 2023-01-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember us-gaap:AllOtherSegmentsMember 2023-01-01 2023-09-30 0001125376 srt:ConsolidationEliminationsMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:StandardBearerSegmentMember 2023-01-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember us-gaap:AllOtherSegmentsMember 2023-01-01 2023-09-30 0001125376 srt:ConsolidationEliminationsMember ensg:RentalMember 2023-01-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:StandardBearerSegmentMember 2023-01-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2023-01-01 2023-09-30 0001125376 srt:ConsolidationEliminationsMember 2023-01-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:StandardBearerSegmentMember 2022-01-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember us-gaap:AllOtherSegmentsMember 2022-01-01 2022-09-30 0001125376 srt:ConsolidationEliminationsMember us-gaap:ServiceMember 2022-01-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:StandardBearerSegmentMember 2022-01-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember us-gaap:AllOtherSegmentsMember 2022-01-01 2022-09-30 0001125376 srt:ConsolidationEliminationsMember ensg:RentalMember 2022-01-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:StandardBearerSegmentMember 2022-01-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2022-01-01 2022-09-30 0001125376 srt:ConsolidationEliminationsMember 2022-01-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-07-01 2023-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-07-01 2023-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicareMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidSkilledMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-07-01 2023-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidSkilledMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-07-01 2023-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:ManagedCareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-07-01 2023-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:ManagedCareMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-07-01 2023-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0001125376 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-07-01 2022-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidMember us-gaap:ServiceMember 2022-07-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-07-01 2022-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicareMember us-gaap:ServiceMember 2022-07-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidSkilledMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-07-01 2022-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidSkilledMember us-gaap:ServiceMember 2022-07-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-07-01 2022-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2022-07-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:ManagedCareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-07-01 2022-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:ManagedCareMember us-gaap:ServiceMember 2022-07-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-07-01 2022-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2022-07-01 2022-09-30 0001125376 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember 2022-07-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicareMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidSkilledMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidSkilledMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:ManagedCareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:ManagedCareMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0001125376 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidMember us-gaap:ServiceMember 2022-01-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicareMember us-gaap:ServiceMember 2022-01-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidSkilledMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidSkilledMember us-gaap:ServiceMember 2022-01-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2022-01-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:ManagedCareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:ManagedCareMember us-gaap:ServiceMember 2022-01-01 2022-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-09-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2022-01-01 2022-09-30 0001125376 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember 2022-01-01 2022-09-30 0001125376 us-gaap:LandMember 2023-09-30 0001125376 us-gaap:LandMember 2022-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2023-09-30 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2022-12-31 0001125376 us-gaap:LeaseholdImprovementsMember 2023-09-30 0001125376 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001125376 us-gaap:EquipmentMember 2023-09-30 0001125376 us-gaap:EquipmentMember 2022-12-31 0001125376 us-gaap:FurnitureAndFixturesMember 2023-09-30 0001125376 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001125376 us-gaap:ConstructionInProgressMember 2023-09-30 0001125376 us-gaap:ConstructionInProgressMember 2022-12-31 0001125376 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ensg:SeniorLivingOperationsMember 2022-01-01 2022-09-30 0001125376 ensg:AssembledOccupancyAcquiredMember 2023-01-01 2023-09-30 0001125376 ensg:AssembledOccupancyAcquiredMember 2023-09-30 0001125376 ensg:AssembledOccupancyAcquiredMember 2022-12-31 0001125376 us-gaap:TradeNamesMember 2023-01-01 2023-09-30 0001125376 us-gaap:TradeNamesMember 2022-12-31 0001125376 us-gaap:CustomerRelationshipsMember 2023-01-01 2023-09-30 0001125376 us-gaap:CustomerRelationshipsMember 2022-12-31 0001125376 ensg:DepreciationAndAmortizationMember 2023-07-01 2023-09-30 0001125376 ensg:DepreciationAndAmortizationMember 2023-01-01 2023-09-30 0001125376 ensg:DepreciationAndAmortizationMember 2022-07-01 2022-09-30 0001125376 ensg:DepreciationAndAmortizationMember 2022-01-01 2022-09-30 0001125376 us-gaap:TradeNamesMember 2023-09-30 0001125376 us-gaap:TradeNamesMember 2022-12-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2023-09-30 0001125376 ensg:MedicareandMedicaidLicensesMember 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2023-09-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2023-09-30 0001125376 us-gaap:CollateralizedDebtObligationsMember 2023-09-30 0001125376 us-gaap:CollateralizedDebtObligationsMember 2022-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2023-09-30 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2022-04-08 2022-04-08 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2022-04-08 2022-04-08 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2022-04-08 0001125376 ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember ensg:TwentyThreeSubsidiariesMember 2023-09-30 0001125376 srt:MinimumMember ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember 2023-09-30 0001125376 srt:MaximumMember ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember 2023-09-30 0001125376 ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember ensg:FirstThreeYearsMember 2023-09-30 0001125376 ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember ensg:InTheFourthYearMember 2023-09-30 0001125376 ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember ensg:YearsFiveThroughTenMember 2023-09-30 0001125376 ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember ensg:AfterYearTenMember 2023-09-30 0001125376 srt:MinimumMember ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember 2023-01-01 2023-09-30 0001125376 srt:MaximumMember ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember 2023-01-01 2023-09-30 0001125376 ensg:A53PromissoryNoteMember us-gaap:CollateralizedDebtObligationsMember 2023-09-30 0001125376 ensg:A53PromissoryNoteMember us-gaap:CollateralizedDebtObligationsMember 2023-01-01 2023-09-30 0001125376 ensg:A2022PlanMember 2023-09-30 0001125376 ensg:A2022PlanMember 2023-01-01 2023-09-30 0001125376 us-gaap:ShareBasedPaymentArrangementNonemployeeMember ensg:A2022PlanMember 2023-01-01 2023-09-30 0001125376 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001125376 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001125376 us-gaap:RestrictedStockMember 2023-07-01 2023-09-30 0001125376 us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0001125376 us-gaap:RestrictedStockMember 2022-07-01 2022-09-30 0001125376 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0001125376 srt:MinimumMember us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0001125376 srt:MaximumMember us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0001125376 srt:MinimumMember us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0001125376 srt:MaximumMember us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0001125376 us-gaap:RestrictedStockMember 2022-12-31 0001125376 us-gaap:RestrictedStockMember 2023-09-30 0001125376 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-07-01 2023-09-30 0001125376 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-01-01 2023-09-30 0001125376 srt:MinimumMember us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-01-01 2023-09-30 0001125376 srt:MaximumMember us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-01-01 2023-09-30 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2019-08-27 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2019-08-27 2019-08-27 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2023-07-01 2023-09-30 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2023-01-01 2023-09-30 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2022-07-01 2022-09-30 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2022-01-01 2022-09-30 0001125376 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001125376 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001125376 ensg:StockAwardsMember 2023-07-01 2023-09-30 0001125376 ensg:StockAwardsMember 2022-07-01 2022-09-30 0001125376 ensg:StockAwardsMember 2023-01-01 2023-09-30 0001125376 ensg:StockAwardsMember 2022-01-01 2022-09-30 0001125376 us-gaap:EmployeeStockOptionMember 2023-09-30 0001125376 ensg:CareTrustREITMember 2023-09-30 0001125376 ensg:CareTrustREITMember ensg:TripleNetLeaseArrangementsMember 2023-09-30 0001125376 ensg:CareTrustREITMember srt:MinimumMember ensg:TripleNetLeaseArrangementsMember 2023-09-30 0001125376 ensg:CareTrustREITMember srt:MaximumMember ensg:TripleNetLeaseArrangementsMember 2023-09-30 0001125376 ensg:CareTrustREITMember ensg:PurchaseOptionMember 2023-09-30 0001125376 ensg:CareTrustREITMember 2023-01-01 2023-09-30 0001125376 ensg:CareTrustREITMember 2023-07-01 2023-09-30 0001125376 ensg:CareTrustREITMember 2022-07-01 2022-09-30 0001125376 ensg:CareTrustREITMember 2022-01-01 2022-09-30 0001125376 ensg:VariousLandlordsMember srt:MinimumMember 2023-09-30 0001125376 ensg:VariousLandlordsMember srt:MaximumMember 2023-09-30 0001125376 ensg:VariousLandlordsMember srt:MinimumMember us-gaap:EquipmentMember 2023-09-30 0001125376 ensg:VariousLandlordsMember srt:MaximumMember us-gaap:EquipmentMember 2023-09-30 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2023-07-01 2023-09-30 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2023-01-01 2023-09-30 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2022-07-01 2022-09-30 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2022-01-01 2022-09-30 0001125376 ensg:VariousLandlordsMember 2023-09-30 0001125376 ensg:AmendedMasterLeaseAgreementMember 2023-03-31 0001125376 ensg:SkilledNursingOperationsMember ensg:NewMasterLeaseAgreeementMember 2023-01-01 2023-03-31 0001125376 ensg:SkilledNursingOperationsMember ensg:AmendedMasterLeaseMember 2023-01-01 2023-03-31 0001125376 ensg:SubleaseOfStandAlongSkilledNursingOperationsMember 2023-01-01 2023-03-31 0001125376 ensg:NewMasterLeaseAgreeementMember 2023-01-01 2023-03-31 0001125376 ensg:SubleaseOfStandAlongSkilledNursingOperationsMember 2023-03-31 0001125376 srt:MaximumMember ensg:NewMasterLeaseAgreeementMember 2023-03-31 0001125376 ensg:AmendedMasterLeaseAgreementMember 2023-09-30 0001125376 ensg:SkilledNursingOperationsMember ensg:NewMasterLeaseAgreeementMember 2023-07-01 2023-09-30 0001125376 ensg:NewMasterLeaseAgreeementMember 2023-07-01 2023-09-30 0001125376 ensg:NewMasterLeaseAgreeementMember 2023-09-30 0001125376 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0001125376 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0001125376 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001125376 us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember ensg:AmendedMasterLeaseAgreementMember 2023-10-01 2023-10-25 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember ensg:AmendedMasterLeaseAgreementMember 2023-10-25 0001125376 ensg:ThePennantGroupInc.Member ensg:LeasesToThirdPartyOperatorsMember 2023-01-01 2023-09-30 0001125376 srt:MinimumMember ensg:LeasesToThirdPartyOperatorsMember 2023-09-30 0001125376 srt:MaximumMember ensg:LeasesToThirdPartyOperatorsMember 2023-09-30 0001125376 ensg:LeaseOfCampusOperationMember 2023-07-01 2023-09-30 0001125376 ensg:LeaseOfCampusOperationMember 2023-09-30 0001125376 ensg:ThePennantGroupInc.Member ensg:LeasesToThirdPartyOperatorsMember 2023-07-01 2023-09-30 0001125376 ensg:ThePennantGroupInc.Member ensg:LeasesToThirdPartyOperatorsMember 2022-07-01 2022-09-30 0001125376 ensg:ThePennantGroupInc.Member ensg:LeasesToThirdPartyOperatorsMember 2022-01-01 2022-09-30 0001125376 ensg:ThirdPartyTenantsMember ensg:LeasesToThirdPartyOperatorsMember 2023-07-01 2023-09-30 0001125376 ensg:ThirdPartyTenantsMember ensg:LeasesToThirdPartyOperatorsMember 2022-07-01 2022-09-30 0001125376 ensg:ThirdPartyTenantsMember ensg:LeasesToThirdPartyOperatorsMember 2023-01-01 2023-09-30 0001125376 ensg:ThirdPartyTenantsMember ensg:LeasesToThirdPartyOperatorsMember 2022-01-01 2022-09-30 0001125376 ensg:LeasesToThirdPartyOperatorsMember 2023-07-01 2023-09-30 0001125376 ensg:LeasesToThirdPartyOperatorsMember 2022-07-01 2022-09-30 0001125376 ensg:LeasesToThirdPartyOperatorsMember 2023-01-01 2023-09-30 0001125376 ensg:LeasesToThirdPartyOperatorsMember 2022-01-01 2022-09-30 0001125376 ensg:ThePennantGroupInc.Member ensg:LeasesToThirdPartyOperatorsMember 2021-01-01 2021-12-31 0001125376 us-gaap:QualifiedPlanMember 2023-01-01 2023-09-30 0001125376 us-gaap:NonqualifiedPlanMember 2023-01-01 2023-09-30 0001125376 us-gaap:SubsequentEventMember 2023-10-25 0001125376 ensg:MedicaidAndMedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001125376 ensg:August2023RepurchaseProgramMember 2023-08-29 0001125376 ensg:August2023RepurchaseProgramMember 2023-08-29 2023-08-29 0001125376 ensg:July2022RepurchaseProgramMember 2022-07-28 0001125376 ensg:July2022RepurchaseProgramMember 2022-07-28 2022-07-28 0001125376 ensg:February92022RepurchaseProgramMember 2022-02-09 0001125376 ensg:February92022RepurchaseProgramMember 2022-02-09 2022-02-09 0001125376 ensg:February92022RepurchaseProgramMember 2022-04-01 2022-06-30 0001125376 ensg:October212021RepurchaseProgramMember 2021-10-21 0001125376 ensg:October212021RepurchaseProgramMember 2021-10-21 2021-10-21 0001125376 ensg:October212021RepurchaseProgramMember 2022-01-01 2022-03-31 0001125376 ensg:SpencerWBurtonMember 2023-07-01 2023-09-30 0001125376 ensg:SpencerWBurtonMember 2023-01-01 2023-09-30 0001125376 ensg:SpencerWBurtonMember 2023-09-30 shares iso4217:USD iso4217:USD shares ensg:facility ensg:bed ensg:senior_living_unit ensg:property ensg:operation ensg:lease ensg:option pure ensg:skilled_nursing_property ensg:renewal ensg:segment ensg:subsidiary ensg:plan ensg:installment ensg:agreement 0001125376 2023 Q3 false --12-31

P3Y0M0D

P10Y

P4M0D

P5Y0M

P3Y0M

P260D 10-Q true 2023-09-30 false 001-33757 ENSIGN GROUP, INC DE 33-0861263 29222 Rancho Viejo Road, Suite 127 San Juan Capistrano CA 92675 949 487-9500 Common Stock, par value $0.001 per share ENSG NASDAQ Yes Yes Large Accelerated Filer false false false 56452238

467870000

316270000

9422000

7802000

472123000

408432000

16433000

15441000

37921000

40982000

994347000

781125000

1067902000

992010000

1773751000

1450995000

86818000 67652000

39968000

39643000

35979000 37291000

6347000

6437000

76869000

4081981000

3452022000

77091000

77087000

311509000

289810000

80956000

65796000

50197000

48187000

148128000

97309000

3916000

3883000

671797000

582072000

146453000 149269000

1657955000

1355113000

97502000

83495000

42832000 33273000

2616539000

2203222000

0.001

150000000

59803000

56413000

100000000

59029000

55661000

60000

59000

451883000

415560000

1124358000

946339000

3390000

3368000

116555000

114626000

1459746000

1247332000

5696000

1468000

1465442000

1248800000

4081981000

3452022000

935324000

765883000

2733343000

2203386000

5467000

4122000

15634000

12550000

940791000

770005000

2748977000

2215936000

741069000

601623000

2160080000

1720905000

50357000 38907000 146754000 111897000

51127000

39247000

156448000

116030000

18446000

15941000

53154000

45475000

860999000

695718000

2516436000

1994307000

79792000

74287000

232541000

221629000

2024000

2108000

6083000

6864000

4277000

276000

15022000

-3127000

2253000

-1832000

8939000

-9991000

82045000

72455000

241480000

211638000

18077000

16213000

53453000

47505000

63968000

56242000

188027000

164133000

105000

63000

319000

-77000

63863000

56179000

187708000

164210000

1.14

1.02

3.38

3.00

1.11

0.99

3.28

2.89

55829000

54882000

55582000

54819000

57337000

56761000

57245000

56829000

55661000

59000

415560000

946339000

3368000

-114626000

1468000

1248800000

145000

1000

2653000

2654000

102000

5068000

1000

20000

0.0575

3215000

6573000

77000

117000

6000

-4000

2000

59852000

55907000

60000

429783000

1002976000

3369000

-114646000

1581000

1319754000

253000

5905000

54000

21000

1909000

0.0575

3231000

8881000

100000

97000

-3937000

3940000

3000

63993000

56193000

60000

440532000

1063738000

3390000

-116555000

5618000

1393393000

180000

4148000

40000

0.0575

3243000

7230000

57000

105000

30000

-27000

3000

63863000

56413000

60000

451883000

1124358000

3390000

-116555000

5696000

1465442000

55190000

58000

369760000

733992000

2944000

-83042000

946000

1021714000

147000

2768000

104000

5241000

15000

0.0550

3042000

5167000

133000

9882000

-245000

271000

26000

-252000

50340000

55308000

58000

383181000

781290000

3077000

-92939000

423000

1072013000

223000

3303000

38000

20000

1687000

0.0550

3040000

5616000

271000

20000000

6693000

112000

8000

57691000

55278000

58000

398793000

835941000

3368000

-114626000

527000

1120693000

151000

2635000

36000

0.0550

3051000

5898000

1774000

-1105000

669000

63000

3000

-3000

56179000

55465000

58000

405555000

889069000

3368000

-114626000

1692000

1181748000

188027000

164133000

53154000

45475000

802000

770000

692000 351000

566000

-325000

-585000

3081000

2301000

22691000

16681000

1396000

3467000

1813000 -5499000

66630000

27552000

-4643000

9846000

-1459000

8479000

11723000

5378000

11663000

5371000

-6345000

215000

704000

4878000

24700000

14307000

40781000

11387000

5163000

13090000

11968000

-37000

-34000

291397000

222337000

77360000 59735000

16400000

53684000 65699000

325000

8287000

1129000

1143000

48000

8626000

20538000

15497000

12103000

11905000

-873000

-173000

-137754000

-143771000

211000

2917000

2908000

12707000

8706000

1929000

1702000

29882000

9647000

9118000

0 6693000

4000

11000

234000 695000

19000

3197000

-2043000

-31903000

151600000

46663000

316270000

262201000

467870000

308864000

5287000

5800000

8480000

57880000

146162000

110942000

4100000

4200000

373832000

254742000

DESCRIPTION OF BUSINESS<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">The Company — The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company's independent operating subsidiaries provide health care services across the post-acute care continuum and engage in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties and other ancillary businesses. As of September 30, 2023, the Company's independent operating subsidiaries operated 295 facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The Company's independent operating subsidiaries have a collective capacity of approximately 30,500 operational skilled nursing beds and 3,000 senior living units. As of September 30, 2023, the Company's independent operating subsidiaries operated 213 facilities under long-term lease arrangements, and had options to purchase 11 of those 213 facilities. The Company's real estate portfolio includes 112 owned real estate properties, which includes 82 facilities operated and managed by the Company's independent operating subsidiaries, 30 operations leased to and operated by third party operators, and the Service Center location. Of those 30 operations, one senior living facility is located on the same real estate property as a skilled nursing facility that the Company owns and operates. </div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">Certain of the Company’s wholly owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly owned captive insurance subsidiary that provides some claims-made coverage to the Company’s operating subsidiaries for general and professional liabilities, as well as coverage for certain workers’ compensation insurance liabilities.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">In 2022, the Company formed a captive real estate investment trust (REIT), which owns and manages its real estate business, called Standard Bearer Healthcare REIT, Inc. (Standard Bearer). The REIT structure provides the Company with an efficient vehicle for future acquisitions of properties that could be operated by Ensign affiliates or other third parties. Refer to Note 6, Standard Bearer for additional information on Standard Bearer.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">Each of the Company's affiliated operations are operated by separate, wholly owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Quarterly Report is not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.</div><div style="margin-top:10pt;text-align:justify;text-indent:27pt">Other Information — The accompanying condensed consolidated financial statements as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 (collectively, the Interim Financial Statements) are unaudited. Certain information and note disclosures normally included in the annual consolidated financial statements have been condensed or omitted, as permitted under applicable rules and regulations. Readers of the Interim Financial Statements should refer to the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2022 which are included in the Company’s Annual Report on Form 10-K, File No. 001-33757 (the Annual Report) filed with the Securities and Exchange Commission (SEC). Management believes that the Interim Financial Statements reflect all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position and results of operations in all material respects. The results of operations presented in the Interim Financial Statements are not necessarily representative of operations for the entire year.</div>

295 30500 3000 213 11 213

112

82 30 30 1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">Basis of Presentation — The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interests in its condensed consolidated statements of income.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The Interim Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. </div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Estimates and Assumptions — The preparation of the Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities and income taxes. Actual results could differ from those estimates.</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Fair Value of Financial Instruments —The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, deferred compensation investment funds, equity investments, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. </div><div style="text-align:justify"> </div><div style="text-align:justify;text-indent:22.5pt">Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions. See Note 5, Fair Value Measurements for additional information.</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Service Revenue Recognition — The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606). The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to patients at the amount that reflects the consideration that the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services provided pursuant to skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services that are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.</div><div style="text-align:justify;text-indent:24.75pt"> </div><div style="text-align:justify;text-indent:24.75pt">Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration that is included in the transaction price may be constrained, and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Rental Revenue Recognition — The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue for operating leases is recognized on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, Leases (ASC 842). The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met. </div><div style="text-align:justify;text-indent:24.75pt"> </div><div style="text-align:justify;text-indent:24.75pt">Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under the new lease standards. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s condensed consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis. </div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Accounts Receivable — Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Property and Equipment — Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. </div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Leases and Leasehold Improvements — The Company leases skilled nursing facilities, senior living facilities and commercial office space. The Company determines if an arrangement is a lease and performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of September 30, 2023, the Company has one financing lease that is not material to the condensed consolidated balance sheets. Rights and obligations of these leases are included as right-of-use assets, current and long-term lease liabilities on the Company's condensed consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate.</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional ten to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. </div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">The Company subleases skilled nursing facilities to third-party operators and considers the subleases to be separate contracts because the Company is not relieved of its primary obligation under its operating lease. The rental income from third-parties related to these subleases is presented on a gross basis from the rent expense associated with the Company's lease obligations and is not material to the condensed consolidated statements of income. </div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Impairment of Long-Lived Assets — The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and determined there was no impairment during the three and nine months ended September 30, 2023 and 2022.</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Intangible Assets and Goodwill — Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. </div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year. Management has evaluated its intangible assets and determined there was no impairment during the three and nine months ended September 30, 2023 and 2022.</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Self-Insurance — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,250 for California affiliated operations and a separate, one-time, deductible of $1,250 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. </div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider. </div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $90,811 and $79,781 as of September 30, 2023 and December 31, 2022, respectively. </div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $28,733 and $27,301 as of September 30, 2023 and December 31, 2022, respectively.</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">In addition, the Company has recorded an asset and corresponding liability of $13,439 and $10,512 as of September 30, 2023 and December 31, 2022, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12, Restricted and Other Assets.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal year 2023. As of September 30, 2023 and December 31, 2022, the Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $14,716 and $14,088, respectively. </div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. </div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer believes it has been organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions. </div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Noncontrolling Interest — The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest. </div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Stock-Based Compensation — The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.</div>

Basis of Presentation — The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interests in its condensed consolidated statements of income.The Interim Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest.

Estimates and Assumptions — The preparation of the Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities and income taxes. Actual results could differ from those estimates.

Fair Value of Financial Instruments —The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, deferred compensation investment funds, equity investments, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Service Revenue Recognition — The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606). The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to patients at the amount that reflects the consideration that the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services provided pursuant to skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services that are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.</div><div style="text-align:justify;text-indent:24.75pt"> </div><div style="text-align:justify;text-indent:24.75pt">Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration that is included in the transaction price may be constrained, and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Rental Revenue Recognition — The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue for operating leases is recognized on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, Leases (ASC 842). The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met. </div>Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under the new lease standards. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s condensed consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.

Accounts Receivable — Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.

Property and Equipment — Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.

P59Y

P10Y

P15Y

Impairment of Long-Lived Assets — The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset.

P8M

P30Y

P20Y

<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Self-Insurance — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,250 for California affiliated operations and a separate, one-time, deductible of $1,250 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. </div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider. </div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $90,811 and $79,781 as of September 30, 2023 and December 31, 2022, respectively. </div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $28,733 and $27,301 as of September 30, 2023 and December 31, 2022, respectively.</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">In addition, the Company has recorded an asset and corresponding liability of $13,439 and $10,512 as of September 30, 2023 and December 31, 2022, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12, Restricted and Other Assets.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal year 2023. As of September 30, 2023 and December 31, 2022, the Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $14,716 and $14,088, respectively. </div>The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.

500000

1250000

1000000

3000000

5000000

1000000

3000000

90811000

79781000

625000

750000

350000

500000

28733000

27301000

13439000

10512000

525000

14716000

14088000

Noncontrolling Interest — The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.

Stock-Based Compensation — The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.

REVENUE AND ACCOUNTS RECEIVABLE<div style="margin-top:9pt;text-align:justify">Disaggregation of Revenue</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The Company disaggregates revenue from contracts with its patients by payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. </div><div style="margin-top:9pt;text-align:justify">Revenue by Payor</div><div style="text-align:justify;text-indent:24.75pt"> </div><div style="text-align:justify;text-indent:24.75pt">The Company’s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rates, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed. </div><div style="text-align:justify;text-indent:24.75pt"> </div><div style="text-align:justify;text-indent:24.75pt">Revenue from the Medicare and Medicaid programs accounted for 72.1% and 72.8% for the three and nine months ended September 30, 2023, respectively, and 73.7% and 73.5% for the three and nine months ended September 30, 2022. Settlements with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on the final settlement. The Company recorded adjustments to revenue which were not material to the Company's revenue for the three and nine months ended September 30, 2023 and 2022.</div><div style="text-align:justify;text-indent:24.75pt"> </div><div style="text-align:justify;text-indent:24.75pt">Service revenue for the three and nine months ended September 30, 2023 and 2022 is summarized in the following tables:</div><div style="margin-top:9.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="21" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">% of Revenue</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">% of Revenue</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Medicaid(1)</div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">374,838 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40.1 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">302,615 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.5 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">237,531 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25.4 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211,104 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicaid — skilled</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,452 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.6 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50,643 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total Medicaid and Medicare</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">674,821 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">72.1 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">564,362 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">73.7 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Managed care</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">170,747 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.3 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132,663 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.3 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Private and other(2)</div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">89,756 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.6 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68,858 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">SERVICE REVENUE</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">935,324 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">765,883 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table>(1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.</div><div style="text-align:justify">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.086%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="21" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">% of Revenue</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">% of Revenue</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Medicaid(1)</div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">1,074,883 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.3 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">863,091 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.2 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">733,335 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26.8 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">610,009 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicaid — skilled</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">182,394 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.7 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">146,355 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total Medicaid and Medicare</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,990,612 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">72.8 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,619,455 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">73.5 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Managed care</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">488,511 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.9 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">389,036 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.7 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Private and other(2)</div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">254,220 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.3 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">194,895 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.8 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">SERVICE REVENUE</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,733,343 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,203,386 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify">(1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.</div><div style="text-align:justify">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt">In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $5,467 and $15,634, respectively, for the three and nine months ended September 30, 2023 and $4,122 and $12,550, respectively, for the three and nine months ended September 30, 2022.</div><div style="margin-top:9pt;text-align:justify">State relief funding</div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt">The Company receives state relief funding through Medicaid programs from various states, including healthcare relief funding under the American Rescue Plan Act (ARPA), increases in the Federal Medical Assistance Percentage (FMAP) under the Families First Coronavirus Response Act (FFCRA) and other state specific relief programs. The funding generally incorporates specific use requirements primarily for direct patient care including labor related expenses that are attributable to the COVID-19 pandemic or are associated with providing patient care.</div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt">Revenues from these additional payments are recognized in accordance with ASC 606, subject to variable consideration constraints. In certain operations where the Company received additional payments that exceeded expenses incurred related to specific qualifiers, the Company recorded deferred revenue for the excess amount until additional expenses are incurred for recognition. Accordingly, the amount of state relief revenue recognized is limited to the actual related expenses incurred. As of September 30, 2023 and December 31, 2022, the Company had $636 and $1,001 in unapplied state relief funds, respectively. During the three and nine months ended September 30, 2023, the Company received $9,900 and $54,744 in state relief funding and recognized $10,298 and $55,109, respectively, as revenue. During the three and nine months ended September 30, 2022, the Company received $20,293 and $64,955 in state relief funding and recognized $21,400 and $63,488, respectively, as revenue.</div><div style="margin-top:9pt;text-align:justify">Balance Sheet Impact</div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt">Included in the Company’s condensed consolidated balance sheets are contract balances, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities and contract assets as of September 30, 2023 and December 31, 2022, or activity during the three and nine months ended September 30, 2023 and 2022.</div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify;text-indent:22.5pt">Accounts receivable as of September 30, 2023 and December 31, 2022, is summarized in the following table:</div><div style="margin-top:9.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2022</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicaid</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">188,572 </td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">157,878 </td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Managed care</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">118,756 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">95,940 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75,717 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">76,526 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Private and other payors</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98,500 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,890 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">481,545 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">416,234 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: allowance for doubtful accounts</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,422)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,802)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">ACCOUNTS RECEIVABLE, NET</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">472,123 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">408,432 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

0.721

0.728

0.737

0.735

<div style="text-align:justify;text-indent:24.75pt">Service revenue for the three and nine months ended September 30, 2023 and 2022 is summarized in the following tables:</div><div style="margin-top:9.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="21" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">% of Revenue</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">% of Revenue</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Medicaid(1)</div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">374,838 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40.1 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">302,615 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.5 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">237,531 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25.4 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211,104 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicaid — skilled</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,452 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.6 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50,643 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total Medicaid and Medicare</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">674,821 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">72.1 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">564,362 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">73.7 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Managed care</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">170,747 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.3 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132,663 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.3 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Private and other(2)</div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">89,756 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.6 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68,858 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">SERVICE REVENUE</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">935,324 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">765,883 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table>(1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.</div><div style="text-align:justify">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.086%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="21" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">% of Revenue</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">% of Revenue</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Medicaid(1)</div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">1,074,883 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.3 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">863,091 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.2 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">733,335 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26.8 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">610,009 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicaid — skilled</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">182,394 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.7 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">146,355 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total Medicaid and Medicare</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,990,612 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">72.8 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,619,455 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">73.5 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Managed care</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">488,511 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.9 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">389,036 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.7 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Private and other(2)</div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">254,220 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.3 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">194,895 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.8 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">SERVICE REVENUE</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,733,343 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,203,386 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify">(1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.</div><div style="text-align:justify">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</div>

374838000

0.401

302615000

0.395

237531000

0.254

211104000

0.276

62452000

0.066

50643000

0.066

674821000

0.721

564362000

0.737

170747000

0.183

132663000

0.173

89756000

0.096

68858000

0.090

935324000

1.000

765883000

1.000

1074883000

0.393

863091000

0.392

733335000

0.268

610009000

0.277

182394000

0.067

146355000

0.066

1990612000

0.728

1619455000

0.735

488511000

0.179

389036000

0.177

254220000

0.093

194895000

0.088

2733343000

1.000

2203386000

1.000

5467000

15634000

4122000

12550000

636000 1001000 9900000 54744000 10298000 55109000 20293000 64955000 21400000 63488000

<div style="text-align:justify;text-indent:22.5pt">Accounts receivable as of September 30, 2023 and December 31, 2022, is summarized in the following table:</div><div style="margin-top:9.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2022</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicaid</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">188,572 </td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">157,878 </td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Managed care</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">118,756 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">95,940 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75,717 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">76,526 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Private and other payors</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98,500 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,890 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">481,545 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">416,234 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: allowance for doubtful accounts</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,422)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,802)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">ACCOUNTS RECEIVABLE, NET</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">472,123 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">408,432 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

188572000

157878000

118756000

95940000

75717000

76526000

98500000

85890000

481545000

416234000

9422000

7802000

472123000

408432000

COMPUTATION OF NET INCOME PER COMMON SHAREBasic net income per share is computed by dividing income from operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.<div style="text-align:justify;text-indent:22.5pt">A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:</div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">NUMERATOR:</td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net income</td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">63,968 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">56,242 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">188,027 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">164,133 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Less: net income (loss) attributable to noncontrolling interests </td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">105 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">319 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(77)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Net income attributable to The Ensign Group, Inc. </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">63,863 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">56,179 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">187,708 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">164,210 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">DENOMINATOR:</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Weighted average shares outstanding for basic net income per share</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,829 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">54,882 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,582 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">54,819 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic net income per common share:</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">1.14 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">1.02 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">3.38 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">3.00 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify;text-indent:22.5pt">A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:</div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.283%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">NUMERATOR:</td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net income </td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">63,968 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">56,242 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">188,027 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">164,133 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Less: net income (loss) attributable to noncontrolling interests</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">105 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">319 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(77)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Net income attributable to The Ensign Group, Inc. </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">63,863 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">56,179 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">187,708 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">164,210 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">DENOMINATOR:</td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Weighted average common shares outstanding</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,829 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">54,882 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,582 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">54,819 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt">Plus: incremental shares from assumed conversion (1)</div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,508 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,879 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,663 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,010 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Adjusted weighted average common shares outstanding</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,337 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56,761 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,245 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56,829 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Diluted net income per common share:</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">1.11 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">0.99 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">3.28 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2.89 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 1,475 and 1,389 for the three and nine months ended September 30, 2023, respectively, and 918 and 734 for the three and nine months ended September 30, 2022, respectively.

<div style="text-align:justify;text-indent:22.5pt">A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:</div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">NUMERATOR:</td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net income</td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">63,968 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">56,242 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">188,027 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">164,133 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Less: net income (loss) attributable to noncontrolling interests </td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">105 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">319 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(77)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Net income attributable to The Ensign Group, Inc. </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">63,863 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">56,179 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">187,708 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">164,210 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">DENOMINATOR:</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Weighted average shares outstanding for basic net income per share</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,829 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">54,882 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,582 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">54,819 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic net income per common share:</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">1.14 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">1.02 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">3.38 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">3.00 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>

63968000

56242000

188027000

164133000

105000

63000

319000

-77000

63863000

56179000

187708000

164210000

55829000

54882000

55582000

54819000

1.14

1.02

3.38

3.00

<div style="text-align:justify;text-indent:22.5pt">A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:</div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.283%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">NUMERATOR:</td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net income </td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">63,968 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">56,242 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">188,027 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">164,133 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Less: net income (loss) attributable to noncontrolling interests</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">105 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">319 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(77)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Net income attributable to The Ensign Group, Inc. </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">63,863 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">56,179 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">187,708 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">164,210 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">DENOMINATOR:</td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Weighted average common shares outstanding</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,829 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">54,882 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,582 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">54,819 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt">Plus: incremental shares from assumed conversion (1)</div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,508 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,879 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,663 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,010 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Adjusted weighted average common shares outstanding</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,337 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56,761 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,245 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56,829 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Diluted net income per common share:</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">1.11 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">0.99 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">3.28 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2.89 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 1,475 and 1,389 for the three and nine months ended September 30, 2023, respectively, and 918 and 734 for the three and nine months ended September 30, 2022, respectively.

63968000

56242000

188027000

164133000

105000

63000

319000

-77000

63863000

56179000

187708000

164210000

55829000

54882000

55582000

54819000

1508000

1879000

1663000

2010000

57337000

56761000

57245000

56829000

1.11

0.99

3.28

2.89

1475000

1389000

918000

734000

FAIR VALUE MEASUREMENTS<div style="text-align:justify;text-indent:22.5pt">The Company's financial assets include the captive insurance subsidiary's deposits and investments designated to support long-term insurance subsidiary liabilities and are carried at a cost basis of $57,290 and $53,924 as of September 30, 2023 and December 31, 2022, respectively. Also included are contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans that are held in a rabbi trust. The cash surrender value of these contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. As of September 30, 2023, and December 31, 2022, the adjusted cost basis of the investment funds was $36,867 and $25,144, respectively. </div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify;text-indent:22.5pt">As of September 30, 2023 and December 31, 2022, the cost basis of the Company's financial assets included in the captive insurance subsidiary's investments and deferred compensation plan investment funds are considered to approximate the fair value of these financial assets and are derived using Level 2 inputs. Additionally, the Company has other investments, which are not material, where the fair value is derived using Level 3 inputs. The Company believes its investments that were in an unrealized loss position as of September 30, 2023 and December 31, 2022 do not require an allowance for expected credit losses, nor has any event occurred through the filing date of this report that would indicate differently.</div>The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value.

57290000

53924000

36867000

25144000

STANDARD BEARER<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"> Standard Bearer's real estate portfolio consists of 107 of the Company's 112 owned real estate properties, of which 78 are operated and managed by the Company and 30 are leased to and operated by third party operators. Of those 30 operations, one senior living facility is located on the same real estate property as a skilled nursing facility that the Company owns and operates. Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. </div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">During the nine months ended September 30, 2023, Standard Bearer acquired the real estate of three stand-alone skilled nursing facilities and one campus operation for an aggregate purchase price of $52,802. Of these additions, the three skilled nursing facilities acquired are operated by the Company's affiliated operating subsidiaries and the campus operation is leased to a third party operator. During the nine months ended September 30, 2022, Standard Bearer acquired the real estate of eight skilled nursing facilities for an aggregate purchase price of $65,619, three of which were previously operated and managed by Ensign's affiliated operations. Refer to Note 7, Operation Expansions, for additional information.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">As part of the formation of Standard Bearer, certain of the Company's operating subsidiaries, Standard Bearer and Standard Bearer's subsidiaries entered into several agreements that include leasing, management services and debt arrangements between the operations. All intercompany transactions have been eliminated in consolidation. Refer to Note 8, Business Segments, for additional information related to these intercompany eliminations as well as Standard Bearer as a reportable segment. </div><div style="margin-top:9pt;text-align:justify">Intercompany master lease agreements</div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt">Certain of the Company's operating subsidiaries and the 78 Standard Bearer subsidiaries have entered into five triple-net master lease agreements (collectively, the Standard Bearer Master Leases). The lease periods range from 15 to 19 years with three five-year renewal options beyond the initial term, on the same terms and conditions. The rent structure under the Standard Bearer Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the operating subsidiaries are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties; (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Rental revenue generated from Ensign affiliated operations was $16,976 and $49,035 for the three and nine months ended September 30, 2023, respectively, and $15,024 and $42,343 for the three and nine months ended September 30, 2022, respectively.</div><div style="margin-top:9pt;text-align:justify">Intercompany management agreement</div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt">Standard Bearer has no employees. The Service Center provides personnel and services to Standard Bearer pursuant to the management agreement between Standard Bearer and the Service Center. The management agreement provides for a base management fee that is equal to 5% of total rental revenue and an incentive management fee that is equal to 5% of funds from operations (FFO) and is capped at 1% of total rental revenue, for a total of 6%. Management fee generated between Standard Bearer and the Service Center for the three and nine months ended September 30, 2023 was $1,259 and $3,636, respectively. Management fees generated between Standard Bearer and the Service Center for the three and nine months ended September 30, 2022 was $1,124 and $3,202, respectively.</div><div style="margin-top:9pt;text-align:justify">Intercompany debt arrangements</div><div style="text-align:justify"> </div><div style="text-align:justify;text-indent:24.75pt">Standard Bearer obtains its funding through various sources including operating cash flows, access to debt arrangements and intercompany loans. The intercompany debt arrangements include mortgage loans and the Credit Facility to fund acquisitions and working capital needs. The interest rate under the Amended Credit Agreement is a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum. </div><div style="text-align:justify;text-indent:24.75pt">In addition, as the Department of Housing and Urban Development (HUD) mortgage loans and promissory note are entered into by real estate subsidiaries of Standard Bearer, the interest expense incurred from these debts are included in Standard Bearer's segment income. Refer to Note 15, Debt, for additional information related to these debts. </div><div style="margin-top:9pt;text-align:justify">Equity Instrument Denominated in the Shares of a Subsidiary</div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:24.75pt">As part of the formation of Standard Bearer in January of 2022, the Company established the Standard Bearer Healthcare REIT, Inc. 2022 Omnibus Incentive Plan (Standard Bearer Equity Plan). The Company may grant stock options and restricted stock awards under the Standard Bearer Equity Plan to employees and management of Ensign's affiliated subsidiaries. These awards generally vest over a period of five years or upon the occurrence of certain prescribed events. The value of the stock options and restricted stock awards is tied to the value of the common stock of Standard Bearer, which is determined based on an independent valuation of Standard Bearer. The awards can be put to Standard Bearer at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination. In the second quarter of 2022, Standard Bearer sold fully vested common shares from the Standard Bearer Equity Plan to shareholders for cash of $6,544. During the nine months ended September 30, 2023 and 2022, the Company did not grant any stock options nor restricted shares under the Standard Bearer Equity Plan.</div><div style="text-align:justify;text-indent:24.75pt">Also in the second quarter of 2022, Standard Bearer established shareholders of its preferred shares through contributions of cash of $149. These preferred shares were fully vested at the time of the contributions by the shareholders. The value of Standard Bearer common and preferred shares held by the Company are eliminated in consolidation and the value held by other shareholders are classified as noncontrolling interests on the Company's condensed consolidated balance sheets.</div>

107

112

30 1 3 1

52802000

3 8

65619000

P15Y

P19Y

P5Y

0.025

16976000

49035000

15024000

42343000

0.05 0.05 0.01 0.06

1259000

3636000

1124000

3202000

0.0025

0.0125

0.0225

P5Y

P6M

6544000

149000

OPERATION EXPANSIONS<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The expansion focus of the Company's subsidiaries is to purchase or lease operations that are complementary to the current affiliated operations, accretive to the business, or otherwise advance the Company's strategy. The results of all operating subsidiaries are included in the Interim Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's affiliated operations also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, a real estate affiliated subsidiary will acquire the property of facilities that have previously been operated under third-party leases. </div><div style="margin-top:9pt;text-align:justify">2023 Expansions</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">During the nine months ended September 30, 2023, the Company expanded its operations and real estate portfolio through a combination of long-term leases and real estate purchases, with the addition of 24 stand-alone skilled nursing operations. Of these additions, Standard Bearer acquired the real estate of three of the stand-alone skilled nursing operations, which were leased back to Ensign affiliated entities. Refer to Note 6, Standard Bearer, for additional information on the purchase of real estate properties. These new operations added a total of 2,340 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses. </div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">In connection with the new operations obtained through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with each prior operator as part of each transaction. </div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">Subsequent to September 30, 2023, the Company expanded its operations through a long-term lease, with the addition of one stand-alone skilled nursing operation. This new operation added 45 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries. </div><div style="margin-top:10pt;text-align:justify">2022 Expansions</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">During the nine months ended September 30, 2022, the Company expanded its operations and real estate portfolio through a combination of long-term leases and real estate purchases, with the addition of 11 stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of five of the stand-alone skilled nursing operations, which was leased back to Ensign affiliated entities. Refer to Note 6, Standard Bearer, for additional information on the purchases of real estate properties. In addition, the Company added five senior living operations that were transferred from The Pennant Group, Inc. (Pennant), three of which are part of campuses operated by the Company's affiliated operating subsidiaries. These new operations added a total of 1,553 operational skilled nursing beds and 674 operational senior living units to be operated by the Company's affiliated operating subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses. </div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">Of the new operations acquired during the nine months ended September 30, 2022, $16,400 was concentrated in goodwill and accordingly, the transactions were classified as business combinations. </div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">In connection with the new operations obtained through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with each prior operator as part of each transaction.</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operations added by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operations, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired operating subsidiaries. The assets added during the nine months ended September 30, 2023 were not material operations to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These additions have been included in the September 30, 2023 condensed consolidated balance sheets of the Company, and the operating results have been included in the condensed consolidated statements of operations of the Company since the date the Company gained effective control.</div>

3 2340

3 1553 674

16400000

BUSINESS SEGMENTS<div style="text-align:justify;text-indent:24.75pt">The Company has two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. </div><div style="text-align:justify;text-indent:24.75pt"> </div><div style="text-align:justify;text-indent:24.75pt">As of September 30, 2023, the skilled services segment includes 258 skilled nursing operations and 26 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. The Company's Standard Bearer segment consists of 107 owned real estate properties. </div><div style="text-align:justify;text-indent:24.75pt"> </div><div style="text-align:justify;text-indent:24.75pt">The Company also reports an “All Other” category that includes results from its senior living operations, which includes eleven stand-alone senior living operations and the senior living operations at 26 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. In addition, the "All Other" category includes mobile diagnostics, medical transportation, other real estate and other ancillary operations. Services included in the “All Other” category are insignificant individually, and therefore do not constitute a reportable segment.</div><div style="text-align:justify;text-indent:24.75pt"> </div><div style="text-align:justify;text-indent:24.75pt">The Company’s reportable segments are significant operating segments that offer differentiated services. The Company's CODM reviews financial information for each operating segment to evaluate performance and allocate capital resources. This structure reflects its current operational and financial management and provides the best structure to maximize the quality of care and investment strategy provided, while maintaining financial discipline. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.</div><div style="text-align:justify;text-indent:24.75pt"> </div><div style="text-align:justify;text-indent:24.75pt"> The accounting policies of the reportable segments are the same as those described in Note 2, Summary of Significant Accounting Policies. Intercompany revenue is eliminated in consolidation, along with corresponding intercompany expenses. Segment income and loss is defined as profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate, real estate insurance recoveries and losses and impairment charges from operations. Included in segment income for Standard Bearer is expense for intercompany services provided by the Service Center as described in Note 6, Standard Bearer, as it is part of the CODM financial information. </div><div style="text-align:justify;text-indent:27pt">The following tables set forth financial information for the segments:</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Standard Bearer</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">All Other(1)</div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Intercompany Elimination</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Total </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Service revenue(2)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">902,967 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">36,254 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(3,897)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">935,324 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Rental revenue(3)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,980 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,870 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(18,383)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,467 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">TOTAL REVENUE</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">902,967 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">20,980 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">39,124 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(22,280)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">940,791 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Segment income (loss)</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">117,816 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,165 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(42,936)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">82,045 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Income before provision for income taxes </td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">82,045 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,936 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,429 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,081 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,446 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Interest expense(4)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">5,139 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">312 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">(3,427)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">2,024 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </div><div style="text-align:justify">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </div><div style="text-align:justify">(3) All Other rental revenue includes rental revenue associated with the Company's subleases to third parties of $1,063 for the three months ended September 30, 2023. Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </div><div style="text-align:justify">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. </div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2022</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Standard Bearer</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">All Other (1)</div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Intercompany Elimination</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Service revenue(2)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">739,318 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">30,002 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(3,437)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">765,883 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Rental revenue(3)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,732 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,842 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16,452)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,122 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">TOTAL REVENUE</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">739,318 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">18,732 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">31,844 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(19,889)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">770,005 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Segment income (loss)</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">101,750 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,941 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(37,036)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71,655 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Gain on sale of assets, net</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">800 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Income before provision for income taxes </td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">72,455 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,397 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,561 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,983 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,941 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Interest expense(4)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">4,080 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">310 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">(2,282)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">2,108 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div>(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </div><div style="text-align:justify">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </div><div style="text-align:justify">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </div><div style="text-align:justify">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. </div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Standard Bearer</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">All Other (1)</div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Intercompany Elimination</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Total </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Service revenue(2)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,638,090 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">106,322 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(11,069)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,733,343 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Rental revenue(3)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,611 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,252 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(53,229)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,634 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">TOTAL REVENUE</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,638,090 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">60,611 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">114,574 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(64,298)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,748,977 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Segment income (loss)</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">348,169 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,517 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(128,106)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">241,580 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Loss on real estate insurance recoveries</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(100)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Income before provision for income taxes</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">241,480 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,417 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,528 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,209 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53,154 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Interest expense(4)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">14,283 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">927 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">(9,127)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">6,083 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </div><div style="text-align:justify">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </div><div style="text-align:justify">(3) All Other rental revenue includes rental revenue associated with the Company's subleases to third parties of $2,834 for the nine months ended September 30, 2023. Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </div><div style="text-align:justify">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. </div><div style="text-align:justify"> </div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2022</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Standard Bearer</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">All Other (1)</div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Intercompany Elimination</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Service revenue(2)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,128,567 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">84,256 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(9,437)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,203,386 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Rental revenue(3)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53,523 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,537 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(46,510)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,550 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">TOTAL REVENUE</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,128,567 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">53,523 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">89,793 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(55,947)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,215,936 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Segment income (loss)</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">302,272 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,679 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(114,580)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">208,371 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Gain on sale of assets, net</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,267 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Income before provision for income taxes</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">211,638 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,411 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,798 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,266 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45,475 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Interest expense</td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">11,385 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1,557 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">(6,078)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">6,864 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </div><div style="text-align:justify">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </div><div style="text-align:justify">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </div><div style="text-align:justify">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. </div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>Service revenue by major payor source were as follows:</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">All Other (3)</div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Total Service Revenue</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue %</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Medicaid(1)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">367,079 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">7,759 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">374,838 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40.1 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">237,531 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">237,531 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25.4 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicaid-skilled</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,452 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,452 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.6 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Subtotal</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">667,062 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,759 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">674,821 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72.1 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Managed care</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">170,747 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">170,747 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.3 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Private and other(2)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,158 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,598 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">89,756 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.6 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">TOTAL SERVICE REVENUE</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">902,967 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">32,357 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">935,324 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </div><div style="text-align:justify">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</div><div style="text-align:justify">(3) All Other incorporates intercompany eliminations.</div><div style="text-align:justify"> </div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2022</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">All Other (3)</div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Total Service Revenue</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue %</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Medicaid(1)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">295,927 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">6,688 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">302,615 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.5 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211,104 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211,104 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicaid-skilled</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50,643 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50,643 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Subtotal</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">557,674 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,688 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">564,362 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.7 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Managed care</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132,663 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132,663 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.3 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Private and other(2)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48,981 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,877 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68,858 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">TOTAL SERVICE REVENUE</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">739,318 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">26,565 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">765,883 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </div><div style="text-align:justify">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</div><div style="text-align:justify">(3) All Other incorporates intercompany eliminations.</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">All Other (3)</div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Total Service Revenue</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue %</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Medicaid(1)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">1,052,904 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">21,979 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">1,074,883 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.3 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">733,335 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">733,335 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26.8 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicaid-skilled</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">182,394 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">182,394 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.7 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Subtotal</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,968,633 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,979 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,990,612 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72.8 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Managed care</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">488,511 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">488,511 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.9 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Private and other(2)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">180,946 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73,274 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">254,220 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.3 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">TOTAL SERVICE REVENUE</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,638,090 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">95,253 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,733,343 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table></div><div style="text-align:justify">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </div><div style="margin-top:3pt;text-align:justify">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</div><div style="text-align:justify">(3) All Other incorporates intercompany eliminations.</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2022</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">All Other (3)</div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Total Service Revenue</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue %</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Medicaid(1)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">845,341 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">17,750 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">863,091 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.2 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">610,009 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">610,009 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicaid-skilled</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">146,355 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">146,355 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Subtotal</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,601,705 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,750 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,619,455 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.5 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Managed care</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">389,036 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">389,036 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.7 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Private and other(2)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">137,826 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,069 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">194,895 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.8 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">TOTAL SERVICE REVENUE</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,128,567 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">74,819 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,203,386 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table></div><div style="text-align:justify">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </div><div style="margin-top:3pt;text-align:justify">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</div><div style="text-align:justify">(3) All Other incorporates intercompany eliminations.</div>

258 26

107

11 26

<div style="text-align:justify;text-indent:27pt">The following tables set forth financial information for the segments:</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Standard Bearer</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">All Other(1)</div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Intercompany Elimination</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Total </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Service revenue(2)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">902,967 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">36,254 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(3,897)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">935,324 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Rental revenue(3)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,980 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,870 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(18,383)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,467 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">TOTAL REVENUE</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">902,967 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">20,980 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">39,124 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(22,280)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">940,791 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Segment income (loss)</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">117,816 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,165 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(42,936)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">82,045 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Income before provision for income taxes </td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">82,045 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,936 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,429 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,081 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,446 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Interest expense(4)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">5,139 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">312 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">(3,427)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">2,024 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </div><div style="text-align:justify">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </div><div style="text-align:justify">(3) All Other rental revenue includes rental revenue associated with the Company's subleases to third parties of $1,063 for the three months ended September 30, 2023. Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </div><div style="text-align:justify">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. </div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2022</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Standard Bearer</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">All Other (1)</div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Intercompany Elimination</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Service revenue(2)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">739,318 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">30,002 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(3,437)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">765,883 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Rental revenue(3)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,732 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,842 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16,452)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,122 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">TOTAL REVENUE</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">739,318 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">18,732 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">31,844 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(19,889)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">770,005 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Segment income (loss)</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">101,750 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,941 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(37,036)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71,655 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Gain on sale of assets, net</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">800 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Income before provision for income taxes </td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">72,455 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,397 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,561 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,983 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,941 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Interest expense(4)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">4,080 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">310 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">(2,282)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">2,108 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div>(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </div><div style="text-align:justify">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </div><div style="text-align:justify">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </div><div style="text-align:justify">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. </div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Standard Bearer</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">All Other (1)</div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Intercompany Elimination</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Total </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Service revenue(2)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,638,090 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">106,322 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(11,069)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,733,343 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Rental revenue(3)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,611 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,252 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(53,229)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,634 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">TOTAL REVENUE</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,638,090 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">60,611 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">114,574 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(64,298)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,748,977 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Segment income (loss)</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">348,169 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,517 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(128,106)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">241,580 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Loss on real estate insurance recoveries</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(100)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Income before provision for income taxes</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">241,480 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,417 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,528 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,209 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53,154 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Interest expense(4)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">14,283 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">927 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">(9,127)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">6,083 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </div><div style="text-align:justify">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </div><div style="text-align:justify">(3) All Other rental revenue includes rental revenue associated with the Company's subleases to third parties of $2,834 for the nine months ended September 30, 2023. Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </div><div style="text-align:justify">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. </div><div style="text-align:justify"> </div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2022</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Standard Bearer</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">All Other (1)</div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Intercompany Elimination</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Service revenue(2)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,128,567 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">84,256 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(9,437)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,203,386 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Rental revenue(3)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53,523 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,537 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(46,510)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,550 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">TOTAL REVENUE</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,128,567 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">53,523 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">89,793 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(55,947)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,215,936 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Segment income (loss)</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">302,272 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,679 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(114,580)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">208,371 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Gain on sale of assets, net</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,267 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Income before provision for income taxes</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">211,638 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,411 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,798 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,266 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45,475 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Interest expense</td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">11,385 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1,557 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">(6,078)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">6,864 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </div><div style="text-align:justify">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </div><div style="text-align:justify">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </div>(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column.

902967000

36254000

-3897000

935324000

20980000

2870000

-18383000

5467000

902967000

20980000

39124000

-22280000

940791000

117816000 7165000 -42936000 0 82045000

82045000

9936000

6429000

2081000

18446000

5139000

312000

-3427000

2024000

1063000

739318000

30002000

-3437000

765883000

18732000

1842000

-16452000

4122000

739318000

18732000

31844000

-19889000

770005000

101750000 6941000 -37036000 0 71655000

800000

72455000

8397000

5561000

1983000

15941000

4080000

310000

-2282000

2108000

2638090000

106322000

-11069000

2733343000

60611000

8252000

-53229000

15634000

2638090000

60611000

114574000

-64298000

2748977000

348169000 21517000 -128106000 0 241580000

-100000

241480000

28417000

18528000

6209000

53154000

14283000

927000

-9127000

6083000

2834000

2128567000

84256000

-9437000

2203386000

53523000

5537000

-46510000

12550000

2128567000

53523000

89793000

-55947000

2215936000

302272000 20679000 -114580000 0 208371000

3267000

211638000

24411000

15798000

5266000

45475000

11385000

1557000

-6078000

6864000

Service revenue by major payor source were as follows:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">All Other (3)</div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Total Service Revenue</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue %</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Medicaid(1)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">367,079 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">7,759 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">374,838 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40.1 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">237,531 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">237,531 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25.4 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicaid-skilled</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,452 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,452 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.6 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Subtotal</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">667,062 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,759 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">674,821 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72.1 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Managed care</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">170,747 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">170,747 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.3 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Private and other(2)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,158 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,598 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">89,756 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.6 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">TOTAL SERVICE REVENUE</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">902,967 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">32,357 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">935,324 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </div><div style="text-align:justify">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</div><div style="text-align:justify">(3) All Other incorporates intercompany eliminations.</div><div style="text-align:justify"> </div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2022</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">All Other (3)</div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Total Service Revenue</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue %</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Medicaid(1)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">295,927 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">6,688 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">302,615 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.5 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211,104 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211,104 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicaid-skilled</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50,643 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50,643 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Subtotal</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">557,674 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,688 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">564,362 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.7 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Managed care</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132,663 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132,663 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.3 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Private and other(2)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48,981 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,877 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68,858 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">TOTAL SERVICE REVENUE</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">739,318 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">26,565 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">765,883 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </div><div style="text-align:justify">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</div><div style="text-align:justify">(3) All Other incorporates intercompany eliminations.</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">All Other (3)</div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Total Service Revenue</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue %</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Medicaid(1)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">1,052,904 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">21,979 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">1,074,883 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.3 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">733,335 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">733,335 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26.8 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicaid-skilled</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">182,394 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">182,394 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.7 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Subtotal</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,968,633 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,979 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,990,612 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72.8 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Managed care</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">488,511 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">488,511 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.9 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Private and other(2)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">180,946 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73,274 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">254,220 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.3 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">TOTAL SERVICE REVENUE</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,638,090 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">95,253 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,733,343 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table></div><div style="text-align:justify">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </div><div style="margin-top:3pt;text-align:justify">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</div><div style="text-align:justify">(3) All Other incorporates intercompany eliminations.</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2022</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">All Other (3)</div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Total Service Revenue</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue %</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Medicaid(1)</div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">845,341 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">17,750 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">863,091 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.2 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">610,009 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">610,009 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicaid-skilled</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">146,355 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">146,355 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Subtotal</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,601,705 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,750 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,619,455 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.5 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Managed care</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">389,036 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">389,036 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.7 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Private and other(2)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">137,826 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,069 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">194,895 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.8 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">TOTAL SERVICE REVENUE</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,128,567 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">74,819 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,203,386 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table></div><div style="text-align:justify">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </div><div style="margin-top:3pt;text-align:justify">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</div><div style="text-align:justify">(3) All Other incorporates intercompany eliminations.</div>

367079000

7759000

374838000

0.401

237531000

0.254

62452000

0.066

667062000

7759000

674821000

0.721

170747000

0.183

65158000

24598000

89756000

0.096

902967000

32357000

935324000

1.000

295927000

6688000

302615000

0.395

211104000

0.276

50643000

0.066

557674000

6688000

564362000

0.737

132663000

0.173

48981000

19877000

68858000

0.090

739318000

26565000

765883000

1.000

1052904000

21979000

1074883000

0.393

733335000

0.268

182394000

0.067

1968633000

21979000

1990612000

0.728

488511000

0.179

180946000

73274000

254220000

0.093

2638090000

95253000

2733343000

1.000

845341000

17750000

863091000

0.392

610009000

0.277

146355000

0.066

1601705000

17750000

1619455000

0.735

389036000

0.177

137826000

57069000

194895000

0.088

2128567000

74819000

2203386000

1.000

PROPERTY AND EQUIPMENT - NET<div style="margin-top:10pt;text-indent:24.75pt">Property and equipment, net consists of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2022</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Land</td><td style="background-color:#e4e9df;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">140,239 </td><td style="background-color:#e4e9df;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">134,864 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Buildings and improvements</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">790,333 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">728,231 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Leasehold improvements</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">166,984 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150,903 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Equipment</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">334,999 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">295,739 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Furniture and fixtures</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,868 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,544 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Construction in progress</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,993 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,521 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,459,416 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,331,802 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Less: accumulated depreciation</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(391,514)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(339,792)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">PROPERTY AND EQUIPMENT, NET</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">1,067,902 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">992,010 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify;text-indent:22.5pt"> The Company completed the sale of assets for a sale price of $8,607 and recorded a gain of $3,467 within the Company's condensed consolidated statement of income as cost of services during the nine months ended September 30, 2022. See also Note 6, Standard Bearer and Note 7, Operation Expansions for information on acquisitions during the nine months ended September 30, 2023.</div>

Property and equipment, net consists of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2022</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Land</td><td style="background-color:#e4e9df;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">140,239 </td><td style="background-color:#e4e9df;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">134,864 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Buildings and improvements</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">790,333 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">728,231 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Leasehold improvements</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">166,984 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150,903 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Equipment</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">334,999 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">295,739 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Furniture and fixtures</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,868 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,544 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Construction in progress</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,993 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,521 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,459,416 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,331,802 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Less: accumulated depreciation</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(391,514)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(339,792)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">PROPERTY AND EQUIPMENT, NET</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">1,067,902 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">992,010 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>

140239000

134864000

790333000

728231000

166984000

150903000

334999000

295739000

4868000

4544000

21993000

17521000

1459416000

1331802000

391514000

339792000

1067902000

992010000

8607000

3467000

INTANGIBLE ASSETS - NET<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="4" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Life (Years)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2022</td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Carrying Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Carrying Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Intangible Assets</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Assembled occupancy</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom">0.3</td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">702 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(570)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">132 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">435 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(388)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">47 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Facility trade name</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">30.0</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">733 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(433)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">300 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">733 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(415)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">318 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Customer relationships</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">18.4</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,582 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,639)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,943 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,582 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,482)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,100 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">TOTAL</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">6,017 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(3,642)</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,375 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">5,750 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(3,285)</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,465 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"> </div><div style="text-align:justify;text-indent:27pt">During the three and nine months ended September 30, 2023, amortization expense was $495 and $1,256, respectively, of which $303 and $899 was related to the amortization of right-of-use assets, respectively. During the three and nine months ended September 30, 2022, amortization expense was $432 and $1,254, respectively, of which $289 and $866 was related to the amortization of right-of-use assets, respectively. </div><div style="text-align:justify"> </div><div style="text-indent:24.75pt">Estimated amortization expense for each of the years ending December 31 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.837%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Year</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount</td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">2023 (remainder)</td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">192 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">234 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">234 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">234 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">234 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">234 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,013 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,375 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:24.75pt"> </div><div style="text-indent:24.75pt">Other indefinite-lived intangible assets consist of the following:</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2022</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Trade name</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">889 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">889 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare and Medicaid licenses</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,083 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,083 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom">TOTAL</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">3,972 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">3,972 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="4" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Life (Years)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2022</td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Carrying Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Carrying Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Intangible Assets</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Assembled occupancy</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom">0.3</td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">702 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(570)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">132 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">435 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(388)</td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">47 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Facility trade name</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">30.0</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">733 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(433)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">300 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">733 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(415)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">318 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Customer relationships</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">18.4</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,582 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,639)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,943 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,582 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,482)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,100 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">TOTAL</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">6,017 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(3,642)</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,375 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">5,750 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">(3,285)</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,465 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>

P0Y3M18D

702000

570000

132000

435000

388000

47000

P30Y

733000

433000

300000

733000

415000

318000

P18Y4M24D

4582000

2639000

1943000

4582000

2482000

2100000

6017000

3642000

2375000

5750000

3285000

2465000

495000

1256000

303000

899000

432000

1254000

289000

866000

Estimated amortization expense for each of the years ending December 31 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.837%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Year</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount</td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">2023 (remainder)</td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">192 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">234 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">234 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">234 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">234 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">234 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,013 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">2,375 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>

192000

234000

1013000

2375000

<div style="text-indent:24.75pt">Other indefinite-lived intangible assets consist of the following:</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2022</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Trade name</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">889 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">889 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare and Medicaid licenses</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,083 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,083 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom">TOTAL</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">3,972 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">3,972 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

889000

3083000

3972000

GOODWILL <div style="text-align:justify;text-indent:24.75pt">The Company anticipates that the majority of goodwill recognized will be fully deductible for tax purposes as of September 30, 2023. Provided that goodwill corresponds to the acquisition of a business and not merely the acquisition of real estate property, the Company's Standard Bearer segment appropriately does not carry a goodwill balance. The following table represents activity in goodwill by skilled service segment and "all other" category as of September 30, 2023 and December 31, 2022:</div><div style="text-align:justify;text-indent:24.75pt"> </div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">All Other</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Goodwill</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">67,886 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">8,983 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">76,869 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

The following table represents activity in goodwill by skilled service segment and "all other" category as of September 30, 2023 and December 31, 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Skilled Services</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">All Other</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">Goodwill</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">67,886 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">8,983 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">76,869 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>

67886000

8983000

76869000

RESTRICTED AND OTHER ASSETS<div style="margin-top:10pt;text-indent:24.75pt">Restricted and other assets consist of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2022</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Debt issuance costs, net</td><td style="background-color:#e4e9df;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,104 </td><td style="background-color:#e4e9df;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,753 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term insurance losses recoverable asset</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,439 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,512 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Capital improvement reserves with landlords and lenders</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,051 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,446 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Deposits with landlords</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,657 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,527 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Escrow deposits</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">325 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,403 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,053 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">RESTRICTED AND OTHER ASSETS</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">35,979 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">37,291 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt">Included in restricted and other assets as of September 30, 2023 and December 31, 2022 are anticipated insurance recoveries related to the Company's workers' compensation and general and professional liability claims that are recorded on a gross, rather than net, basis.</div>

Restricted and other assets consist of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2022</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Debt issuance costs, net</td><td style="background-color:#e4e9df;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,104 </td><td style="background-color:#e4e9df;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,753 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term insurance losses recoverable asset</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,439 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,512 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Capital improvement reserves with landlords and lenders</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,051 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,446 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Deposits with landlords</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,657 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,527 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Escrow deposits</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">325 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,403 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,053 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">RESTRICTED AND OTHER ASSETS</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">35,979 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">37,291 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>

3104000

3753000

13439000

10512000

5051000

6446000

2657000

2527000

325000

11403000

14053000

35979000 37291000

OTHER ACCRUED LIABILITIES<div style="text-indent:24.75pt">Other accrued liabilities consists of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2022</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Quality assurance fee</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">8,786 </td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">7,701 </td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Refunds payable</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46,274 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40,783 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Resident advances</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,920 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,698 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Unapplied state relief funds</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">636 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,001 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash held in trust for patients</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,357 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,400 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dividends payable</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,243 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,201 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Property taxes</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,371 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,926 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Income tax payable</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40,781 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Legal finding accrued</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,734 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,553 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,026 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,046 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">OTHER ACCRUED LIABILITIES</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">148,128 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">97,309 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"> </div><div style="text-align:justify;text-indent:24.75pt">Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the condensed consolidated balance sheets.</div>

Other accrued liabilities consists of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2022</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Quality assurance fee</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">8,786 </td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">7,701 </td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Refunds payable</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46,274 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40,783 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Resident advances</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,920 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,698 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Unapplied state relief funds</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">636 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,001 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash held in trust for patients</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,357 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,400 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dividends payable</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,243 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,201 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Property taxes</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,371 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,926 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Income tax payable</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40,781 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Legal finding accrued</td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,734 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,553 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,026 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,046 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">OTHER ACCRUED LIABILITIES</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">148,128 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">97,309 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>

8786000 7701000 46274000 40783000

5920000

9698000

636000 1001000 6357000 6400000

3243000

3201000

15371000

10926000

40781000

3734000

4553000

17026000

13046000

148128000

97309000

INCOME TAXES<div style="margin-top:10pt;text-align:justify;text-indent:22.5pt">The Company recorded income tax expense of $53,453 and $47,505 during the nine months ended September 30, 2023 and 2022, respectively, or 22.1% of earnings before income taxes for the nine months ended September 30, 2023, compared to 22.4% for the nine months ended September 30, 2022. The effective tax rate for both periods is driven by the impact of excess tax benefits from stock-based compensation, offset by non-deductible expenses including non-deductible compensation. </div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify;text-indent:22.5pt">The Company is not currently under examination by any major income tax jurisdiction. During 2023, the statutes of limitations will lapse on the Company's 2019 federal tax year and certain 2018 and 2019 state tax years. The Company does not believe the federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the Interim Financial Statements for the nine months ended September 30, 2023 and 2022.</div>

53453000

47505000

0.221

0.224

DEBT<div style="text-align:justify;text-indent:24.75pt">Debt consists of the following:</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2022</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Mortgage loans and promissory note</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">153,354 </td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">156,271 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Less: current maturities</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,916)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,883)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Less: debt issuance costs, net</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,985)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,119)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">LONG-TERM DEBT LESS CURRENT MATURITIES</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">146,453 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">149,269 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify">Credit Facility with a Lending Consortium Arranged by Truist </div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify;text-indent:22.5pt">The Company maintains a revolving credit facility between the Company and its subsidiaries, including Standard Bearer as co-borrowers, and Truist Securities (Truist) (the Credit Facility) with a revolving line of credit of up to $600,000 in aggregate principal amount with a maturity date of April 8, 2027. Borrowings are supported by a lending consortium arranged by Truist. The interest rates applicable to loans under the Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the credit agreement). In addition, there is a commitment fee on the unused portion of the commitments that ranges from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio. When the Company amended the Credit Facility in 2022 with the terms and conditions described above, it wrote off deferred financing costs of $566 and additional deferred financing costs of $3,197 were capitalized during the nine months ended September 30, 2022.</div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify;text-indent:22.5pt">Borrowings made under the Credit Facility are guaranteed, jointly and severally, by certain of the Company’s wholly owned subsidiaries, and are secured by a pledge of stock of the Company's material operating subsidiaries as well as a first lien on substantially all of such operating subsidiaries' personal property. The credit agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. The Company must comply with financial maintenance covenants to be tested quarterly, consisting of (i) a maximum consolidated total net debt to consolidated EBITDA ratio (which shall not be greater than 3.00:1.00; provided that if the aggregate consideration for approved acquisitions in a six month period is greater than $50,000, then the ratio can be increased at the election of the Company with notice to the administrative agent to 3.50:1.00 for the first fiscal quarter and the immediately following three fiscal quarters), and (ii) a minimum interest/rent coverage ratio (which cannot be less than 1.50:1.00). As of September 30, 2023, there was no outstanding debt under the Credit Facility. The Company was in compliance with all loan covenants as of September 30, 2023.</div><div style="margin-top:9pt;text-align:justify">Mortgage Loans and Promissory Note</div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify;text-indent:22.5pt">The Company has 23 subsidiaries that have mortgage loans insured with HUD in the aggregate amount of $151,063, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates in a range of 3.1% to 4.2%, including fixed interest rates in a range of 2.4% to 3.3% per annum. In addition to the interest rate, the Company incurs other fees for HUD placement, including but not limited to audit fees. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees based on the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10.0% and is reduced by 3.0% in the fourth year of the loan, and reduced by 1.0% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms for all the mortgage loans are 25 to 35 years. </div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify;text-indent:22.5pt">In addition to the HUD mortgage loans above, the Company has a promissory note of $2,291 that bears a fixed interest rate of 5.3% per annum and has a term of 12 years. The note, which was assumed as part of an acquisition, is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility. </div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt">Based on Level 2 inputs, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.</div><div style="margin-top:9pt;text-align:justify">Off-Balance Sheet Arrangements</div><div style="text-align:justify"> </div><div style="text-align:justify;text-indent:22.5pt">As of September 30, 2023, the Company had approximately $6,710 of borrowing capacity under the Credit Facility pledged as collateral to secure outstanding letters of credit.</div>

<div style="text-align:justify;text-indent:24.75pt">Debt consists of the following:</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2022</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Mortgage loans and promissory note</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">153,354 </td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">156,271 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Less: current maturities</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,916)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,883)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Less: debt issuance costs, net</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,985)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,119)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">LONG-TERM DEBT LESS CURRENT MATURITIES</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">146,453 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">149,269 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

153354000

156271000

3916000

3883000

2985000

3119000

146453000

149269000

600000000

0.0025

0.0125

0.0225

0.0020

0.0040

566000

3197000

3.00 P6M 50000000 3.50 1.50

151063000

0.031

0.042

0.024

0.033

0.100 0.030 0.010 0

P25Y

P35Y

2291000

0.053

P12Y

6710000

OPTIONS AND AWARDS<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">Stock-based compensation expense consists of stock-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s condensed consolidated statements of income for the three and nine months ended September 30, 2023 and 2022 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">2022 Omnibus Incentive Plan (2022 Plan) — The Company has one active stock incentive plan, the 2022 Omnibus Incentive Plan (the 2022 Plan). Including the shares rolled over from the 2017 Plan, the 2022 Plan provides for the issuance of 3,452 shares of common stock. The number of shares available to be issued under the 2022 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) two shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Non-employee director options, to the extent granted, will vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years from the date of grant. At September 30, 2023, the total number of shares available for issuance under the 2022 Plan was 1,856.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for stock option awards. Determining the appropriate fair-value model and calculating the fair value of stock option awards at the grant date requires judgment, including estimating stock price volatility, expected option life, and forfeiture rates. The fair-value of the restricted stock awards at the grant date is based on the market price on the grant date, adjusted for forfeiture rates. The Company develops estimates based on historical data which can change significantly over time. </div><div style="margin-top:9pt;text-align:justify">Stock Options</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The Company granted 193 and 606 stock options during the three and nine months ended September 30, 2023, respectively. The Company used the following assumptions for stock options granted during the three months ended September 30, 2023 and 2022: </div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Grant Year</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Options Granted</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Risk-Free Rate</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Expected Life</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Volatility</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Dividend Yield</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">193</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">4.4%</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">6.1 years</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">41.3%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">0.2%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2022</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">145</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">3.1%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">6.3 years</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">41.8%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">0.2%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify;text-indent:24.75pt">The Company used the following assumptions for stock options granted during the nine months ended September 30, 2023 and 2022:</div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Grant Year</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Options Granted</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Risk-Free Rate</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Expected Life</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Volatility</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Dividend Yield</td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">606</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">4.0%</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">6.2 years</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">41.4%</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">0.3%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2022</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">463</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2.5%</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">6.2 years</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">42.1%</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">0.3%</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">For the nine months ended September 30, 2023 and 2022, the following represents the exercise price and fair value displayed at grant date for stock option grants:</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.687%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Grant Year</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Granted</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Exercise Price</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Fair Value of Options</td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">606</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">92.54 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">42.50 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2022</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">463</td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">83.41 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">36.22 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify;text-indent:27pt">The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the nine month periods ended September 30, 2023 and 2022 and therefore, the intrinsic value was $0 at the date of grant. </div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt">The following table represents the employee stock option activity during the nine months ended September 30, 2023:</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of Options Outstanding</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Exercise Price</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of Options Vested</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Exercise Price of Options Vested</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">January 1, 2023</td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,833 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">46.72 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,069 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">28.87 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">606 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92.54 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Forfeited</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(77)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69.64 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Exercised</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(578)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.99 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">September 30, 2023</td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,784 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">57.37 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,960 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">37.69 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.892%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The aggregate intrinsic value of options outstanding, vested and expected to vest as of September 30, 2023 and December 31, 2022 is as follows:</div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Options</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2022</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding</td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">135,648 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">183,593 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">108,275 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">136,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Expected to vest</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,910 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,232 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options. The aggregate intrinsic value of options that vested during the nine months ended September 30, 2023 and 2022 was $16,856 and $15,810, respectively. The total intrinsic value of options exercised during the nine months ended September 30, 2023 and 2022 was $43,299 and $36,151, respectively.</div><div style="margin-top:9pt;text-align:justify">Restricted Stock Awards</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The Company granted 49 and 215 restricted stock awards during the three and nine months ended September 30, 2023, respectively. The Company granted 41 and 199 restricted stock awards during the three and nine months ended September 30, 2022, respectively. All awards were granted at an issue price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the nine months ended September 30, 2023 and 2022 ranged from $89.83 to $98.31 and $73.17 to $90.50, respectively. The fair value per share includes quarterly stock awards to non-employee directors. </div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">A summary of the status of the Company's non-vested restricted stock awards as of September 30, 2023 and changes during the nine months ended September 30, 2023 is presented below: </div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Non-Vested Restricted Awards</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Grant Date Fair Value</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Nonvested at January 1, 2023</td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">487 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">64.92 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">215 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">91.96 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(225)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64.29 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forfeited</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(19)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">70.64 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Nonvested at September 30, 2023</td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">458 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">77.81 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">During the three and nine months ended September 30, 2023, the Company granted 4 and 13 automatic quarterly stock awards to non-employee directors for their service on the Company's board of directors, respectively. The fair value per share of these stock awards ranged from $89.94 to $98.31 based on the market price on the grant date. </div><div style="margin-top:9pt;text-align:justify">Long-Term Incentive Plan</div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:24.75pt">On August 27, 2019, the Board approved the Long-Term Incentive Plan (the 2019 LTI Plan). The 2019 LTI Plan provides that certain employees of the Company who assisted in the consummation of the spin-off of Pennant from the Company in 2019 (spin-off transaction) were granted shares of restricted stock upon successful completion of the spin-off transaction. The 2019 LTI Plan provides for the issuance of 500 shares of Pennant restricted stock. The shares are vested over five years at 20% per year on the anniversary of the grant date. If a recipient is terminated or voluntarily leaves the Company, all shares subject to restriction or not yet vested shall be entirely forfeited. The total stock-based compensation related to the 2019 LTI Plan was approximately $218 and $620 for the three and nine months ended September 30, 2023, respectively, compared to $248 and $638 for the three and nine months ended September 30, 2022, respectively.</div><div style="margin-top:9pt;text-align:justify">Stock-based compensation expense</div><div style="text-align:justify"> </div><div style="text-align:justify;text-indent:24.75pt">Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the three and nine months ended September 30, 2023 and 2022 was as follows:</div><div style="text-align:justify;text-indent:24.75pt"> </div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.869%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Stock-based compensation expense related to stock options</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">4,051 </td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">2,983 </td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">12,439 </td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">8,289 </td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Stock-based compensation expense related to restricted stock awards</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,774 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,579 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,983 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,337 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">405 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">336 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,262 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,055 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">TOTAL</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">7,230 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">5,898 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">22,684 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">16,681 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify;text-indent:24.75pt"> </div><div style="text-align:justify;text-indent:24.75pt">In future periods, the Company expects to recognize approximately $54,532 and $32,210 in stock-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of September 30, 2023. Future stock-based compensation expense will be recognized over 3.8 and 3.6 weighted average years for unvested options and restricted stock awards, respectively. There were 1,824 unvested and outstanding options as of September 30, 2023, of which 1,667 shares are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest as of September 30, 2023 was 6.5 years.</div>

3452000

1 2 3

P3Y

P5Y

0.20

P10Y

1856000

193000

606000

The Company used the following assumptions for stock options granted during the three months ended September 30, 2023 and 2022: <div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Grant Year</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Options Granted</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Risk-Free Rate</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Expected Life</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Volatility</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Dividend Yield</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">193</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">4.4%</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">6.1 years</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">41.3%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">0.2%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2022</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">145</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">3.1%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">6.3 years</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">41.8%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">0.2%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify;text-indent:24.75pt">The Company used the following assumptions for stock options granted during the nine months ended September 30, 2023 and 2022:</div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Grant Year</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Options Granted</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Risk-Free Rate</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Expected Life</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Volatility</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Dividend Yield</td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">606</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">4.0%</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">6.2 years</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">41.4%</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">0.3%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2022</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">463</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2.5%</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">6.2 years</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">42.1%</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">0.3%</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>

193000

0.044

P6Y1M6D

0.413

0.002

145000

0.031

P6Y3M18D

0.418

0.002

606000

0.040

P6Y2M12D

0.414

0.003

463000

0.025

P6Y2M12D

0.421

0.003

<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">For the nine months ended September 30, 2023 and 2022, the following represents the exercise price and fair value displayed at grant date for stock option grants:</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.687%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Grant Year</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Granted</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Exercise Price</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Fair Value of Options</td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">606</td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">92.54 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">42.50 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2022</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">463</td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">83.41 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">36.22 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>

606000

92.54

42.50

463000

83.41

36.22

<div style="margin-top:12pt;text-align:justify;text-indent:24.75pt">The following table represents the employee stock option activity during the nine months ended September 30, 2023:</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of Options Outstanding</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Exercise Price</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of Options Vested</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Exercise Price of Options Vested</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">January 1, 2023</td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,833 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">46.72 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,069 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">28.87 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">606 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92.54 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Forfeited</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(77)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69.64 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Exercised</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(578)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.99 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">September 30, 2023</td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,784 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">57.37 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,960 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">37.69 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

3833000

46.72

2069000

28.87

606000

92.54

77000

69.64

578000

21.99

3784000

57.37

1960000

37.69

<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The aggregate intrinsic value of options outstanding, vested and expected to vest as of September 30, 2023 and December 31, 2022 is as follows:</div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Options</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2022</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding</td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">135,648 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">183,593 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">108,275 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">136,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Expected to vest</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,910 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,232 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>

135648000

183593000

108275000

136000000

25910000 43232000

16856000

15810000

43299000

36151000

49000

215000

41000

199000

P5Y

89.83

98.31

73.17

90.50

<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">A summary of the status of the Company's non-vested restricted stock awards as of September 30, 2023 and changes during the nine months ended September 30, 2023 is presented below: </div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Non-Vested Restricted Awards</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Grant Date Fair Value</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Nonvested at January 1, 2023</td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">487 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">64.92 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">215 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">91.96 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(225)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64.29 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forfeited</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(19)</td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">70.64 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Nonvested at September 30, 2023</td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">458 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom">77.81 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

487000

64.92

215000

91.96

225000

64.29

19000

70.64

458000

77.81

4000

13000

89.94

98.31

500000

P5Y

0.20

218000

620000

248000

638000

<div style="text-align:justify;text-indent:24.75pt">Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the three and nine months ended September 30, 2023 and 2022 was as follows:</div><div style="text-align:justify;text-indent:24.75pt"> </div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.869%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Stock-based compensation expense related to stock options</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">4,051 </td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">2,983 </td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">12,439 </td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">8,289 </td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Stock-based compensation expense related to restricted stock awards</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,774 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,579 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,983 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,337 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">405 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">336 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,262 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,055 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">TOTAL</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">7,230 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">5,898 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">22,684 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">16,681 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>

4051000

2983000

12439000

8289000

2774000

2579000

8983000

7337000

405000

336000

1262000

1055000

7230000

5898000

22684000

16681000

54532000

32210000

P3Y9M18D

P3Y7M6D

1824000 1667000

P6Y6M

LEASES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 affiliated skilled nursing and senior living facilities used in the Company’s operations, 96 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and been continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024. </div><div style="margin-top:10.05pt;text-align:justify;text-indent:22.5pt">The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense under the Master Leases was approximately $16,741 and $49,698 for the three and nine months ended September 30, 2023, respectively, and $16,259 and $47,911 for the three and nine months ended September 30, 2022, respectively.</div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt">Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of September 30, 2023. </div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt">In connection with the spin-off transaction that occurred in 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued. </div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt">The Company leases certain affiliated operations and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $50,480 and $147,126 for the three and nine months ended September 30, 2023, respectively, and $38,940 and $111,976 for the three and nine months ended September 30, 2022, respectively.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">Eighty of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under 13 separate master lease arrangements. In the first quarter of 2023, the Company expanded its operations through two separate master lease arrangements for 20 stand-alone skilled nursing operations, of which 17 are operated by the Company's affiliated operating subsidiaries and the remaining three are subleased to a third-party operator. These two master leases increased the lease liabilities and right-of-use assets by $325,369 to reflect the new lease obligations and have initial lease terms of 18 and 20 years. In the third quarter of 2023, the Company expanded its operations through one separate master lease arrangement for two stand-alone skilled nursing operations. This master lease increased the lease liabilities and right-of-use assets by $21,420 to reflect the new lease obligations and has an initial lease terms of 20 years. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.</div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify;text-indent:22.5pt">The components of operating lease expense are as follows:</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.455%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Rent - cost of services(1)</div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">50,357 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">38,907 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">146,754 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">111,897 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">General and administrative expense</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">123 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">372 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Depreciation and amortization(2)</div></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">303 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">289 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">899 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">866 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Variable lease costs(3)</div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,376 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,121 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,362 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,256 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">56,159 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">43,350 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">163,387 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">126,098 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>(1) Rent- cost of services includes deferred rent expense adjustments of $211 and $692 for the three and nine months ended September 30, 2023, respectively, and $111 and of $351 for the three and nine months ended September 30, 2022, respectively. Additionally, rent- cost of services includes other variable lease costs such as CPI increases and short-term leases of $2,859 and $7,317 for the three and nine months ended September 30, 2023, respectively, and $1,758 and $3,997 for the three and nine months ended September 30, 2022, respectively.</div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt">(2) Depreciation and amortization is related to the amortization of favorable and direct lease costs.</div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt">(3) Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.</div><div style="text-align:justify">Future minimum lease payments for all leases as of September 30, 2023 are as follows: </div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Year</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount</td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom">2023 (remainder)</td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">47,730 </td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">191,035 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">190,946 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">190,729 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">190,147 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">188,906 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,719,921 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">TOTAL LEASE PAYMENTS</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,719,414 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Less: present value adjustment </td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(980,503)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">PRESENT VALUE OF TOTAL LEASE LIABILITIES</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,738,911 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Less: current lease liabilities</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(80,956)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">LONG-TERM OPERATING LEASE LIABILITIES</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">1,657,955 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of September 30, 2023, the weighted average remaining lease term is 15.1 years and the weighted average discount rate used to determine the operating lease liabilities is 6.5%. </div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt">Subsequent to September 30, 2023, the Company expanded its operations through a long-term lease arrangement with the addition of one stand-alone skilled nursing facility, adding a total of 45 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries. </div><div style="margin-top:9pt;text-align:justify">Lessor Activities</div><div style="text-align:justify"> </div><div style="text-align:justify;text-indent:22.5pt">The Company leases its owned real estate properties to third party operators, of which 29 senior living operations are operated by The Pennant Group, Inc. (Pennant). All of these properties are triple-net leases, whereby the respective tenants are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range between 14 to 16 years. </div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify;text-indent:22.5pt">During the first quarter of 2023, the Company entered into a sublease agreement for three stand-alone skilled nursing operations with a third-party operator with an initial lease term of 18 years. Additionally, during the three months ended September 30, 2023, the Company entered into a lease agreement with a third-party operator for one campus operation with an initial lease term of 15 years.</div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt">Total rental income from all third-party sources for the three and nine months ended September 30, 2023 and 2022 is as follows:</div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.455%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Pennant(1)</div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">3,740 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">3,664 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">11,224 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">11,169 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Other third-party</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,727 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">458 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,410 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,381 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">TOTAL</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">5,467 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">4,122 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">15,634 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">12,550 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify">(1) Pennant rental income includes variable rent such as property taxes of $324 and $974 during the three and nine months ended September 30, 2023, respectively, and $331 and $988 for the three and nine months ended September 30, 2022, respectively. In addition, the number of senior living operations leased to and operated by Pennant was 29 during the nine months ended September 30, 2023 and decreased from 32 to 29 during the nine months ended September 30, 2022.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">Future annual rental income for all leases as of September 30, 2023 were as follows:</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Year</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Amount(1)</div></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">2023 (remainder)</td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">5,493 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,526 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,023 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,788 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,762 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,737 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">128,013 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">TOTAL</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">238,342 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of September 30, 2023.

97 96 9

P13Y

P20Y

2 3

P5Y

4 97 0

0.025

16741000

49698000

16259000

47911000

P20Y

P5Y

50480000

147126000

38940000

111976000

80 13 2

3 2

325369000

P18Y

P20Y

21420000

P20Y

<div style="text-align:justify;text-indent:22.5pt">The components of operating lease expense are as follows:</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.455%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Rent - cost of services(1)</div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">50,357 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">38,907 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">146,754 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">111,897 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">General and administrative expense</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">123 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">372 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Depreciation and amortization(2)</div></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">303 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">289 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">899 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">866 </td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Variable lease costs(3)</div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,376 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,121 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,362 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,256 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">56,159 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">43,350 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">163,387 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">126,098 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>(1) Rent- cost of services includes deferred rent expense adjustments of $211 and $692 for the three and nine months ended September 30, 2023, respectively, and $111 and of $351 for the three and nine months ended September 30, 2022, respectively. Additionally, rent- cost of services includes other variable lease costs such as CPI increases and short-term leases of $2,859 and $7,317 for the three and nine months ended September 30, 2023, respectively, and $1,758 and $3,997 for the three and nine months ended September 30, 2022, respectively.</div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt">(2) Depreciation and amortization is related to the amortization of favorable and direct lease costs.</div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt">(3) Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.</div>

50357000

38907000

146754000

111897000

123000

33000

372000

79000

303000

289000

899000

866000

5376000

4121000

15362000

13256000

56159000

43350000

163387000

126098000

211000 692000 111000 351000

2859000

7317000

1758000

3997000

<div style="text-align:justify">Future minimum lease payments for all leases as of September 30, 2023 are as follows: </div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Year</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount</td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom">2023 (remainder)</td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom">47,730 </td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">191,035 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">190,946 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">190,729 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">190,147 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">188,906 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,719,921 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">TOTAL LEASE PAYMENTS</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,719,414 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Less: present value adjustment </td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(980,503)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">PRESENT VALUE OF TOTAL LEASE LIABILITIES</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,738,911 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Less: current lease liabilities</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(80,956)</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">LONG-TERM OPERATING LEASE LIABILITIES</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">1,657,955 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

47730000

191035000

190946000

190729000

190147000

188906000

1719921000

2719414000

980503000

1738911000

80956000

1657955000

P15Y1M6D

0.065

45 29

P14Y

P16Y

P18Y

P15Y

<div style="margin-top:10pt;text-align:justify;text-indent:22.5pt">Total rental income from all third-party sources for the three and nine months ended September 30, 2023 and 2022 is as follows:</div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.455%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Pennant(1)</div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">3,740 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">3,664 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">11,224 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">11,169 </td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Other third-party</td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,727 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">458 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,410 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,381 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">TOTAL</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">5,467 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">4,122 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">15,634 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">12,550 </td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify">(1) Pennant rental income includes variable rent such as property taxes of $324 and $974 during the three and nine months ended September 30, 2023, respectively, and $331 and $988 for the three and nine months ended September 30, 2022, respectively. In addition, the number of senior living operations leased to and operated by Pennant was 29 during the nine months ended September 30, 2023 and decreased from 32 to 29 during the nine months ended September 30, 2022.</div>

3740000

3664000

11224000

11169000

1727000

458000

4410000

1381000

5467000

4122000

15634000

12550000

324000

974000

331000

988000

29 32 29

<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">Future annual rental income for all leases as of September 30, 2023 were as follows:</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Year</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Amount(1)</div></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">2023 (remainder)</td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">5,493 </td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,526 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,023 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,788 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,762 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,737 </td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">128,013 </td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom">TOTAL</td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom">238,342 </td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of September 30, 2023.

5493000

21526000

21023000

20788000

20762000

20737000

128013000

238342000

DEFINED CONTRIBUTION PLANS<div style="text-align:justify;text-indent:22.5pt">The Company has a 401(k) defined contribution plan (the 401(k) Plan), whereby eligible employees may contribute up to 90% of their annual basic earnings, subject to applicable annual Internal Revenue Code limits. Additionally, the 401(k) Plan provides for discretionary matching contributions (as defined in the 401(k) Plan) by the Company.</div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify;text-indent:22.5pt">The Company has a non-qualified deferred compensation plan (the DCP), whereby certain highly compensated employees who are otherwise ineligible to participate in the Company's 401(k) plan, may defer the receipt of a portion of their base compensation and, for certain employees, up to 100% of their eligible bonuses. Additionally, the DCP allows for the employee deferrals to be deposited into a rabbi trust and the funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to fund savings plans of this nature. The Company paid for related administrative costs, which were not significant during three and nine months ended September 30, 2023 and 2022. </div><div style="text-align:justify;text-indent:22.5pt"> </div><div style="text-align:justify;text-indent:22.5pt"> As of September 30, 2023 and December 31, 2022, the Company accrued $42,613 and $33,017, respectively, as long term deferred compensation in other long term liabilities on the consolidated balance sheet. Cash surrender value of the contracts is based on investment funds that shadow the investment allocations specified by participants in the deferred compensation plan. Refer to Note 5, Fair Value Measurements for more information on the funds.</div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt">For the three months ended September 30, 2023, the Company recorded a loss related to its DCP of $1,424, which is included in other income (expense), net, and recorded an offsetting reduction in expense of $1,352, which is allocated between cost of services and general and administrative expenses. For the nine months ended September 30, 2023, the company recorded a gain related to its DCP of $1,065, which is included in other income (expense), net, and recorded an offsetting expense of $1,261, which is allocated between cost of services and general and administrative expenses.</div>For the three and nine months ended September 30, 2022, the Company recorded a loss related to its DCP of $1,135 and $5,650, respectively, which is included in other income (expense), net. During the same periods, the Company recorded an offsetting reduction in expense of $1,055 and $5,566, respectively, which is allocated between cost of services and general and administrative expenses.

0.90

42613000

33017000

-1424000

-1352000

1065000

1261000

-1135000

-5650000

-1055000 -5566000

COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Regulatory Matters — Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is monitoring performed by the Office of Civil Rights which covers the Health Insurance Portability and Accountability Act of 1996, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Cost-Containment Measures — Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">Indemnities — From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental obligations or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent operating subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and others, under which the Company may be required to indemnify such persons for liabilities arising out of the nature of their relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s condensed consolidated balance sheets for any of the periods presented.</div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt">In connection with the spin-off transaction in 2019, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the transaction. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties. </div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt">U.S. Department of Justice Civil Investigative Demand — On May 31, 2018, the Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice (DOJ) stating that it was investigating whether there had been a violation of the False Claims Act (FCA) and/or the Anti-Kickback Statute (AKS) with respect to relationships between certain of the Company’s independently operated skilled nursing facilities and persons who serve or have served as medical directors. The Company fully cooperated with the DOJ and promptly responded to its requests for information. In April 2020, the Company was advised that the DOJ declined to intervene in any subsequent action filed in connection with the subject matter of this investigation. Despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator has moved forward with the lawsuit. The Company is vigorously defending this lawsuit, but expects the costs of defense to be significant given the nature of the allegations and the date range contemplated by the complaint. At this time, the Company is unable to estimate the range of loss and cannot predict the final outcome of this lawsuit. If this lawsuit is ultimately resolved against the Company, the amounts owed, including fines, penalties and other consequences relating to the lawsuit, could have a material adverse effect on the Company's results of operations, financial condition and cash flows. As a general matter, the Company’s independent operating entities have established and maintain policies and procedures to promote compliance with the FCA, the AKS, and other applicable regulatory requirements. </div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">U.S. House of Representatives Select Subcommittee Request — In 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company received a document and information request from the House Select Subcommittee in connection with its investigation. The Company cooperated in responding to this inquiry. In July 2022 and thereafter, the Company received follow up requests for additional documents and information. The Company responded to these requests and continued to cooperate with the House Select Subcommittee in connection with its investigation. On December 9, 2022, the House Select Subcommittee issued its final report summarizing its investigation and related recommendations designed "to strengthen the nation's ability to prevent and respond to public health and economic emergencies." According to the information provided by the House Select Subcommittee, the issuance of this report was the House Select Subcommittee's final official act.</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Litigation — The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents served by the Company's independent operating subsidiaries. The Company, its independent operating subsidiaries, and others in the industry are subject to an increasing number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. In addition, the Company, its independent operating subsidiaries, and others in the industry are subject to claims and lawsuits in connection with COVID-19 and a facility's preparation for and/or response to COVID-19. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards. </div><div style="text-align:justify;text-indent:24.75pt">In addition to the potential lawsuits and claims described above, the Company and its independent operating subsidiaries are also subject to potential lawsuits under the FCA and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from federally funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Under the qui tam or "whistleblower" provisions of the FCA, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the federal Government and receive a percentage of the federal Government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. For example, and despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator has moved forward with the lawsuit and is pursuing claims that the Company and certain of its independent operating subsidiaries allegedly violated the FCA and/or AKS. The Company is vigorously defending this lawsuit, but expects the costs of defense to be significant given the nature of the allegations and the date range contemplated by the complaint. </div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">In addition to the FCA, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the FCA. As such, the Company and its independent operating subsidiaries could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent operating subsidiaries do business.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) which made significant changes to the FCA and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a FCA violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent operating subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements, and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent operating subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and related causes of action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company’s business, cash flows, financial condition or results of operations.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The Company and its independent operating subsidiaries have been, and continue to be, subject to claims, findings and legal actions that arise in the ordinary course of the various businesses, including healthcare and non-healthcare services. These claims include, but are not limited to, potential claims filed by residents, customers, patients and responsible parties related to patient care and treatment (professional negligence claims); non-care based activities of certain of the subsidiaries; and employment related claims filed by current or former employees. A significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. In addition, these claims could impact the Company's ability to procure insurance to cover its exposure related to the various services provided by its independent operating subsidiaries to their residents, customers and patients.</div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The Company and its independent operating subsidiaries are also subject to requests for information and investigations by other state and federal governmental entities (e.g., Offices of the Attorney General and Offices of the Inspector General). The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent operating subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under federal Medicare statutes, the FCA, or similar state and federal statutes and related regulations, or if the Company or its independent operating subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations, and may also include the assumption of specific procedural and financial obligations by the Company or its independent operating subsidiaries under a Corporate Integrity Agreement and/or other such arrangement.</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Medicare Revenue Recoupments — The Company's independent operating subsidiaries are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate (TPE) Program. Beginning in August 2020, CMS resumed TPE Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. The Company anticipates that these Reviews could increase in frequency in the future. As of September 30, 2023 and through the filing date of this report, 41 of the Company's independent operating subsidiaries had Reviews scheduled or in process. </div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">CMS announced a new nationwide audit, the “SNF 5-Claim Probe & Educate Review”, in which the Medicare Administrative Contractors (MACs) will review five claims from each SNF to check for compliance. In implementing this SNF 5-Claim Probe & Educate Review, CMS acknowledged that the increase in observed improper payments from 2021 to 2022 may have arisen from a "misunderstanding" by SNFs about how to appropriately bill for claims of service after October 1, 2019. All facilities that are not undergoing TPE reviews, or have not recently passed a TPE review, will be subject to the nationwide audit. MACs will complete only one round of probe-and-educate for each SNF, rather than three rounds that typically occur in the TPE Program. Additionally, CMS's education for each SNF will be individualized and based on observed claim review errors, with rationales for denial explained to the SNF on a claim-by-claim basis. This program applies only to claims submitted after October 1, 2019, and will exclude claims containing a COVID-19 diagnosis.</div><div style="margin-top:9pt;text-align:justify">Concentrations</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Credit Risk — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. </div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt">The Company’s receivables from Medicare and Medicaid payor programs accounted for 54.9% and 56.3% of its total accounts receivable as of September 30, 2023 and December 31, 2022, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 72.1% and 72.8% of the Company's revenue for the three and nine months ended September 30, 2023, respectively, and 73.7% and 73.5% for the three and nine months ended September 30, 2022.</div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt">Cash in Excess of FDIC Limits — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of September 30, 2023, the Company's uninsured cash deposits are not material. All uninsured bank deposits are held at high quality credit institutions.</div>

41 41

0.549

0.563

0.721

0.728

0.737

0.735

COMMON STOCK REPURCHASE PROGRAMOn August 29, 2023, the Board of Directors approved a stock repurchase program pursuant to which the Company may repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from September 1, 2023. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The Company did not purchase any shares pursuant to this stock repurchase program during the three months ended September 30, 2023.<div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt">On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company may repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from August 2, 2022. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program does not obligate the Company to acquire any specific number of shares. The stock repurchase program expired on August 2, 2023 and is no longer in effect. The Company did not purchase any shares pursuant to this stock repurchase program. </div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt">On February 9, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from February 10, 2022. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the three months ended June 30, 2022, the Company repurchased 271 shares of its common stock for $20,000. This repurchase program expired in 2022 upon the repurchase of the fully authorized amount under the plan and is no longer in effect. </div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt">On October 21, 2021, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from October 29, 2021. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the first quarter of 2022, the Company repurchased 133 shares of its common stock for $9,882 pursuant to this stock repurchase program. This repurchase program expired in 2022 upon the repurchase of the fully authorized amount under the plan and is no longer in effect.</div>

20000000

P12M

20000000

P12M

20000000

P12M

271000

20000000

P12M

133000

9882000

false false false Spencer W. Burton, President & Chief Operations Officer, entered into a Rule 10b5-1 trading arrangement on September 12, 2023 (the "Rule 10b5-1 Plan"). Mr. Burton's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 8,280 shares of the Company's common stock between December 14, 2023 and August 30, 2024. Pursuant to the 10b5-1 Plan, Mr. Burton may also make a gift of up to 2,380 shares of the Company's common stock starting on December 14, 2023. Spencer W. Burton President & Chief Operations Officer true September 12, 2023 8280

EXCEL 100 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
65<_-1J2 MHP8 ! Y / " 7Y @!X;"]W;W)K8F]O:RYX;6Q02P$" M% ,4 " !W@%E70,IUT8X" !,,P &@ @ %.1P( >&PO M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !W@%E7(=OYL3$" M #-,0 $P @ $42@( 6T-O;G1E;G1?5'EP97-=+GAM;%!+ 4!08 7P!? ! : !V3 ( ! end XML 101 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 102 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 103 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 488 411 1 false 120 0 false 18 false false R1.htm 0000001 - Document - Cover Sheet http://www.ensigngroup.net/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME Statements 4 false false R5.htm 0000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 0000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 0000008 - Disclosure - DESCRIPTION OF BUSINESS Sheet http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS DESCRIPTION OF BUSINESS Notes 8 false false R9.htm 0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 0000010 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE Sheet http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE REVENUE AND ACCOUNTS RECEIVABLE Notes 10 false false R11.htm 0000011 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE Sheet http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE COMPUTATION OF NET INCOME PER COMMON SHARE Notes 11 false false R12.htm 0000012 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 12 false false R13.htm 0000013 - Disclosure - STANDARD BEARER Sheet http://www.ensigngroup.net/role/STANDARDBEARER STANDARD BEARER Notes 13 false false R14.htm 0000014 - Disclosure - OPERATION EXPANSIONS Sheet http://www.ensigngroup.net/role/OPERATIONEXPANSIONS OPERATION EXPANSIONS Notes 14 false false R15.htm 0000015 - Disclosure - BUSINESS SEGMENTS Sheet http://www.ensigngroup.net/role/BUSINESSSEGMENTS BUSINESS SEGMENTS Notes 15 false false R16.htm 0000016 - Disclosure - PROPERTY AND EQUIPMENT??? NET Sheet http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET PROPERTY AND EQUIPMENT??? NET Notes 16 false false R17.htm 0000017 - Disclosure - INTANGIBLE ASSETS ??? NET Sheet http://www.ensigngroup.net/role/INTANGIBLEASSETSNET INTANGIBLE ASSETS ??? NET Notes 17 false false R18.htm 0000018 - Disclosure - GOODWILL Sheet http://www.ensigngroup.net/role/GOODWILL GOODWILL Notes 18 false false R19.htm 0000019 - Disclosure - RESTRICTED AND OTHER ASSETS Sheet http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS RESTRICTED AND OTHER ASSETS Notes 19 false false R20.htm 0000020 - Disclosure - OTHER ACCRUED LIABILITIES Sheet http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES OTHER ACCRUED LIABILITIES Notes 20 false false R21.htm 0000021 - Disclosure - INCOME TAXES Sheet http://www.ensigngroup.net/role/INCOMETAXES INCOME TAXES Notes 21 false false R22.htm 0000022 - Disclosure - DEBT Sheet http://www.ensigngroup.net/role/DEBT DEBT Notes 22 false false R23.htm 0000023 - Disclosure - OPTIONS AND AWARDS Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDS OPTIONS AND AWARDS Notes 23 false false R24.htm 0000024 - Disclosure - LEASES Sheet http://www.ensigngroup.net/role/LEASES LEASES Notes 24 false false R25.htm 0000025 - Disclosure - DEFINED CONTRIBUTION PLANS Sheet http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS DEFINED CONTRIBUTION PLANS Notes 25 false false R26.htm 0000026 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 26 false false R27.htm 0000027 - Disclosure - COMMON STOCK REPURCHASE PROGRAM Sheet http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM COMMON STOCK REPURCHASE PROGRAM Notes 27 false false R28.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 28 false false R29.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 29 false false R30.htm 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 30 false false R31.htm 9954472 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE (Tables) Sheet http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables REVENUE AND ACCOUNTS RECEIVABLE (Tables) Tables http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE 31 false false R32.htm 9954473 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Tables) Sheet http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables COMPUTATION OF NET INCOME PER COMMON SHARE (Tables) Tables http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE 32 false false R33.htm 9954474 - Disclosure - BUSINESS SEGMENTS (Tables) Sheet http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables BUSINESS SEGMENTS (Tables) Tables http://www.ensigngroup.net/role/BUSINESSSEGMENTS 33 false false R34.htm 9954475 - Disclosure - PROPERTY AND EQUIPMENT??? NET (Tables) Sheet http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETTables PROPERTY AND EQUIPMENT??? NET (Tables) Tables http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET 34 false false R35.htm 9954476 - Disclosure - INTANGIBLE ASSETS ??? NET (Tables) Sheet http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables INTANGIBLE ASSETS ??? NET (Tables) Tables http://www.ensigngroup.net/role/INTANGIBLEASSETSNET 35 false false R36.htm 9954477 - Disclosure - GOODWILL (Tables) Sheet http://www.ensigngroup.net/role/GOODWILLTables GOODWILL (Tables) Tables http://www.ensigngroup.net/role/GOODWILL 36 false false R37.htm 9954478 - Disclosure - RESTRICTED AND OTHER ASSETS (Tables) Sheet http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables RESTRICTED AND OTHER ASSETS (Tables) Tables http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS 37 false false R38.htm 9954479 - Disclosure - OTHER ACCRUED LIABILITIES (Tables) Sheet http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables OTHER ACCRUED LIABILITIES (Tables) Tables http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES 38 false false R39.htm 9954480 - Disclosure - DEBT (Tables) Sheet http://www.ensigngroup.net/role/DEBTTables DEBT (Tables) Tables http://www.ensigngroup.net/role/DEBT 39 false false R40.htm 9954481 - Disclosure - OPTIONS AND AWARDS (Tables) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables OPTIONS AND AWARDS (Tables) Tables http://www.ensigngroup.net/role/OPTIONSANDAWARDS 40 false false R41.htm 9954482 - Disclosure - LEASES (Tables) Sheet http://www.ensigngroup.net/role/LEASESTables LEASES (Tables) Tables http://www.ensigngroup.net/role/LEASES 41 false false R42.htm 9954483 - Disclosure - DESCRIPTION OF BUSINESS (Details) Sheet http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails DESCRIPTION OF BUSINESS (Details) Details http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS 42 false false R43.htm 9954484 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) Details 43 false false R44.htm 9954485 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details) Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details) Details 44 false false R45.htm 9954486 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details) Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details) Details 45 false false R46.htm 9954487 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details) Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details) Details 46 false false R47.htm 9954488 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Revenue from Medicare and Medicaid Programs and State Relief Funding (Details) Sheet http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails REVENUE AND ACCOUNTS RECEIVABLE - Revenue from Medicare and Medicaid Programs and State Relief Funding (Details) Details 47 false false R48.htm 9954489 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) Sheet http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) Details 48 false false R49.htm 9954490 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details) Sheet http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details) Details 49 false false R50.htm 9954491 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Details) Sheet http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails COMPUTATION OF NET INCOME PER COMMON SHARE (Details) Details http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables 50 false false R51.htm 9954492 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails FAIR VALUE MEASUREMENTS (Details) Details http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS 51 false false R52.htm 9954493 - Disclosure - STANDARD BEARER (Details) Sheet http://www.ensigngroup.net/role/STANDARDBEARERDetails STANDARD BEARER (Details) Details http://www.ensigngroup.net/role/STANDARDBEARER 52 false false R53.htm 9954494 - Disclosure - OPERATION EXPANSIONS (Details) Sheet http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails OPERATION EXPANSIONS (Details) Details http://www.ensigngroup.net/role/OPERATIONEXPANSIONS 53 false false R54.htm 9954495 - Disclosure - BUSINESS SEGMENTS - Narrative (Details) Sheet http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails BUSINESS SEGMENTS - Narrative (Details) Details 54 false false R55.htm 9954496 - Disclosure - BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details) Sheet http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details) Details 55 false false R56.htm 9954497 - Disclosure - BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details) Sheet http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details) Details 56 false false R57.htm 9954498 - Disclosure - PROPERTY AND EQUIPMENT??? NET - Schedule of Property and Equipment (Details) Sheet http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails PROPERTY AND EQUIPMENT??? NET - Schedule of Property and Equipment (Details) Details 57 false false R58.htm 9954499 - Disclosure - PROPERTY AND EQUIPMENT??? NET - Narrative (Details) Sheet http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails PROPERTY AND EQUIPMENT??? NET - Narrative (Details) Details 58 false false R59.htm 9954500 - Disclosure - INTANGIBLE ASSETS ??? NET - Schedule of Finite Lived Intangible Assets (Details) Sheet http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails INTANGIBLE ASSETS ??? NET - Schedule of Finite Lived Intangible Assets (Details) Details 59 false false R60.htm 9954501 - Disclosure - INTANGIBLE ASSETS ??? NET - Narrative (Details) Sheet http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails INTANGIBLE ASSETS ??? NET - Narrative (Details) Details 60 false false R61.htm 9954502 - Disclosure - INTANGIBLE ASSETS ??? NET - Future Amortization (Details) Sheet http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails INTANGIBLE ASSETS ??? NET - Future Amortization (Details) Details 61 false false R62.htm 9954503 - Disclosure - INTANGIBLE ASSETS ??? NET - Schedule of Indefinite-lived Intangible Assets (Details) Sheet http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails INTANGIBLE ASSETS ??? NET - Schedule of Indefinite-lived Intangible Assets (Details) Details 62 false false R63.htm 9954504 - Disclosure - GOODWILL (Details) Sheet http://www.ensigngroup.net/role/GOODWILLDetails GOODWILL (Details) Details http://www.ensigngroup.net/role/GOODWILLTables 63 false false R64.htm 9954505 - Disclosure - RESTRICTED AND OTHER ASSETS (Details) Sheet http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails RESTRICTED AND OTHER ASSETS (Details) Details http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables 64 false false R65.htm 9954506 - Disclosure - OTHER ACCRUED LIABILITIES (Details) Sheet http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails OTHER ACCRUED LIABILITIES (Details) Details http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables 65 false false R66.htm 9954507 - Disclosure - INCOME TAXES (Details) Sheet http://www.ensigngroup.net/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://www.ensigngroup.net/role/INCOMETAXES 66 false false R67.htm 9954508 - Disclosure - DEBT - Schedule of Long-term Debt (Details) Sheet http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails DEBT - Schedule of Long-term Debt (Details) Details 67 false false R68.htm 9954509 - Disclosure - DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details) Sheet http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details) Details 68 false false R69.htm 9954510 - Disclosure - DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details) Notes http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details) Details 69 false false R70.htm 9954511 - Disclosure - OPTIONS AND AWARDS - Stock Options, Narrative (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails OPTIONS AND AWARDS - Stock Options, Narrative (Details) Details 70 false false R71.htm 9954512 - Disclosure - OPTIONS AND AWARDS - Valuation Assumptions (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails OPTIONS AND AWARDS - Valuation Assumptions (Details) Details 71 false false R72.htm 9954513 - Disclosure - OPTIONS AND AWARDS - Exercise Price and Fair Value (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails OPTIONS AND AWARDS - Exercise Price and Fair Value (Details) Details 72 false false R73.htm 9954514 - Disclosure - OPTIONS AND AWARDS - Options Outstanding Rollforward (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails OPTIONS AND AWARDS - Options Outstanding Rollforward (Details) Details 73 false false R74.htm 9954515 - Disclosure - OPTIONS AND AWARDS - Intrinsic Values (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails OPTIONS AND AWARDS - Intrinsic Values (Details) Details 74 false false R75.htm 9954516 - Disclosure - OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details) Details 75 false false R76.htm 9954517 - Disclosure - OPTIONS AND AWARDS - Restricted Award Rollforward (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails OPTIONS AND AWARDS - Restricted Award Rollforward (Details) Details 76 false false R77.htm 9954518 - Disclosure - OPTIONS AND AWARDS - Long-Term Incentive Plan (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails OPTIONS AND AWARDS - Long-Term Incentive Plan (Details) Details 77 false false R78.htm 9954519 - Disclosure - OPTIONS AND AWARDS - Compensation Expense (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails OPTIONS AND AWARDS - Compensation Expense (Details) Details 78 false false R79.htm 9954520 - Disclosure - LEASES - Lessee Narrative (Details) Sheet http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails LEASES - Lessee Narrative (Details) Details 79 false false R80.htm 9954521 - Disclosure - LEASES - Lessee Lease Cost (Details) Sheet http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails LEASES - Lessee Lease Cost (Details) Details 80 false false R81.htm 9954522 - Disclosure - LEASES - Lessee Future Minimum Lease Payments (Details) Sheet http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails LEASES - Lessee Future Minimum Lease Payments (Details) Details 81 false false R82.htm 9954523 - Disclosure - LEASES - Lessor Narrative (Details) Sheet http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails LEASES - Lessor Narrative (Details) Details 82 false false R83.htm 9954524 - Disclosure - LEASES - Lessor Rental Income (Details) Sheet http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails LEASES - Lessor Rental Income (Details) Details 83 false false R84.htm 9954525 - Disclosure - LEASES - Lessor Future Minimum Lease Payments Receivable (Details) Sheet http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails LEASES - Lessor Future Minimum Lease Payments Receivable (Details) Details 84 false false R85.htm 9954526 - Disclosure - DEFINED CONTRIBUTION PLANS (Details) Sheet http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails DEFINED CONTRIBUTION PLANS (Details) Details http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS 85 false false R86.htm 9954527 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES 86 false false R87.htm 9954528 - Disclosure - COMMON STOCK REPURCHASE PROGRAM (Details) Sheet http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails COMMON STOCK REPURCHASE PROGRAM (Details) Details http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM 87 false false All Reports Book All Reports ensg-20230930.htm ensg-20230930.xsd ensg-20230930_cal.xml ensg-20230930_def.xml ensg-20230930_lab.xml ensg-20230930_pre.xml ensg-20230930_g1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 106 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ensg-20230930.htm": { "nsprefix": "ensg", "nsuri": "http://www.ensigngroup.net/20230930", "dts": { "inline": { "local": [ "ensg-20230930.htm" ] }, "schema": { "local": [ "ensg-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "ensg-20230930_cal.xml" ] }, "definitionLink": { "local": [ "ensg-20230930_def.xml" ] }, "labelLink": { "local": [ "ensg-20230930_lab.xml" ] }, "presentationLink": { "local": [ "ensg-20230930_pre.xml" ] } }, "keyStandard": 344, "keyCustom": 67, "axisStandard": 36, "axisCustom": 5, "memberStandard": 52, "memberCustom": 64, "hidden": { "total": 11, "http://fasb.org/us-gaap/2023": 5, "http://xbrl.sec.gov/dei/2023": 5, "http://xbrl.sec.gov/ecd/2023": 1 }, "contextCount": 488, "entityCount": 1, "segmentCount": 120, "elementCount": 775, "unitCount": 18, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1285, "http://xbrl.sec.gov/ecd/2023": 10, "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://www.ensigngroup.net/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "0000002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R4": { "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "longName": "0000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R5": { "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "0000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-54", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-60", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R6": { "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical", "longName": "0000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R8": { "role": "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS", "longName": "0000008 - Disclosure - DESCRIPTION OF BUSINESS", "shortName": "DESCRIPTION OF BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE", "longName": "0000010 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE", "longName": "0000011 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE", "shortName": "COMPUTATION OF NET INCOME PER COMMON SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS", "longName": "0000012 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.ensigngroup.net/role/STANDARDBEARER", "longName": "0000013 - Disclosure - STANDARD BEARER", "shortName": "STANDARD BEARER", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "ensg:StandardBearerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ensg:StandardBearerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.ensigngroup.net/role/OPERATIONEXPANSIONS", "longName": "0000014 - Disclosure - OPERATION EXPANSIONS", "shortName": "OPERATION EXPANSIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTS", "longName": "0000015 - Disclosure - BUSINESS SEGMENTS", "shortName": "BUSINESS SEGMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET", "longName": "0000016 - Disclosure - PROPERTY AND EQUIPMENT\u2014 NET", "shortName": "PROPERTY AND EQUIPMENT\u2014 NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNET", "longName": "0000017 - Disclosure - INTANGIBLE ASSETS \u2014 NET", "shortName": "INTANGIBLE ASSETS \u2014 NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.ensigngroup.net/role/GOODWILL", "longName": "0000018 - Disclosure - GOODWILL", "shortName": "GOODWILL", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS", "longName": "0000019 - Disclosure - RESTRICTED AND OTHER ASSETS", "shortName": "RESTRICTED AND OTHER ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES", "longName": "0000020 - Disclosure - OTHER ACCRUED LIABILITIES", "shortName": "OTHER ACCRUED LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.ensigngroup.net/role/INCOMETAXES", "longName": "0000021 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.ensigngroup.net/role/DEBT", "longName": "0000022 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDS", "longName": "0000023 - Disclosure - OPTIONS AND AWARDS", "shortName": "OPTIONS AND AWARDS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.ensigngroup.net/role/LEASES", "longName": "0000024 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS", "longName": "0000025 - Disclosure - DEFINED CONTRIBUTION PLANS", "shortName": "DEFINED CONTRIBUTION PLANS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES", "longName": "0000026 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM", "longName": "0000027 - Disclosure - COMMON STOCK REPURCHASE PROGRAM", "shortName": "COMMON STOCK REPURCHASE PROGRAM", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": null }, "R29": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-13", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables", "longName": "9954472 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE (Tables)", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables", "longName": "9954473 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)", "shortName": "COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables", "longName": "9954474 - Disclosure - BUSINESS SEGMENTS (Tables)", "shortName": "BUSINESS SEGMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETTables", "longName": "9954475 - Disclosure - PROPERTY AND EQUIPMENT\u2014 NET (Tables)", "shortName": "PROPERTY AND EQUIPMENT\u2014 NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables", "longName": "9954476 - Disclosure - INTANGIBLE ASSETS \u2014 NET (Tables)", "shortName": "INTANGIBLE ASSETS \u2014 NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.ensigngroup.net/role/GOODWILLTables", "longName": "9954477 - Disclosure - GOODWILL (Tables)", "shortName": "GOODWILL (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables", "longName": "9954478 - Disclosure - RESTRICTED AND OTHER ASSETS (Tables)", "shortName": "RESTRICTED AND OTHER ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables", "longName": "9954479 - Disclosure - OTHER ACCRUED LIABILITIES (Tables)", "shortName": "OTHER ACCRUED LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.ensigngroup.net/role/DEBTTables", "longName": "9954480 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables", "longName": "9954481 - Disclosure - OPTIONS AND AWARDS (Tables)", "shortName": "OPTIONS AND AWARDS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.ensigngroup.net/role/LEASESTables", "longName": "9954482 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "longName": "9954483 - Disclosure - DESCRIPTION OF BUSINESS (Details)", "shortName": "DESCRIPTION OF BUSINESS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "ensg:NumberOfHealthCareFacilities", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ensg:NumberOfHealthCareFacilities", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails", "longName": "9954484 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-97", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-97", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails", "longName": "9954485 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "ensg:NumberOfFinancingLeases", "unitRef": "lease", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:LesseeLeasesPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ensg:NumberOfFinancingLeases", "unitRef": "lease", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:LesseeLeasesPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails", "longName": "9954486 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-100", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-100", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails", "longName": "9954487 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EstimatedInsuranceRecoveries", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "us-gaap:SelfInsuranceReservePolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-110", "name": "us-gaap:MalpracticeLossContingencyAccrualUndiscounted", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "us-gaap:SelfInsuranceReservePolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R47": { "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails", "longName": "9954488 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Revenue from Medicare and Medicaid Programs and State Relief Funding (Details)", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE - Revenue from Medicare and Medicaid Programs and State Relief Funding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "ensg:FamilyFirstCoronavirusResponseActPaymentsReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R48": { "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "longName": "9954489 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details)", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": null }, "R49": { "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "longName": "9954490 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details)", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsReceivableGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsReceivableGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "longName": "9954491 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Details)", "shortName": "COMPUTATION OF NET INCOME PER COMMON SHARE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails", "longName": "9954492 - Disclosure - FAIR VALUE MEASUREMENTS (Details)", "shortName": "FAIR VALUE MEASUREMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-185", "name": "us-gaap:DeferredCompensationPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-185", "name": "us-gaap:DeferredCompensationPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "longName": "9954493 - Disclosure - STANDARD BEARER (Details)", "shortName": "STANDARD BEARER (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NumberOfRealEstateProperties", "unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-215", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R53": { "role": "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "longName": "9954494 - Disclosure - OPERATION EXPANSIONS (Details)", "shortName": "OPERATION EXPANSIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "ensg:OperationalSkilledNursingBeds", "unitRef": "bed", "xsiNil": "false", "lang": "en-US", "decimals": "-2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-225", "name": "ensg:OperationalSkilledNursingBeds", "unitRef": "bed", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R54": { "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "longName": "9954495 - Disclosure - BUSINESS SEGMENTS - Narrative (Details)", "shortName": "BUSINESS SEGMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "longName": "9954496 - Disclosure - BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details)", "shortName": "BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "ensg:SegmentIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R56": { "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "longName": "9954497 - Disclosure - BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details)", "shortName": "BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-292", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R57": { "role": "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails", "longName": "9954498 - Disclosure - PROPERTY AND EQUIPMENT\u2014 NET - Schedule of Property and Equipment (Details)", "shortName": "PROPERTY AND EQUIPMENT\u2014 NET - Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails", "longName": "9954499 - Disclosure - PROPERTY AND EQUIPMENT\u2014 NET - Narrative (Details)", "shortName": "PROPERTY AND EQUIPMENT\u2014 NET - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-344", "name": "us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-344", "name": "us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "longName": "9954500 - Disclosure - INTANGIBLE ASSETS \u2014 NET - Schedule of Finite Lived Intangible Assets (Details)", "shortName": "INTANGIBLE ASSETS \u2014 NET - Schedule of Finite Lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "longName": "9954501 - Disclosure - INTANGIBLE ASSETS \u2014 NET - Narrative (Details)", "shortName": "INTANGIBLE ASSETS \u2014 NET - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails", "longName": "9954502 - Disclosure - INTANGIBLE ASSETS \u2014 NET - Future Amortization (Details)", "shortName": "INTANGIBLE ASSETS \u2014 NET - Future Amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails", "longName": "9954503 - Disclosure - INTANGIBLE ASSETS \u2014 NET - Schedule of Indefinite-lived Intangible Assets (Details)", "shortName": "INTANGIBLE ASSETS \u2014 NET - Schedule of Indefinite-lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.ensigngroup.net/role/GOODWILLDetails", "longName": "9954504 - Disclosure - GOODWILL (Details)", "shortName": "GOODWILL (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-360", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R64": { "role": "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails", "longName": "9954505 - Disclosure - RESTRICTED AND OTHER ASSETS (Details)", "shortName": "RESTRICTED AND OTHER ASSETS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails", "longName": "9954506 - Disclosure - OTHER ACCRUED LIABILITIES (Details)", "shortName": "OTHER ACCRUED LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-3", "name": "ensg:QualityAssuranceFee", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ensg:QualityAssuranceFee", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.ensigngroup.net/role/INCOMETAXESDetails", "longName": "9954507 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R67": { "role": "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails", "longName": "9954508 - Disclosure - DEBT - Schedule of Long-term Debt (Details)", "shortName": "DEBT - Schedule of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DeferredFinanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R68": { "role": "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "longName": "9954509 - Disclosure - DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details)", "shortName": "DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:WriteOffOfDeferredDebtIssuanceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-366", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R69": { "role": "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "longName": "9954510 - Disclosure - DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)", "shortName": "DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LettersOfCreditOutstandingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LettersOfCreditOutstandingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "longName": "9954511 - Disclosure - OPTIONS AND AWARDS - Stock Options, Narrative (Details)", "shortName": "OPTIONS AND AWARDS - Stock Options, Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-3", "name": "ensg:NumberOfOptionPlans", "unitRef": "plan", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R71": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails", "longName": "9954512 - Disclosure - OPTIONS AND AWARDS - Valuation Assumptions (Details)", "shortName": "OPTIONS AND AWARDS - Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R72": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails", "longName": "9954513 - Disclosure - OPTIONS AND AWARDS - Exercise Price and Fair Value (Details)", "shortName": "OPTIONS AND AWARDS - Exercise Price and Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R73": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails", "longName": "9954514 - Disclosure - OPTIONS AND AWARDS - Options Outstanding Rollforward (Details)", "shortName": "OPTIONS AND AWARDS - Options Outstanding Rollforward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails", "longName": "9954515 - Disclosure - OPTIONS AND AWARDS - Intrinsic Values (Details)", "shortName": "OPTIONS AND AWARDS - Intrinsic Values (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "longName": "9954516 - Disclosure - OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details)", "shortName": "OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-1", "name": "ensg:SharebasedCompensationRestrictedAwardsExercisePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ensg:SharebasedCompensationRestrictedAwardsExercisePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "longName": "9954517 - Disclosure - OPTIONS AND AWARDS - Restricted Award Rollforward (Details)", "shortName": "OPTIONS AND AWARDS - Restricted Award Rollforward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-394", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-394", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "longName": "9954518 - Disclosure - OPTIONS AND AWARDS - Long-Term Incentive Plan (Details)", "shortName": "OPTIONS AND AWARDS - Long-Term Incentive Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-400", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R78": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "longName": "9954519 - Disclosure - OPTIONS AND AWARDS - Compensation Expense (Details)", "shortName": "OPTIONS AND AWARDS - Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R79": { "role": "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "longName": "9954520 - Disclosure - LEASES - Lessee Narrative (Details)", "shortName": "LEASES - Lessee Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:LesseeLeasesPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-426", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R80": { "role": "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails", "longName": "9954521 - Disclosure - LEASES - Lessee Lease Cost (Details)", "shortName": "LEASES - Lessee Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:LeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:LeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails", "longName": "9954522 - Disclosure - LEASES - Lessee Future Minimum Lease Payments (Details)", "shortName": "LEASES - Lessee Future Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "longName": "9954523 - Disclosure - LEASES - Lessor Narrative (Details)", "shortName": "LEASES - Lessor Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-452", "name": "ensg:LessorOperatingLeaseNumberOfLeases", "unitRef": "lease", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-434", "name": "ensg:LessorOperatingLeaseNumberOfLeases", "unitRef": "lease", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R83": { "role": "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails", "longName": "9954524 - Disclosure - LEASES - Lessor Rental Income (Details)", "shortName": "LEASES - Lessor Rental Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-464", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-464", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails", "longName": "9954525 - Disclosure - LEASES - Lessor Future Minimum Lease Payments Receivable (Details)", "shortName": "LEASES - Lessor Future Minimum Lease Payments Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails", "longName": "9954526 - Disclosure - DEFINED CONTRIBUTION PLANS (Details)", "shortName": "DEFINED CONTRIBUTION PLANS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R86": { "role": "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "longName": "9954527 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-3", "name": "ensg:IndependentOperatingSubsidiariesUnderMedicareProbeReviews", "unitRef": "subsidiary", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-472", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } }, "R87": { "role": "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails", "longName": "9954528 - Disclosure - COMMON STOCK REPURCHASE PROGRAM (Details)", "shortName": "COMMON STOCK REPURCHASE PROGRAM (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-74", "name": "us-gaap:TreasuryStockValueAcquiredCostMethod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-476", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20230930.htm", "unique": true } } }, "tag": { "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubleaseIncome", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sublease Income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r547", "r753" ] }, "us-gaap_AccruedIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxes", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax payable", "label": "Accrued Income Taxes", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes." } } }, "auth_ref": [ "r112", "r113", "r158", "r168", "r576" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING", "verboseLabel": "DENOMINATOR:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Lease, cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r543", "r753" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY AND EQUIPMENT\u2014 NET", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r142", "r186", "r189", "r190" ] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CPI increases and short term-lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r545", "r753" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS" ], "lang": { "en-us": { "role": { "terseLabel": "DESCRIPTION OF BUSINESS", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r110", "r161", "r615", "r616" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r544", "r753" ] }, "us-gaap_LessorLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorLeaseDescriptionLineItems", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor, Lease, Description [Line Items]", "label": "Lessor, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r556" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease, costs", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r546", "r753" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends declared", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r150" ] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of deferred financing costs", "terseLabel": "Payments of deferred financing costs", "label": "Payments of Financing Costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r38" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r133" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r26", "r200", "r232", "r307", "r348", "r349", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r509", "r512", "r513", "r526", "r754", "r890", "r999", "r1000" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r896" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents beginning of period", "periodEndLabel": "Cash and cash equivalents end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r42", "r133", "r229" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r143" ] }, "us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromDepositsOnRealEstateAcquisitions", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Escrow deposits", "label": "Payments for (Proceeds from) Deposits on Real Estate Acquisitions", "documentation": "Net cash outflow or inflow from the amount given in advance to show intention to complete the acquisition piece of land, anything permanently fixed to it, including buildings, structures on it, and so forth." } } }, "auth_ref": [] }, "us-gaap_LessorLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorLeaseDescriptionTable", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor, Lease, Description [Table]", "label": "Lessor, Lease, Description [Table]", "documentation": "Disclosure of information about lessor's leases." } } }, "auth_ref": [ "r556" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate, effective percentage", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r27", "r102", "r389", "r536" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate, stated percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r27", "r363" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r344", "r345", "r346", "r347", "r426", "r434", "r466", "r467", "r468", "r566", "r567", "r608", "r630", "r631", "r684", "r686", "r688", "r689", "r691", "r712", "r713", "r725", "r732", "r745", "r756", "r759", "r884", "r894", "r1002", "r1003", "r1004", "r1005", "r1006" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r569" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "negatedTerseLabel": "Less: allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r210", "r305", "r310" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r423", "r733", "r734", "r735", "r736", "r737", "r738", "r739" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r344", "r345", "r346", "r347", "r434", "r567", "r608", "r630", "r631", "r684", "r686", "r688", "r689", "r691", "r712", "r713", "r725", "r732", "r745", "r756", "r894", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r327", "r329", "r330", "r332", "r569", "r570" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r344", "r345", "r346", "r347", "r426", "r434", "r466", "r467", "r468", "r566", "r567", "r608", "r630", "r631", "r684", "r686", "r688", "r689", "r691", "r712", "r713", "r725", "r732", "r745", "r756", "r759", "r884", "r894", "r1002", "r1003", "r1004", "r1005", "r1006" ] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingAndBuildingImprovementsMember", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings and improvements", "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r423", "r733", "r734", "r735", "r736", "r737", "r738", "r739" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r344", "r345", "r346", "r347", "r434", "r567", "r608", "r630", "r631", "r684", "r686", "r688", "r689", "r691", "r712", "r713", "r725", "r732", "r745", "r756", "r894", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006" ] }, "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromInsuranceSettlementOperatingActivities", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash received from insurance proceeds", "label": "Proceeds from Insurance Settlement, Operating Activities", "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities." } } }, "auth_ref": [ "r225", "r714" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Controlling Interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r91", "r403", "r863", "r864", "r865", "r1017" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r66", "r69" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r87", "r88", "r505", "r743", "r744" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r28", "r236", "r362", "r363", "r364", "r365", "r366", "r368", "r373", "r374", "r375", "r376", "r378", "r379", "r380", "r381", "r382", "r383", "r536", "r727", "r728", "r729", "r730", "r731", "r859" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r91", "r92", "r94", "r194", "r195", "r217", "r237", "r238", "r239", "r241", "r247", "r308", "r309", "r403", "r475", "r476", "r477", "r496", "r497", "r514", "r515", "r516", "r517", "r518", "r519", "r521", "r527", "r528", "r532", "r559", "r610", "r611", "r623", "r642", "r658", "r680", "r681", "r694", "r767", "r860", "r871", "r989", "r1017" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r505", "r743", "r744" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r205", "r330" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r505" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r840" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r984" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r818" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r774", "r785", "r795", "r820" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r984" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r819" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r140" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r140" ] }, "us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesOfIndividuallyImmaterialAssetAcquisitionsMember", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series of Individually Immaterial Asset Acquisitions", "label": "Series of Individually Immaterial Asset Acquisitions [Member]", "documentation": "Series of individually immaterial asset acquisitions." } } }, "auth_ref": [ "r984" ] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r96", "r97", "r98" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r140" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r817" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r140" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r140" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 (remainder)", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNET" ], "lang": { "en-us": { "role": { "terseLabel": "INTANGIBLE ASSETS \u2014 NET", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r326" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21", "r754" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, purchase price", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r749", "r985", "r986", "r987" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r838" ] }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series of Individually Immaterial Business Acquisitions", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period." } } }, "auth_ref": [ "r88" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r819" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r838" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r237", "r238", "r239", "r266", "r568", "r617", "r626", "r632", "r633", "r634", "r635", "r636", "r637", "r640", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r653", "r654", "r655", "r656", "r657", "r659", "r661", "r662", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r679", "r760" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Services", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r806" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r24", "r232", "r307", "r348", "r349", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r509", "r512", "r513", "r526", "r638", "r723", "r768", "r890", "r999", "r1000" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r819" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r774", "r785", "r795", "r820" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred financing fees", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r383", "r535", "r730", "r731", "r858" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r819" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r784", "r792", "r802", "r819", "r827", "r831", "r839" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r784", "r792", "r802", "r819", "r827", "r831", "r839" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r838" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, options outstanding, weighted average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r155" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r120", "r172", "r581", "r754", "r860", "r871", "r989" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected Life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r465" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r834" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/GOODWILLDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r236", "r273", "r284", "r285", "r286", "r287", "r288", "r290", "r294", "r348", "r349", "r350", "r351", "r353", "r354", "r356", "r358", "r359", "r890", "r891" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r837" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r833" ] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Taxes Paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r41", "r43" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r769" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r838" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/GOODWILLDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r236", "r273", "r284", "r285", "r286", "r287", "r288", "r290", "r294", "r348", "r349", "r350", "r351", "r353", "r354", "r356", "r358", "r359", "r890", "r891" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r835" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Estimates and Assumptions", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r55", "r56", "r57", "r184", "r185", "r187", "r188" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r117", "r150", "r579", "r612", "r613", "r621", "r641", "r754" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r836" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r837" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price (in dollars per share)", "verboseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r449" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r771" ] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, unused capacity, commitment fee percentage", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r450" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r837" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r233", "r483", "r490", "r491", "r494", "r498", "r502", "r503", "r504", "r622" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of shares of common stock (Note 20)", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r39" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r772" ] }, "ensg_PayorAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "PayorAxis", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payor [Axis]", "label": "Payor [Axis]", "documentation": "Payor [Axis]" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "srt_ParentCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ParentCompanyMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Parent Company", "label": "Parent Company [Member]" } } }, "auth_ref": [ "r236" ] }, "us-gaap_OtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "RESTRICTED AND OTHER ASSETS", "label": "Other Assets Disclosure [Text Block]", "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r805" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r215", "r484", "r485", "r491", "r492", "r493", "r495", "r618" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "verboseLabel": "Options Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r449" ] }, "us-gaap_PaymentsToMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToMinorityShareholders", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-controlling interest distribution", "label": "Payments to Noncontrolling Interests", "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest." } } }, "auth_ref": [ "r38" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r533", "r562" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ensg_OwnedPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "OwnedPropertiesMember", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Owned Properties", "label": "Owned Properties [Member]", "documentation": "Owned Properties" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Less: net income (loss) attributable to noncontrolling interests", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest." } } }, "auth_ref": [ "r91", "r162" ] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Investments\u2014current", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r173", "r174", "r853" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r71", "r203", "r583" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility with Truist", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases and Leasehold Improvements", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r541" ] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "ensg_OperationalSkilledNursingBeds": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "OperationalSkilledNursingBeds", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operational skilled nursing beds", "label": "Operational Skilled Nursing Beds", "documentation": "Number of skilled nursing beds available for use at a skilled nursing facility" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases of lessee, contingent rentals, basis spread on variable rate", "label": "Lessee, Operating Lease, Discount Rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": [ "r752" ] }, "ensg_PurchasesOfNonControllingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "PurchasesOfNonControllingInterest", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of non-controlling interest", "label": "Purchases of Non-Controlling Interest", "documentation": "Purchases of Non-Controlling Interest" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "ensg_February92022RepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "February92022RepurchaseProgramMember", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "February 9, 2022 Repurchase Program", "label": "February 9, 2022 Repurchase Program [Member]", "documentation": "February 9, 2022 Repurchase Program" } } }, "auth_ref": [] }, "ensg_LessorOperatingLeaseNumberOfLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "LessorOperatingLeaseNumberOfLeases", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of leases", "label": "Lessor, Operating Lease, Number Of Leases", "documentation": "Lessor, Operating Lease, Number Of New Leases" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease Expenses", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r992" ] }, "ensg_ThirdPartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "ThirdPartiesMember", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third Parties", "label": "Third Parties [Member]", "documentation": "Third Parties" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationPlanAssets", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred rent receivable", "label": "Deferred Compensation Plan Assets", "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements." } } }, "auth_ref": [ "r852" ] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r542" ] }, "ensg_NumberOfOperations": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "NumberOfOperations", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operations lease and operated by third parties", "label": "Number Of Operations", "documentation": "Number Of Operations" } } }, "auth_ref": [] }, "ensg_NumberOfLivingOperationsTransferredFromThirdParties": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "NumberOfLivingOperationsTransferredFromThirdParties", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operations transferred from third parties", "label": "Number of Living Operations Transferred From Third-Parties", "documentation": "Number of Living Operations Transferred From Third-Parties" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.ensigngroup.net/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r537" ] }, "ensg_TotalNetDebtRatioMinimum": { "xbrltype": "pureItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "TotalNetDebtRatioMinimum", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total net debt ratio, minimum", "label": "Total Net Debt Ratio, Minimum", "documentation": "Total Net Debt Ratio, Minimum" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization", "netLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r7", "r276" ] }, "ensg_SegmentIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "SegmentIncomeLoss", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment income (loss)", "label": "Segment Income (Loss)", "documentation": "Segment Income (Loss)" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r770" ] }, "ensg_InsuranceCoverageLimitTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "InsuranceCoverageLimitTypeDomain", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance Coverage Limit Type [Domain]", "label": "Insurance Coverage Limit Type [Domain]", "documentation": "Insurance Coverage Limit Type [Domain]" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r375", "r427", "r428", "r429", "r430", "r431", "r432", "r563", "r564", "r565", "r728", "r729", "r740", "r741", "r742" ] }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property taxes", "label": "Accrual for Taxes Other than Income Taxes", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes." } } }, "auth_ref": [ "r86", "r107", "r1008" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDS" ], "lang": { "en-us": { "role": { "terseLabel": "OPTIONS AND AWARDS", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r435", "r440", "r471", "r472", "r474", "r746" ] }, "ensg_InsuranceCoverageLimitTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "InsuranceCoverageLimitTypeAxis", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance Coverage Limit Type [Axis]", "label": "Insurance Coverage Limit Type [Axis]", "documentation": "Insurance Coverage Limit Type [Axis]" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r28" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r770" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r542" ] }, "ensg_CareTrustREITMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "CareTrustREITMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CareTrust REIT", "label": "CareTrust REIT [Member]", "documentation": "CareTrust REIT [Member]" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r770" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts Receivable", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r32" ] }, "ensg_VariousLandlordsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "VariousLandlordsMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Various Landlords", "label": "Various Landlords [Member]", "documentation": "Various Landlords[Member]" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r770" ] }, "ensg_NumberOfRealEstatePropertiesLeased": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "NumberOfRealEstatePropertiesLeased", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of real estate properties leased", "label": "Number of Real Estate Properties Leased", "documentation": "Number of Real Estate Properties Leased" } } }, "auth_ref": [] }, "ensg_StandardBearerHealthcareREITIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "StandardBearerHealthcareREITIncMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Standard Bearer Healthcare REIT, Inc.", "label": "Standard Bearer Healthcare REIT, Inc. [Member]", "documentation": "Standard Bearer Healthcare REIT, Inc." } } }, "auth_ref": [] }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of installments", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments", "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments" } } }, "auth_ref": [] }, "ensg_LesseeOperatingLeaseNumberOfLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "LesseeOperatingLeaseNumberOfLeases", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of stand-alone leases", "label": "Lessee, Operating Lease, Number Of Leases", "documentation": "Lessee, Operating Lease, Number Of Leases" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities of investments", "label": "Proceeds from Sale, Maturity and Collection of Investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": [ "r35" ] }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends payable", "label": "Dividends Payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } }, "auth_ref": [ "r112", "r113", "r169", "r765", "r1008" ] }, "ensg_PerFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "PerFacilityMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Per Facility", "label": "Per Facility [Member]", "documentation": "Per Facility [Member]" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r747" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r32" ] }, "ensg_MedicareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "MedicareMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicare", "verboseLabel": "Medicare", "netLabel": "Medicare", "label": "Medicare [Member]", "documentation": "Revenue from Medicare [Member]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r6" ] }, "ensg_AmendedSeparateMasterLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "AmendedSeparateMasterLeases", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended of separate master leases", "label": "Amended Separate Master Leases", "documentation": "Amended Separate Master Leases" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total Ensign Group, Inc. stockholders' equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r115", "r118", "r119", "r137", "r642", "r658", "r680", "r681", "r754", "r768", "r860", "r871", "r989", "r1017" ] }, "ensg_ManagementServiceTotalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "ManagementServiceTotalMember", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Management Fee", "label": "Management Service, Total [Member]", "documentation": "Management Service, Total" } } }, "auth_ref": [] }, "us-gaap_SelfInsuranceReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SelfInsuranceReserveCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued self-insurance liabilities\u2014current", "label": "Self Insurance Reserve, Current", "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer)." } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r867" ] }, "us-gaap_SelfInsuranceReserveNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SelfInsuranceReserveNoncurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued self-insurance liabilities\u2014less current portion", "label": "Self Insurance Reserve, Noncurrent", "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer)." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r23" ] }, "us-gaap_GoodwillDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/GOODWILL" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL", "label": "Goodwill Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill." } } }, "auth_ref": [ "r312", "r314", "r324", "r726" ] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Noncontrolling interests attributable to subsidiary equity plan", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": [ "r150" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r51", "r53", "r99", "r100", "r300", "r699" ] }, "us-gaap_RealEstatePropertiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstatePropertiesLineItems", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Properties [Line Items]", "label": "Real Estate Properties [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Lender [Domain]", "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r23", "r859" ] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lender Name [Axis]", "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r23", "r859" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of options that vested in period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Change in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r6" ] }, "us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Less:", "label": "Net Income (Loss) Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: present value adjustment", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r552" ] }, "ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "OtherStatesExceptCaliforniaTexasAndWashingtonMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other States, Except California, Texas and Washington", "label": "Other states, except California, Texas and Washington [Member]", "documentation": "Other states, except California, Texas and Washington" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 }, "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "PRESENT VALUE OF TOTAL LEASE LIABILITIES", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r539" ] }, "us-gaap_NumberOfRealEstateProperties": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfRealEstateProperties", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of real estate properties", "label": "Number of Real Estate Properties", "documentation": "The number of real estate properties owned as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Payables and Accruals [Abstract]", "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r524" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities\u2014current", "negatedLabel": "Less: current lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r539" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted net income per common share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r220", "r242", "r243", "r244", "r245", "r246", "r253", "r258", "r259", "r260", "r264", "r522", "r523", "r572", "r589", "r722" ] }, "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesOfLessorDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessor, Operating Leases [Text Block]", "documentation": "The entire disclosure for lessor's operating leases." } } }, "auth_ref": [ "r553" ] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease obligations", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r850", "r857" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r271", "r285", "r291", "r294", "r724" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r839" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term lease liabilities\u2014less current portion", "verboseLabel": "LONG-TERM OPERATING LEASE LIABILITIES", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r539" ] }, "us-gaap_ScheduleOfRealEstatePropertiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRealEstatePropertiesTable", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Real Estate Properties [Table]", "label": "Schedule of Real Estate Properties [Table]", "documentation": "Schedule detailing quantitative information concerning real estate properties and units within those properties by ownership of the property." } } }, "auth_ref": [] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends declared", "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r4", "r150" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r76" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r42", "r201", "r718" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r838" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Nonvested Restricted Stock Awards", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r81" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "% of Revenue", "terseLabel": "Revenue %", "netLabel": "Concentration percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r51", "r53", "r99", "r100", "r300" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]", "label": "Liability for Claims and Claims Adjustment Expense [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting rights, percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r958" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Exercise Price and Fair Value Displayed at Grant Date for Stock Option Grants", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year." } } }, "auth_ref": [ "r82" ] }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]", "label": "Liability for Claims and Claims Adjustment Expense [Table]", "documentation": "Disclosure of information about the liability for claims and claims adjustment expense." } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r199", "r212", "r232", "r307", "r348", "r349", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r508", "r512", "r526", "r754", "r890", "r891", "r999" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee Stock Option Roll Forward", "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in common stock outstanding." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r197" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Aggregate Intrinsic Value of Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block]", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r156" ] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecurityDeposit", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": { "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits with landlords", "label": "Security Deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": [ "r852" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r807" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Resident advances", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r404", "r405", "r424" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assumptions for Stock Options Granted", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r157" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r807" ] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS" ], "lang": { "en-us": { "role": { "terseLabel": "DEFINED CONTRIBUTION PLANS", "label": "Compensation and Employee Benefit Plans [Text Block]", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": [ "r151", "r152", "r153", "r154" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r810" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r743", "r744" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r809" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade name", "verboseLabel": "Facility trade name", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r89" ] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized amount", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r808" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS SEGMENTS", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r267", "r268", "r269", "r270", "r271", "r283", "r288", "r292", "r293", "r294", "r295", "r296", "r297", "r300" ] }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanDisclosureLineItems", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Contribution Plan Disclosure [Line Items]", "label": "Defined Contribution Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r433" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r808" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r743", "r744" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r809" ] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Service Revenue by Major Payor Source", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r61", "r62" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Financial Information", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r58", "r59", "r60", "r63" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r58", "r59", "r60", "r63" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r810" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r810" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "COMPUTATION OF NET INCOME PER COMMON SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r250", "r261", "r262", "r263" ] }, "us-gaap_DefinedContributionPlanTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanTable", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Contribution Plan [Table]", "label": "Defined Contribution Plan [Table]", "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans." } } }, "auth_ref": [ "r433" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) attributable to noncontrolling interest", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r95", "r164", "r213", "r214", "r248", "r249", "r587", "r855" ] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of credit outstanding, pledged amount", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingRevenueReconcilingItemLineItems", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r810" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Income before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r121", "r175", "r271", "r285", "r291", "r294", "r573", "r585", "r724" ] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r61", "r62" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "NET INCOME", "terseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r198", "r213", "r214", "r224", "r232", "r240", "r248", "r249", "r271", "r285", "r291", "r294", "r307", "r348", "r349", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r507", "r510", "r511", "r523", "r526", "r573", "r586", "r624", "r660", "r677", "r678", "r724", "r750", "r751", "r767", "r855", "r890" ] }, "us-gaap_SelfInsuranceReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SelfInsuranceReserve", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Self insurance reserve", "label": "Self Insurance Reserve", "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property." } } }, "auth_ref": [ "r29" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r854" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r964" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r964" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "terseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r103", "r178", "r219", "r275", "r534", "r664", "r766", "r1016" ] }, "ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt\u2014less current maturities", "label": "Long Term Debt, net of Current Maturities and Debt Discount", "documentation": "Long Term Debt, net of Current Maturities and Debt Discount" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Notes 15, 17 and 19)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r30", "r108", "r577", "r639" ] }, "us-gaap_EstimatedInsuranceRecoveries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimatedInsuranceRecoveries", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": { "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term insurance losses recoverable asset", "label": "Estimated Insurance Recoveries", "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts." } } }, "auth_ref": [ "r852" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares in treasury, at cost", "periodStartLabel": "Balance at beginning of period (in shares)", "periodEndLabel": "Balance at end of period (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r76" ] }, "ensg_NumberOfAssetAcquisitions": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "NumberOfAssetAcquisitions", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of asset acquisitions", "label": "Number of Asset Acquisitions", "documentation": "Number of Asset Acquisitions" } } }, "auth_ref": [] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Common stock in treasury, at cost, 3,390 and 3,368 shares at September\u00a030, 2023 and December 31, 2022, respectively", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r33", "r76", "r79" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "ensg_SeniorLivingFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "SeniorLivingFacilitiesMember", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Living Facilities", "label": "Senior Living Facilities [Member]", "documentation": "Assisted Living Facilities [Member]" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ensg_A53PromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "A53PromissoryNoteMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.3% Promissory Note", "label": "5.3% Promissory Note [Member]", "documentation": "5.3% Promissory Note" } } }, "auth_ref": [] }, "us-gaap_EscrowDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EscrowDeposit", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": { "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Escrow deposits", "label": "Escrow Deposit", "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy." } } }, "auth_ref": [ "r106", "r701" ] }, "ensg_SkilledServicesAndSeniorLivingCampuses": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "SkilledServicesAndSeniorLivingCampuses", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transitional and skilled services and senior living campuses", "label": "Skilled Services And Senior Living Campuses", "documentation": "Transitional and Skilled Services and Assistant and Independent Living Campuses" } } }, "auth_ref": [] }, "ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "SkilledNursingSeniorLivingAndIndependentLivingFacilities", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Skilled nursing, assisted living and independent living facilities", "label": "Skilled Nursing, Senior Living and Independent Living Facilities", "documentation": "Skilled Nursing, Senior Living and Independent Living Facilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredCompensation", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation liability", "label": "Increase (Decrease) in Deferred Compensation", "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future." } } }, "auth_ref": [ "r6" ] }, "ensg_AggregateDeductibleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "AggregateDeductibleMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Deductible", "label": "Aggregate Deductible [Member]", "documentation": "Aggregate Deductible [Member]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued wages and related liabilities", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "ensg_NumberOfFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "NumberOfFacilities", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of facilities", "label": "Number Of Facilities", "documentation": "Number Of Facilities" } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r52", "r300" ] }, "ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "NumberOfRealEstatePropertiesLeasedWithOptionToPurchase", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of real estate properties leased with an option to purchase", "label": "Number of Real Estate Properties Leased with an Option to Purchase", "documentation": "Number of Real Estate Properties Leased with an Option to Purchase" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt threshold for EBITDA ratio increase election period", "label": "Long Term Debt Threshold For EBITDA Ratio Increase Election Period", "documentation": "Long Term Debt Threshold For EBITDA Ratio Increase Election Period" } } }, "auth_ref": [] }, "ensg_PrepaymentFeePeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "PrepaymentFeePeriodDomain", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment Fee, Period [Domain]", "label": "Prepayment Fee, Period [Domain]", "documentation": "Prepayment Fee, Period [Domain]" } } }, "auth_ref": [] }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": { "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs, net", "label": "Debt Issuance Costs, Line of Credit Arrangements, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r19" ] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAbstract", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NUMERATOR:", "label": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "ensg_AfterYearTenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "AfterYearTenMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "After Year Ten", "label": "After Year Ten [Member]", "documentation": "After Year Ten" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r116" ] }, "ensg_TotalNetDebtRatioMaximum": { "xbrltype": "pureItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "TotalNetDebtRatioMaximum", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total net debt ratio, maximum", "label": "Total Net Debt Ratio, Maximum", "documentation": "Total Net Debt Ratio, Maximum" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares of common stock used to satisfy tax withholding obligations", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "ensg_SeniorLivingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "SeniorLivingOperationsMember", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Living Operations", "label": "Senior Living Operations [Member]", "documentation": "Senior Living Operations" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r261" ] }, "ensg_AllStatesExceptColoradoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "AllStatesExceptColoradoMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All States Except Colorado", "label": "All States Except Colorado [Member]", "documentation": "All States Except Colorado [Domain]" } } }, "auth_ref": [] }, "ensg_PayorDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "PayorDomain", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payor [Domain]", "label": "Payor [Domain]", "documentation": "Payor [Domain]" } } }, "auth_ref": [] }, "ensg_InTheFourthYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "InTheFourthYearMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In The Fourth Year", "label": "In The Fourth Year [Member]", "documentation": "In The Fourth Year" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r6" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r130" ] }, "ensg_OperatingEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "OperatingEntityDomain", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Entity [Domain]", "label": "Operating Entity [Domain]", "documentation": "[Domain] for Operating Entity [Axis]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC.", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r775", "r786", "r796", "r821" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r3", "r14" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r538" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r776", "r787", "r797", "r822" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInSelfInsuranceReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInSelfInsuranceReserve", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued self-insurance liabilities", "label": "Increase (Decrease) in Self Insurance Reserve", "documentation": "The increase (decrease) during the period in the carrying amount of accrued known and estimated losses incurred for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's' compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property." } } }, "auth_ref": [ "r857" ] }, "us-gaap_GeneralLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralLiabilityMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General Liability", "label": "General Liability [Member]", "documentation": "Type of business insurance which provides insurance coverage for a wide variety of liability exposures including, but not limited to, contractual liability, product liability and personal injury liability." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r10", "r18" ] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r136" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of shares of common stock to satisfy tax withholding obligations", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r222" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for doubtful accounts", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r221", "r311" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r9", "r186", "r189", "r582" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r780", "r791", "r801", "r826" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r777", "r788", "r798", "r823" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r839" ] }, "ensg_ThirdPartyOperatorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "ThirdPartyOperatorsMember", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third Party Operators", "label": "Third Party Operators [Member]", "documentation": "Third Party Operators" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r8", "r15" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r777", "r788", "r798", "r823" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic net income per common share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r220", "r242", "r243", "r244", "r245", "r246", "r251", "r253", "r258", "r259", "r260", "r264", "r522", "r523", "r572", "r589", "r722" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r778", "r789", "r799", "r824" ] }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherDeferredLiability", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Increase (Decrease) in Other Deferred Liability", "documentation": "Amount of increase (decrease) in deferred obligations classified as other." } } }, "auth_ref": [ "r6" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r779", "r790", "r800", "r825" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "TOTAL REVENUE", "netLabel": "Revenue", "verboseLabel": "Total Service Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r272", "r273", "r284", "r289", "r290", "r296", "r298", "r300", "r422", "r423", "r568" ] }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDecreaseFromRedemptions", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of noncontrolling interest shares", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)." } } }, "auth_ref": [ "r93", "r150", "r163" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 3.0 }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current maturities of long-term debt", "negatedTerseLabel": "Less: current maturities", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r207" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r781", "r792", "r802", "r827" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r325", "r726" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r781", "r792", "r802", "r819", "r827" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets and Goodwill", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r11", "r63" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on debt (Note 15)", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r40", "r620" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProfessionalMalpracticeLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalMalpracticeLiabilityMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and Professional Liability", "label": "Professional Malpractice Liability Insurance [Member]", "documentation": "Business insurance coverage for professionals, such as doctors, lawyers, insurance agents, accountants, real estate agents, veterinarians, and others. This liability coverage insures losses for claims arising from mistakes and errors or omissions in the course of professional activities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r325", "r726" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r782", "r793", "r803", "r828" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r781", "r792", "r802", "r827" ] }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash financing and investing activity", "label": "Other Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r781", "r792", "r802", "r827" ] }, "us-gaap_RetirementPlanTaxStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTaxStatusAxis", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Tax Status [Axis]", "label": "Retirement Plan Tax Status [Axis]", "documentation": "Information by tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r847", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r782", "r793", "r803", "r828" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable\u2014less allowance for doubtful accounts of $9,422 and $7,802 at September\u00a030, 2023 and December 31, 2022, respectively", "totalLabel": "ACCOUNTS RECEIVABLE, NET", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r301", "r302" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of services", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r125", "r568" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r781", "r792", "r802", "r827" ] }, "us-gaap_RetirementPlanTaxStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTaxStatusDomain", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Tax Status [Domain]", "label": "Retirement Plan Tax Status [Domain]", "documentation": "Tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r847", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r781", "r792", "r802", "r827" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "LONG-TERM DEBT LESS CURRENT MATURITIES", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r208" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r143", "r202", "r584" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 }, "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "PROPERTY AND EQUIPMENT, NET", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r574", "r584", "r754" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r555" ] }, "us-gaap_QualifiedPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "QualifiedPlanMember", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Qualified Plan", "label": "Qualified Plan [Member]", "documentation": "Plan with tax-exempt status designed and operated in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r847", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957" ] }, "us-gaap_NonqualifiedPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonqualifiedPlanMember", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonqualified Plan", "label": "Nonqualified Plan [Member]", "documentation": "Plan without tax-exempt status in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r847", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r533", "r562" ] }, "us-gaap_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r555" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 (remainder)", "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year", "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r994" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r435", "r444", "r463", "r464", "r465", "r466", "r469", "r478", "r479", "r480", "r481" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Annual Rental Income", "label": "Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]", "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease." } } }, "auth_ref": [ "r994" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessor, Operating Lease, Payment to be Received, after Year Five", "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r555" ] }, "us-gaap_OperatingLeaseVariableLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseVariableLeaseIncome", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, variable lease income", "label": "Operating Lease, Variable Lease Income", "documentation": "Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable." } } }, "auth_ref": [ "r265", "r558" ] }, "us-gaap_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of the share repurchase program." } } }, "auth_ref": [] }, "us-gaap_InvestmentsAndCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsAndCash", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance subsidiary's deposits and investments", "label": "Investments and Cash", "documentation": "Sum of investments and unrestricted cash as of the balance sheet date." } } }, "auth_ref": [ "r1007", "r1009" ] }, "ensg_NumberOfFinancingLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "NumberOfFinancingLeases", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of financing lease", "label": "Number Of Financing Leases", "documentation": "Number Of Financing Leases" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r143" ] }, "us-gaap_ManagementFeeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ManagementFeeExpense", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Management fees", "label": "Management Fee Expense", "documentation": "Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment." } } }, "auth_ref": [ "r105", "r662", "r766", "r1015" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983" ] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandMember", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r897" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r840" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/GOODWILLDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r196", "r268", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r294", "r300", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r334", "r338", "r341", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r726", "r851", "r1011" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r441", "r442", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r466", "r467", "r468", "r469" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Ensign Group, Inc. stockholders' equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "verboseLabel": "Stock-based compensation expense related to stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM" ], "lang": { "en-us": { "role": { "verboseLabel": "COMMON STOCK REPURCHASE PROGRAM", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r147", "r231", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r520", "r682", "r683", "r695" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "EQUITY", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r486", "r487" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Awards", "verboseLabel": "Stock-based compensation expense related to restricted stock awards", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r48" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r333", "r337", "r663" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate margin", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Service revenue", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r733" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r533", "r562" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchase of common stock (in shares)", "verboseLabel": "Repurchase of common stock (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r13", "r115", "r150" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/GOODWILLDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r268", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r294", "r300", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r338", "r341", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r726", "r851", "r1011" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/DEBT" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r146", "r230", "r361", "r367", "r368", "r369", "r370", "r371", "r372", "r377", "r384", "r385", "r387" ] }, "us-gaap_AccountsReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableGross", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, gross", "label": "Accounts Receivable, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r209", "r301", "r1010" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, weighted average discount rate, percent", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r551", "r753" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Options Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r842" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r457" ] }, "us-gaap_AllOtherSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllOtherSegmentsMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Other", "label": "Other Segments [Member]", "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r268", "r284", "r285", "r286", "r287", "r288" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r807" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of common stock (Note 20)", "verboseLabel": "Repurchase of common stock, value", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r13", "r76", "r150" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Adjusted weighted average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r252", "r260" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on sales property, plant and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grant date intrinsic value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value", "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r459" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r236", "r362", "r363", "r364", "r365", "r366", "r368", "r373", "r374", "r375", "r376", "r378", "r379", "r380", "r381", "r382", "r383", "r386", "r536", "r727", "r728", "r729", "r730", "r731", "r859" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r20", "r111", "r112", "r167", "r170", "r236", "r362", "r363", "r364", "r365", "r366", "r368", "r373", "r374", "r375", "r376", "r378", "r379", "r380", "r381", "r382", "r383", "r536", "r727", "r728", "r729", "r730", "r731", "r859" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Vested Restricted Awards", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock award compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r84", "r85", "r437" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r552" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/GOODWILLDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r284", "r285", "r286", "r287", "r288", "r294" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r28", "r73", "r74", "r101", "r102", "r104", "r109", "r148", "r149", "r236", "r362", "r363", "r364", "r365", "r366", "r368", "r373", "r374", "r375", "r376", "r378", "r379", "r380", "r381", "r382", "r383", "r386", "r536", "r727", "r728", "r729", "r730", "r731", "r859" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Weighted average shares outstanding for basic net income per share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r251", "r260" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LEASE PAYMENTS", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r552" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage loans and promissory note", "verboseLabel": "Outstanding debt", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r20", "r170", "r388" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r552" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r552" ] }, "us-gaap_TypeAndTierIdentifierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeAndTierIdentifierDomain", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type and Tier Identifier [Domain]", "label": "Type and Tier Identifier [Domain]", "documentation": "Name of the type of insurance coverage or layer of insurance that covers malpractice claims." } } }, "auth_ref": [ "r179" ] }, "us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance Type and Tier Identifier [Axis]", "label": "Insurance Type and Tier Identifier [Axis]", "documentation": "Information by type of insurance coverage or layer of insurance that covers malpractice claims." } } }, "auth_ref": [ "r179" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expense", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r126", "r662" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r552" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r552" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r80" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r552" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 (remainder)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r993" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Lease Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r993" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rent expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r990" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Options Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r461" ] }, "us-gaap_RealEstatePropertiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstatePropertiesDomain", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Properties [Domain]", "label": "Real Estate Properties [Domain]", "documentation": "Represents categories of ownership of real estate properties." } } }, "auth_ref": [] }, "us-gaap_WhollyOwnedPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WhollyOwnedPropertiesMember", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Owned Properties", "label": "Wholly Owned Properties [Member]", "documentation": "Real estate properties and units within those properties that are wholly owned." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted restricted shares (in shares)", "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r456" ] }, "us-gaap_HealthInsuranceProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HealthInsuranceProductLineMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Health", "label": "Health Insurance Product Line [Member]", "documentation": "Product line consisting of insurance against loss by illness or injury." } } }, "auth_ref": [ "r1013" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r456" ] }, "us-gaap_RealEstatePropertiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstatePropertiesAxis", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Property Ownership [Axis]", "label": "Real Estate Property Ownership [Axis]", "documentation": "Information by ownership of the property." } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r555" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested at beginning of period (in shares)", "periodEndLabel": "Nonvested at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r453", "r454" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested at beginning of period (in dollars per share)", "periodEndLabel": "Nonvested at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r453", "r454" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessor, Operating Lease, Payment to be Received, Year Five", "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r555" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r234", "r235", "r365", "r392", "r560", "r719", "r721" ] }, "us-gaap_OperatingLeaseLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncome", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rental revenue", "label": "Operating Lease, Lease Income", "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": [ "r265", "r554", "r557" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_MalpracticeLossContingencyAccrualUndiscounted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MalpracticeLossContingencyAccrualUndiscounted", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Malpractice loss contingency, accrual, undiscounted", "label": "Malpractice Loss Contingency, Accrual, Undiscounted", "documentation": "Amount of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability) at the end of the accounting period." } } }, "auth_ref": [ "r886" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, nonvested awards, cost not yet recognized", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r473" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceived", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL", "label": "Lessor, Operating Lease, Payment to be Received", "documentation": "Amount of lease payments to be received by lessor for operating lease." } } }, "auth_ref": [ "r555" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r457" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WriteOffOfDeferredDebtIssuanceCost", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Write-off of deferred financing fees", "label": "Deferred Debt Issuance Cost, Writeoff", "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt." } } }, "auth_ref": [ "r129" ] }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Rental Income from Third-Party Sources", "label": "Operating Lease, Lease Income [Table Text Block]", "documentation": "Tabular disclosure of components of income from operating lease." } } }, "auth_ref": [ "r265", "r557" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r841" ] }, "us-gaap_OtherRestrictedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherRestrictedAssets", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": { "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital improvement reserves with landlords and lenders", "label": "Other Restricted Assets", "documentation": "Total assets that cannot be used for operating purposes because of contract or regulatory requirements that are in effect for a period that extends beyond one year." } } }, "auth_ref": [ "r697", "r698", "r852" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r555" ] }, "ensg_FamilyFirstCoronavirusResponseActPaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "FamilyFirstCoronavirusResponseActPaymentsReceived", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FMAP payments received", "label": "Family First Coronavirus Response Act, Payments Received", "documentation": "Family First Coronavirus Response Act, Payments Received" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expense", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r123" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONS" ], "lang": { "en-us": { "role": { "terseLabel": "OPERATION EXPANSIONS", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r160", "r506" ] }, "ensg_MedicaidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "MedicaidMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicaid", "label": "Medicaid [Member]", "documentation": "Revenue from Medicaid for custodial services [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.ensigngroup.net/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r28", "r73", "r74", "r101", "r102", "r104", "r109", "r148", "r149", "r728", "r730", "r862" ] }, "ensg_CostofSalesandGeneralandAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "CostofSalesandGeneralandAdministrativeExpenseMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales and General and Administrative Expense", "label": "Cost of Sales and General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing cost of services and general and administrative expense" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r811" ] }, "ensg_LesseeOperatingLeaseNumberOfRenewalOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, number of renewal options", "label": "Lessee, Operating Lease, Number Of Renewal Options", "documentation": "Lessee, Operating Lease, Number Of Renewal Options" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r458" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r817" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Service and Rental Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r193", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r715" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r811" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r183", "r192", "r248", "r249", "r279", "r488", "r499", "r590" ] }, "ensg_StockAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "StockAwardsMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors", "label": "Stock awards [Member]", "documentation": "Stock awards [Member]" } } }, "auth_ref": [] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r839" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r811" ] }, "ensg_SkilledServiceFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "SkilledServiceFacilities", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transitional and skilled service facilities", "label": "Skilled Service Facilities", "documentation": "Skilled Service Facilities" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r816" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r83" ] }, "ensg_MasterLeaseAgreements": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "MasterLeaseAgreements", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Master lease agreements", "label": "Master Lease Agreements", "documentation": "Master Lease agreements" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r811" ] }, "us-gaap_SelfInsuranceReservePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SelfInsuranceReservePolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Self-Insurance", "label": "Self Insurance Reserve [Policy Text Block]", "documentation": "Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR)." } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r300", "r735", "r896", "r1011", "r1012" ] }, "ensg_MedicaidSkilledMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "MedicaidSkilledMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicaid \u2014 skilled", "verboseLabel": "Medicaid-skilled", "label": "Medicaid-skilled [Member]", "documentation": "Revenue from Medicaid for skilled services [Member]" } } }, "auth_ref": [] }, "ensg_HealthLiabilityInsuranceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "HealthLiabilityInsuranceMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Health Liability Insurance", "label": "Health Liability Insurance [Member]", "documentation": "Health Liability Insurance [Member]" } } }, "auth_ref": [] }, "ensg_TruistBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "TruistBankMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Truist", "label": "Truist Bank [Member]", "documentation": "Truist Bank [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r726", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER ACCRUED LIABILITIES", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r22" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r811" ] }, "ensg_InvestmentExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "InvestmentExpenseIncome", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offsetting expense (income)", "label": "Investment Expense (Income)", "documentation": "Investment Expense (Income)" } } }, "auth_ref": [] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r811" ] }, "ensg_NumberOfOptionPlans": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "NumberOfOptionPlans", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of option plans", "label": "Number Of Option Plans", "documentation": "Number Of Option Plans" } } }, "auth_ref": [] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r812" ] }, "ensg_DepreciationAndAmortizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "DepreciationAndAmortizationMember", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and Amortization", "label": "Depreciation And Amortization [Member]", "documentation": "Depreciation And Amortization [Member]" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r815" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r166", "r206", "r232", "r271", "r286", "r292", "r307", "r348", "r349", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r508", "r512", "r526", "r575", "r652", "r754", "r768", "r890", "r891", "r999" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE AND ACCOUNTS RECEIVABLE", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r193", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r425" ] }, "ensg_HUDInsuredMortgagesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "HUDInsuredMortgagesMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "HUD Insured Mortgages", "label": "HUD Insured Mortgages [Member]", "documentation": "HUD Insured Mortgages" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r812" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r812" ] }, "ensg_PrivatePayAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "PrivatePayAndOtherMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Private and other", "terseLabel": "Private and other payors", "label": "Private Pay and Other [Member]", "documentation": "Revenue from self-pay and Other payors [Member]" } } }, "auth_ref": [] }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, options expected to vest, number (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number", "documentation": "As of the balance sheet date, the number of shares which are expected to vest into stock options outstanding can be converted under the option plan." } } }, "auth_ref": [] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r812" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r812" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r180", "r181", "r182", "r303", "r304", "r306" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r812" ] }, "ensg_ManagedCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "ManagedCareMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Managed care", "verboseLabel": "Managed care", "netLabel": "Managed care", "label": "Managed Care [Member]", "documentation": "Revenue from managed care payors [Member]" } } }, "auth_ref": [] }, "ensg_StandardBearerMasterLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "StandardBearerMasterLeasesMember", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Standard Bearer Master Leases", "label": "Standard Bearer Master Leases [Member]", "documentation": "Standard Bearer Master Leases" } } }, "auth_ref": [] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r812" ] }, "ensg_October212021RepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "October212021RepurchaseProgramMember", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "October 21, 2021 Repurchase Program", "label": "October 21, 2021 Repurchase Program [Member]", "documentation": "October 21, 2021 Repurchase Program" } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "ensg_SpencerWBurtonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "SpencerWBurtonMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Spencer W. Burton [Member]", "documentation": "Spencer W. Burton" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "ensg_PropertyManagementFeePercentFeeOfFundsFromOperations": { "xbrltype": "percentItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "PropertyManagementFeePercentFeeOfFundsFromOperations", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Management fees, as a percentage of funds from operations", "label": "Property Management Fee, Percent Fee of Funds from Operations", "documentation": "Property Management Fee, Percent Fee of Funds from Operations" } } }, "auth_ref": [] }, "ensg_PurchaseOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "PurchaseOptionMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Option", "label": "Purchase Option [Member]", "documentation": "Purchase Option" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r813" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r757", "r758", "r759", "r761", "r762", "r763", "r764", "r863", "r864", "r988", "r1014", "r1017" ] }, "ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of subsidiary shares (Note 6)", "label": "Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans", "documentation": "Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r699" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r814" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r298", "r299", "r627", "r628", "r629", "r685", "r687", "r690", "r692", "r696", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r717", "r734", "r759", "r896", "r1011" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r51", "r53", "r99", "r100", "r300", "r614", "r699" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r13", "r194", "r216", "r217", "r218", "r237", "r238", "r239", "r241", "r247", "r249", "r266", "r308", "r309", "r403", "r475", "r476", "r477", "r496", "r497", "r514", "r515", "r516", "r517", "r518", "r519", "r521", "r527", "r528", "r529", "r530", "r531", "r532", "r559", "r609", "r610", "r611", "r625", "r679" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r540", "r548" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r51", "r53", "r99", "r100", "r300", "r699" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r28", "r72" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL EXPENSES", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r124" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r64", "r68" ] }, "ensg_PerOccurenceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "PerOccurenceMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Per Occurence", "label": "Per Occurence [Member]", "documentation": "Per Occurence [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "ensg_RentCostOfServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "RentCostOfServices", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Rent\u2014cost of services", "label": "Rent Cost Of Services", "documentation": "Rent cost of services" } } }, "auth_ref": [] }, "ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of senior living operations sharing property with skilled nursing facilities", "label": "Number Of Senior Living Operations Sharing Property With Skilled Nursing Facilities", "documentation": "Number Of Senior Living Operations Sharing Property With Skilled Nursing Facilities" } } }, "auth_ref": [] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Expense:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r748" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares available for grant (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r80" ] }, "ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "GainLossOnInsuranceClaimsAndDisposalOfAssets", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "(Gain)/loss on insurance claims, legal adjustments and asset disposals", "label": "Gain (Loss) On Insurance Claims And Disposal Of Assets", "documentation": "Gain (Loss) On Insurance Claims And Disposal Of Assets" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic value of options exercised in period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r460" ] }, "us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Indefinite-lived Intangible Assets", "label": "Schedule of Acquired Indefinite-Lived Intangible Assets by Major Class [Table Text Block]", "documentation": "Tabular disclosure of acquired indefinite-lived intangible assets. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. Indefinite-lived assets are assets that are not subject to amortization. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total." } } }, "auth_ref": [ "r67" ] }, "ensg_AmendedMasterLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "AmendedMasterLeaseAgreementMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended Master Lease Agreement", "label": "Amended Master Lease Agreement [Member]", "documentation": "Amended Master Lease Agreement" } } }, "auth_ref": [] }, "ensg_NumberOfLeaseArrangements": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "NumberOfLeaseArrangements", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of master lease arrangements", "label": "Number of Lease Arrangements", "documentation": "Number of Lease Arrangements" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of real estate", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r131" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Fair Value of Options (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r459" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r298", "r299", "r627", "r628", "r629", "r685", "r687", "r690", "r692", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r717", "r734", "r759", "r896", "r1011" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails", "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r139", "r569" ] }, "ensg_FirstThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "FirstThreeYearsMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Three Years", "label": "First Three Years [Member]", "documentation": "First Three Years" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/GOODWILLDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r204", "r313", "r571", "r726", "r754", "r874", "r881" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r80" ] }, "ensg_StandardBearerEquityPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "StandardBearerEquityPlanMember", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Standard Bearer Equity Plan", "label": "Standard Bearer Equity Plan [Member]", "documentation": "Standard Bearer Equity Plan" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period, (in shares)", "periodEndLabel": "Balance at end of period, (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r445", "r446" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r139", "r570" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period (in dollars per share)", "periodEndLabel": "Balance at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r445", "r446" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued capital expenditures", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r44", "r45", "r46" ] }, "ensg_SkilledServicesSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "SkilledServicesSegmentMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/GOODWILLDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Skilled Services", "label": "Skilled Services Segment [Member]", "documentation": "Skilled Services Segment" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price of Options Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r447" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange for new and modified operating lease obligations", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r549", "r753" ] }, "ensg_NumberOfHealthCareFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "NumberOfHealthCareFacilities", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Health care facilities", "label": "Number Of Health Care Facilities", "documentation": "Number Of Health Care Facilities" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Dividend Yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r467" ] }, "ensg_ThePennantGroupInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "ThePennantGroupInc.Member", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The Pennant Group, Inc.", "verboseLabel": "Pennant", "label": "The Pennant Group, Inc. [Member]", "documentation": "The Pennant Group, Inc." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Long-Lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r144" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Risk-Free Rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r468" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other indefinite-lived intangibles", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r141" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": [ "r466" ] }, "ensg_ReductionInPrepaymentPenalty": { "xbrltype": "percentItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "ReductionInPrepaymentPenalty", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction in prepayment penalty", "label": "Reduction In Prepayment Penalty", "documentation": "Percentage that the prepayment penalty percentage is reduced during the fourth year." } } }, "auth_ref": [] }, "ensg_EmployeeServiceShareBasedCompensationNonvestedAwards": { "xbrltype": "sharesItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwards", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, nonvested awards (in shares)", "label": "Employee Service Share-based Compensation, Nonvested Awards", "documentation": "Employee Service Share-based Compensation, Nonvested Awards" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r441", "r442", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r466", "r467", "r468", "r469" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r436", "r438", "r441", "r442", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r466", "r467", "r468", "r469" ] }, "ensg_SeniorLivingFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "SeniorLivingFacilities", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior living facilities", "label": "Senior Living Facilities", "documentation": "Number of Assisted and Independent Living Facilities" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r436", "r438", "r441", "r442", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r466", "r467", "r468", "r469" ] }, "ensg_AccruedLiabilitiesStateReliefContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "AccruedLiabilitiesStateReliefContractLiabilities", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unapplied state relief funds", "label": "Accrued Liabilities, State Relief Contract Liabilities", "documentation": "Accrued Liabilities, State Relief Contract Liabilities" } } }, "auth_ref": [] }, "ensg_MedicareandMedicaidLicensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "MedicareandMedicaidLicensesMember", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicare and Medicaid licenses", "label": "Medicare and Medicaid Licenses [Member]", "documentation": "Medicare licenses for home health and hospice segment and all other segment." } } }, "auth_ref": [] }, "ensg_LesseeOperatingLeaseConsumerPriceIndex": { "xbrltype": "percentItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "LesseeOperatingLeaseConsumerPriceIndex", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consumer price index", "label": "Lessee, Operating Lease, Consumer Price Index", "documentation": "Lessee, Operating Lease, Consumer Price Index" } } }, "auth_ref": [] }, "ensg_CashHeldInTrustForResidents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "CashHeldInTrustForResidents", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash held in trust for patients", "label": "Cash Held in Trust for Residents", "documentation": "Cash held in trust for residents reflects monies received from, or on behalf of, residents. Maintaining a trust account for residents is a regulatory requirement and, while the trust assets offset the liability, the Company assumes a fiduciary responsibility for these funds." } } }, "auth_ref": [] }, "us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LifeInsuranceCorporateOrBankOwnedChangeInValue", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash surrender value of life insurance policy premiums", "label": "Life Insurance, Corporate or Bank Owned, Change in Value", "documentation": "The change in cash surrender or contract value during the period which adjusted the amount of premiums paid in determining the expense or income recognized under the contract for the period." } } }, "auth_ref": [ "r872" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interest", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r34", "r171", "r232", "r307", "r348", "r351", "r352", "r353", "r359", "r360", "r526", "r580", "r642" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "ensg_NonCaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "NonCaliforniaMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-california", "label": "Non-California [Member]", "documentation": "Non-California [Domain]" } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: debt issuance costs, net", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r103", "r895" ] }, "ensg_SharebasedCompensationRestrictedAwardsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "SharebasedCompensationRestrictedAwardsExercisePrice", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, restricted awards, exercise price (in dollars per share)", "label": "Share-based Compensation, Restricted Awards, Exercise Price", "documentation": "Share-based Compensation, Restricted Awards, Exercise Price" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r300", "r735", "r896", "r1011", "r1012" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "ensg_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends paid", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r39" ] }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid during the period for:", "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r51", "r53", "r99", "r100", "r300", "r699", "r849" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r145", "r342", "r343", "r700", "r885" ] }, "stpr_TX": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "TX", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Texas", "label": "TEXAS" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r699" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal finding accrued", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r475", "r476", "r477", "r625", "r863", "r864", "r865", "r988", "r1017" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r50", "r51", "r53", "r54", "r99", "r165", "r699" ] }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityClassOfTreasuryStockLineItems", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity, Class of Treasury Stock [Line Items]", "label": "Equity, Class of Treasury Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfTreasuryStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfTreasuryStockTable", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Treasury Stock [Table]", "label": "Class of Treasury Stock [Table]", "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r76", "r77", "r78", "r79" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r489" ] }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedPaymentArrangementNonemployeeMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-employee Directors", "label": "Share-Based Payment Arrangement, Nonemployee [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r436", "r441", "r442", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r466", "r467", "r468", "r469" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r773", "r843" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r770" ] }, "us-gaap_NumberOfBusinessesAcquired": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfBusinessesAcquired", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of businesses acquired", "label": "Number of Businesses Acquired", "documentation": "The number of businesses acquired by the entity during the period." } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeaseTermOfContract", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of operating lease", "label": "Lessor, Operating Lease, Term of Contract", "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r995" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, term of contract", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r991" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r991" ] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnInvestments", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gain (loss) on deferral investment", "label": "Gain (Loss) on Investments", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r127", "r845" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plus: incremental shares from assumed conversion (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r254", "r255", "r256", "r260", "r439" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, weighted average remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r550", "r753" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r67", "r141" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r328", "r331" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to The Ensign Group, Inc.", "verboseLabel": "Net income attributable to the Ensign Group, Inc.", "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r122", "r135", "r176", "r198", "r213", "r214", "r218", "r232", "r240", "r242", "r243", "r244", "r245", "r248", "r249", "r257", "r271", "r285", "r291", "r294", "r307", "r348", "r349", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r523", "r526", "r588", "r660", "r677", "r678", "r724", "r766", "r890" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r115" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r335", "r336", "r339", "r340" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r770" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r375", "r427", "r432", "r525", "r564", "r728", "r729", "r740", "r741", "r742" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock: $0.001 par value; 150,000, 59,803 and 56,413 shares authorized, shares issued and shares outstanding at September\u00a030, 2023, respectively, and 100,000, 59,029 and 55,661 shares authorized, shares issued and shares outstanding at December 31, 2022, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r115", "r578", "r754" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r115", "r640" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r773", "r843" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares outstanding", "periodStartLabel": "Balance at beginning of period (in shares)", "periodEndLabel": "Balance at end of period (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r13", "r115", "r640", "r658", "r1017", "r1018" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r13", "r31", "r194", "r216", "r217", "r218", "r237", "r238", "r239", "r241", "r247", "r249", "r266", "r308", "r309", "r403", "r475", "r476", "r477", "r496", "r497", "r514", "r515", "r516", "r517", "r518", "r519", "r521", "r527", "r528", "r529", "r530", "r531", "r532", "r559", "r609", "r610", "r611", "r625", "r679" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r194", "r237", "r238", "r239", "r241", "r247", "r249", "r308", "r309", "r475", "r476", "r477", "r496", "r497", "r514", "r516", "r517", "r519", "r521", "r609", "r611", "r625", "r1017" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r770" ] }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation liability, noncurrent", "label": "Deferred Compensation Liability, Classified, Noncurrent", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer)." } } }, "auth_ref": [] }, "us-gaap_WorkersCompensationInsuranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WorkersCompensationInsuranceMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Workers' Compensation", "label": "Workers' Compensation Insurance [Member]", "documentation": "Contract providing insurance coverage for employer's liability related to injury, disability, or death." } } }, "auth_ref": [ "r1013" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "IndependentOperatingSubsidiariesUnderMedicareProbeReviews", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facilities under medicare probe reviews", "label": "Independent Operating Subsidiaries Under Medicare Probe Reviews", "documentation": "Facilities under Medicare Probe reviews relating to Medicare services, billings and potential overpayments" } } }, "auth_ref": [] }, "ensg_ResidentRefundsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "ResidentRefundsPayable", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refunds payable", "label": "Resident Refunds Payable", "documentation": "Resident refunds payable includes amounts due to residents for overpayments and duplicate payments" } } }, "auth_ref": [] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r830" ] }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability": { "xbrltype": "pureItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion to reduce shares availability", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability" } } }, "auth_ref": [] }, "us-gaap_ProfitLossFromRealEstateOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLossFromRealEstateOperations", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on real estate insurance recoveries/sale of assets, net", "label": "Profit (Loss) from Real Estate Operations", "documentation": "The net cost of operation of other real estate (including provisions for real estate losses, rental income, and gains and losses on sales of real estate)." } } }, "auth_ref": [ "r177" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r783", "r794", "r804", "r829" ] }, "ensg_NoncontrollingInterestPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "NoncontrollingInterestPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest", "label": "Noncontrolling Interest [Policy Text Block]", "documentation": "The noncontrolling interest in a subsidiary initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r844" ] }, "ensg_StandardBearerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "StandardBearerTextBlock", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARER" ], "lang": { "en-us": { "role": { "terseLabel": "STANDARD BEARER", "label": "Standard Bearer [Text Block]", "documentation": "Standard Bearer" } } }, "auth_ref": [] }, "ensg_LeaseOfCampusOperationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "LeaseOfCampusOperationMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Of Campus Operation", "label": "Lease Of Campus Operation [Member]", "documentation": "Lease Of Campus Operation" } } }, "auth_ref": [] }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability": { "xbrltype": "pureItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other than options, conversion to reduce shares availability", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability", "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability" } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r832" ] }, "ensg_SkilledNursingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "SkilledNursingOperationsMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Skilled Nursing Operations", "label": "Skilled Nursing Operations [Member]", "documentation": "Skilled Nursing Operations" } } }, "auth_ref": [] }, "ensg_SelfInsuranceRetentionPerClaimMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "SelfInsuranceRetentionPerClaimMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Self-Insurance Retention Per Claim", "label": "Self-insurance Retention Per Claim [Member]", "documentation": "Self-insurance retention per claim [Member]" } } }, "auth_ref": [] }, "ensg_OperatingEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "OperatingEntityAxis", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Entity [Axis]", "label": "Operating Entity [Axis]", "documentation": "Operating Entity [Axis]" } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r90" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash payments for business acquisitions (Note 7)", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r36" ] }, "ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "LongTermDebtThresholdForEBITDARatioIncreaseElection", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, threshold for EBITDA ratio increase election", "label": "Long-Term Debt, Threshold For EBITDA Ratio Increase Election", "documentation": "Long-Term Debt, Threshold For EBITDA Ratio Increase Election" } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r335", "r336", "r339", "r340" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r128" ] }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum annual contributions per employee", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan." } } }, "auth_ref": [] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r773", "r843" ] }, "ensg_TwentyThreeSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "TwentyThreeSubsidiariesMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Twenty Three Subsidiaries", "label": "Twenty Three Subsidiaries [Member]", "documentation": "Twenty Three Subsidiaries" } } }, "auth_ref": [] }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected to vest", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "stpr_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "CA", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "California", "label": "CALIFORNIA" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r66", "r69", "r569" ] }, "ensg_DeferredRentAndOtherLongTermLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "DeferredRentAndOtherLongTermLiabilities", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Other long-term liabilities", "label": "Deferred rent and other long-term liabilities", "documentation": "Rental expense in excess of actual rental payments and other long-term liabilities" } } }, "auth_ref": [] }, "stpr_CO": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "CO", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Colorado", "label": "COLORADO" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of noncontrolling interests through subsidiary equity plan", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders." } } }, "auth_ref": [ "r12", "r75", "r163" ] }, "ensg_PrepaymentPenalty": { "xbrltype": "percentItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "PrepaymentPenalty", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment penalty", "label": "Prepayment Penalty", "documentation": "Percentage that the prepayment penalty percentage is reduced during the first three years." } } }, "auth_ref": [] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r830" ] }, "ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, FMAP payments received", "label": "Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized", "documentation": "Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r66", "r69" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "ensg_LossSensitiveLimitPerClaimMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "LossSensitiveLimitPerClaimMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss-Sensitive Limit Per Claim", "label": "Loss-Sensitive Limit Per Claim [Member]", "documentation": "Loss-Sensitive limit per claim [Member]" } } }, "auth_ref": [] }, "ensg_ThirdPartyTenantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "ThirdPartyTenantsMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other third-party", "label": "Third Party Tenants [Member]", "documentation": "Third Party Tenants [Member]" } } }, "auth_ref": [] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]" } } }, "auth_ref": [ "r236", "r508", "r509", "r512", "r513", "r561", "r711", "r889", "r892", "r893" ] }, "ensg_BlanketAggregateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "BlanketAggregateMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Blanket Aggregate", "label": "Blanket Aggregate [Member]", "documentation": "Blanket Aggregate [Member]" } } }, "auth_ref": [] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r830" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r236", "r508", "r509", "r512", "r513", "r561", "r711", "r889", "r892", "r893" ] }, "us-gaap_SpinoffMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SpinoffMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Spinoff", "label": "Spinoff [Member]", "documentation": "Creation of an independent entity from an existing entity through divestiture, for example, but not limited to, sale or distribution of new shares." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity." } } }, "auth_ref": [ "r16", "r141" ] }, "ensg_July2022RepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "July2022RepurchaseProgramMember", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "July 2022 Repurchase Program", "label": "July 2022 Repurchase Program [Member]", "documentation": "July 2022 Repurchase Program" } } }, "auth_ref": [] }, "ensg_LeaseArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "LeaseArrangementAxis", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Arrangement [Axis]", "label": "Lease Arrangement [Axis]", "documentation": "Information by group of related lease arrangements." } } }, "auth_ref": [] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r830" ] }, "ensg_DeferredRentAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "DeferredRentAdjustment", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred rent", "label": "Deferred Rent Adjustment", "documentation": "Adjustment to deferred rent arising from the difference between rent expense recognized and rental payments made in the current period." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidTaxes", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 22.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid income taxes", "label": "Increase (Decrease) in Prepaid Taxes", "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods." } } }, "auth_ref": [ "r6" ] }, "ensg_AssembledOccupancyAcquiredMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "AssembledOccupancyAcquiredMember", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assembled occupancy", "label": "Assembled Occupancy Acquired [Member]", "documentation": "Assembled occupancy acquired [Member]" } } }, "auth_ref": [] }, "ensg_YearsFiveThroughTenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "YearsFiveThroughTenMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Years Five Through Ten", "label": "Years Five Through Ten [Member]", "documentation": "Years Five Through Ten" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r296", "r568", "r602", "r603", "r604", "r605", "r606", "r607", "r716", "r733", "r755", "r851", "r887", "r888", "r896", "r1011" ] }, "ensg_TripleNetLeaseArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "TripleNetLeaseArrangementsMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Triple Net Lease Arrangements", "label": "Triple Net Lease Arrangements [Member]", "documentation": "Triple Net Lease Arrangements" } } }, "auth_ref": [] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r830" ] }, "ensg_PrepaymentFeePeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "PrepaymentFeePeriodAxis", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment Fee, Period [Axis]", "label": "Prepayment Fee, Period [Axis]", "documentation": "Prepayment Fee, Period" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee leasing arrangements, operating leases, number of renewal terms", "label": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms", "documentation": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms" } } }, "auth_ref": [] }, "naics_ZZ524292": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/naics/2023", "localname": "ZZ524292", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third-Party Payor", "label": "524292 Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds [Member]" } } }, "auth_ref": [] }, "ensg_PropertyManagementFeePercentFeeOfTotalRevenues": { "xbrltype": "percentItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "PropertyManagementFeePercentFeeOfTotalRevenues", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Management fees, as a percentage of total revenues", "label": "Property Management Fee, Percent Fee of Total Revenues", "documentation": "Property Management Fee, Percent Fee of Total Revenues" } } }, "auth_ref": [] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r830" ] }, "ensg_PaymentsToAcquireAssetAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "PaymentsToAcquireAssetAcquisitions", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash payments for asset acquisitions (Note 7)", "label": "Payments To Acquire Asset Acquisitions", "documentation": "Cash paid to acquire acquisitions." } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "verboseLabel": "Stock-based compensation expense related to stock options", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r470", "r482" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r296", "r568", "r602", "r603", "r604", "r605", "r606", "r607", "r716", "r733", "r755", "r851", "r887", "r888", "r896", "r1011" ] }, "ensg_FacilitiesUnderMasterLeaseArrangement": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "FacilitiesUnderMasterLeaseArrangement", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facilities under master lease arrangement", "label": "Facilities Under Master Lease Arrangement", "documentation": "Facilities operated under two separate three-facility master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ensg_NumberOfOperatingSubsidiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "NumberOfOperatingSubsidiaries", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating subsidiaries", "label": "Number Of Operating Subsidiaries", "documentation": "Number Of operating subsidiaries entered into mortgage loans that are insured with HUD." } } }, "auth_ref": [] }, "ensg_A2022PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "A2022PlanMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Plan", "label": "2022 Plan [Member]", "documentation": "2022 Plan" } } }, "auth_ref": [] }, "ensg_RentalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "RentalMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Rental revenue", "label": "Rental [Member]", "documentation": "Rental" } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r831" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ensg_AmendedMasterLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "AmendedMasterLeaseMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended Master Lease", "label": "Amended Master Lease [Member]", "documentation": "Amended Master Lease" } } }, "auth_ref": [] }, "ensg_A2019LTIPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "A2019LTIPlanMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019 LTI Plan", "label": "2019 LTI Plan [Member]", "documentation": "2019 LTI Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r162", "r232", "r240", "r271", "r285", "r291", "r294", "r307", "r348", "r349", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r523", "r526", "r585", "r724", "r890" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 23.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r6" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ensg_StopLossInsuranceLimitPerClaimMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "StopLossInsuranceLimitPerClaimMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stop-Loss Insurance Limit Per Claim", "label": "Stop-Loss Insurance Limit Per Claim [Member]", "documentation": "Stop-Loss Insurance limit per claim[Member]" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r830" ] }, "ensg_August2023RepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "August2023RepurchaseProgramMember", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "August 2023 Repurchase Program", "label": "August 2023 Repurchase Program [Member]", "documentation": "August 2023 Repurchase Program" } } }, "auth_ref": [] }, "ensg_LeaseArrangementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "LeaseArrangementDomain", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Arrangement [Domain]", "label": "Lease Arrangement [Domain]", "documentation": "Lease Arrangement" } } }, "auth_ref": [] }, "ensg_NonCashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "NonCashLeaseExpense", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash leasing arrangement", "label": "Non-Cash Lease Expense", "documentation": "Non-Cash Lease Expense" } } }, "auth_ref": [] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GranteeStatusAxis", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grantee Status [Axis]", "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r436", "r438", "r441", "r442", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r466", "r467", "r468", "r469" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r831" ] }, "ensg_OperationalSeniorLivingUnits": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "OperationalSeniorLivingUnits", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operational senior living units", "label": "Operational Senior Living Units", "documentation": "Operational Assisted Living and Independent Living Units" } } }, "auth_ref": [] }, "ensg_RestrictedAndOtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "RestrictedAndOtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted and other assets", "totalLabel": "RESTRICTED AND OTHER ASSETS", "label": "Restricted And Other Assets, Noncurrent", "documentation": "Restricted And Other Assets, Noncurrent" } } }, "auth_ref": [] }, "ensg_LeasesToThirdPartyOperatorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "LeasesToThirdPartyOperatorsMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leases To Third Party Operators", "label": "Leases To Third Party Operators [Member]", "documentation": "Leases To Third Party Operators" } } }, "auth_ref": [] }, "ensg_TotalNetDebtRatioMaximumAfterIncreaseElection": { "xbrltype": "pureItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "TotalNetDebtRatioMaximumAfterIncreaseElection", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total net debt ratio, maximum after increase election", "label": "Total Net Debt Ratio, Maximum After Increase Election", "documentation": "Total Net Debt Ratio, Maximum After Increase Election" } } }, "auth_ref": [] }, "us-gaap_CollateralizedDebtObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollateralizedDebtObligationsMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage loans and promissory note", "label": "Collateralized Debt Obligations [Member]", "documentation": "Securities collateralized by a pool of assets." } } }, "auth_ref": [ "r869", "r870", "r920" ] }, "ensg_CampusOperationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "CampusOperationMember", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Campus Operation", "label": "Campus Operation [Member]", "documentation": "Campus Operation" } } }, "auth_ref": [] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GranteeStatusDomain", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grantee Status [Domain]", "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r436", "r438", "r441", "r442", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r466", "r467", "r468", "r469" ] }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Diluted Net Income Per Common Share", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]", "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share." } } }, "auth_ref": [ "r47", "r49", "r866" ] }, "us-gaap_CashUninsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashUninsuredAmount", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, uninsured amount", "label": "Cash, Uninsured Amount", "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, useful life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r7", "r65", "r70" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r7", "r159", "r191", "r500", "r501", "r861" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "ensg_SubleaseOfStandAlongSkilledNursingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "SubleaseOfStandAlongSkilledNursingOperationsMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sublease Of Stand Along Skilled Nursing Operations", "label": "Sublease Of Stand Along Skilled Nursing Operations [Member]", "documentation": "Sublease Of Stand Along Skilled Nursing Operations" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic Net Income Per Common Share", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]", "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share." } } }, "auth_ref": [ "r47", "r49", "r866" ] }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherAssetsTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted and Other Assets", "label": "Schedule of Other Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "srt_SubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SubsidiariesMember", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Captive Insurance Subsidiary", "label": "Subsidiaries [Member]" } } }, "auth_ref": [ "r943", "r996", "r997", "r998" ] }, "ensg_NumberOfPropertiesAcquired": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "NumberOfPropertiesAcquired", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of real estate skilled nursing properties acquired", "label": "Number Of Properties Acquired", "documentation": "Number Of Properties Acquired" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r300", "r848" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock to employees and directors resulting from the exercise of stock options", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r13", "r114", "r115", "r150", "r625", "r679", "r693", "r767" ] }, "ensg_PaymentsToAcquirePropertyAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "PaymentsToAcquirePropertyAndEquipment", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments To Acquire Property And Equipment", "documentation": "Payments To Acquire Property And Equipment" } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock, net of forfeitures", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r13", "r150" ] }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions": { "xbrltype": "durationItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Threshold event period after vesting of restricted awards or exercise of stock options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Event Period After Vesting Of Restricted Awards Or Exercise Of Stock Options", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Event Period After Vesting Of Restricted Awards Or Exercise Of Stock Options" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r316", "r726" ] }, "ensg_MedicaidAndMedicareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "MedicaidAndMedicareMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsandStateReliefFundingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Medicare and Medicaid", "verboseLabel": "Total Medicaid and Medicare", "label": "Medicaid and Medicare [Member]", "documentation": "Total revenue from Medicaid and Medicare [Member]" } } }, "auth_ref": [] }, "us-gaap_ManagementServiceIncentiveMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ManagementServiceIncentiveMember", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incentive Management Fee", "label": "Management Service, Incentive [Member]", "documentation": "Contractually stipulated right to receive incentive compensation for operating and managing business." } } }, "auth_ref": [ "r897" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r237", "r238", "r239", "r266", "r568", "r617", "r626", "r632", "r633", "r634", "r635", "r636", "r637", "r640", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r653", "r654", "r655", "r656", "r657", "r659", "r661", "r662", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r679", "r760" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "NET CASH USED IN FINANCING ACTIVITIES", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r226" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock to employees and directors resulting from the exercise of stock options (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r13", "r114", "r115", "r150", "r619", "r679", "r693" ] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on sale of assets", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r858" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r375", "r427", "r428", "r429", "r430", "r431", "r432", "r525", "r563", "r564", "r565", "r728", "r729", "r740", "r741", "r742" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r226" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "NET CASH PROVIDED BY OPERATING ACTIVITIES", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r133", "r134", "r135" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromInsuranceSettlementInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromInsuranceSettlementInvestingActivities", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash from insurance proceeds", "label": "Proceeds from Insurance Settlement, Investing Activities", "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities." } } }, "auth_ref": [ "r5", "r35" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r3" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r13", "r114", "r115", "r150", "r450" ] }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of preferred shares", "label": "Proceeds from Issuance of Convertible Preferred Stock", "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r3" ] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Shares of common stock used to satisfy tax withholding obligations (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "documentation": "Number of shares related to Restricted Stock Award forfeited during the period." } } }, "auth_ref": [ "r13", "r114", "r115", "r150" ] }, "us-gaap_ManagementServiceBaseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ManagementServiceBaseMember", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Management Fee", "label": "Management Service, Base [Member]", "documentation": "Contractually stipulated right to receive base compensation for operating and managing business." } } }, "auth_ref": [ "r897" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r223", "r227", "r228" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r69" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock, net of forfeitures (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r13", "r114", "r115", "r150" ] }, "ensg_InsuranceSubsidiaryDepositsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "InsuranceSubsidiaryDepositsAndInvestments", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance subsidiary deposits and investments", "label": "Insurance Subsidiary Deposits And Investments", "documentation": "Captive insurance subsidiary cash and equivalents designated to support long-term insurance subsidiary liabilities and debt security investments held to maturity." } } }, "auth_ref": [] }, "srt_ConsolidationEliminationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationEliminationsMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intercompany Elimination", "label": "Consolidation, Eliminations [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r337", "r663" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued wages and related liabilities", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": { "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r211", "r754" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r87", "r88", "r505" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award requisite service period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r746" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r746" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from debt (Note 15)", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r37", "r619" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, nonvested awards, cost not yet recognized, period for recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r473" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "totalLabel": "OTHER ACCRUED LIABILITIES", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r83" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible asset, useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramPeriodInForce1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramPeriodInForce1", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, period in force", "label": "Stock Repurchase Program, Period in Force", "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r132" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Life (Years)", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r138" ] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/GOODWILLDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "All Other", "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r17", "r285", "r286", "r287", "r288", "r294", "r868" ] }, "ensg_NewMasterLeaseAgreeementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "NewMasterLeaseAgreeementMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Master Lease Agreeement", "label": "New Master Lease Agreeement [Member]", "documentation": "New Master Lease Agreeement" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r29" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r115" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "ensg_QualityAssuranceFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "QualityAssuranceFee", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quality assurance fee", "label": "Quality Assurance Fee", "documentation": "Quality assurance fee represents amounts payable to California, Utah, Idaho, Washington, Colorado, Iowa, and Nebraska in respect of a mandated fee based on resident days" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other restricted assets", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r846", "r856" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r234", "r235", "r365", "r392", "r560", "r720", "r721" ] }, "ensg_StandardBearerSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20230930", "localname": "StandardBearerSegmentMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Standard Bearer", "label": "Standard Bearer Segment [Member]", "documentation": "Standard Bearer Segment" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash proceeds from the sale of assets", "label": "Proceeds from Sale of Productive Assets", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r131" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21B", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21B" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b),(d)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "SubTopic": "30", "Topic": "835", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479359/835-30-S45-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "720", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483384/720-30-45-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-24" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//710/tableOfContent" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//712/tableOfContent" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.14(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-30/tableOfContent" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-16" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-2" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r845": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "325", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481551/325-30-35-2" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-9C" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 107 0001125376-23-000184-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001125376-23-000184-xbrl.zip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�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
^.D!_T'Q> M!9J;+(>UWF?2%: GSRK*J[BSGJRI%8BMAK6]A?%LK)4F!^;6[@V_(ZM_TB(W M@[FM>#TW'0:?NC'OI<5._X:.?R@W[S M^3#ZM_H4EC3NS+"A[/[)8G/6^77M]H7A@' M\*$PB:?+DLX?E&$=CI8)SZ@]F NP4> LY..0 M$UV#9U^W5#XBC'M==05()_=6U[3E69QM^?JZ7%2Y]S7M^WU9KJ6813%+ Q80 MR$2B]*[&L+RJ*((I3E@8A1C+P,D)NM#/U$Q=+>:FHD9>R>A88 M!K92#4*5B#=-.8H;<-^.E'OYM'8<^JJ6=J&7<8NCM:MZ4@NMXW%/=I:&PN-! M?5U6U:NE,-&*16YX0()X"+DP M<8:,$$3=:O=<(\W43,H^.\I6';#3IR$^J1+V71E/KAHU.XLTVE@,;+7T M_)TN&N*/?U:*;(@_9D0[=3Q)4\/2K_>V4< ACK" "&=,QB$32@0>I>'782 _,/ =&_ANPT:#BM]SI4-.N=./O M;-VO0+ G0^TCP:@V]PJ(CLWG-4WY6<)GDZ:P+GY6.XWZA*>BXILA@K7'S@GD M82HA2LV!;*3-G0I%AE$:LE 0#Y?]4G\3=;$WI[+5#ET[3ZM&_!L32F7"3VY M?!.3H)J.^J<4;VLBK\ W_?%4,9?_\W^$:? ?<7 #JJIZE#TV3IW/^UF@N]>W^?*GE$VQ^/,>Y/9LI#ZL?%ZNZ'S_[^;2_NMR]5]R M]23Y\F5AB@?7GN+G9='\RCP7SL(HS20-,.2)0A!EYIH]RA(81!*SB"="8"N: MJO<1?VH>X.72O(OM22>M=*ZC]?2O5^"G7&ECM]'S!KQ5FE9!JL5.5S<3./)7 M9&=8I_MMC'BNL3VOV&T";_;.P9MC#*.E_FW]<3SM?1R/NX_CR>+C<#;Y[S-& M/2TD(PL_ZO+T/@-SO.B]DQ2^Y_G+8F4J"NT"(45&,4,"016%H:%U32".2 5 MCG#&">5<.%7*/>UB:DO2Q\=[[:G7Z==UG;G2R%S5>X=UE"EOBZ2T1=;V4/L: MO 8WTUJXN@35(#&FEY7O[1#WI(.1CULO*7AZ,'KQR2ON[GP*?W>>M-Z^O!35 M#OM^L2KR19GSRLVO#V!G:829(E);$*Y=9T3B %(L OU3)E&$8L;<"E:^DQY3 MLUI;80WU="TM^%'5"EDJL*P5,EY/SUGZ3,ZG/QN$*<-H?P_]O;@1W M7]P6DOHX97-9V/,5X?L-:Y\WAN^@Q?@7B.\W5&?O$]]1'%]F]%LA"D.N6O_K M2[Z0X0RG*%I:97NW MJ\MO<$UL.7W1LJ#3;T%B2M(U<^U.C*W>HMBIQ3K;0][L&-\ M6^G-IC8]'Z0V2,5_2CI??>?ZQZ>[^^?[!6\(613E+$RUZRS"6&_( XDA2V,% M X)E2%% PL2>)<.JRZF9A(W0H)8:[,0&1NX;0]WY=P?Z!SO7'&HT@%24(A"W@&$0H5Q FC$)-8"LY5)+@3'=;X*DQM M93VI9KX1'%22C[N0>GP1XRREPX[S7V@QW0/B!G1\.^#W6U:N"LI7$UI(_4=R M(DNIAP)_J<74?X#Z7DZOD,1O0?U,\Z+:R7R@>@*;2"0I5_\HENLW+<+G?*%_ ME]/YMTV9IX^TEM.<:M[K7Y6S** 1(3R%"",&44P4I*GY";,4&\K>(&,NR^.U M DUML3/Z;"Y &Y5 I1/8*'4#MFJ!K5Y@HQCXO3JIKW1S+!1Y]=C:+71CCMC MR]8X@^6\ /6%<$_+R=7BC+HX] 7>L:GOK5V/.Z$OR[+\IG_*35K/E_PU7SW* MXN.Q6&&8BA8H$TS"A#$<41A&F-$2,Q%;%=Y4RN]L+U.SLCLA026EX['-62 M3U:NA6?H MPX\C9'J[+U;'[Z61E![=/E*5K2E]WKA6+SD;"YK M M.CF[8L12+$@L)8I0@B%NH=,2(4LE"F*$DC;2J<4D$]9)B(Q$".H/8.PV@O03O1/[G#-%ERC_WIKS+'2]? MY7:+NSEZG]&0LHC@%&;: ]*[SYA#%J$(A@E)DBB+:)HX90=>Z&=J5JZI#;X[ M%K*XC'#"U6*5,G3\YQ[*F M-GBT5SAM;6'$8J/H*%4TPY6I/>7 F>)HK,?LF!+Z_VE5<J[J0W6!)"8>I?5 M^YN\:'\&9+NAM-R)]CX\0V\^*Q!KB4$M6NG^B14](-J+XVF':= MCKNG= +B9!OI]K;WSK%B4ODDZW_?+QX+^49S\4S_U#,CBEG, R:AP)$VZ]64VA\KLA&1$,^8S9-*R.J\W:R#6SK7>6UV(VV MN:P$!+]L1/U;Q4_>P/C>3\7\ M*]:&.;91P7(+905IQ]ZS;S0'-QQ.0(+?C?Q]7-Z[X-221Z_;:8P(%SO;8=?Z M.)LN%T6W^RZGE_R\D:]R59^)F>B![6DKQUB(@"$8J81#1'$(F4@)E $.(Z6" MF*:1RRGVV5ZF9DV^_O;KW=/M\\/3_W+S,:(^M?C(A_ M [>K59&S]:JZ.M/;S4?M&P]TC-T*3D]^Q?D^1G4G6M4\]B+:'_:LFVZ(?.H[ MLH_KP@SG+ ID(G#"8!8%#*(HC2$- PH5XRFBJ32<]4YUTT^ZF-KLKR1TK))^ MBIO=K+\.C8&G?,ULMJE-W,C78Y7TB[KW527]M(-QJZ1?5/"D2OKE)SWNH7Z5 M(C=,#LTQ?Y@)%::"P""3,40$(4B8)#!. I;$&14QM>+&.M/VU*;N1CJ'*Y(C ML$1"&9>!A%'(B/%W"*1,8)A0&E*4,1DR87>R?"5(+9 M7SKZPS'2+>.3_"$7:UE?H]ACY';5>!Z%UKO%HU?&NTP\+^O![>&%1_S\U2>Y MRHLJ?N-1#\PS_=/$"6EJ].]/R.D9BM:%LY^;VA-W 5LX?-F??UP*0GIS@ MMIY&]88M5#YVBVU>\3,<7^A"- M20F*]B8T0C'BDW6.L,DA1$$&<,8+22(8< MQ2YV8M?TU,R"D%X;H09(/SG5M:-55*)E4*+W %J8UX&'96#[NS\B'P]&9*=!S496WGAQU'E#[\*!/>P0C,6( M/Z('-K^6A\R:E_1CN]ZY$.S5F6&UP&MMTI;?<-5FB]> M'M2QJ _%1M@'547$-@1MLXP@@4UH:H!,5(B*&<0B#"!+>:*$2 +.K/;,[ZS' MU%9'DU-1?E_.!9 594)3O)<:Y:K:9"8B:ZE.UTK]T5P.X7BMUJHQ^H4QN<"-_?^^-R=24F_Y&- MZI%,_V/S\'+>=8B[G:7W$6]DG^M=Q^#4=7M?<=S#_:M:V)58QF>0Q=-J@%IX$] E^(G&+SVU'P M"LB_T.1H4?CM*NV'WG<\Z7<%V5B1LBI3_Z8_AN_4V(:/51)O92%F(DN#- TR MB'FL( J#%!+.36G+6! 2ITJR9),!:'ORY4$4>"8I&PQ"'87GST!.]*=2R,L4$MC+/;AK06NW:[^KDKMT>GI"M6B MPU&O5NT!.+YR=7C3MZ#N7EMU@O,> ?\LD22A.$;:Z"04(D92R$C"(4DB*L(L M$SRPBO^WZVYJ[D!CM1CSNG^X60>O"$'LZ'-UE0<]:Q3P+UF_Y3L0GQ?BR63#[) M'[G\HYS10*882PG# &40I=J/($(*F"'.>!#&B<#VM;F]Q9B:+?E,>3[/5R;! M?FUD!J^;+((W(S4H:K$=3MG]1\CB!F84W ,,B0C73>] MMFB?A\[!\H#WWH1X-_Z>.?X5R-P< Q_?6N>M(/RQ7P6GY:O M-%_,@HRD6 4A)"'C$(6FB'BH(IBF,I84Q4B*U(F[?K_UJ:U C7 E^+V6SS$W MZ! YN[,R;SR&OEJWAL*=EN^!%P$,8H M(*G>-,:F^H]0D# 40,Y3O8%$/*9AX%<1O*W;J=F572EIL!6V.I7Y>OM/+RH* M2_3M3$W_F [N;OK#>46];1MT>J^JW=KI.]7.M@'BB,G-54>WF,$8%BB:*9Y#@2$*D,@5IA%*((TJ(BK7'&5(;$]36R=0,SH&< M=0EZQX.M5DC;[4I?0 UL1;PPLC8?-B"T&0O]_IZAT/^U,Q*M38]B$FR4VQ@ MJV>]::]T(U+H30FE,$@4A%$J4PADQ&# M240";0H"++E5M3'[+J=F"C82 ]F([$QZU86QG9?1+W(#VX8M:!MIP2][\H)& MX,M!MCY$6);H],>'U=7AV+18E@"<8<>R?7/,[.(FK^7NSS=ILE^>ER8E9B^^ M[/;EI:CBQN\7JR)?E#FO?*)9$,<9#\,01ID*(,I0!JE2'&9,TH3(."6A%=/\ MNT@_->.WD=_;4_YZQDCM'>$K>F>*D4E\32-E\5XYFL/D[OH*]1?( MV+T2[W[R=*\5PL.#^KHVC&,/JHED,CP$$5,TQ3B"A 491%4N'\T(# 1FF2!, M\LPJLNA"^U/S0FH)35K9Z?>6T\RWQ9Y@/; MV?*8WS'40<&2;;DK' J"HD1"'B6Q*0A!(0X2! 5.$:,AYT'L=/)TMI>I6;I& M/$ K81W+AIW'T>YTZ6IT!C9F1]6#!JD.UHI!3\=&Y_L8]:2H5]>RQSXQ'1>;4Q*6LUMBE%]2\K3<"\4@7P1A>7HS&[ ;$Y#NT= MYJ$/,1M -Q(#+3*H90:UT.#C8("ZG!#V#NQ(.Z*33_@$X3M8&-MC]@'I0M[6A<0=9RH>&1:5K:U3LE:.EXWIV:Q1R7 MW_+5FL[G/Q]I+OY9GB&U ]L2SRA'H 4Q@]"+ZX8QZY&HY#Q@V"?6<:S!;]CIZ]R]9&6WRLC**3X M\/.W4HK[Q98@0 NB'2=S;[0]7@D3DC")!511Q/2F-E'FD(K!--*N#\(4H]"I MII^[").S=5I\H.;+/\JZ6NURRWQ"M[(['EM[C(O=L=>P: ]]>R=7H )[([ZY MW?S%: #RQ=_V&&=V6@QRCN8/8D]G;1X"C'H>YP_0\9G=%2TYIGNLWHK9QX=9 M%L9*1!F&,0TH1(G>S.$H#&"H:(("Q%@06B6K-NU-SE8MY\N"BJ5EPD8#2KMM M\5!U:)?HX MLUS?E\^4#%(]Q0A$#(40R81!DD8*2:PFG-GTOU_AK"A(! M>12=? ,6=42'*?%7$WP[U_7K>]AMCN'?>3"'/K0?-%:T5O>]1_G=HH?=1WND MFX3;BEM_]5T"1O4?N-034FJ?5M"5O*E^O]A&]35<_']\S_EW8#CXCB>V=GGU M3P?5R,!R%W0).%T )K656/R0A7FOIOTSO=2/@SH(T_:F+Q\6Y9T_H]BN7XK[Q=\OC9?KOZU1DX[]VLI=O%T7_6\ M:C*%41 $H=(.@Y!$>PU*4$AX%D":(HJYY$F@G*+@/.68FF^P40-4>@ CJ"?Q MH._ V!U!C #WP*NW%]+NS#37X=0798VG%.-RV5P'U0G)S97-^1*E&AK6!W6O MU^\?N:@.@.]?7[5O4.1T_F%=Y@M9EK?\W^N\#DYZ)%$(TL5OF'/GS M?/G'W;SR=ZO8H/7;6_U?NS_?+]2R>*V]X\W=2L1"C"0/88 0@2B@,20D#B$/ M,H52H7":8:>\BQZ$FIJUK2YFWLRMLU@7%8&\WFDV5;:U\*YY&WT,FYV)'7LP M!C:W.W7JNS(C,=AH5,6L.DDO2(I=[:([V_9Z&A=L1)*C@36!*KK7W3WO1LY#S7D"URZG+_ M=FMU_^:D[-#W;[=?[C\_/'V]O^WK!NZV9>;;W<#=CGD#=WL\QXY_[7$#]RB+ MIHC+SV8+(=,TP'J7!S'CF79+$(*,*>VEQ!)SE29!A.PI^$^:G]KDT0*"C80. M=QNGL%E5!K%9%SM8K MPXW^O/RJ-=,O:2UU)R_W"VU@9+F:H9AS&@013 ,F(8ID!FD62:BB+, 1CE4F M\.R'+-C2=BLVC* NLV)?W&%CY_)*5[>-V$ #:;__!&=B6UPJ"7XR*?ZNC M1W=:[C%PW S?DL%GNF?-V"K-&BT!OMJFPOB0\7!1O/^-G/#CDQ/V[N!A!QU MPS(V;WZNYR:>?P'S1?@EWGEC&FOJM B UG)K'WGO;_/E M3RGUCUP;RQG+S($G1E &7$"4*@QQHA 4$8]XB)GDTHIJIT>9IF;<&MFUEV&$ M!WQ?>G-1"V0COW-ENJM'S\[&C3PF QO!1ANP+W%5XNX&;$:J5NG@B1*8T\V- M5C>@T:O7>GA]@=Q?T;RK)1J[LEY?$)XIO]=;T^[EL$RHXX/ZE?YO[;9J+W7Y M*HLF\CU">@^-P^GT?'I:[ZM2B-53O=^A-R+(K>IG][X?.S;XY8W+Q- M\L,"YJU/>J977)D MU?0XFDYGW]>%N:/,\I-QAD.(&),>SX2)Y"E60PECD26 M")4QMXWG,&).S;[NJEI)G'^3QOZ&%Z/R=TQZLG MX^G0\:@&T1V08R/GT8*?X=JRIU45$;:WT3.F0B6B((8D- YME$I(@U3 (%8! M4Y% >>SE6&CM+-2%_IQ,DG;W@:\CGRZ^W;W]1G\\_;+;W?@X3-X?GB^_0*^ MW-U^NP-?[F\_W'^Y?[Z_^^9FH2Z!;&>.>H!N8-NS8UNL1+P!6R'[,S(=*/1D M42[U,JKYZ%#UV%9T/>Y)!WLV?$^;H\+T8JY_OZU9F8N<%C_O_KW6'=Z7Y=I$ M1&7]!1F77_9JP$YX9J]OT;^.U-=U4>I>]RN5W"[$7@V9 M^G=-@DXNS7X2*Z62#))$(HA8JB 5,8<4)VF (QDZ$6=Z2C$U0[NIR[.H%;DQ M87EY::COFL)2)KXVWZO,T_Q:;35R+Y#D/G06%T%C#,C0YX;-6'S=C,5A1:H+ M-9(^CSH2[L6K!AV1L1S1R2K@Y:'UR:TTM'"CD#[E8.QY> M'N)F>=/DB\;0AKX!8A"VKE.-^Z/@VFM[;%ZM4[7.D&6=>>B*4N)[O%JW?^;E M3-)$I3(F4#*1011GF=ZNZ_^,DC!5^O<,Z19<*XD?=3*U.5O)N,\Q!WXW8CIF MM9V%TVX.7PO2P%/9&1^_:N(7 .BSF/AQ%^/7$K^@Y-E2XI>>]3S<+U[H(O_O MRHO\N%R4RWDNZMO2A7C4G\O&PWQ0G_.%WL#F=%Z5PJN(G@S%Z7Q9K@NY*YW& MA @)S1!D/(T@PBR$5 8$"HJ")$@#J;A5]-]0 D[-S'RZ^_;QZ?[Q^?[AJ[E, M^/#;M_NO=]]<;P_Z'D7+:X=W')NA[ROV5+L!!\I5FYY]]T /0UU5)W^*->\->F_1,[HO,J*VO8Q6CU11Z7W M"XFZONH9!-=DES4[U@N!>O-J:"N39R*37K1UE.*Q(@?^N"Q7Y92*LI2 MI*",I?8VJ>00RY1!'#&DI%!(T,0I4JY?^:9FV3;J@TYGXZ??ORLKHK"K/MN'U=V1Y"'[XU-0]<2U=4=A%H&9<+N5R71YG3U>;< M_K#Y"*3N,V5_?(8.,+@2&J?CXO,H>)T*'S4UVN'O>17VSW@O/.'GOCSKU_34 M?LYE<6^B!7.5;VFI(E-+E(L(TB1!$&'.]$^4PBQ.4Q6% 4HBIWBAEKZF-J&- MJ-5:9X0%.VD]BRNWH6SG7_2$W=#W1-ZP.;L+%H#TY!.T]33JPF^A\O'J;O.* MQQ(^G]_]*?G:Y"U_U*;]96F8D9O05ML%O:6-J5D#+2O8"@MVTCJLYVV(6:SN M/8$U]%I_ :<^"S)9HN&WYK@3]@\[PG@;P>7L,Y6,6[QBHD 4$1 M9"HPU%=9!ED4*"B02E&88(43)SZ3_<:G-N.-;, (YQ4N? ";W?KN"\; ,]H: M!W=R]C,*]T7#OM_TN(3K9Y0ZH58_]XQGE#_G9N]4/M*?IA2/7NCU;XJU%!MN M &T'SL6%1CS!44;T_,VP(4ZG1/^4A<;%1VE(TY@G3M&]GG),;=(_//_GW1.X M_?CQZ;>[3_XD(+ZC8F[R[RZ@VEFSZZ$:V%AYH.11?J$-A-XJ*ISM9.0B"6V* MGM8]:'UZ^+J"S\8TS9(D9#*(0L@CRK5UB#DD,@I@F)(TBT7,.;,J3^\MP=0, MAT\9NTJ1 4L)UD-E9W,&'8"!S=$ V ]:/? OW>H'%CW/]FJ@0?P7%,Q\+ A M3R*XBI_;!'Z^+8NJMNLW^5*E)\T0XI'BDD+M$2F(%&.04OT/@9FY"!(BHE;4 M0]U=3'J![6!+=0.L)V8X%L78.[T:9U8]$6/ M=KFC<>G/.A4^H3?K?L,S_8<6BWSQ8NI,56'D6Y\?ITI1F7(889% E&HOB9(L MA3A($ I4&#E>&%_J:')&XNX9W'_]^/#K'7B\>P+?_O/VZ0[SVI\7+Z^+A??5DO^KW_2^5K. I:B M() "!HE(M5.A)"0IRJ#^;9B(@%&>.3D5QQU,S4K4\H'2"/B_P/\1_#T(0O!& M"_##2/L?($R"FR (;D!";G 05VY]DMZ@, :E&0?MZ*]7WY=%G>[5_"HORW63 M#=;\9KE7<8.N]-+[MJJN O_G_PC3X#]BW;[Y3F^T/U.^U=3C\Y\W50-AL!,@ MB$@M0'*3IN$U GR2O.H?Q&'5=738M9L%//F(["S?-9_&P!:O^2HJV6Y )=U- M13\@TZ-*_)SMWTORH]NV2)S[\"YLUVY)8Y3G 0AS%3,(@,;M[$&;ES*G8&\Q7YD M^NN0ZW3YH?TV[AD>75 A3;3&)E8OP2H.*4YAEJ74E#R((48AABH-.1(A5SQR MHJHX[F!JIK>2#Y@G'".>CX&3(MBMRE."$4I4B2%DFZFHP)*,4!H$0"&E[R11W,8VV M'4_-9-;ID?,M*<-\%])R;<+J!>3MK,(0> YL+2XDI=8(;P0?H@B5*U:#I9]> MZ/:=$T[;P>A.,>UXWS.T0Y;ELC@LDM5P*)7/RP_R27*9_Y#BL_Y'56)Z%G*1 MIAG-(,$D@(@K"G&B?1*%2"0C$:19X%3'V5F"J9DN_4%BQR -9]#MC-6@4 YL MM6K931'DHVIY&T:OU1*PJEQGI<)-52H>&$UZ#-+PQ:^O( WG_L<-TO"%YR1( MP[NAOKRQ;W*N[A?ENC"%J9[TMKCX(60$(4PP8*G MH5.$OUVW4S-GFZ#R4LL*\XVP?3ID9\'W=<>NA?1]G#$C-=B*#1JYAW3%VG : MS!$[V^D[NV%M0'0[8:UO^UFGI[HRCBF=9TH8FP.X_R=???^X+E?+5UEL3\,I MB6D6A@AFDG"(A @A"7 "@T11%B=VO8YJL!RA.+98KJ][\1C<+T3^(Q=K M.G?G+SAY=VKVQ>3C[PGI1%=P"DR[I>@#DX%-PA$<_;,27%3>EXW@M,$Q60@N MJG/$/G#Y.>^TYD(W]GE9/-,_95D=%CU_IPOMPNB)7_WNX[HH]!;K=B%,$=_Z M/V810DA0%4.N!(&()2&D<"R6>GMJ;J&,Q,ZY MS%Y#8>=5C #PT":EUJ#*QJGD;<:9F6YT:\O-&5/=79/X,T.!" @*,BB(PA#AA&BC%PHH6(+21'(9 MI$Y1M.W=383Y7!8-0]3/61H00^]( MH(QX8/*:,ZC]I%#[33B2-(V18J&-X;C0_M0L12TBJ&3<4)-9!I]?0K#=,O2 MR\"FP T2Z\G?H7C+7DB_64]T_<-N?E]J;Y0)W:',9@9W/>9^-O'5\-,OO\KE M[8^7JJJ7(V'RI?>G-B^UG/#Q[@%\U?^__:'MWHOVF*MR#&=/_+S. M/7G>1XV/ZFF?5^S8L[[PE+LGW6SP/^O>MHL@D M!H@($B(X%";X F.E8IS:Q;>W=>/RL8X3X]Y("FI1ZU F+2PPTMJ[UQ=A[?:Q M^X!JX'GMA9&3O]T%@I?3?;'1T3SO+K7VW>_.9WU7YR7_UY-\T]_"=Q/;52Q? M"OIZNTV$KGVL<,8C&E,4*2A3H3?1F920(!7 1*4Q$4@*0:VVTX[]3F\]UV(; MKIQ&;O!6"WZSESL.J(,S[SH.MBY [^@.[AL88'W/X/6'JS9VP MZW5D/\,)BE,'Q.UU]P,#LS71WX_M^4#S^-3L1[6KM[>V/OH?+ D[I3 M6ZK;T,;6)I0U,L6JRJ4VJO=AD3QFGR:'B[ 5$.V9? M/S@-/!NW"65/5=GUK8C7H^-0;/=ZE$:JI+M'-;I:'GY.@!9Y:6X6J^#+U7<) M1*[TWZ4)$&=R]8>4B_K!YL96_\>FV'C%"V'^IC=*;TTB!7@U2JF MR 6$XQV1T[N>9S?\NQ3KN7Q0QYR&G_+Y>B7%AY\U*=C'.2W+O?HXB,=4! +R MD&80R!1F MXE2K^">Y6+[FB^J_?ROUTMZLX!_IG*_GVQ<;#,!7/5^;4"3#_KDAQC,P.1X5 M>0Z[Y='1\(,Y]%'2WCB>$J[>; :D,J?-*%2ZW)CAF:\K8L?G/Y;U+\&OXQU750G1Q;7=FR23RA01 @1K6O M:.@14<@5)'%(82RD# *.$Z*<.+<.FY^:E372@2?KV[,+F-G9,G\D!C916Q & M((DZKW1/1N*H\5'G_GG%CJ?TA:>N];#^L5R*/_+Y?,^+2D(D.,Y@RL,8(B03 M2%3(8!0RQC(19"1UJA?:TM?4YO#^"KL1UM>'.076U4^Y"JX1?9&-G"/Y$A=A MZ=U?..WIG7R"BRI?7O]R9>TZM MD[EZ]B&/R[*OVHVGY?>*PVB3_91%BBXG U=B4Z(]V+.:+D=DW5 D'K'=6Y]\:[H&J1^N!VJNVY*Y)G3TL+-[&" M,X%#&45A ..$:O=#&?ZGIGP'QG9N87_( M#;S0U!_FF9+P-Z 1MN<4Y4Y0^DQ1OMS9^"G*G8J?35'N?LNW1%CQMBSH2NJ% MH*E5V.Q[@D!A1E(!$QDRB#C76\00)9"'2O^;:(/"B5OU@(M]N&]!RY[J:J:?4?Y2R(1"9$%$(9J<08!@XQ4RG,"$UH2'"8(:NT"\O^IN;" M[:KMSBOY'#9C%N!:[%C[A6Q@:W&1F+N!\4'5O^@91H,V;C\\DIY1?ERMI:M!_6=)%61.;FWN: M+_E"WJ_D:SDC69H%:2!A&"?:2Y.FLH))B0T4USL]$BNNG&(\;3N>FE7>R&V< MDI79M52"5S%13:DR/4=V>H#?C2:@4L4Q[--Z:.Q]S-KGR1;W2_*55&MD?<+;1EDN3*A$15;@'B4^A/5 MB^>+*54=1IQ1!*DBQK#)!-*,ZCUH*AG#1*;,+93!ONNIF38C.O;?/E3RBMW+B33#4IW.1F+-J[D1]LK]/RX M+/.J%/2FC$D2IPF5,8.!B .($-/.648RJ#*".8\52@.W0#*+3J=FQG;T80>E MU#=B>Y>2L1H .QO6-ZP#VZX>$/5G:K. J&_^MK8NWX?5S0*$BUQO-N]>00KU M?3G7;Y1W_UZ;&KPDEF$4ARD,:1I"E! .<4)2J)* XD"$DD>Q2YC#:1=3"VVH M"4?O%F7^LJ@3;:L$L;_K/>!.]/\3R$IX#[*G0WQM[G&.R ME^11RPXKX<%.>E"+[\D":S\HEF9D$*B'=E;Z0_F*K!I;P'I/LNGL^)UR;FP! MN9R"8]V"1XC%:2A7Y3[I35PNU:;LWOY9!4TC@E&0P$RD$40!CB!%00B#D 51 MQ!/$L=6YD5?O4S-LORWHVYN65=3GWN;82 L.U'HA7&((G >AW8H-#NWP5WJG M@9^5]* 6?U?/T^;0J >\'2(XAL1]+&:O?O%W"^SPQ:\US,.YT?&"/GSU/0@! M\6[$M\RSWD7G?"5%Y5\W4:6MO9'K2);? M]U<06.SB-F#VZD&]9H$!7"[[CK%5ML?EVXV9^I#@TU9W.N66TG6O^]73;98F,.!2#9##B!(?(C[,DR!#R!3.+>3X;T7'BG6OA(,&*,HAN MUS/9L 4V5P;R[%QN\*_=#@ [PU_OJ' VI@,OI@BK#EX%&/NY^(5YXM9R @/PZ"F7,00X2R%&1,$ MH@P)(G":9;X67;1E_U,SU=UGX@M0Z]"26BDMP/=&#U,F1L-1TC,S V(_L %R M#[LY5Z,=>*YH&PU['Y?!T0Z: S)'RV9L\\06*F*FK'<%CWGU]T\?3[*ERS_R M:A;[$?)8C&'"4:3J\*2J"#B#0<:XP+[GI=0HKJ6CKZD9N!U1@9(5*%'!=R6L MH17K@EC/8CD";F#K9(F91?Y8+QK.,LA.]S1R#EFORH=99/VO6-[;*,["^DBQ M72'QEC\\A#PSM>'^76-+72FKV_OJFW*L5-H+9V3[Q\]6=1$D<8"P0I M"C.(&&(P2PB#.$6>FE=$DQBEH:^4 ME ;P4WT2WZTLNM%3L<1N/]?JVCA"+L"&GAML*7P!UF.O='9X$37XL+BZN!I. MT'$ON@8'_.!B;/@>K>.OBU?^I:BJ&PF3/G%1E+QY[@G_ MP67W0+7'[422UW$G;EL"WF\[H ?!,M/@MID*8T(=#C/(4HE(L,YD$ MLSCC01;R* H\D_"B 66=6IQ2RRE.:GU4/;H?>:5LF/P5Y,W?EDH_XP#OP09; M;P6:R! .O 2UH_>+TO-/34&9C:I@H^MJ?-OG:W5K4H@M]=9Y-$X#S(<>!'?Q MZ(-).G;X^M"0'XEV'[S+,VOOW"[>WI?5%_Z#SX/V H,A+G"613"C@D*4<@Q3 ME'J01R$1(HJR,!!6)7<.^YK:R6*[*$PC[06HY06!95V=(_AJ>F[=H#:TE_8T M8 /<&&E@XKIFSI&>?DZIG-,JGZR0T_'*&:G/W%5X0@B7U7NBFD*$RY2(OR0(V;D437I?&IVI4E_;H4' M5$E_ 1;OR,9T-0CN8\F[9A$;YZA5_?WJOU-JQ=F)&7!:G/*:0"Q4V,:IH( M)@_+S!.)[]$HTJN3?+*+J=FE1LC-<<@@&/(XA-U6QPTP0U_M[&'2OX_1!<<@ M'/1LD$:*^=3^@,RB.3O5[PS9//[F>'&9G9+O!%]V/VFY0T2GZ?R9(2N F M]1#LBFP9N],/N^9NS"680V_!SL/1?,^EBXVKC59O?^/NKG35/]A2:;_HF@[K M6@A.E_D/OL6^% F:1;Y0);TPE5LLX4,QS>\=TDU<4S^41.R_8C?RW:I91.7*9 MP#".>%N?FPA"H8]8&D8H2@C6(K[O[&5J.\.5H*"1%#2B@EI6/]@UF\!O%1?OQ8 MB7T!WFO!P=PXA4UK /2V5:YA'=AT=%("7(!&YNZD0(<< (<0#9[XO]7E1++] M#T'03_$_\JZ=25+''LYW*YFM6*L^VDRNZO,[_R^.RQOY-3+S(2%,[E8$$IS2)&"^$>N[J0!3,U7R$TS,C) QY'H&:4@@!S9.C>A'JAFN MY;]0AS;"P0/.V050*@"E@SM;98N>([MEW/VH-LP6G'U[9MV.G6W;[>BZ83*; M^:&71JIR+:.J8J)(,X@Y%XHMVHL3ELC-EV=BP([V,C4K]:A.#2V7FYFU.@ZB MGDDZ&YJ![LPW"3\A.=U)@I> MR@7^.5\LU'PL!&@D +_D"\"*^1R7E?HG4"D@_F3!7#+"UX%CG 8L\B'B)&[W MQDVA=!X$D=P=\RAMOX[K!?L7_S96&HSR9? %^Q?])O16R@F.\L!KKP.>F_L5 MLF_'&S"4)S@A2C\^(,]Y0'*7'&;%[EWND61;' M'LU(!",11Q"A))6+%DNA%[.$^#3U8I$9CF;F@&M813,%QF=L8V%%$ETC4>&740D[9G.TEX]Y!6W;VK M#+M[\<@7_'<\5]1=U2S &8TQBB G20A1PJ7E\/T,AB'G)(W\@!.BG?-[CB13 M,RZ-+F#>* /P3C9]L78ZS&N%+L"B5DGM;\M&*;!46AGDS)XUC-W6:M3!&<7/ M#%H]]E@.]IQ!*H"H&9=[ 5I]:N+$T<;%(.5YK/$9*3-ZX'$RRZ=V@6UGVO59 M'8R7G>T"AYTD;B<-GE%,]I&_R0_V!:O==?%4]> ;N0%#RM ']: WG0":E>;5A,AE]5J^[H545Y<==L>2K:E19A(-(>##V5?YCDF"($5+$.CR)B;)"D4'= MQ^.=3,W@1'\._Q?8" KN])."NJ#4V.,Z &A@VW$,&QN&G5,@F91>'?$*HC=TN\6.^QYUCS^_2I??ER6'%\5C,\"GX:"A D, M>:@<"8F V.,^1*GBNT DR6*MD(S]AJ=FW)1L0 D'E'3Z<>T[8'6;LG,@&-A\ M:6IO%*]^3%6K$/6=AD:+2C\F_G8@^M&_VQUYKG&I;M8KN6VIW8B;/%GLTXB@ MA$$4^YZ<^_/OSV=/ET>W\'[F_ W?43 MN+V3_W@-'JX?@?SAJ_S#M_^X?+PV.]VO0R@CP@H%63*.R;B>![#8"+N 9 M>.Y;(*,][?O4[YKM\MVMF2Y_V\SRD\V.,KG[E%K-Z=[G+)P+WU1@ 2[9)RZ- M0]GPF#S(X6S/?!GE$?%8(&#.]0&]UV>!,S&#=&#G($WPAV"(SDE;#X],]^$'B2= M+HJ>)L;S5.CILN.PT'S%PI[^YSM6V2JJGEFIHE-O.)_Y7I3A)/5@0JF06R.4 M01P+ FGF,YX@+R:9U@GJ5 =3LYRMB"H=MY$1"&[BI3V&H8:A/!.9@:WC"I2U M>.#F;% ,;."9X(QD^(Y^.>I^47:BKGX!?BW>U7^_X8\55\N5?$44\I2#+\!O M2_QR 6X9?BDNP%]Q]2*//LMB<0&NBGE18B;_];;X73ZH]J9WG)2X^CM6=VJR M?55U4 798/"JC(,*$5:=-S& 1?U(SE2,&\,?KH('.D:ET_8>>V\\@]LA]8Z5 M[7KN7$J4)@>P(43!2<+D%I5B%:"J4O<()B%D+/3"*$Y"PK2VJ!U]3,W [A-] MM FO9Y"A;.#L]Q\[ &E@6VN!SQDT* <(."!!V;3YDRA0#I0Z38!R^*BY2^D; M?U8-_LK5W?G;2RZ;7555B&F,6)!"@K($(DSE]"8AAKZ@(LH"'GF^%M]19R]3 MF^#;$AH63NA&L]^YY 2C@>>W&3Q&SJ5>]<_P,)UN>S0W4Z]ZV[ZF_H\,?E@MTO7WC9'N@]RFF*$P\2FOCRE!0SB#W%"2I/29G (O/#3(^) MLK,?D\]X'&K)5M)Z3UHH00U.!2?1#!,4,:Z*T80.=.XF3P9G4 M!5XC'4P?^0^^>.<-H6C%YP*^[2#8?&<.Z[)J =1Y1CSY\G@'Q3[Y=TZ+O0^[ M8[!2,>+W0I%ZEI@N9W&:X-#S!0P8EBL/2GV8QEX(?10D:4*3#(7!N9Q5NUU. MS7"N&);VDH\NZDPCY12AK>#G4UGM8=]M5H=!=& ;>Y*NZJD%\ZH/3"?T5,?Q M&9"0:J_#GTY!=1P '=*I$V^:&: %SFDU^^__C@(49,$LP+$GM[>9W) %7!J9 M#,$TX-+2R,_)#TF4AGK9D+O-3LV0/+WD)8,/N%3756I-U#,8>UAU&P5[! :> M^(U X.$%EZ^8?H!/?,%%O@1?\0*WC!6;'4.-%&B0NF2O^2*OEFU55&DB;AO@'@AHUXWJ2">><,V<7WWZ^(K_5I1U>=XZOC;R0KD1)R&,.5.>48]"++(81AY-(^*E M% FM^V*+OJ5](+@'-A9.D7;(M'\2L\$) M]P][G@CO_DE(].GW3S=AF9Q5!RC6K=V+)U5_\KW\J-/.O^0+?KODK]6,,$[" M#">0HB11A=PR2,+(APQE.,L\/PJQ435[5B-\58P7Q3#AJ2^W7 (3 M,P))H]ZG9J)6PM=NO<-]P$8!N0=H53 T56:#HV>T!H-\8//E%&UC,V:%FB.# M9M;WJ*;-"I9](V?7B)VY>R@+D2]5*S9;'$7JV/OT(@<- M"SET,Y]20;% $(D,0\0QDC:2J4T?9XA1FJ;8:+*;BS UH["1S#QHQA!\/>,Q M+*0#&YE&^"-!-2OF\:8 W$J'"U KT&9^R']Q&VMC!Z/#V!M# 4:/Q;$#Z%AL MCF5+%I'IMXL?<@52C;>$]IZU9>%451TEJ68=G4Y$>V[]'.$TL$7:2+@J< !^N74& MD4$8M0.H1HJBMH',+&*Z!XO.@.E3[XX7+]TC_4ZX=-^S%@9PQ:2]-KC?WDF5 MLQR7.:]F.*09(_+8&U$JS:!/"$P]X4$>!T*9R,P76E%._5U-S1C>K0LP;.*C MJRUY#:9[-\0:=M$9<$,?"M>D^YL=V[H:6/-\_JJG\@3=5]SWS#(<'SLM?R^+][4E-S-JR-4T_+A>7 MKTO=E(>>9J:V+53B@EI>4 L,MB0&CWSY7B[:'81^?D0?DCTN K<@#FPE'.!G ME%>AB8Q5HD5?VZ-E7F@JN9V*H?N*R[K2&M6O;W!>_@7/WU5,1+/O-I+)CB_8M9D*@*%2E,Y>D6QCCQD)>D7L:ULJY&DWAJAFQ5 M51RT9<6!$AHJJ8$2UT71:Y?CK7FTG=(HCGC$W7%*;*FKDDR.'H65SA= :0UJ MM<&6WA?UIP#J3V&E>__%;U429SA+B<1IB3\4#R-,QRU)(4AY!GW"/(.R'H6^TYG3V-K7UHA8/ M%@*^5UQQ-?.EYGV.'K9Z]MT98@/;YH.(I35Z4M@F%-V=,=4"Q9$A[.YK5".F MI?:^ =)[R;NHEF5]3UB[CV=)YA.21 GT2)1*NQ%@B$5 (4VRC",< MDHQK,0!U]#$U0[%]M?]TPT>48Q'J6XTS@AM[+[6/V M9(69L>GH0,61P3C6PZAFHD/%?>/0]:@5ZZVZPE]^;*B@;CA_X/*3J7^Z%_71 MNV69K&8D#D*N? P9C6.(_,"#A',!@Y"$@L=RN^%I,1):]#TU$[)%GB4XEP<2 M7 &LRLLK\=5954Z3^CH E*T&1BRF1L/2XWP;%NRAG7&MX-ML93>*QK 57OU2 M9P#76#\.CK41C^Q0F(\4Z.,8>U.261OT>JAGC9H!U,#(NX=V)./N M!F(SFVX&5JO+E(5\[)QIFY=E!^SH7@)5=%L!:; M&#W-:W&S5J=FG-OBE6OQMZX7P$:!"W!3%,M%H7O;9(%V_]7Y<$ /;,9-,79< MC-T>.ZN[=L.N1KMZMX-@^R;>L@4['Z4R=D*/P^S+FN6*\RC(4I4,22(*$?U9;%R;MFZ/\F#P:\NOY#*;NI,2N-+U;A MDYOBLFW=(YQ&GO (AZ&O"##\-(($\0R&7)[#4\_W:*1'_6PIP-2,8E/EH-%! MI5@H+79J]=:*U-'!&U4,3I@V8Z1Q@A\8^:'OFFO0JQ9TK@>Z3?DO&_0-#OL# MC\)()W^KT7#D 3@#P4YW@$V[X_D&SM!ZQU%P3CONRI2M O8_5IPGCUQ5(F J M\W13>G?&6>('J2J3E<# D>OOO<8#^61[DM287+3?3 \[9!5CKHRZTMNIS#UL,S0S6 8ND:0KR MTXNGF0&F4U3-L$5SY^M3R2[+\O-[4T5+U[FZ^];4+-AV_/9*1GT'Z1XB_0Y0 M>S &MC)/):[I)(WP,/)?'E?=RC^YU]1H_L?C*FS[%T\\83;7&,]GUXNEG,F7 MC,E!KJ[DC_?E4_'[8D98[*>![T%!4*2J$'!%D*NHZSQJ6;/LZ?7YZ^(MOUI4K&0W<_QL5+OLX.VIS=RF@M=3_JI6 MEJ]W#[?UE7S.%*>2846S0Z3Z%]OS01IXWG;A [XK81W='78C85_X[+#)<0N@ MG53IH!#:Z2?/)9'ZQI_5;NF1ORDF[L7S[4(4Y6N]_G_Z:/^XN2/WTH0R04+( M1237;RHRQ=Z>PC038>)[64)2HRI"EG),S5+L$$ ULLJSZP(O:"Z/KUNJV+(_ MF8V2GGMA!.P'-D#'8%\KL0W[19WO4;.16 GGMV=M8Q[7@AK4CM;#7LX7.$1W8\FF >0$:J<'W]K\',7A& MP+DJ&JG5Y[CE(DU@."@4:?2RG:'ZFB^*4A[\5@GPGSE5I=_XC53ED3/>YLG/ M LXQ36.YK4L2!!&C7&[P? *]6.!(B""06[[9@C_C)6=/^A9+LWNM&98U,^Q MB $/.O0?[WF5U^&2BTK1$1@:,=UQT3-C+F$>B0?Z>)V?"[ 2 M':C)!K:$5YZAA[8"NQJ-U2L.\ITL871DUG1['=6P&4*Q;]I,7[>]U5$YT-)T MUJ&PB@+(Z')G[^6I;9RVQ .?M>F63F.C>\US!BP_X;9'&R6+6Y\32)QQ^;/? MXLAW0"<4.KP*.O6@W2;DJGA]+18ULV1-W5-=OB]?I'WX)V>SE">$!QF#:1#% M$"4)@80G K(4AR1@$<5)9')&ZNAK:A.\$;7=/@"\EM-L)]$%KM[NP1%D T_^ M%JU:S(N&L:P"E_V@&>\"-.!PM/)W]33J:J^A\OX*K_.*18CU)GVZI<.NTZ;; M2-',]PB.< *CF#!Y2 GD(<5+/1CZA$:AR.( :7FA>WN:FJ5H$OQW60 ,HG([ M0>W9%KB$:F +L85/*^=%2XU@$X;=E_J.M%[C_)5-_X#SVL*2L:K_'FA+FE4AD?U_J8N MY,%\S?-YM*7Y7FD8IH@M*T[?E1MY>Y* %SZO&W[%R_J/K@H7&@]23]58W=;& MK"-KJ.%>95G3MP?GG[C\(Z]F$>$4!0F&0<@Q1#SC$ >9@()23^",)5YF%&5A MV/_T5IQ^U@DE]W!\$_6HZ&U^!\1Z\/6GGV6B&^8A^26VP1J?6J+N?:JL$MO0 MG$$HL=.,G:&[9'][;TWF4Z&*^BWD7IW?\653LOM+4IEB6FRUDJ]]343.:6CFIC4:ZT! N^E%L/I:?Z=_5;O>%Y:U55T:6;$LQXK>>_F9G6 M0;X#/?O[LT=W8".]-[!K!8'4$#0J@E^4DG]2?U9Z@H>ML?U%Z2H_@#]M93%O M])7VO=78H8T?=O?U.:Z=LY M24K(>:'*V[NF^NJ%XJRDI-T61\]).JK0L92DXP]:5D3)U5>_8-4#_E#Y&5?O M92DGBSQ1JA#!YI<9X3&)X]2#)$$>1(&?PI1B!$G$ \03[.'0*$A$I].I;5+6 M,H.W1FC#LB@Z..MM&ERC-[!IV #WT .<>6T4 R1<%4O1Z7+1MR0,[(@[2"TWD>I)D4/RD/T@JJTWF0=LW9&==?<;Y01YC[ MQ?;-&(^\*/10!$-.A"*#]F$:!C$D(8NSF/A>G.+9#UZ20M=X'NW'9!)N]S;< M7%1B@E_FM4.A6 #&!2]+/-^ZOC*S?:^H>A^V,X,7%=2WM_;V\ 9C87P/82@QW@&$?,$Q!0',,4H M%LR/,^$E)CNGG=:GMA]JA%N'=)C-[UW<].:U-1H#S^<6B%8P=W/XJ+Z.YNYN MVZ/.V:-J[<_5XP^=>PZZ?GV;%Q^1V.4TDPHOY'5**\4NP.6KVMN=>Y)R^068GK-^TK@.?0JK MA_33@$-ZQEEL ,B=G]1]H:N:]O5B6@IJR0IR$4L_(N@!H M8#NYP68IZW,P@/)7_#.6M7O,L%J\LF-"%4 M5ZL;O9A3S"F'*0LQ1"3#\HSHRU])G&9!XL<>,KK1T^AS:F:B%1GP1N;&35O4 MM4':FP^ :_G-;(@.^GKFQ#&F UN6%9RMN#6:3:651N(+T,KLSK@8 .3(SNCT M.*K),8!@W_J8O&K)TGBE$GN*D M8+$\U$980'7QQUB2!1XQVKA8RC$U@R6_QMB0JL]R /3LTPBP#FRS;KH"R)LS M(U5I--OJ7-1E44"MBD,^O_.P=,7P9RG%N)Q_YT%UP )X9G,629PK&K7J7MP5 MBZL-#]N*KFM&(^Z'(J&0!JI* _4BF"(_A82S+/.1B'UY=&N9^+IMH%Z'6G-R MEP!PZ-W9%M79CG 6J6"JF-3V<*9'\KXZ4^:FNTD_*H_Y9Y)/9M4S*AY;2[+,LO!N'8 MIU^>D EHA01':/N&B,ONQ\0J.+NCV=$BM/M5VP[3UGC:FIF+7>&2MRQ(8>J1 M)$D#F"6JYCOA!&)5&<*//"88%H(%F2$=UU;S4SO]M ("*B4TYI':ABU.6!!E MGH!9%GF*:CF&F1^',, ^ID$48,&17G34^<"-$Q;E#+H@]@,<9_),'H7R=)[Y M/DPY)9 R@<.(9I&/$[DM70X&VWH+NOQ7@4QC6WG6%S3P&K+"00EG3^.V#8@Q M=YLE,"-M"Q_Y#[YX;^FR7[>^&I4F4I15/V@V!&Y',-%@;=M^:VRJMB,2'^%G M._:49;C-\0O9S1;HT\?FD39BH,ZONF^HL>_?E]42+UBSV2QSN:;3NEC S,L" MN>I2!'TO44809Y P3F&4$-_+1,@S9!9R,Y2D4UO!MP0U#)P9;"SU')V3&*&! M#?UV ,VVECMDWZJ:T[% &Z6K*C5=:RM_V.A[ =8:-W53',;7##TJKF)L!I-S MW#B;H>$^B+49O$/;^KJ/_#E7F>"+Y9V<4;,,"Q;&:0HCC_IR04ABB-.4P#3T M(\'2P,>9UH)PJH.IV?%&1K 1$B@I36OJ[H'8;8E=0#.P 35$Q:*.[G'5SRBB MN]?@R!5TCZMS6#[WQ'/F'K^ORW*N"BM4]V)596$5WZ59M^1T"U.;HU^Q[$55 M)JO%52[K(UY _8HF'=#U.TO=H#;X05<#,/#=:9"<'CA67M..9D?SFO:KMNTU MU7CZC'+9?/E2,./Y?N+UJ4WVW8+0M:P6=;+W(.J?UP[0&7A2'P%F@"G<@\-Y M=;+WVAR_4/9QI8Y6RC[QZ&C!8[\7LR"1>I(L@C%ARCG#,X@IXI @DE)$8OE_ M9B5?;:28FGV07U8T>."8!%_/FS(XI ,;E7."QGXO?FK(V ;'GQKC8 M!B8'P6);C5GL7]C?G@KE_KA\76IO6K;>F9HEVK#QU82/6WZ=51Z>P<9E&QN- MW8HE+$-O44XBT@>(V1[EB/9V&Y/MAL;;C1P1?V<+D)*(QP1B%*"(4D\&/H>9S[:>#S(/3,2B3N]3"U6:H$5"?@-K?1, 'F M$$"]?<%9L P\2]>(*.D<7NGVZNZLTN%^^R/7-SRAWF%5PU,/NBF_/B,X"#*/ M()A02E0$2PHSPC$D?B;"*(PCGQEQH^QW,+6I?'=6Z/1)&/5F]#G@#.VM_\=[ M73GK*56KGWGSW[>+SS7AXF[ QHRGR M] MP6&(1 I1BBG$0AZD?$(]CE,6<1P:TI!H=#LU,[R2$=#M(_ZJZMJ',4^)#O)Z MNS3W> YLEU<"@U]6(O])[FO!&N%ML9TRF1C Y([71*?3L5E.#( XPGEB\K:Y MR[3V M'E.Y[//QYPSOY2K8M]&-__ZK0U-4.SZT)LA0=*>O"C^O-6Y1U]3ZL6 MI/T>6-=H#N[ST01R@"ME$ZBLW+A:'8SFWC51=]OM:_2>N2EYX+S\M2S>WVZK MZEU.W9N%L07I:&)JAD.)"FI902OL!;@IBN6B6!K8BB[,^DV$([@&M@Q=2 U@ M##1 L;(!7>V.-O4UE-N>\3J/6U:#I/($_#Y7U!:?^5O):5Y;?OGSG->!YPNV M?<7[4*K*@\N/!_EEJ'HIRJ'X]EI3JR4\)BFG,*8!A2C$ %7]&\ ;)16E]UI+PX*.KH92[P UZLB, MY/K:&H=MG2[ 6JN:X&TWQF6EF?Q)Z791/[)6SV&11L> NRK,Z$JL<8LQ.@;S MH "CZ_8M\T&7G5 M-7FYEA]42H&+NG:O_(/8R&^8 GKN\.F9\C$'96 37@O9[$^E#:^5 8TV%TTF MY@78: 2:I]M$SKMFL&XT!LL\:],1PJZ2,\\59]P<3$?@':1:NFKW' ;S;TNY M1M1YG7BN#,FW%\[5"G#)6*Y6!CS?JBO[Z4/^\E94>%Z?!BK9Q/Q=I>NH9XK% M,E](7=H2OL6BKA8_BR,4LA"',$D%@RAA <09)S#T_"B(XU0(;A0;/H[84[/S M*P7: [#*R0/?E:"&U3!&&G3M.Y")#>7 JX/%*%IROX\%JE,F^<&%_@F\]&,- MQ'&6^]%Z_SET,==_\)+FE0HC^RO/GU_DYB/(92GSA^4$( MPRQ1IP@/02*2%'HX\#B..(HH&I,\1E/NJ2U"*UE!*RQ820MJ<=7NM540_$7N M7^2#O^0+P(KY')<5D!\.J!0J?QJ7AT;W(]$\JTQOZ(<^TCCDJ-G2_@+T?$[3 MX:PQ'+.),-CH2OTOQ6=C.!2NV6U,N[>A*5<%(NJ.;SAO3H2?BU><+V9!0GR6 MRF6+\M27JYA/(&$QAAGV(Q(1+N) B_&FNYNI+3H;08&4]*+UIH#OC;0F<:"G MD>VY(G6&U] WI"- 9<(W[@*RL7C&+:$S9!CO0Z2;6?SDVR,RBO=IL,LDWONT MW;E!5?5;T'R>KZO\U72@-U+6;_RYIMI6B8F+JICGK+Y+K8MV9I&7A@%",/+# M!"*JV,*R+()^) 1*:.(A2DR. 79B3,W [FJA-O$[[*HK39I$V8TN=M58+4=. M;V\^_'@,;,"'&@KC'?-Y2#K: %L*,>I^]CR@]K>G9[9F:TQ;&UW=BR_%XEG1 M07WF9#DC8>3)C26%Q$M3B' 2P11'$?0"3\0^3H3/8XN0FE/]331$ICT%5$!. M2";%!+_VG8':6-;K;8V5 $I(J*0$2DR7IJD;"&?&YT0W M(YN7;F4/#4C/\[;DJU>RS1+/;Q>,__'_^,<,1\)+$Q9+V^#+K13!*4P3SB') M,,O\E 19K!67<;*'J>V26J+15DI0BPFDG*8$K/M =L]^)_ ,/.V-D;$@83VA M_1DLK/LMCDS#>D*A0Q[64P]:AMMNQ7S=BYM\@>5V8_%<5T6_7+#ZHN==6H]9 M$)$XH"2%'B,11'*MAUD6AA!["6(8L82%1K?VNAU/;=IORZU6-;9*=Q,K%8#@ MIF%5VJ.@MS48 MN!;<8^K&J- NM8MEKR.HQU+;O#,%9#M%R%J>IV.VX8JB$8 M!V&FIN];FJUY/:Z<'???M\1O,Q0%7B10"I-444:E!$&<>!DD4< S[O'0Q]S( M:&EU.S63U=S#D?H>CNHDY9X#>>K3*$T]>4;$C$$415SN UD A2"JH+W/"??T MRGH-!_HXY;[J.+TCL*\JW8.2-Y']RZ()SP5%W^?<]TCD*QKS\G6Q M9#=S_*R;,WJR@:G9=T4NIB0%2E3H[X1AJ/.^7(0ESOJYHZ>1Z[D6=07:P#9# M#R_P78GM*'>T%Q:KS-'3K8Z6-]JKV';6:/_#SCG*?RV+JIIE-!28!!2FF!&( M N)#S((,(A(3+TR$%WFQ(SKRNL.I68A:*%4\LORH2VD84/QJ8ZRWP7")W,!F MHI-@O+H M;RC\(CO(#,\97C3W538P7>4-R "WWW/(N[J4:X'+1%J2\ [8UD2 M>SX+(8D5;:D\RL#,RV+HR7-FFI*4I[%6V/")]J=F-I2$__M_IH$?_%_:,N]6 M1ES$IW#LV4>%21UX;+T[JM,P[ 5(=CUF8L*>7O&0/N%Q^-%D:1;GB J=,&BZ& NAQ[$%$ MJ8!IS"(881RD @591K3<^=W=3,V@U8*"6E*P%M5@WI[&4\.B.4%I8,-V%" ; MBM732!D8.B>(C63OS#XM,WO7BT.GV3O]]GC6KU>#'2/8_[3=.?'Z]6U>?'#^ MV#A>O[2LGSFOKM[+4C'-4,$]+PY3F(8D@"@, IC%:0R3U,>(2@L9H\#DH-C; MX]0LY"6EI6(J^!T_\^;&;>6EGF]D-SLY]J.N=W1TBN7 =G0E*URAMR7M!6CE M=7=VU(;&T>&QO[]13X_:ZN\?'_5?M#,X#^O8J]V;T)FT,8QXU(-QBB.5N4,A M1JF C*41$AFB?L@M(BE/]:C"T-2QGA5W =S QGL;L[6030R*.Y/=AX,C M2WVRFU$-=)^R^W:Y]WE+=@%5T*@-H;_CJUH/7I0E).($LBB2>S[NQS!558DB M@I,D3"(O#\;E<%=>DU>S2>^H"^ON/S[ .7% M.C%PE21^M(]Q4[J[U#Q(P.Y\V/S:ORE:?KM@BDM']ZI_YZ6I354ED_[E_:[^ M/6ZI\=ST(F*T=W\402L[N-W6QKM#OZH MOW M[LAA>;ZA&4S3*()8L(#Y M<8R0;U2K4ZO7J4W<;_2%,Q5GHN*9=Q382N0T6X'UT-=;D9UC.K!%. EAF^T* MG#*^6Z'D: W7ZW/4-=T(AOTUWNQE]\3"=_SW^B_5+(FRD'O2&G$OCB%*,P0Q MD1:*!'&:>-(J)8B:12=K]6LRB\8)3MZF":;%ZZN<4$T,\K( O/6*-?Y?EI>< MUM= LO_W^;+.<%')Y\L7#OB*H$E=\MK',.L-GN9!P_6 #&S6- B"I=C- R,1 M !_ - ++[Z;/R5#Y'L!@PM=[^+*=75,%&8JF;.!G7M$RK^?7EWS!;Y?\M9KY MS ]2%GHP\9B0VZW44RDN!#(4\%3$6<999++3ZNEO:GNL1MR+IH2E*HNP%AE\ M5T*#6FI#3I(^S/4,D4,D!S9!YX)H;'PTH7%D=OIZ&]7@:*J^;VIT7[-E_%C3 MBERILMN8+O^:+U^NWN6:_LK+ZS]:WE<562G_CSWA/V8)EV<[)A ,?.%!A 6% M:40$]%%,(XQHC)@6^=P9,DS-&#W=/UU^ 8_7?[F^^^W:E S$? 2R,(FB),Y@ M& 4!1"@D,)-# G'DB4A0.1J>/UOPY<_%?WVMN)RB2]L*=Y'Z),L(I&&<0I0% M(4R9"&$H0A9%\H_,-TQQ'/C;'^=(\50L\7P5#6OGWK 9#;W%>&"$1[J$O^0@L<)9:EBXUJV;%Q/LHFZ3 IB 4E$+$_S M7&XH4!0G, NB%,99A((@C$2(C:J;'>MD:M.PYH5;KGCA+H"2TZJ4S5%$-<_J M9^(T] %]ASI/#R+S0WD'!JY.XL>Z&/?XW:'DP9F[ZUGS-?;RE2]837VL4NDQ M"Z(0$0:]()"+K(_DX2WF\B"-$I&*(!.A%^HNLCLM3VUZKX4#2CK]1787KOY5 MUAJ$@>>NIOY&J^Q17:V6V=V61EMGCRJPO= >?\ B!>YV\?3";^1H+E_^B^.R MC5E+?0^+3'A0Q!S).<<9S#+F0Q_'H8CCA(A *S[A=!=3FX:W"R"E!(V80,EI MD,UU',3N.>D&FH$GYR$J-LENQ^$Q2'0[&Z:1DMP,/B*S#+=. #JSVXZ_.5YF M6Z?D.UEMW4_:ENS<)3W8%&_;BL5* D)#C"#!W(U&*6(0R0H11 MK3.-/B=G_.Z>+N]^O?WTY1I9C_B>F<.QS@.;BGW M"%# 1E[P?9#0*P. G%6=[.]QY)*1VA < M*LZV5:*WA[*0(1["F(0A1"0*(68,PX"%,0\(\D6B55Q%K[NIF9R5P'4,U4ID M,&]E-MA<] .ML0]S"M_ EN8XK[ Z(HP4OQ MRL$+QW.YEU-8OQ35F[JZJYK*(O6_X?D<%,L75:FS^=<_.]KQ:VKFMQ8/K*XX#)S)QW#K=SZ=@<;0KF,#((Q\4"=4MO)"[;#>1HD>%&M>R0\>:]P?>G W/@[:@N?H;&C<_:@'15MP M]D^-UNU8^Z^X_$J7#W+;<\>7,\PRGLG3(11QQ""B$8$XBU.8,2Y/BY@E&3>B MZ=AK?VK&;"6>L0MJ!S1M=Y,M%,.[EFK)@!)M.X[M"K_E2SS/_]D0\-8/78"- M);JDR_Q'-R.5C=/I&$SN'$P[K8_M3#JFVA''T=''[&;X5SQ_4\%K\DSSI:@J M%*XY&5;GK?U M+R8180$/0NAS$4,4IP%,XY3 &/D4,4)$S+7L6E]'4S-A*U%!(ZN!S[8+30V' MMR.,!C8Z>_"LZGG;^+B[\#+P;CO";22_]@G\'+FH-;#H=$YWO3^>6UI#BQV' MM,[S-M:1+_*B_"+WZXOG=@=?+%;7+Z$O/!]['A0X2)5Y]&":AJC.J/))Z@5< MCYVQMZ?)V<=:5M ("S;2FDS\+F!U+*4CN(8VE2>0LK*579"9&$M'T(UE+4T_ M-D-SJ8%&M[WL:F!$@ZFAQZ[%U'G!/DED5;+]3LK>$F8GG"59[ MI*F.L:,HS MF)&80S_DA-*09$SXLZ7*Q]0[)A_OQLA8KCL;\"KK_NY7^'3]^!5\OO[T!+Y< M?_L&KGY[?+R^>P)?+Y]^>[Q]NKW^9IXS<@1@O;/N^; -??FWES>RY5IK9 5? M\?*]=.Q"ZX;%82K)D4Y&3R8YK>BQ=)*.I^T,Q*]%P7[/Y_-C88A^E$4!(3'T M$E]:"<4/@SV?0Q9'F/FIE_'0B(2OHZ^I[:M^O;___-?;+U_,C$$7F'H6P1%$ M YN%E93#AW!JX.'('G3U-*I1T%!YWS+HO&++'H4K_E+,V>WK6UG\J&E4U_&9 M(A+8]U*($U4*,T$!S"+D08I]3!E/J<>UTKPU^IJ:>5B+"O(M64U)HDY#J[E] M< /8T'N(-5;;8@[ CJT!AS-"J-,]C4P&U:OR(1%4_RMVMF+OLO_N7;5Y+S[G M\_=5F>[J_GU9*?^0W$+.",\\'# *B0A]B B1AQ ?1Y )#Z<15E016@3^AH8(B\2#$>-!B 2FPF#VMOJM#ZY$>QCVLGE;QX)#:\:AYF98;*7&QX(^7NULZX"-IAK?Q\8)HUG.Q:KQJ2WU.>D[QV#7VP Y!7-@XW60H+,2M_D=W';C>&8Z3@/$!5I*"5E1P M^:KB=_5W0$>!ZM_@G(O1P"; %AZC#4H7!E;[CZ,-CK:]Z%)G>_?0^9S=YJ#A M99DA',=A&&40A1(:E"(?IC%1J?E!R#$)O#0S\N,VS4[-/=O41FC8E\P6\Q8F MO17;7/F!YV0CD+ME=U=!1VMKV^BH"^BN(ONKY-Y?S9?"R]]QR:JK>5'QI^+K MXBU7E^N&96&[VIC:TFA6);83G?YUT!4P0\^]6DQ0RRG/$> I?^6JP-W7NX?; MK=B7:J#"LCHH6:V8G0V/MG+JJ+>]@FH];UG\45T_//(W^>&\R'WT0UD\E_BU MYF[A019P1"GT@EAEE,=R84V(!Q&G&?8R'-#0**/\=%=3LPBUI& C*FAEM>)6 M[T!8;V%V@]O !L,6,O/JB[UHN"JY>+JC<>LL]BI\4%RQ_PT[8W']C_?\;2L[ M#E/L"T\5,B.9#Q%+*)I"'& Y6H>QB%,!4MAF. X"P.4)2S03AD\WL?49FXK'7AKQ#-(>#N! M8<]&WPTR \_CE8!@A;O3)7\KEV%%6#O M]5&I;%]H&$/5Q9E\HXD KHN#O[_-M(R'HTGHI+QG+U3>&YXO.Y7;2<2O7NBLA]%5-.8RE+_>$]$G+'E A(DBR#-!-1ROU81,BH M2M70 D_-D%^_OLV+#\Y!5==^Q^I@K*)4UVH9.DB''F]-U^N$1G%HQ]+#[=5% M$]D*/REMU*I3;R8ORU(^6$?E*Z\2+>N[5V4[KXIJ";9TQ MV(#_:*_YJ=GW6D!8 []CU@'_0_W,Y:YJCM7]K-Q@-4M \=:06:@]E>+>*_/Z M_G9K?:C4PXMB ?EJ\6!YR:FT#$9D(0!=*II\ZXGOBT;X>WM@J?/C:/M#N) MNGOE1EE^W"ZD0:B_E>I>E6)X>L&+^\9@_(6KE*?;16/#]W(TZHCMS]+0W."\ M;'9R(@H]+R(8>@E5]65]"HFJR4(2(G?T*?)]CQG?ADQ!LZDM 8WX=8(9*^9S M7%:*B+Q)-C/,-9L,QB8W/5.0=TK+U-9181N5[?,"(!_'CQ0*FPO0H .VX $U M/F I 0(M0A>@_?#D=]>@=(2HO48***B P@K48#F^VYK2^+N\2IN$7N/?W$U" M[:Z+PDD):!ZM=%;LNJ=@EOK;1F>]).>/6V MB:Y &W@V[^.U$G2 L $=1!SM93J[&G5[H:/T_HJO]8Z=W;CCRRM'060@PJI6S!VC?]IW1DM6Q MY($768SK;' ME)VVQCRH'%-B[ZAR]!&;RU);]\6^MT+NBG[(V2-_?"H>.7NGO&%ENOR!\WG+ M:S"+.44XX2&,2$8A"E6E!9Q%$!'.<2#_ZJ6A_D7LF*)/S8IL.5^+E?.5KO5H M8N>4)BO>.;REB\D%Y:B?A\YM\%0'?107/NEVX7]:N?#),1=^\\D\[?CK-RB MIP(T.*PX\R[_%3X9D_ORJ7XZ8]W%3_03,KSU_QFCV!U1,*I$(T8K_ RD=R,A M?HH$%MG>[&]/A1*QSDC43>_>?FEJVXM-?)_:2FRCK^DY.82E_\ABCZ>E\5*RCRFPDX-]] $[5ZFJ8[*Y//V2+_CMDK]6,^H3BB+F M0Q8S!%' Y!$C$PG$B?S?.$8LC8QN5T[T,[4)J\3=UH^X( 96FX52,0L#'0S[,0SW7_?K!1PI%* 2>$@] M0@N^;"DI-P&=8PV;W@(PV& ,O"P8UA"HQ1^\@D W:L/6#SC1]Q2J!W3#HED[ MH*<1"U_Z4YF_S?D=7]9TFEO'U%5H"O*]@,;8AT2H^/<@%3 -&8-9Q)%(:$PI MT\IIM:H:ND1>H2^.&$G9;9 /_8B_*&EYDE]@-;)K%S\"EZA+' MD;R@=I^AF8]2%Y9.MV)O(^-Y G7UV7'>:;]D'6))96--N>/'O/K[IX]/?$%? M7G'Y]]K?%(8AQQE*H!>K^J/<2V 6I!PB$E(O4C7=N=$NLZ_#J=G;'7F!$ABL MY;4B8>M%7&^#Z!+'@6WO.1#:Q%]JX>(N!K.[N['C,+64/Q*+J?>>9>HD?>'L M?<[OQ5<\;VLT\-M%]2Z-&>5/LM'+!7O*>7FK:%1R(7^J9X+OIR(C603#E"-Y MP@U2F&$_@BF.>, )9R'5HH;*Z'!1FH[=DC+4=*S5R-@ M/[ 9.Q]V\RR\\T!SE3-G*<6X&6[G0760CW9F<^<:RML%XR)?Y$O^)?^A8D/E MZ?HY)W/><&H_U>1F$?<)1QF%:22W92B,0I@1CT/!D-P$BR0- JTX,+ONIV86 M5]+7-9[6\L-: ;#1 #0J@.^U$M8V4FN 3$VC:]@'MHB.$3_#/)H Y]PJ:G7^ MDXRA"3"G;:!1*Y:F3]%UW%;5.V>?W\M\\=SDZS;NQ<.F* 67$K$9 M]H2T=5X&8YHJ3O 00XQBH@J+DC#S Q1P-%OP9\76\V1@#:TETIJB63-%#^0: M;KJNY;._ZCACE#1MX;"@C\EGU&@!&C761 Z-)A=@HPMH'F]C ]?Z.#239V/J MRF3:"S*N^3P;L -3>GZ++FH7;A?/(X%(TXA[$,G"LDH,3*35H M7&+036G!AQ]OS<%$,[AV]?S4IO #_@ _*K6FBJ)\K7TRFTI ^I&U:SAZ[CHM MD1AXGG:"X.ZP=4Q[JW#:=2.C1=+NB[T=1'OP-[OU]4N^D.>CJY*S?'F#:1T" M_]OB7<7:8SEN\K>KXO4UK\.>;[BB:56.=OS,9U&2!"*.8XB#A"G&@11FOG+> M8(I4[!Q.0JUY>K8D4YO<2A'E4:"U*D"TNER ]UH;0%MU5*;>2B$@>!W*U:ID MMJC;CZ'>HC_*R QL;%:#TF@!;M:#TB@"KM:#LM$%2&7 0_^@&&\=S@;4T=;" M7HY1MQYGP[6_-3F_05L?$5[RW7!ZX?LA$6D /5\0B (1R@,,22$C.&4B2R*6 MF%6&.^AB:N9Q+>$9R0E'@-1USYP#S^!N%R-D+/PHIY1WYA\YZ&!DO\?=!2'U&S,PRA, MZAKO3X7ZIZW0]"9F?2:PC^,XHI J#A64A1RF3![$LHPQ3+TLQ@$9A3_=4/"I MF:E-:D>K"-@B3+>[7AKK$]#<[4QP8(?>0YW/<;[/8JX"I58 J,QO]<\7NVE M#0P38"^W'+B?34YN*O:_!O>XY6 XHQ:W[=^2M%2B6<@UM9C+AYYO%]*"RU[6 M9,<1#OW(APE6Z?B^ET(M]/D:?.[4$EYJ%7=_]+ MEN4LK;8EMR17=9T;+@P!F5T4Z28IIUU/_P=(:A9EBL3FAK,&6Z:DO0,1'P(Q M(>+?_L^WJ]$O7V$Z&T[&__XG]F?ZIU]@'"=I.+[\]S]]NGA'[)_^SW_\R[_\ MV_]#R'^_.7O_R]M)O+Z"\?R7PRGX.:1??A_./_\R_PR__&TR_G_ZHH4.:9),XD2Z0SF3CO&>'6 M2"9TH(S;_^_R7[4'ZZ-W)%I)B4SXLYXG3RCE.>N0%;-L\=#1Q^&GFG/MU\=W;'YT-G_M!?"S[];\_O#^/G^'*D^%X-O?C6%XP&_[K;/'A M^TGT\P77?TC7+VM_HOR+W/P8*1\1QHE@?_XV2W_ZCW_YY9GL^,$K83P;7HXOIY/K+W\>P_S7\C._'DX0$TCMXK?GW[_ O_]I-KSZ,H*; MSSY/(?_[G_!W+TD1*W6"EG?^O\M?_/7NU5^F,$.\+);Z'C]8_7YYRU9DP+'MY/8W1S[ :/'I(,%PL'CJ09C-IS[.!YI)ZXP.Q('P M1$IJB:7.$1&L]Z XM>'1J@O5,R1[(8H9Q#]?3K[^B@_^M7"B?+%@R8(=3UZW M9,UV=-_LO0O\V0$'F;D5E&05(Y$>OPJW> P/ MLC4A@,HDQ!SP=%2 "W )%R"!@G=>.5$%$ ]>NQ$<1/MPV)Z7C8#A8NKQ^"R, M7P&ZD F, :$\&")C]"2@D41RD%*F:$%J7^=T>/3FC2 AVX?$3ASM&15'X_EP M_OW=< 0GUU<9+2@G:!ZLW82)1V$$*D>.R%G=#P^(T;H4"UBX*= M.-B$],_@EN"R, %\>6KK+S$HT]K(7<['YY[ZT8H MT*VC8 =.-H&$8W3GIZC"%HP_1_[#X>1Z/)]^/YPD&"0T<7C40)B7CDB6(_&& M.4)U%DPG4"!JJ(87B=@()Z9UG-3C+K-X**;1TJ-7C;!$@.4D(1S%9_O1^.@:&A ME$34Z$\KKM"]EAG=:Q8UR0QY8_!+$V(%@#SSZHW X5H'QZX\;0D8A_CEZ?1B M\OMXX#4X'T11@$JB N2<.'2S"$U&*^$]=\K4@\7=BS<+7=&?!!5;,K0E3"R. MQM/IQ^GDZW <82"0+U0*U'))X#I<,L0QP#\4),\T*UYX/6 \>OMFZ&@XLEF- MM2U!Y.-D-O>C_W_X96$Z91-"%CX2S2DC,@$0GTTD @TGFXRDPM3P79Y[]V;P M:#C@68FM/8.C:+V#*?@%W<9HDQRSA+&,K$AH4SON$U'H@UO#4?U)M1,<[K]M M,P T'.+\F M]L=OW$ST#8@R'BZ&\Q%J*_ J"&\(*$:1"8H3KU@BP64. MT4?.Z&X9K\=OW$S\#<T^\ MBX9PYU(TC 67\DZR?_"ZS03?<-AR>^8ULNF/OL7/?GP)BW@K4"63%(QH)9%^ M%8N^$IF$D*AD/K"TH_7WW%LWPT##(#1O,AR JL;0(BQV-\&K)C^!7> M^KE?+6O FG,]&XYA-AN@/G/.,DX49X45EI/ D!72X9JAD93:W 1KDW-2/CL<) MOOTGH.HST;$ 0++6Q51.J9C*DE#)#;-4*NMK9*X>O78S:#02R'IZ>O#TZ M.5]\<7[Z_OCM 7[XYN#]P+X-U+B#36! MR^BM?LF0SWX6%FA9O72Y,6$TG]U\K]((%SR4C M6D=3RL\5<98"X3& #9;G2&7E53ZDH)]KYITAX48W56!WCX?50^I7.O9V$8K9 MF#A:X)QIB;HZ 0G),T+1^!(RZ>3C2XFV[3'SB)!^H;.+9)\%R2YL;@ KAW[V M^6"N;1T MR5YEY9EVB5?&SD:$M8"EG0 PZ5H:#4#L(,9RO6YV!A%P26$$)S"_R5$S"X&S M((B3(A#I-<4-&'%!OO3\R%2#>^FRR59:Z05Z^FF;T1V@JO&^ 1R=?YY,YQ
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end